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ABSTRACT OF DISSERTATION 
 
 
 
NOVEL SMALL MOLECULE ANTIFUNGALS FOR INVASIVE FUNGAL 
INFECTIONS 
 
Human fungal pathogens cause a range of diseases from benign skin conditions (i.e., 
ringworm) to thrush, mucosal membrane infections, and life-threatening systemic 
infections including bloodstream infections (i.e., aspergillosis and candidiasis) and 
Cryptococcal meningitis. These systemic infections occur most often in 
immunocompromised individuals and have high mortality rates. Current antifungal agents 
used in the clinic belong to three main classes: the polyenes (e.g., amphotericin B (AmB)), 
the echinocandins (e.g., caspofungin (CFG)), and the azoles (e.g., fluconazole (FLC)). In 
addition, the antimetabolite pyrimidine analogue flucytosine is used in combination with 
AmB. The three main classes class of antifungals each target different aspects of cell wall 
synthesis or cell membrane function and each class has different strengths and weaknesses 
depending on the strains of fungi that they are effective against, their route of 
administration, and their potential side effects. Problems associated with current 
antifungals include toxicity to patients, only effective against a limited spectrum of fungal 
strains, and the development of resistance of fungal strains to treatment. Discovering new 
antifungal therapies is a promising strategy to decrease mortality rates. Herein, three 
classes of molecules are evaluated for their potential as novel antifungals and reveal that 
(i) the antihistamines, terfenadine (TERF) and ebastine (EBA) improve the efficacy of 
azole antifungals when used in combination against a range of Candida strains, (ii) square-
planar gold(I)-phosphine complexes exhibit broad-spectrum antifungal activity, and (iii) 
fluorinated aryl- and heteroaryl-substituted monohydrazones display broad-spectrum 
activity against fungi with little toxicity to mammalian cells, and (iv) other classes of 
molecules in recent literature that have shown antifungal activity. This work serves to 
identify promising scaffolds for novel classes of antifungals with the ultimate goal of 
bringing newer and more effective antifungals to be used clinically for systemic fungal 
infections. 
 
KEYWORDS: drug synergy, biofilm, drug resistance, Candida, gold complexes, 
monohydrazone  
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PREFACE 
The following dissertation contains 6 chapters covering the most important projects of my 
Ph.D. studies aimed at the in vitro biological evaluation of novel small molecule 
antifungals. The first 4 chapters are adapted from my previous publications. Chapter 1 
provides a comprehensive overview of currently available antifungal agents and scaffolds 
in preclinical studies published in recent years (Howard, K.C.,† Dennis, E.K.,† Watt, D.S., 
& Garneau-Tsodikova, S. (2020). A comprehensive overview of the medicinal chemistry 
of antifungal drugs: Perspectives and promise. Chem. Soc. Rev. 49:2426-2480). Chapter 2 
discusses the synergistic activity of two antihistamines in combination with azole 
antifungals (Dennis, E.K. & Garneau-Tsodikova, S. (2019). Synergistic combinations of 
azoles and antihistamines against Candida species in vitro. Med. Mycol. 57(7):874-884.) 
Chapter 3 reports 6 gold(I)-phosphine complexes and their broad-spectrum activity against 
fungal strains (Dennis, E.K., Kim, J.H., Parkin, S., Awuah, S.G., & Garneau-Tsodikova, 
S. (2020). Distorted gold(I)-phosphine complexes as antifungal agents. J. Med. Chem. 
(special issue on Women in Medicinal Chemistry), 63(5):2455-2469). Chapter 4 looks at 
the promise of fluorinated aryl- and heteroaryl-substituted hydrazones (Chandrika, N.T., 
Dennis, E.K., Brubaker, K.R., Kwiatkowski, S., Watt, D.S., & Garneau-Tsodikova, S. 
Fluorinated aryl- and heteroaryl-substituted hydrazones: Broad spectrum antifungal agents. 
(Submitted for publication in August 2020). Chapter 5 describes works in progress related 
to the projects that are unfinished at this time. Finally, Chapter 6 provides the conclusions 
and future directions for the projects discussed here. 
Reproduced with permission from Howard, K. C.;† Dennis, E. K.;† Watt, D. S.; Garneau-Tsodikova, S., A 
comprehensive overview of the medicinal chemistry of antifungal drugs: Perspectives and promise. Chem. 
Soc. Rev., 2020, 49, 2426-2480. Copyright 2020 Royal Society of Chemistry. 
Chapter 1 
 
A comprehensive overview of antifungal drug development: Perspectives and 
promise 
 
1.1. ABSTRACT 
The emergence of new fungal pathogens makes the development of new antifungal drugs 
a medical imperative that in recent years motivates the talents of numerous investigators 
across the world. Understanding not only the structural families of these drugs but also 
their biological targets provides a rational means for evaluating the merits and selectivity 
of new agents for fungal pathogens and normal cells. An equally important aspect of 
modern, antifungal drug development takes a balanced look at the problems of drug 
potency and drug resistance. The future development of new antifungal agents will rest 
with those who employ synthetic and semisynthetic methodology as well as natural product 
isolation to tackle these problems and with those who possess a clear understanding of 
fungal cell architecture and drug resistance mechanisms. This review endeavors to provide 
an introduction to a growing and increasingly important literature, including coverage of 
the new developments in medicinal chemistry since 2015 and also endeavors to spark the 
curiosity of investigators who might enter this fascinatingly complex fungal landscape. 
 
1.2. INTRODUCTION 
Spurred on by the specter of widespread, drug-resistant, fungal infections that might derail 
modern medical advances and threaten human health, scientists seek to understand fungal 
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pathogens at a molecular level and design new agents to control their promulgation in 
human populations. New research techniques and ever more complex drugs than their 
antifungal progenitors provide hope that medicinal chemistry will prove equal to the 
challenges presented by these infections. Are we entering a “Golden Age” of antifungal 
drug discovery? Certainly, a steady, annual increase in the number of scientific 
publications (Fig. 1.1) appears to herald such a period of discovery. Perhaps even more 
telling is the appearance of front-page articles in the popular press such as the New York 
Times that alert the general population as to the threat that these fungal infections represent 
and underscore the importance of research in this arena.1-3 The first antifungal drug, 
amphotericin B (AmB), entered the pharmaceutical market only sixty years ago.4 The 
discovery of subsequent antifungal drugs for human use continued at a slow, but not 
insignificant, pace. Although many interesting reviews summarize the therapeutic use of 
antifungal agents since 2010 (Fig. 1.2),5-6 only a few provide a comprehensive overview of 
the discovery and development of new agents for molecular, fungal targets and provide 
guidance as to the direction that future drug discovery may take.7-11 This overview of 
human, fungal pathogens, antifungal agents used in the clinic or in clinical trials, and 
mechanisms of resistance against current antifungal agents will focus on summarizing the 
voluminous literature related to the discovery and development of new antifungals and will 
ambitiously predict the future for drug discovery in this important arena. 
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Fig. 1.1. Graph showing the number of publications related to antifungal research found in PubMed (yellow 
circles) or in SciFinder (purple circles) from 1945-2018. 
 
 
Fig. 1.2. Graph showing the number of reviews found in PubMed published from 2010-2018 when searching 
for the combinations of terms shown in the legend above. 
 
1.2.1. Fungal pathogens and their associated ailments 
The most common types of fungal infections are cutaneous, ringworm infections of the 
skin and nails. Most people, who are unfamiliar with the sinister, systemic fungal 
infections, associate fungal infections only with those affecting the skin because these 
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infections produce an effect visible even to the untrained eye. The name ringworm is itself 
misleading as these infections are not caused by worms but by pathogenic fungi called 
dermatophytes that live on the skin. The cutaneous fungal infections known as ringworm 
typically occur in otherwise healthy individuals, and although they are contagious, these 
infections are treatable and not life-threatening. On the other hand, systemic fungal 
infections, including infections that appear in immunocompromised individuals, are life-
threatening, as evidenced by current mortality rates exceeding 50%.12 
 
For healthy individuals, fungi are ubiquitous and a generally benign part of our 
environment. Conditions that either destroy immune cells, such as acquired immune 
deficiency syndrome, or require treatments that weaken the immune response, such as 
organ transplantations or cancer chemotherapies, temporarily compromise the ability of the 
immune system to surmount systemic fungal infections. For these immunocompromised 
patients, fungal infections represent anything but a benign presence. As medical advances 
lead to a larger population of immunocompromised individuals than those in the past, 
clinical practitioners will require an ever increasing number of new, selective antifungal 
drugs to treat patients affected by systemic, fungal diseases.13 
 
Fungi are arbitrarily divided into four categories according to cellular, structural features: 
yeasts, filamentous fungi, dimorphic fungi, and dermatophytes. Without digressing into a 
detailed discussion of taxonomical variations in these four categories, we will briefly 
summarize the well-known strains and the pernicious strains in each category that affect 
human health since these are the strains that attracted the interest of medicinal chemists 
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interested in drug development. We refer the reader to detailed, well-written discussions of 
molecular and morphological differences among these organisms.14-16 
 
Yeasts immediately bring to mind thoughts of bread and beer that use the non-pathogenic 
and much-valued Baker’s yeast, Saccharomyces cerevisiae. Cutaneous candidiasis is a 
common cause of diaper rash in newborns and Candida spp. also affect mucosal 
membranes in the form of oral thrush in newborns and vaginal infections in women. 
However, several other closely related Candida spp. are also responsible for an estimated 
400,000-700,000 cases of systemic human infections. Candida albicans is the causal agent 
in approximately 70% of the cases,13 but other Candida spp., including Candida glabrata 
and Candida auris, represent strains of increasing importance as will become clear in our 
subsequent discussion of antifungal drug resistance. These systemic infections, if left 
untreated, may result in damage to the heart, liver, and kidneys. The spore-forming yeast, 
Cryptococcus spp., specifically Cryptococcus neoformans and Cryptococcus gattii, 
represent important species of pathogenic fungi in the yeast group that lead primarily to 
infections in the lungs and the central nervous system. 
 
Infections caused by pathogenic, filamentous fungi or molds, commonly described as 
aspergillosis, develop after the inhalation of Aspergillus spp. spores. Aspergillosis occurs 
primarily in the lungs of individuals who are already compromised by unrelated, 
underlying lung problems, such as asthma or chronic obstructive pulmonary disorder. 
Invasive aspergillosis represents a severe form of this infection that spreads from the lungs 
to the brain, heart, and kidneys. Invasive pulmonary aspergillosis typically occurs in 
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patients whose immune systems are weakened as a result of cancer chemotherapy, bone 
marrow transplantation or a disease of the immune system, and if left untreated, this form 
of aspergillosis may be fatal. 
 
The pathogenic, dimorphic fungi have a complex lifecycle that involves a stage in which 
the dimorphic fungi resemble yeast and another stage where they resemble molds. These 
chameleon-like, dimorphic fungi cause an extensive list of infections that include those 
described as mucormycosis, blastomycosis, histoplasmosis, fungal keratitis, and valley 
fever resulting from Mucor spp., Blastomyces spp., Histoplasma spp., Fusarium spp., and 
Coccidioides spp., respectively.12-13 
 
Finally, as noted earlier in our discussion, the pathogenic dermatophytes affect the 
superficial skin, hair, and nails. These cutaneous infections, commonly referred to as 
ringworm, athlete’s foot or jock itch (so-called “tinea” infections), involve some forty types 
of fungi in the Trichophyton, Microsporum, or Epidermophyton genera and tend to involve 
irritation or reddening of the skin as a consequence of dilation of capillary blood vessels. 
Although rarely life-threatening or painful and barely noticeable in some cases, 
dermatophytoses produce “chronic progressive eruptions that last months or years, causing 
considerable discomfort and disfiguration”.17 
 
In summary, this brief tour through the four categories of pathogenic fungi provides the 
rationale for testing new antifungal agents against the following fungal strains: Candida 
albicans, non-albicans Candida (e.g., C. auris, C. dubliniensis, C. famata, C. glabrata, C. 
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guilliermondii, C. inconspicua, C. kefyr, C. krusei, C. lambica, C. lipolytica, C. lusitaniae, 
C. mycoderma, C. parapsilosis, C. pulcherrima, C. pseudotropicalis, C. rugosa, C. sake, 
C. tropicalis, and C. utilis), Aspergillus spp. (e.g., A. brasiliensis, A. candidus, A. clavatus, 
A. fumigatus, A. ochraceus, A. niger, and A. terreus), as well as Cryptococcus spp. (C. 
neoformans, C. gatti, and C. humicolus). Other fungal strains less commonly tested include 
the yeasts S. cerevisiae and Rhodotorula spp. (e.g., R. bogoriensis and R. pilimanae); the 
molds  Fusarium spp. (e.g., F. graminearum, F. oxysporum, F. sambucinumi and F. solani) 
and Rhizopus spp. (e.g., R. oryzae); the dimorphic  Histoplasma spp. (e.g. H. capsulatum), 
Mucor spp. (e.g., M. hiemalis), and Sporothrix spp. (e.g. S. schenkii); the dermatophytes 
Microsporum spp. (e.g., M. canis), Trichophyton spp. (e.g., T. mentagrophytes and T. 
rubrum), and Trichosporon spp. (e.g., T. cutaneum); those that are primarily plant 
pathogens (e.g., Colletotrichum coccodes and Botrytis cinereal) and the non-pathogenic 
mold and model organism for genetics, Neurospora crassa. 
 
The key to developing successful antifungal agents rests with their specificity for arresting 
(i.e., fungistatic) or killing (i.e., fungicidal) pathogenic fungal cells in preference to normal 
cells. What features discriminate between these two eukaryotic cell types and thereby offer 
unique targets for drug therapy? Most importantly, fungal cells, but not normal cells, 
possess a cell wall, called the pellicle, constructed principally of an aminopolysaccharide, 
chitin. This chitin layer in yeast cells possesses an overlaying matrix of β-1,3-glucans and 
then β-1,6-glucans, and this chitin layer in filamentous cells possesses an overlaying matrix 
of β-1,3-glucans and then α-1,3-glucans (Fig. 1.3). Final variable layers of 
galactosaminoglycans and proteins in yeast cells or galactosaminoglycans, 
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galactomannans and proteins in filamentous cells complete the architectural picture. 
Fungal cells also have cell membranes underlying the cell walls that contain a sterol called 
ergosterol rather than cholesterol that appears in the membranes of normal cells. In 
summary, fungal cells (e.g., the yeasts Candida spp. and Cryptococcus spp., and the 
filamentous Aspergillus spp.), possess cell walls that display structural variations and cell 
membranes that differ from those of normal eukaryotic cells. The chitin “basement layer” 
of the cell wall provides a strong, shell-like framework that resists internal osmotic pressure 
from the cytoplasm. The glucan-based, outer layer of the cell wall in fungi provides 
chemical diversity and distinguishes one fungal species from another. For example, 
Cryptococcus have a thick capsule outside their cell wall made from the capsular 
polysaccharide, glucuronoxylomannan; Histoplasma and Blastomyces have a layer of α-
1,3-glucan; and, most interestingly, Aspergillus conidium has a layer of melanin.14 The 
variance between fungal and normal cells as well as the variance among different fungal 
cells provide the basis on which to identify druggable targets for new antifungal agents. 
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Fig. 1.3. Contrasting structures of fungal cell walls and membranes for yeast and filamentous fungi. Proteins 
and ergosterol are found in the cell membrane. Chitin and (1,3)-β-glucans are layered on top of the membrane 
to reinforce it and build the foundation for the cell wall. The rest of the cell wall is composed of proteins and 
various polysaccharides including (1,6)-β-glucans, (1,3)-α-glucans, galactomannans, and 
galactosaminoglycans. 
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1.2.2. Classes of antifungal agents and their mechanisms of action 
Understanding the structural differences between pathogenic fungi and normal cells 
provides a rational basis on which to discuss the five classes of antifungal agents approved 
for human consumption: (i) the azoles (Fig. 1.4), (ii) the polyenes (Fig. 1.5), (iii) the 
echinocandins (Fig. 1.6), (iv) the allylamines (Fig. 7A), and (v) the antimetabolites (Fig. 
1.7B). It also provides the basis on which to discuss directions that new therapeutic 
advances might take. The prior discussion of fungal cell architecture (Fig. 1.3) represented 
the affiliations among the glycans, chitin and the fungal cell membranes as flexible, even 
disorganized, arrangements in “layers”. In fact, the evolution of these species derives from 
specific needs and affiliations among these polymeric species. Probing the structures and 
precise affiliations at molecular levels will provide the basis for designing drugs capable 
of dismantling these affiliations and achieving the desired fungistatic or fungicidal 
activities. 
 
The azoles are a principal class of small-molecules used to treat fungal infections by 
targeting the lanosterol 14α-demethylase enzyme crucial for ergosterol biosynthesis. All 
antifungal azoles consist of an imidazole or triazole attached to a quaternary carbon (Fig. 
1.4). The original azoles that emerged from the mid 1970s to the 1990s were imidazole-
based and included the now, well-known representatives such as miconazole (MCZ; 
marketed in 1974), clotrimazole (CLT; 1975), econazole (ECO; 1982); ketoconazole 
(KTC; 1981), tioconazole (TIO; 1983), and sulconazole (SUL; 1989). More recently, 
additional imidazole-containing antifungals gained approval (e.g., serconazole (SER; 
2003) and luliconazole (LUL; 2013)). Starting as early as 1981 but emerging 
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predominantly in the 1990s, additional, important azoles, such as terconazole (TER; 1981), 
fluconazole (FLC; 1990), itraconazole (ITC; 1992), voriconazole (VRC; 2002), 
posaconazole (POS; 2006), efinaconazole (EFI; 2014), and the prodrug of isavuconazole 
called isavuconazonium (ISA; 2015), entered the armamentarium of medical practitioners. 
These new azoles possessed a triazole ring in place of the imidazole ring. The nitrogen-
containing, aromatic ring in triazole-based azoles offered greater specificity against the 
fungal cytochrome P450 (CYP) enzyme than the early imidazole-based counterparts. In 
addition to the triazoles that are already on the market, two additional azoles are in clinical 
trials: albaconazole (ALB) and PC945.18-19 
 
Most recently, tetrazoles gained popularity as potential antifungals because of their activity 
against a broad spectrum of fungal species and their good oral bioavailability.20-21 In a 
similar fashion to the triazoles that showed better specificity for fungal CYP enzymes than 
the imidazoles, the tetrazoles showed the best improvement in this respect. Otesaconazole 
(VT-1161), which is currently in phase III clinical trials, inhibits the fungal cytochrome 
P450 (CYP) enzyme, has undetectable levels of binding to human CYP enzymes, and 
exhibits similar potency to VRC in minimal inhibitory concentration (MIC) assays.20, 22 In 
addition to VT-1161, two other tetrazoles, quilseconazole (VT-1129) and VT-1598, are in 
preclinical development for treatment of Cryptococcus and Coccidioides infections, 
respectively.21, 23-25 Today, imidazole-based antifungals are typically used as topical agents 
with the exception of KTC that still finds some systemic applications, whereas triazoles 
are generally used for systemic infections with the exception of EFI and TER that are used 
for topical infections. Of particular note are VT-1161 and ALB that, if successful in clinical 
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trials, will be only the second and third orally formulated treatments for onychomycosis, a 
fungal infection of the fingernails and most commonly, the toenails. The azoles possess 
two important benefits: oral activity and a broad spectrum of activities against various 
fungal strains. Their continued, wide-spread use drives both new analog development and 
concerns about the emergence of resistant strains that might accommodate 14α-methylated 
sterols in place of ergosterol in fungal membranes. 
 
 
Fig. 1.4. Structures of approved imidazole-based and triazole-based antifungals along with the year of their 
introduction on the market and the fungal genera they target. Also depicted are tetrazole-based antifungal in 
preclinical and clinical development. Imidazoles: clotrimazole (CLT), econazole (ECO), ketoconazole 
(KTC), luliconazole (LUL), miconazole (MCZ), sertaconazole (SER), sulconazole (SUL), and tioconazole 
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(TIO). Triazoles: albaconazole (ALB), efinaconazole (EFI), fluconazole (FLC), isavuconazonium (ISA), 
itraconazole (ITC), PC945, posaconazole (POS), terconazole (TER), and voriconazole (VRC). Tetrazoles: 
otesaconazole (VT-1161), quilseconazole (VT-1129), and VT-1598. * = topical use; † = systemic use. 
 
A second-line of defense against pathogenic fungi are the polyene class of antifungals (Fig. 
1.5). Unlike the azoles that are synthesized in a laboratory setting, the polyenes are 
naturally occurring macrolides that are produced by Gram-positive bacteria, Streptomyces 
spp. presumably as a defense mechanism. Antifungal polyenes consist of a 25- or 37-
carbon, unsaturated macrolactone ring attached to a mycosamine saccharide. The 
unsaturated macrolide ring disrupts the cell membrane by binding to and sequestering 
ergosterol in the fungal cell membrane.26 The most potent polyenes, such as amphotericin 
B (AmB), contain seven units of unsaturation in the ring (i.e., heptaenes). As the fungal 
ergosterol is structurally and functionally similar to the mammalian cholesterol, the 
polyenes display unfortunate, high levels of toxicity in addition to their desired, potent 
antifungal activity. Heptaenes such as AmB also display higher levels of toxicity than that 
of the related hexaenes such as nystatin (NYT) and natamycin (NAT).27-28 
 
Despite requiring intravenous injection for drug delivery, AmB is the most commonly used 
polyene and the “gold standard” of antifungal agents for systemic infections. It is not 
surprising that different liposomal formulations of AmB were developed to improve the 
safety and efficacy of this important antifungal agent.29 Both NYT and NAT are also used 
topically for skin and eye infections, respectively.4 For some fungal infections, such as 
those caused by Cryptococcus spp. and dimorphic fungi, AmB remains as the final line-of-
defense because other antifungals, such as echinocandins, are inactive against these fungi. 
In these cases, AmB often finds use in combination with other classes of antifungals 
14 
including the antimetabolites.30 In addition, sertraline, a selective, serotonin-reuptake 
inhibitor, possesses unexpected activity against Cryptococcus spp. and a combination of 
sertraline and AmB is currently in phase III clinical trials.31-32 
 
 
Fig. 1.5. Structures of polyene antifungal agents along with the year of their introduction on the market and 
the fungal genera they target. Polyenes: amphotericin B (AmB), natamycin (NAT), and nystatin (NYT). 
 
A third class of antifungals comprise the semisynthetic natural products in the 
echinocandin family (Fig. 1.6). These antifungal agents possess hexapeptide cores bearing 
hydrophobic, lipid side-chains. Unlike the azoles that are man-made and the polyenes that 
are natural products, the echinocandins represent semisynthetic agents in which natural 
products undergo laboratory-based modifications to achieve a desired, therapeutic result. 
Specifically, the lipid moiety attached to the echinocandin hexapeptide framework is the 
site most frequently modified in efforts to develop new variants of the echinocandins. The 
mechanism of action of the echinocandins involves the inhibition of a β-1,3-glucan 
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synthase necessary for cell wall integrity. The absence of cell walls in normal cells makes 
the echinocandins particularly attractive agents for treating fungal pathogens. 
 
The echinocandins that are in current clinical use consist of a hexapeptide core with 
variable lipid side-chains. Representative members of this family include caspofungin 
(CAS), micafungin (MFG), and anidulafungin (AFG). In addition, rezafungin (CD101) is 
currently in phase III clinical trials. The echinocandins produced by filamentous fungi 
presumably evolved as a defense mechanism to kill other fungi competing for nutrients. 
Their specificity for cell walls in fungi required a level of complexity that emerged from 
evolutionary pressures without regard to issues such as membrane absorption. Not 
surprisingly, the echinocandins have poor oral bioavailability and like AmB, require 
intravenous injection. In contrast to the polyenes, the echinocandins have a different and 
somewhat better toxicity profile than AmB and find application within a narrow spectrum 
of fungal infections including candidiasis and aspergillosis.33 
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Fig. 1.6. Structures of echinocandin antifungal agents along with their year of introduction on the market and 
the fungal genera that they target. Echinocandins: anidulafungin (AFG), rezafungin (CD101), caspofungin 
(CFG), and micafungin (MFG). 
 
Returning to the theme of wholly, man-made, antifungal agents, two additional classes of 
antifungal agents in this category warrant discussion: the allylamines (Fig. 1.7A) and the 
antimetabolites (Fig. 1.7B). The allylamines target another critical, biosynthetic enzyme, 
squalene epoxidase, the first enzyme in the biosynthesis pathway leading from squalene to 
lanosterol and hence to ergosterol and cholesterol. Representative examples of the 
allylamines include terbinafine (TRB), naftifine (NAF), and butenafine (BUT). These 
agents are typically formulated as powders or creams for the treatment of cutaneous 
ringworm infections. In addition to its powder-based formulation, TRB is also the only 
approved, oral drug for the treatment of onychomycosis (i.e., fungal infections of the 
fingernails or toenails). At first glance, it might seem unusual to use TRB for an application 
requiring drug absorption since TRB would concomitantly interfere with cholesterol 
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biosynthesis in normal cells as well as ergosterol biosynthesis in fungal cells. Presumably, 
dietary foodstuffs make up for any potential inhibition of cholesterol biosynthesis in 
humans. 
 
5-Flucytosine (5FC) is a pyrimidine antimetabolite that unfortunately also possesses a high 
level of toxicity and triggers the development of fungal resistance. As a consequence, 5FC 
is primarily used sparingly for severe cases of candidiasis and in combination with AmB.30 
Toxicity and resistance may be linked: the deamination of 5FC to 5-fluorouracil (5FU), 
capture of 5FU as a nucleotide FUMP, and subsequent inhibition of thymidylate synthase 
affects this key enzyme that links the RNA and DNA worlds. 
 
 
Fig. 1.7. Structures of A. allylamine and B. antimetabolite antifungal agents along with the year of their 
introduction on the market and the fungal genera that they target. Allylamines: butenafine (BUT), naftifine 
(NAF), and terbinafine (TRB). Antimetabolite: 5-flucytosine (5FC). 
 
The limited armamentarium of antifungal agents and the increasing number of drug-
resistant fungal pathogens mandates the continued development of new classes of 
antifungal agents. In the echinocandin-like class, ibrexafungerp (SCY-078) 
(NCT03734991) (Fig. 1.8), that is currently in phase III clinical trials, resembles the 
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echinocandins in that it is a glucan synthase inhibitor but, unlike the echinocandins, is 
orally available.34-35 Preclinical studies showed that SCY-078 is active against Candida 
spp. and Aspergillus spp. with fungicidal activity at concentrations above MIC values. 
SCY-078 also shows synergistic effects in combination therapy with AmB.36-38 While 
SCY-078 has the same cellular target as the echinocandins, resistance studies showed 
variance in the binding sites for these two types of molecules and suggested that SCY-078 
may be an attractive, treatment option for multidrug-resistant infections.39-40 
 
F901318 (NCT03583164) is a first-in-class “orotomide” antifungal agent that targets the 
dihydroorotate dehydrogenase enzyme in pyrimidine nucleotide biosynthesis.41 The 
orotomides are narrow-spectrum antifungal agents that display oral activity against 
Aspergillus spp. and some dimorphic fungi including Scedosporium spp.42 with MIC 
values that are better than those of azoles and AmB.43-44 Another new drug in phase II 
clinical trials is an inhibitor of the biosynthesis of glycosylphosphatidylinositol (GPI), a 
lipid-rich anchor attached to membrane-associated proteins.45 APX001 (formerly E1210, 
NCT03604707) has broad-spectrum activity against Candida spp., Cryptococcus spp., 
Coccidioides spp., Aspergillus spp., Fusarium spp., and Scedosporium spp.,46-53 and 
although it shows potency comparable to that seen in current antifungals, it has a high 
clearance rate. APX001 is actually a prodrug that leads to the active metabolite named 
APX001A that lacks the methylphosphate group on the 2-aminopyridyl ring in APX001.46, 
54-55 In addition, given the wide-spread use of GPI anchors in normal cells, it is unclear 
what selectivity this drug has for fungal pathogens versus normal cells. 
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A third new drug in phase II studies, ME1111 (NCT02022215), is a topical treatment for 
onychomycosis. ME111 inhibits the succinate dehydrogenase complex that appears as 
complex II in the electron-transport chain and effects the succinate-to-fumarate conversion 
in the citric acid cycle and thereby disrupts oxidative phosphorylation.56 MIC values for 
ME1111 are comparable to current antifungal nail lacquers,57 but its small molecular mass 
relative to other agents, affords it considerable improvement in its ability to penetrate 
nails.58-59 
 
A fourth potential antifungal agent completing phase II studies is a natural product isolated 
from Acremonium persicinum, found among Malaysian leaf litter.60 This fungal genus is 
formerly known as Cephalosporium and different strains produce antibiotics in the 
cephalosporin family.61 Like the echinocandins, VL-2397 (formerly ASP2397, 
NCT03327727) is a cyclic hexapeptide that resembles the fungal siderophore, ferrichrome, 
but preferentially chelates aluminum ions instead of ferric ions.60 VL-2937 is narrow 
spectrum antifungal agent with activity against Aspergillus spp.62 
 
AR-12 (formerly OSU-03012, NCT00978523) represents another new class of antifungal 
agents. Although it is currently in phase I clinical trials as an antineoplastic agent, it also 
displays a broad spectrum of antifungal activity including some synergistic interactions 
with FLC.63-64 AR-12 has antineoplastic activity that derives from its mechanism of action 
as a protein-kinase inhibitor, but in fungi, its activity  resides in the inhibition of acetyl-
CoA synthetase.65-66 In addition to the new antifungal agents described above, synthetic 
lactoferricin, derived antimicrobial peptide, hLF1-11 (NCT00509834), is undergoing 
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clinical trials to treat candidemia,67 and two other trials are underway to evaluate vaccines 
for vulvovaginal candidiasis (NCT01926028 and NCT01067131).68  
 
Several antifungal agents entered clinical trials but were unsuccessful due to a lack of 
efficacy in patients. For example, nikkomycin Z (NCT00614666) was a chitin-synthase 
inhibitor with a nucleoside-peptide scaffold that was under development to treat 
Coccidioides infections (Fig. 1.8).69 Similar to AR-12, a histone deacetylase inhibitor, 
MGCD290 (NCT01497223), originally developed as an antineoplastic agent, failed as an 
agent to be used in combination with FLC for vulvovaginal candidiasis.70 Finally, a human 
recombinant monoclonal antibody, called mycograb (NCT00847678), targeted heat shock 
protein 90 passed phase I trials for cryptococcal meningitis, but failed to complete phase II 
trials.71 
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Fig. 1.8. Structures of new classes of antifungal agents in development: inhibitors of glucan synthase (SCY-
078) in Phase III; a pyrimidine biosynthesis (F901318) in Phase II, GPI biosynthesis (APX001), citric acid 
cycle (ME1111), and a siderophore-like molecule (VL-2397). The kinase inhibitor (AR-12) is in phase I trials 
for cancer and has potential to enter clinical trials as an antifungal. In addition, the chitin synthase inhibitor, 
nikkomycin Z, started phase II development, but trials were terminated. 
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1.2.3. Modes of resistance to various classes of antifungal agents 
Fungal resistance to drug treatment occurs not only with 5-flucytosine (5FC), as described 
earlier in this review, but also with other antifungal drug classes. While it is common for 
some fungi to be intrinsically resistant to a class of antifungal agents, it is quite rare for a 
pathogen to be pan-resistant to all antifungal agents. As an exception to this generalization, 
C. auris is a pathogen that has made headlines1-3 recently because of its easy 
transmissibility and because it is frequently resistant to all three main classes of antifungals. 
Fungi employ four main strategies to resist drug therapy: (i) overexpression of targeted 
proteins (observed in azoles); (ii) mutations induced in targeted proteins (observed in 
azoles and echinocandins); (iii) upregulation of biosynthesis of efflux pumps and/or 
augmented insertion of efflux pumps in cell membranes (observed in azoles); and (iv) 
decreased access to target as in the sequestration of ergosterol (observed in polyenes). 
 
Most reports of antifungal drug resistance involve infections by fungal pathogens that show 
decreased susceptibility to the azoles, probably because of their widespread use and not 
because of some intrinsic property of the azoles. For Candida spp., approximately 7% of 
all systemic infections display decreased susceptibility to the azoles.72 Resistance to the 
azoles is due to three mechanisms that fungal cells use alone or in combination to defeat 
the fungicidal activity of these drugs: [1] overexpression of ERG11 (i.e., resistance strategy 
“i”) (Fig. 1.9A), [2] mutations in ERG11 (i.e., resistance strategy “ii”) (Fig. 1.9B, Table 
1.1), and [3] expression of efflux pumps (i.e., resistance strategy “iii”) (Fig. 1.9C). The 
ERG11 gene encodes the putative enzymatic target of the azoles, lanosterol 14α-
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demethylase, and various studies reported increased transcriptional levels of ERG11 
mRNA in azole-resistant Candida strains that in turn leads to elevated levels of the targeted 
enzyme. This robust expression of lanosterol 14α-demethylase overcompensates for any 
loss of activity due to azole inhibition (Fig. 1.9A).73-74 
 
The second effective strategy that fungi use to acquire resistance to azoles involves 
principally the appearance of lanosterol 14α-demethylase mutations in C. albicans clinical 
isolates (Table 1.1) and the appearance of a few mutations in non-albicans Candida (see 
last row of Table 1.1). Furthermore, the widespread use of azoles in agriculture led, perhaps 
as expected, to reports of resistance to Aspergillus spp., and susceptibility monitoring of 
molds in different environments suggests this is also a concern (Table 1.2).75-82 Mutations 
conferring resistance to the azoles are numerous but appear to localize near the heme-
binding group in lanosterol 14α-demethylase (Fig. 1.9B).83-84 Of the mutations observed, 
only eight mutations have been confirmed by in vitro methods to have a role in azole 
resistance (i.e., A61V, Y132H, K143R, F145L, S405F, V456I, G464S, and R467K), and 
these single-site, mutations decrease susceptibility to azoles by 4- to 64-fold.85 Of these 
eight mutations, two (e.g., K143R and V456I) play a particularly important role in the 
induction of resistance. In pan-azole strains, the strains invariably have both mutations as 
well as augmented expression of efflux pumps86-90 such as Cdr1, Cdr2, and Mdr1 in yeasts 
that are ATP-binding cassette transporters and appear to be strongly correlated with azole 
cross-resistance (i.e., resistant to VRC and ITC in addition to FLC) (Fig. 1.9C).83, 91 
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Table 1.1. Mutations found in ERG11 of C. albicans clinical isolates. 
Mutation(s) Hot 
spot§ 
R/S Ref. Mutation(s) Hot 
spot§ 
R/S Ref. 
Q21R  R 86 F449V III R 86 
Y79C  R 87 G450E III R 86-87, 92-93 
K99T  R 87 V452A III R 94 
F105L I R/S 92 V456I III  95 
A107T I R 94 G464S c III R 86, 90, 94, 96-99 
A114S I R 100-102 G465S III R 103 
A114V I R 74 R467K  III R 96, 104-105 
D116E  I R/S 74, 83, 93-94, 96-98, 100, 103, 
106-111 
I471T  III R 100, 112 
D117E I R 74 Q474H III R 83 
F126L  I R 93 Q474K III  100 
K128T  I R/S 92-93, 96-98, 100, 106-107, 
113 
L480F III R 111 
G129A  I R 96 V488I III R 87, 90, 92 
V130I I R 87 P503L  R 87 
Y132F a, b, c I R 86-87, 90, 113-118 V509M  R 94 
Y132H I R 93, 96, 100, 112 T525I  R 119 
N136Y  I R 95 F72L, E266D II S 120 
K143E  I R 87, 93 F105L, E266D II R/S 92 
K143R a, c I R 86-87, 94, 106, 115-117, 119, 
121-122 
F105L, G464S III R 92 
F145L I R 83, 87, 94 F105L, G450E III R 92 
F145R I R 86 A114S, Y257H I R/S 86, 88, 103, 110 
K147R I S 92 D116E, K128T I R/S 94, 98, 102-103, 110 
D153E I R 108 D116E, Y132H I R 111 
V159I I R/S 95, 107 D116E, E165K I R 74 
E165Y I S 120 D116E, Y205E I S 109 
I166S e I R 88 D116E, G346A I R 111 
E174A  R 74 D116E, E266D I, II R/S 89, 98 
T199I  R 87 D116E, S405F I, III R 111 
G206D  R 105 D116E, V437I I, III R/S 89, 109 
Y221H  R 95 D116E, G450E I, III R 113 
T229A   R 93 D116E, V488I I, III R 103, 110 
I253V  R 87 T123I, Y132H I R 74, 111 
Y257H   R 100 F126L, Y132F I R 86   
I261V  R 89 F126L, K143R I R 113 
R265G  R 87 K128T, S145L I R 94 
E266Q  II R 96 K128T, V452A I, III R 94 
E266D II R/S 74, 83, 87, 93, 97-98, 106-108, 
110-111 
K128T, Q474K I, III R 102 
L276S II R 95 Y132F, K143R I R 86 
D278E II R 98 Y132F, F145L I R 86 
H283D II R 87 Y132F, S154F c I R 88, 123 
H283R II R 90 Y132H, S405F I, III R 94 
K287R II R 92 Y132H, G448E I, III R/S 94, 103, 110 
A294V  R 97 Y132H, G450E I, III R 94, 110-111, 119 
G303D  R 87 K143R, E226D I R 86 
L305P  R 87 F145L, E226D I R 86 
G307S   R 87, 98 D153E, F145I I R 105 
V332L  R/S 103 D153F, E266D II S 120 
K342R  R 87, 110 Y205E, V437I III S 109 
F380S  R 87 E208K, T525I  R 119 
S405F  III R 90, 93-94, 96, 113 D225H, E266D II R 110 
S405L III R 86 Y257H, G464S II, III R 94 
P406L III R/S 83 M258L, G464S III R 86 
A434V III R/S 111 E266D, V332L II R 103 
V437I  III R/S 83, 87, 89, 93-94, 96, 98, 105-
106, 108, 110, 113, 119 
E266D, K342R II R 110 
D446E III R 86 E266D, V437I II, III R/S 89, 98 
D446N  III R 86 E266D, G464S II, III R 86, 92 
G448E III R 86, 92 E266D, L480F II, III R 111 
G448R III R/S 106 E266D, V488E II, III R 92 
G448V  III R 97 E266D, V488I II, III R/S 86, 88-89, 98, 105, 
110 
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Table 1.1. Mutations found in ERG11 of C. albicans clinical isolates (Continued) 
F449L III R 93 D278N, G464S II, III R 86 
F449S III S 94, 113 K287R, G464S II, III R 92 
G307S, G450E III R 86 F145L, E266D, V488I I, III R/S 94, 98 
V332L, V437I III S 103 Y205E, E226D, V437I III S 109 
V371I, D446N III R/S 113 Y205E, A255V, V437I  S 109 
V371I, G464S III R 113 Y257H, G307S, G464S  II, III R 94 
F449S, T229A III R 113 E266D, L280Y, L281M II S 108 
G450E, D153E I, III S 90 G307S, L403F, G448R III R 86 
G450E, I483V III R 86 G307S, V437I, Y447S III R 86 
G450E, G464S III R 94 A61V, Y257H, G307S, G464S  II, III R 94 
G450E, V488E III R 92 A114S, Y205E, Y257H, V437I I, III R 109 
F72L, Y132H, G450E I, III R 119 A114V, D153E, E266D, G450E I, II, 
III 
R 86 
A114V, E226D, 
H283R 
I R 86 A114V, Y132F, E266D, V437I I, II, 
III 
R 86 
D116E, K128T, 
A149V 
I R 120 D116E, K128T, Y205E, V437I I, III R 109 
D116E, K128T, 
E266D 
I, II S 108 D116E, K128T, Y132H, G465S I, III R/S 103, 110-111 
D116E, K128T, 
Y132H 
I R 102 D116E, D153E, F72S, F416S I, III R 105 
D116E, K128T, 
F499Y 
I R 102 D116E, I261V, E266D, V437I I, II, 
III 
R 89 
D116E, K128T, 
Q474K 
I, III R 102 D116E, E266D, G464S, G465S I, II, 
III 
R 108 
D116E, E226D, V437I I, III R/S 89, 110 D116E, L280F, L281M, S284I I, II R 108 
D116E, E226D, V488I I, III R/S 98, 110 Y132F, E266D, I471M, I483V I, II, 
III 
 86 
D116E, Y132H, 
S405F 
I, III R 120 Y132H, Y205E, V437I, G472R I, III R 109 
D116E, Y132H, 
G448R 
I R 103 Y132H, Y205E, V437I, G448E I R 109 
D116E, G307S, 
G450E 
I, III R 113 Y132H, G448E, G464S, T482A I, III R 105 
T123I, Y123H, L376F I R 111 E266D, L281Y, I282D, T285H II S 108 
K128T, Y132F, F145L I R 94 E266D, G307S, G450E, V488I II, III S 124 
K128T, G464S, R467I I, III R 94 E266D, V488I, N349S, G227D II, III R 105 
Y132F, S154F, 
F145Lc 
I R 88 A61E, E266D, G307S, G450E, V488I II, III R 124 
Y132F, T229A, F449L I, III R 86 D116E, K128T, K143R, Y205E, V437I I, III R 109 
Y132F, V437I, F449L I, III R 86 D116E, Y132F, K143Q, Y205E, Y257H I R 109 
Y132H, S279F, 
G464S 
I, II, III R 120 D116E, Y132F, K143Q, Y205E, V437I I, III R 109 
Y132H, Y257H, 
E266D 
I, II R 94 Y132H, Y205E, N435V, G448E, D502E I, III R 109 
Y132H, H283R, 
G464S 
I, II, III R 94 Y132H, G448E, F103L, F198L, F422L I, III R 105 
Y132H, G464S, 
R467K 
I, III R 120 K143R, E226D, S412T, R469K, V488I I, III R 108 
K143R, E266D, V488I I, III R 98, 108 Y132H, Y205E, Y257H, E260V, V437I, 
G448E 
I, III R 109 
a = C. auris, b = C. parapsilosis, c = C. tropicalis, d = C. neoformans, e = C. glabrata 
Bold = verified to contribute to resistance by either heterologous gene expression in S. cerevisiae, functional expression of C. albicans 
PCR-amplified ERG11, or decreased affinity of ERG11 for azole. 
R = resistant, S = sensitive. 
§Hot spots I, II, and III refer to clusters of residues where mutations commonly occur. I = residues 105-166, II = 266-287, III = 405-
488. 
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Fig. 1.9. Mechanisms of resistance to azole antifungals include A. target protein overexpression, B. target 
protein mutations, and C. efflux pumps. 
 
The polyenes are the chronologically oldest class of antifungal drugs but still find frequent 
use in treating fungal infections. AmB is used clinically for systemic infections, especially 
in severe cases of candidemia and aspergillosis and in cases where fungal strains display 
decreased susceptibility to other antifungals, such as the azoles. Investigators report only a 
few instances of fungal resistance to AmB and other polyenes presumably because the 
toxicity of polyenes limits patient exposure levels. A few reports describe fungal strains 
that show reduced susceptibility to AmB at clinically relevant doses (>2 mg/mL).125-128 
With only a few resistant clinical isolates, it is not surprising that there are equally few 
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reports focused on the specific mechanisms of resistance in clinical isolates. However, 
studies reveal two resistance mechanisms: (1) decreased amounts of ergosterol in fungal 
cell membranes (i.e., resistance strategy “iv”) (Fig. 1.10A); and (2) increased filamentation 
(i.e., resistance strategy “iv”) (Fig. 1.10B). Typically, polyenes bind to ergosterol in the 
fungal cell membrane, disrupt the membrane, and induce metal-ion leakage. Fungi capable 
of surviving with reduced levels of ergosterol thereby decrease their susceptibility to 
polyenes (Fig. 1.10A)125-126, 129 and acquire a form of resistance that confers increased 
survivability. Some evidence suggests that resistant fungi replace ergosterol with another, 
related sterol, zymosterol (Fig. 1.10A), from the lanosterol-to-ergosterol biosynthetic 
pathway, and this replacement leads to the retention of membrane integrity (Fig. 1.10A).125 
This process possibly occurs naturally and involves the inhibition of ergosterol 
biosynthesis by the azoles that in turn drives fungal cells to scavenge for other, structurally 
related sterols. 
 
Another resistance mechanism against polyenes prevents access of the drug to the 
ergosterol target by increasing filamentation (Fig. 1.10B). These structures, hyphae, are 
important for gathering nutrients and also have roles in virulence.130 Interestingly, in 
experiments designed to promote the development of resistance with C. albicans, increased 
filamentation also correlated with a decrease in virulence, a finding consistent with the 
observation that relatively few fungal strains develop resistance to the polyenes.127, 131  
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Fig. 1.10. Mechanisms of resistance to polyenes. A. Decreased ergosterol levels or ergosterol replacement 
by zymosterol. B. Cartoon illustrating increased filamentation. 
 
The echinocandins are chronologically the newest class of antifungals and have a narrow-
spectrum of applications. While resistance to echinocandins is still considered rare, several 
reports, primarily using C. glabrata, show decreased susceptibility to CAS and other 
echinocandins.132-138 The target of the echinocandins, β-1,3-glucan synthase, appears in the 
fungal plasma membrane and possesses Fks1, a catalytic subunit regulated by the GTP-
binding protein, Rho (Fig. 1.11A). In addition to Fks1, fungi also possess highly 
homologous Fks2 and Fks3 proteins that may have resulted from gene duplication events. 
Although Fks2 and Fks3 have lower expression levels than Fks1, they may play some role 
in the regulation of Fks1.139 Resistance to echinocandins ties to mutations in the Fks1 and 
Fks2 proteins (i.e., resistance strategy “iii”) (Fig. 1.11). Of the strains that show reduced 
susceptibility to echinocandins, most possess mutations in Fks1. These mutations 
commonly occur in three hot spot regions of the Fks1 protein: hot spot region I involves 
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residues FLTLSLRDPI, region III involves WRNIFTRL, and region II involves residues 
PAIDWIRR (Fig. 1.11B, Table 1.2).140-141 These hot spot regions are highly conserved 
sequences among the Candida species and are the focus for Fks mutations. However, 
residue numbering for these hot spots varies among reports; therefore, we summarize this 
information in Table 1.2 in Fig. 1.12 and we normalize the numbering systems to 
emphasize the specificity of mutations in these hot spots. All of these hot spot regions occur 
on the extracellular surface of the protein that is the binding site for echinocandins.141 These 
mutations not only decrease fungal susceptibility to CAS, but also to other 
echinocandins.132, 142 Studies of resistance development in vitro corroborate the locations 
and effects of these mutations.143 Although less common, other echinocandin-resistant 
strains contain mutations in the Fks2 regulatory subunit.144-145 Finally, a few reports 
describe examples of strains resistant to echinocandins with no mutations in the glucan 
synthase genes. In these strains, the resistance results from decreased expression levels of 
the fks genes, and an increase in chitin production compensates for the loss of β-1,3-
glucan.139, 146-148 
 
 
Fig. 1.11. Mechanism of resistance to echinocandins. Mutations in the target protein, Fks1, are located in 
three hot spot regions. 
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Table 1.2. Mutations found in Fks1 and Fks2 of C. glabrata clinical isolates unless otherwise noted by a superscript letter beside the 
mutations. 
Fks1 Mutations Hot spot§ R/S Ref. Fks2 Mutations Hot 
spot§ 
R/S Ref. 
F625C I S 149 F641Ya I R 150 
F625Y I S 151-152 F641V I R 150 
F625S I R 152-155 L644W I S 156 
S629Pa I R 136, 149, 152-153, 155, 157 S645P I R 156, 158 
L630I I S 152-153 E655K I R 159 
R631G I R/S 136, 152, 154 F658S I R 160 
R631S I R 153 F658Y I R 160 
S631Ye I R 161 F658del I R 160 
D632E I R/S 152, 154 F659S I R/S 153, 155, 162-163 
D632Y I R/S 152-153, 159 F659V I R 153 
I634V I R/S 149, 152, 154, 160 F659Y I R 151, 153, 155 
S638Pe I R 161 F659del I R 153, 162 
S638Ye I R 161 S662F I R/S 160, 164 
F641Sa,f I R 152, 156, 158 S662P I R 160 
F641Ya I R/S 152, 156 L662W I R 153 
S645Sa I R 152 S663F I R/S 136, 149, 153, 157 
S645Pa,b,f I R 151-152, 155-159, 163 S663P I R 136, 149, 151, 153, 155, 
157 
F645Ya I R 152 S663Y I R 153 
R647Ga I R/S 165 L664R I R/S 153 
D648Ya I S 152 R665G I S 136 
P649La I S 165 D666Y I R/S 153 
P649Ha I S 152 P667H I R 136, 160 
F658del I R 152, 154 P667T I R/S 155 
F659L I R/S 159 P1371S II R/S 153 
F659S I R/S 152, 159 R1377K II R 164 
F659V I R 152, 154 Multiple mutations    
F659Y I R/S 152 F625S, F659Y I R 155 
S662P I R 160 F629P, R631S I R 152 
L662W I R/S 152 F629P, S663P I R 155 
S663Y I R 152 R664G, D665V I R 160 
S663F I S 152 S629P, D665V I R/S 160 
S663P I R 152, 154, 159 L635V, T655Ab I S 157 
R664G I R/S 160 R647G, P649La I R 165 
R665G I R/S 152, 154 W695L, Y696N III R 166 
R665S I R/S 152, 154 F659S, S663A I R 163 
D665V I R 160 F659S, S663A, D666E I R 163 
D665Y I S 160     
P667F I R/S 152     
P667T I R 154     
H675Qd  R/S 157     
W695L III R 166     
L701Md III R/S 152-153     
I1379V II S 152, 154      
R1344Sc II R 151, 159     
a = C. albicans, b = C. dubliensis, c = C. kefyr, d = C. krusei, e = C. lusitanea, f = C. tropicalis. 
Bold = verified to contribute to resistance by either heterologous gene expression in S. cerevisiae or C. glabrata, site-directed 
mutagenesis, or inhibition of purified protein. 
R = resistant, S = sensitive. 
§Regions of the Fks proteins where mutations are commonly found are divided into three regions: residues 625-667 (I), 695-701 (III), 
and 1371-1379 (II).  
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Fig. 1.12. Summary of Table 1.2 showing the different numbering based on the different fungal strains. Note: 
CA = C. albicans, CD = C. dubliniensis, CG = C. glabrata, CK = C. krusei, CL = C. lusitaniae, CT = C. 
tropicalis. 
 
1.2.4. Fungal biofilms 
Within the human body, fungi survive only if successful in scavenging for nutrients, 
avoiding the host immune system, and resisting antifungal drug treatment. Many fungal 
pathogens produce biofilms as a barrier to evade antifungal drugs and as a mechanism to 
avoid detection by the immune system. Fungi that manufacture biofilms include 
Candida,167 Aspergillus,168 Cryptococcus,169 Fusarium,170 Coccidioides,171 
Trichosporon,172 Malassezia,173 Blastoschizomyces,174 and Zygomycetes (Mucor and 
Rhizopus).175 Biofilm production commonly occurs on biological surfaces such as mucosal 
membranes and, most diabolically, also occurs on medical devices such as catheters. The 
first step in biofilm formation requires the attachment of fungal cells to surfaces (Fig. 1.13). 
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During the initiation of this process, the fungal cells divide and produce hyphal filaments 
to increase their surface area as a means of scavenging for nutrients. As the biofilm 
matures, the fungi produce an extracellular matrix that is the identifying characteristic of a 
biofilm. This extracellular matrix possesses many of the same elements that appear in 
fungal cell walls including glucan and mannan polymers. This matrix acts as a “glue” that 
surrounds fungal cells within the biofilm’s perimeter, sequesters antifungal drugs, and 
prevents them from penetrating into the fungal cells. In addition, fungal cells also express 
efflux pumps that expel any drug that might avoid capture in the biofilm. As a result, fungal 
cells with biofilms show as much as a 10,000-fold decrease in their susceptibility to 
antifungal drugs relative to the susceptibility of planktonic (free-floating) fungal cells.172 
Given the magnitude of the protection from drugs that biofilms provide, it is not surprising 
that fungal cells within biofilms are better able to survive than those without it. Once the 
biofilm reaches maturity, it opens to release fungal cells that disperse and form new 
biofilms elsewhere. The importance of this in vivo process for the survival of fungal cells 
underscores the importance of developing in vitro biofilm models to study biofilm growth 
patterns during infection176 and to understand the role of biofilms in the re-occurrence of 
fungal infections. 
 
Fig. 1.13. Fungal cells that successfully adhere to medical devices or biological surfaces initiate biofilm 
development (shown as a green rectangle) by replicating and forming hyphae. Mature biofilms develop an 
extracellular matrix of various glucans to form a protective barrier to drugs. 
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1.3. DISCOVERY AND DEVELOPMENT OF NEW COMPOUNDS WITH 
ANTIFUNGAL ACTIVITY 
The development of new mutants of known fungi and the appearance of new species of 
fungi unresponsive to current drug therapies provide the momentum for studies of fungal 
resistance. Given the rapidity with which an unknown organism, such as C. auris, leaps 
from obscurity to the popular press, it is not surprising that none of the compounds 
described in the following sections of this review, are yet tested against C. auris. This 
pathogen must be included in future, antifungal drug discovery. Studies designed to combat 
resistance utilize four strategies: (i) design and synthesis of new derivatives of current 
antifungal agents, (ii) design and synthesis of new synthetic scaffolds as antifungal agents, 
(iii) repositioning of drugs or their derivatives used for other medicinal purposes as 
antifungal agents, and (iv) isolation and/or derivatization of newly discovered natural 
products possessing antifungal activity. In the sub-sections below, we will discuss these 
categories and present the leading, representative compounds developed under each of 
these strategies. 
 
We will only briefly summarize the synthetic routes and the data from the subsequent 
biochemical, computational, and biological assays. In this review, we will arbitrarily define 
antifungal activity as follows: excellent (≤2 µg/mL), good (3.9-8 µg/mL), and poor (≥15.6 
µg/mL). We will not endeavor to show all molecules synthesized for each scaffold; but 
instead, we will depict a select group of the most active representatives. We acknowledge 
and understand the many contributions of scientists who synthesized molecules not 
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appearing in this review, and we trust that they understand the space limitations that dictate 
this course of action. 
 
1.3.1. Design and synthesis of derivatives of current antifungal agents 
Extensive derivatization of compounds from the five classes of FDA-approved antifungal 
agents, namely the azoles, polyenes, echinocandins, allylamines, and antimetabolites (Figs. 
1.4-1.7), continues unabated. This section of this review briefly defines prior efforts and 
describes the challenges that these studies must overcome. These efforts, coupled with a 
renewed interest in the identification of new pharmacophores, underscore the “promise and 
perspective” phrase in the title of this review. 
 
1.3.1.1. Azole derivatives - imidazoles 
Although azoles find widespread use in clinical settings because of their broad-spectrum 
antifungal activity and oral bioavailability, further efforts to modify this important 
pharmacophore focus on reducing cytotoxicity and drug-drug interactions as well as 
identifying new candidates to help in the fight against fungal resistance. Among the 
imidazole-based antifungals, MCZ and ECO served as a starting point for the preparation 
of four new types of antifungal agents (Fig. 1.14).177-180 In two cases (i.e., 1-4 and 10-12), 
either the 4-chlorobenzyloxy group of ECO or the 2,4-dichlorobenzyloxy group of MCZ 
was replaced by different substituents in the 1-(2,4-dichlorophenethyl)-1H-imidazole core. 
In two other cases, either the 4-chlorobenzyloxy group and the 2,4-dichlorophenyl group 
in ECO underwent modification (i.e., 5-9) or the imidazole, the 4-chlorobenzyloxy group 
and the 2,4-dichlorophenyl group in MCZ underwent modification (i.e., 13). The following 
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discussion will consider the four cases in turn and will summarize the synthetic approach 
and highlight the reported activities. 
 
In the first case, replacement of either the 4-chlorobenzyloxy of ECO or the 2,4-
dichlorobenzyloxy of MCZ led to analogs with benzyloxy or phenethyloxy substituents in 
the 1-(2,4-dichlorophenethyl)-1H-imidazole core. A three-step synthesis that illustrated the 
approach taken to these pharmacophores involved a Corey-Chaykovsky epoxidation of 
aldehydes181-182 using dimethylsulfonium methylide followed by epoxide opening and 
coupling with alkyl halides (1-4; Fig. 1.14).177 The imidazoles 1-4 displayed excellent 
activity (MIC values of 0.06-1 µg/mL (comparable to those of ITC that served as a 
standard) against twenty-nine C. albicans and seven non-albicans Candida strains (C. 
glabrata, C. krusei, C. lipolytica, C. parapsilosis, C. pseudotropicalis, C. tropicalis, and 
C. utilis). However, these analogs were inactive against four filamentous fungal strains (M. 
hiemalis, A. fumigatus, T. cutaneum, and R. oryzae). MIC data were provided without 
comparable MIC values for MCZ and ECO from which these compounds were derived, 
and consequently, the potential benefits of these new derivatives 1-4 relative to those of 
the parent antifungals ECO and MCZ remained unclear. 
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Fig. 1.14. Representative, new scaffolds tested as potential antifungals that are derived from current 
imidazoles MCZ and ECO. 
 
In the second case, both the 4-chlorobenzyloxy group and the 2,4-dichlorophenyl group in 
ECO underwent modification. Replacement of the 4-chlorobenzyloxy of ECO with 
aliphatic or aromatic esters and replacement of the 2,4-dichlorophenyl of ECO by either a 
4-chlorophenyl or a phenyl group afforded a total of thirty new ECO derivatives including 
representative examples 5-9 (Fig. 1.14).178 When tested against C. albicans and C. 
parapsilosis, thirteen of these compounds displayed excellent activity with MIC values of 
0.125-2 µg/mL that were comparable to that of FLC (Fig. 1.4) (MIC = 0.25 µg/mL). When 
examined against a FLC-resistant C. glabrata clinical isolate, five of these compounds 5-
9 displayed excellent activity (MIC values 0.25-2 µg/mL) (Fig. 1.14). Compounds 5-7 and 
9 also inhibited C. albicans biofilm formation at a concentration of 8 µg/mL, but required 
concentrations in the 512-1024 µg/mL range to eradicate the biofilm. Computational 
modeling of the relative binding affinity of compounds 5, 6, and 9 in the C. albicans CYP51 
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active site was consistent with the observed levels of antifungal activity. Although 
comparison of MIC values was not made with the parent ECO, these imidazole-containing 
molecules possessed promise as antifungals. 
 
In a third case, replacement of either the 4-chlorobenzyloxy group of ECO or the 2,4-
dichlorobenzyloxy group of MCZ by a series of 1,2,3-triazoles made use of 1,3-dipolar 
cycloadditions to furnish 10-12 (Fig. 1.14).179 When tested against A. fumigatus, C. 
albicans, C. tropicalis, C. utilis, M. hiemalis. R. oryzae, and T. cutaneum, the triazole-
imidazole 10 displayed excellent activity against these fungal strains with MIC values of 
0.06-2 µg/mL that was comparable to that of ITC (Fig. 1.4) (MIC = 0.03-1 µg/mL). 
Triazole-imidazole 11 also showed excellent activity against four of these strains (MIC 
values of 0.03-2 µg/mL), but triazole-imidazole 12 only showed activity against two 
Candida spp. strains (MIC values of 0.03-0.06 µg/mL). In yeast sensitivity assays, C. utilis 
was generally resistant to 10-12, while C. albicans and C. tropicalis were susceptible to 
these agents. Although the MCZ analogs showed promise because of their low MIC values, 
further comparisons with MCZ as well as determinations of cytotoxicity in mammalian 
cells, mechanism of action studies, and potential for resistance development will be needed 
to establish the promise of these compounds as antifungal agents. 
 
In a final case, the imidazole, the 2,4-dichlorobenzyloxy group and the 2,4-dichlorophenyl 
group in MCZ underwent modification to afford the difluoro analogs such as 13 (Fig. 
1.14).180 Among the reported twenty-four compounds that were synthesized, only 
compound 13 displayed excellent to good antifungal activity against five fungal strains (A. 
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flavus, Beer yeast, C. mycoderma, C. albicans, and C. utilis) with MIC values of 0.5-8 
µg/mL that were better than those of the standards: FLC (MIC = 1-256 µg/mL) and MCZ 
(MIC = 4-256 µg/mL). Computational modeling of 13 in the CYP51 active site provided a 
preliminary explanation of the observed antifungal activity as a lanosterol 14α-
demethylase inhibitor. Testing against a broad panel or resistant fungal clinical isolates, 
cytotoxicity studies, as well as confirmation of the mode of action of compound 13 will be 
needed to ascertain the value of this scaffold as an antifungal agent. 
 
1.3.1.2. Azole derivatives - triazoles 
Fluconazole (FLC) (Fig. 1.15) served as a departure point for numerous studies leading to 
promising, new antifungal agents. In most cases, investigators modified only one of the 
two 1-(1H-1,2,4-triazol-1-yl)methylene subunits in FLC. Two synthetic strategies 
involving replacement of one of the 1-(1H-1,2,4-triazol-1-yl)methylene subunits led to 
racemic mixtures: (1) nucleophilic addition of Grignard reagents to a 2-(1H-1,2,4-triazol-
1-yl)-acetophenone derivative (i.e., “ketone strategy”); and (2) nucleophilic addition of 
primary or secondary amines, azides, or thiols to the unsubstituted terminus of an epoxide 
group in modified 1-((2-(phenyl)oxiran-2-yl)methyl)-1H-1,2,4-triazole (i.e., “epoxide 
strategy”) (Fig. 1.15). Both strategies are, in fact, linked in the sense that the epoxides are 
derived from the acetophenones using a sulfur ylid addition. 
 
39 
 
Fig. 1.15. Representative examples of six new scaffolds derived from FLC and tested as potential antifungals. 
 
In a comprehensive study, one of 1-(1H-1,2,4-triazol-1-yl)methylene subunits in FLC was 
replaced by hydrophobic, alkyl chains to render the molecule more amphiphilic than FLC, 
and in addition, the 2,4-difluorophenyl of FLC was modified as either a monofluoro-, 
monochloro-, difluoro-, or dichlorophenyl group in relatively few synthetic steps to afford 
twenty-seven FLC derivatives 14-22 (Fig. 1.15).183 When tested against seven strains of C. 
albicans, three strains of non-albicans Candida (C. glabrata, C. krusei, and C. 
parapsilosis), and three strains of Aspergillus spp. (A. flavus, A. terreus, and A. nidulans), 
nine of these monotriazoles 14-22, displayed excellent activity against at least eight of the 
thirteen strains tested (MIC values of <0.03-1.95 µg/mL that were comparable to that of 
FLC (MIC = 1.95 µg/mL) and also displayed activity against three ITC- and FLC-resistant 
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C. albicans strains. These FLC derivatives displayed chain-length dependent, hemolysis 
activity (<50% at 10× MIC). In cytotoxicity experiments using the normal human bronchial 
epithelial cell line (BEAS-2B), eight of these FLC derivatives had no toxicity at 
concentrations of >31.3 µg/mL. Monotriazoles 14 and 18 showed fungistatic activity at 1× 
MIC and fungicidal activity at 4× MIC against C. albicans. The mechanism of action of 
these monotriazoles was investigated using a membrane-permeabilization assay and an 
analysis of the sterol composition of the fungal cell lysates with and without monotriazole 
treatment. Consistent with FLC, the monotriazole 18 inhibited the lanosterol 14α-
demethylase enzyme of the ergosterol biosynthetic pathway. These FLC derivatives 
showed great promise as antifungal agents because of their low MIC values, minimal 
toxicity, and no adverse hemolysis outcomes. 
 
In another thorough study, the 1-(1H-1,2,4-triazol-1-yl)methylene subunit of FLC was 
similarly replaced by a series of N-(alkylamino)-, N-(arylamino)-, and N-
(cycloalkylamino)methylene substituents or by a series of N,N-(dialkylamino)methylene 
substituents using the epoxide strategy described earlier to afford twelve FLC derivatives 
23-26 (Fig. 1.15).184 When tested against the same thirteen strains as those in the study 
focused on the FLC derivatives 14-22,183 eight of the twelve compounds displayed 
excellent activity against at least one of the thirteen strains. Compounds 23-26 displayed 
excellent activity against anywhere from three to six of the thirteen strains tested, including 
three ITC- and FLC-resistant C. albicans strains with MIC values of 0.03-1.95 µg/mL 
comparable to that of FLC (MIC = 1.95 µg/mL). The compounds 23-26 also exhibited 
excellent activity against clinical isolates of C. glabrata, C. parapsilosis, and C. 
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neoformans with MIC values of 0.03-1.95 µg/mL comparable to that of FLC (MIC = 0.975-
1.95 µg/mL). In cytotoxicity experiments using the human embryonic kidney (HEK-293), 
BEAS-2B, and human adenocarcinoma (A549) mammalian cell lines, compounds 23 and 
24 were less toxic than 25 and 26 at concentrations up to 31 µg/mL. Compounds 23 and 
24 displayed fungistatic activity at 4× MIC against C. albicans and C. parapsilosis. In a 
mechanism of action study using a membrane-permeabilization assay, compound 25 with 
a C12 alkyl chain caused membrane disruption in C. albicans, while compound 26 with a 
C14 alkyl chain did not. Determination of sterol composition showed that 25 and 26 inhibit 
ergosterol biosynthesis, once again a finding that was consistent with the known 
mechanism of action of the parent compound FLC. With low MIC values, minimal toxicity, 
and no adverse hemolysis outcomes, these FLC derivatives warranted further investigation. 
 
The epoxide strategy was also utilized in a third study that was limited in scope to the 
determination of MIC80 values for seventeen FLC derivatives in which the 1-(1H-1,2,4-
triazol-1-yl)methylene subunit in FLC was replaced by a tertiary amine bearing a second, 
more distant 1-(1H-1,2,4-triazol-1-yl)methylene subunit than the one in FLC.185 
Unfortunately, none of the seventeen, tertiary amines synthesized in the course of this study 
affected any of the eight fungal strains (two C. albicans, C. glabrata, C. parapsilosis, C. 
neoformans, A. fumigatus, T. rubrum, M. gypseum). Only two compounds, 27-28 (Fig. 
1.15), had similar MIC80 values to FLC against two C. albicans and one C. neoformans, 
and displayed better activity than FLC against one M. gypseum found in skin and nail 
infections. These data clearly underscored the notion that the structure and the relative 
proximity of the two 1-(1H-1,2,4-triazol-1-yl)methylene subunits in FLC was crucial for 
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antifungal activity and analogs along the lines of those in tertiary amines 27-28 did not 
warrant further investigation. 
 
The epoxide strategy again appeared in a fourth study involving the addition of N-
alkylpiperazines that led to nine new FLC analogs 29-37, two of which contained a 2,4-
dichlorophenyl in place of the 2,4-difluorophenyl of FLC (Fig. 1.15).184 Two of these nine 
compounds (i.e., those with N-methyl and N-n-pentyl chains on the N-alkylpiperazines) 
did not display strong activity against the thirteen fungal strains (seven C. albicans, three 
non-albicans Candida, and three Aspergillus). The remaining nine derivatives 29-37 (Fig. 
1.15) displayed excellent activity against the three Aspergillus spp. tested (A. flavus, A. 
nidulans, and A. terreus) with MIC values of 0.975-1.95 µg/mL. These values were much 
better than that that of FLC (MIC = 62.5 µg/mL). Eight of these nine compounds had 
excellent activity against C. parapsilosis (excluding 35) as well as C. krusei and one C. 
albicans (excluding 29) with MIC values of 0.015-1.95 µg/mL that were comparable or 
better than that of FLC (MIC = 1.95 µg/mL against C. parapsilosis, ≥31.3 µg/mL against 
C. krusei, and 62.5 µg/mL against C. albicans). In general, most compounds had good 
activity (3.9-7.8 µg/mL) against C. glabrata and six other C. albicans strains for which the 
parent FLC was inactive (≥15.6 µg/mL). Compounds 31, 33, 36, and 37 were also able to 
eliminate pre-formed C. albicans biofilms. Two of these compounds, 31 and 33, 
demonstrated fungicidal activity at 4× MIC against C. albicans and C. glabrata. 
Compounds with alkyl chains greater than C10 exhibited higher hemolytic activity 
compared to compounds with alkyl chains with eight or fewer carbons. Compound 31 
displayed the lowest hemolytic effect, similar to that of the standard VRC (Fig. 1.4). Chain 
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length dependence appeared in cytotoxicity studies using HEK-293, A549, and BEAS-2B 
mammalian cell lines, and compounds 31 and 36 with a C10 alkyl chain were generally safe 
up to 7.8 µg/mL whereas compounds 33 and 37 with a C12 alkyl chain were toxic at the 
same concentrations. Membrane-permeabilization assays of 31 and 37 in C. albicans 
showed that the mechanism of action was not membrane disruption but once again, 
inhibition of ergosterol biosynthesis. Molecular docking into the CYP51 active site of C. 
albicans with compound 31 was consistent with this proposed mechanism of action. On 
balance, the development of these FLC derivatives as antifungal agents warranted 
additional investigation. 
 
In a fifth study along similar lines, the epoxide strategy furnished new FLC analogs 38-39 
(Fig. 1.15) in which 4-arylpiperidines replaced one of the 1-(1H-1,2,4-triazol-1-
yl)methylene subunits in FLC.186 The aryl substituents (i.e., R1 in Fig. 1.15) on the 
piperidine ring included 1,2,4- and 1,3,4-oxadiazoles substituted with various aromatic 
groups. Among the twenty-five FLC derivatives, several of these compounds were safe at 
concentrations of 160 µg/mL in the nematode, Caenorhabditis elegans, but none of these 
analogs completely killed (only MIC80 values provided) any of the seven fungal strains 
tested, including C. albicans, C. parapsilosis, C. neoformans, C. glabrata, A. fumigatus, T. 
rubrum, and M. gypseum. Overall the compounds showed MIC80 values similar to or 
slightly better than that of the standard FLC. When tested against three strains of FLC-
resistant C. albicans, analogs 38 and 39 were not particularly active (mean MIC80 8-16 
µg/mL). Mechanism of action studies involved molecular docking studies consistent with 
38 and 39 binding to the CYP51 active site, but they also showed mild activity against 
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hyphal formation in C. albicans. In the absence of complete fungal growth inhibition, 
additional studies in this series would not appear to be promising. 
 
In a sixth study, the nucleophilic ring-opening of an epoxide by thiols served to generate 
eighteen new FLC analogs in which one of the 1-(1H-1,2,4-triazol-1-yl)methylene subunits 
in FLC was replaced by 5-aryl 4H-1,2,4-triazole-3-thiomethylene subunit and in some 
instances the 2,4-difluorophenyl group was also replaced by a 2,4-dichlorophenyl group 
(40-41; Fig. 1.15).187 Among these new analogs, six displayed excellent activity with MIC 
values in the 0.03-1 µg/mL range against two C. albicans strains. These outcomes 
represented a 2- to 16-fold improvement over the values for the control FLC. Two of these, 
40 and 41, were also found to be active (MIC values of 0.25 µg/mL) against an FLC-
resistant (MIC of FLC = 64 µg/mL) C. glabrata strain. None of the eighteen compounds 
synthesize were active against A. fumigatus and C. neoformans. The preliminary nature 
and limited scope of biological testing in this work precluded a complete understanding of 
the potential value of these compounds. 
 
In a final study, albaconazole (ALB) instead of FLC was used as the departure point for 
the development of still other, antifungal agents.188 Replacing the quinazolinone ring in 
ALB, which is currently in clinical development, with a 5,6-dihydro-4H-thieno[2,3-
c]pyrrol-4-one ring or a 4,5-dihydro-6H-thieno[2,3-c]pyrrol-6-one ring led to the analogs 
42-62 (Fig. 1.16). Two different synthetic strategies involving eight or nine steps and 
relying heavily on Suzuki couplings, were used to produce thirty ALB analogs 42-62 with 
varied orientation of the substituted thiophene indicated by a or b in Fig. 1.16. These 
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derivatives were potent against all Candida strains, including C. albicans, C. parapsilosis, 
and C. glabrata with MIC values of 0.0078-1 µg/mL comparable to that of ALB (MIC = 
0.0078-0.0625 µg/mL). They also displayed excellent activity against C. neoformans (MIC 
values of 0.0078-0.25 µg/mL). Only derivatives with the thiophene in series a displayed 
good activity against A. fumigatus (MIC values mostly of 4-8 µg/mL compared to that of 
0.25 µg/mL for ALB). These compounds warrant additional study focused on the level of 
cytotoxicity, the potential development of resistance, and the mechanism of action. 
 
 
Fig. 1.16. Representative examples of compounds possessing a new scaffold derived from ALB and tested 
as potential antifungals. 
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In summary, the success of FLC in clinical practice naturally attracted interest in 
identifying new analogs that shared its broad spectrum of activities and possessed activity 
against FLC-resistant strains. Investigators sought to retain the facile, synthetic 
accessibility of this pharmacophore with the goal of increased potency against strains not 
affected by FLC, reduced cytotoxicity against normal mammalian cells, and reduced 
tendency to develop resistance. Reports for a number of these new analogs including 14-
22, 22-26, 29-37, and possibly 40-41 are sufficiently interesting to warrant additional effort 
to define the parameters that would comprise an improvement over FLC. Many of the new 
analogs shared a common feature in their mechanism of action that disrupted ergosterol 
biosynthesis. All of the new analogs shared an additional common feature in the possession 
of one (Fig. 1.15) or two stereogenic centers (Fig. 1.16). No reports, however, of 
stereoselective syntheses or resolution of enantiomers appeared in the literature 
surrounding these compounds. It would be interesting to determine, particularly since many 
of these analogs bind a specific enzyme in the ergosterol biosynthetic pathway, if one 
enantiomer in the FLC series (Fig. 1.15) or one diastereomer in the ALB series (Fig. 1.16) 
possessed differential antifungal activities. 
 
1.3.1.3. Polyene derivatives 
Polyenes such as amphotericin (AmB) and nystatin (NYT) are currently used as the second-
line of defense against intractable fungal infections, and structural modifications invariably 
focus on the goal of decreasing their inherent toxicity and increasing both their therapeutic 
efficiency and water solubility. Structural modifications of AmB and NYT were non-trivial 
adventures given the complexity of these natural products. Several interesting reports 
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described three general types of modifications to AmB: (i) hydration of the ∆30- and ∆32-
double bonds to furnish the C-31 and C-33 hydroxylated products, (ii) acylation of the 
primary amine on mycosamine, and/or (iii) coupling of the C-16 carboxylic acid to 
specialized, primary amines to afford carboxamides (Fig. 1.17A). Modifications of NYT 
followed a similar, specialized pathway involving (i) oxidation of NYT to introduce the 
∆28-double bond and/or (ii) acetal formation between the C-4 hydroxyl of mycosamine and 
the anomeric center of N-acetylglucosamine (Fig. 1.17B). 
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Fig. 1.17. Representative examples of compounds from five new scaffolds tested as potential antifungals, 
which are derivatives of A. AmB or B. NYT. 
 
In a study designed to establish the importance of the unsaturated heptaene substructure in 
AmB, the FeIII-catalyzed hydration of AmB led to the C-31,33 diol 63 (Fig. 1.17A).189 
Although AmB analog 63 displayed lower cytotoxicity than that of AmB in green monkey 
kidney cells, it unfortunately showed reduced antifungal activity when tested against C. 
albicans and C. parapsilosis (MIC values of 4-8 µg/mL compared to 0.25-0.5 µg/mL for 
the parent AmB). In addition, AmB analog 63 showed a decreased therapeutic index, 
defined as the ratio between half-maximal cytotoxic concentration and MIC value. This 
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outcome suggested that in vivo hydration of AmB leading to 63 would be harmful to 
patients. 
 
In another study, acylation of the primary amine on the mycosamine moiety with various 
carboxylic acids led to nine, new AmB derivatives, including the carboxamide in analog 
64 (Fig. 1.17A).190 Five of these compounds displayed MIC values of 2-4 µg/mL, similar 
to that of the parent AmB (MIC = 1 µg/mL). One of these derivatives, namely the 
carboxamide 64, showed increased water solubility and reduced toxicity in HEK-293 
mammalian cells and mice compared to AmB. Preliminary safety studies were performed 
but an in-depth study will be necessary to assess the safety of AmB analogs of this type. 
 
Eight additional AmB analogs were generated coupling the C-16 carboxylic acid to various 
amines to generate carboxamides including L-histidine methyl ester moiety to provide, for 
example, the analog 65 (Fig. 1.17A).191 When tested against two strains of C. albicans and 
one C. krusei, analog 65 displayed excellent antifungal activity with MIC values of 0.28-
7.5 µM comparable to that of AmB (MIC = 0.20 to >10 µM). This compound was neither 
hemolytic nor cytotoxic. Analog 65 showed an increase in safety when tested in adult male 
BALB/c mice compared to AmB. This compound warrants further investigation as a 
potential antifungal agent due to its excellent antifungal activity, selectivity, and safety 
profiles. 
 
Finally, dual modifications of the C-16 carboxylic acid and the primary amino group in 
mycosamine led to eleven AmB derivatives including the carboxamide 66 and the 
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carboxamide 67 bearing an unusual β-hydroxy benzoxaborole moiety (Fig. 1.17A).192 The 
latter analog 67 displayed the best antifungal activity, and four of these analogs displayed 
excellent antifungal activity against at least one of the following strains, C. albicans, 
Cryptococcus humicolus, A. niger, and F. oxysporum with MIC values of 0.5-2 µg/mL 
comparable to that of AmB (MIC = 0.25-2 µg/mL). Although compound 66 displayed 
excellent antifungal activity, it had high hemolytic toxicity. Compound 67, however, 
showed the best antifungal activity and low cytotoxicity in human colon carcinoma 
HCT116 cells and showed sufficient promise as an antifungal agent to warrant further 
testing. 
 
In lead optimization studies, wild-type Pseudonocardia autotrophica provided the NYT 
derivative 68a with a unique disaccharide and a mutant of P. autotrophica lacking an enoyl 
reductase (ER) led to analog 68b possessing the ∆28-double bond (Fig. 1.17B).27, 193 The 
analog 68a with a tetraene core resembled NYT, and the analog 68b with an heptaene core 
resembled AmB. In comparison to NYT, analog 68a showed increased water solubility and 
lower hemolytic toxicity; however, its antifungal activity was slightly poorer than that of 
NYT when tested against C. albicans (MIC values of 16 µg/mL compared to that of NYT 
(MIC = 4 µg/mL) and AmB (MIC = 0.5-1 µg/mL)). Compound 68b displayed comparable 
antifungal activity to AmB when tested against four C. albicans strains, one C. humicolus, 
and one S. cerevisiae (MIC = 1-4 µg/mL). In general, these biochemically driven NYT 
derivatives show promise as antifungal agents with low toxicity in rats and mice along with 
improved efficacy and pharmacological profile and herald future developments in which 
selective chemical and, in particular, biochemical modifications of these polyenes will 
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afford still other analogs useful in the second-line of defense against the continued 
appearance of resistant strains. 
 
1.3.1.4. Echinocandin derivatives 
In contrast to the azoles and polyenes, the echinocandins were the subject of relatively few 
modifications in the last decade, but the unique target of these echinocandins made them 
interesting scaffolds for continued exploration. Anidulafungin (AFG) inhibited a glucan 
synthase that played a crucial role in the formation of (1→3)-β-D-glucans in the fungal cell 
wall. Because this enzyme was not found in humans, synthesizing new, semisynthetic 
analogs of AFG represented an attractive target for antifungal drug development. A recent 
study reported the evaluation of six AFG analogs, in which the reactive, hemiaminal moiety 
within the hydroxylated ornithine subunit of AFG, underwent acetalization reactions with 
alcohols or amines (Fig. 1.18).194 Among these, CD101, in which choline replaced the 
hydroxyl group in the hemiaminal moiety, showed excellent antifungal activity against 
seven Candida strains (C. albicans, C. glabrata, C. guilliermondii, C. krusei, C. lusitaniae, 
C. parapsilosis, and C. tropicalis) with MIC values of  ≤0.015-2 µg/mL comparable to that 
of AFG (MIC ≤0.015-2 µg/mL). CD101 also displayed excellent minimum effective 
concentration (MEC) values of ≤0.015-0.03 µg/mL against seven Aspergillus strains (A. 
candidus, A. clavatus, A. flavus, two A. fumigatus, A. niger, and A. ochraceus) similar to 
that of AFG (MIC ≤0.015-0.03 µg/mL). In pharmacokinetic studies in dogs and mice, 
CD101 had an improved safety profile compared to AFG and showed promise for 
development as an antifungal agent. 
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Fig. 1.18. A representative example of a potential semisynthetic antifungal, CD101, derived from AFG. 
 
1.3.1.5. Allylamine derivatives 
Just as in the case of the echinocandins, relatively few studies focused on the development 
of new allylamine analogs in the last decade. A recent study employed a five-step synthesis 
to incorporate phloroglucinol into seventeen allylamine analogs of naftifine (NAF) (Fig. 
1.19).195 Only analog 69 displayed good activity against Trichophyton rubrum and 
Trichophyton mentagrophytes (MIC values of 3.05-5.13 µg/mL), but this activity was not 
as good as that of the parent NAF (MIC = 1.036-1.072 µg/mL). Molecular docking studies 
indicated that 69 could potentially bind to squalene epoxidase, a target of NAF. The limited 
antifungal activity of most of these phloroglucinol-containing NAF derivatives suggested 
that additional effort on this series of analogs was unwarranted. 
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Fig. 1.19. A representative phloroglucinol-containing NAF analog as a potential antifungal agent. 
 
1.3.1.6. Antimetabolite derivatives 
Antimetabolites play a prominent role in recent efforts to develop new antifungal agents 
(Fig. 1.20). Modifications of 5-flucytosine (5FC), 5-fluorouracil (5FU), and pyrimidine 
scaffolds focused principally on structural changes that would reduce their cytotoxicity and 
the propensity of antimetabolites to develop fungal resistance. In general, investigators 
explored two types of modifications of 5FC: (i) incorporation of two 5FC subunits linked 
through a benzene moiety, and (ii) incorporation of 5FC and other antifungal agents, such 
as FLC, into a composite structure (Fig. 1.20A). Other modifications to antimetabolites 
included the linkage of 5FU to substituted benzimidazoles (Fig. 1.20B) and substitutions 
of pyrimidines and purines with various amino, cyano, aryl, and heterocyclic groups (Fig. 
1.20C). 
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Fig. 1.20. Representative examples of potential antifungals derived from A. 5FC, B. 5FU, and C. 
pyrimidines. 
 
Synthesis of analogs that incorporated two 5FC subunits with a phenyl group “spacer” 
made use of the Biginelli reaction, an acid-catalyzed, three-component reaction among an 
aldehyde, a β-ketoester and an urea/thiourea leading to dihydropyrimidones (Fig. 1.20A). 
Although limited in scope, this study led to a bis(thiopyrimidinone) 70 (Fig. 1.20A)196 with 
antifungal activity (MIC values of 1-2 µg/mL against four out of eight C. albicans strains 
that were tested) that was comparable to that of AmB (MIC = 1-2 µg/mL). It was interesting 
that the corresponding bis(pyrimidinone) that lacked the thiocarbonyl groups displayed no 
antifungal activity. In combination studies with FLC or AmB against the same eight C. 
albicans strains, analog 70 displayed synergistic activity in twelve instances and additive 
in four instances. Although these 5FC-like derivatives showed some promise as antifungal 
agents in combination with AmB or FLC, the lack of comparison of MIC data with 5FC 
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from which these compounds were derived, the absence of cytotoxicity experiments, and 
experiments designed to evaluate fungal resistance limit our assessment of the potential 
benefits of these analogs. 
 
Additional analogs derived from the incorporation of 5FC into FLC in which the 4-
aminopyrimidinone replaced one of the 1-(1H-1,2,4-triazol-1-yl)methylene subunits in 
FLC and in which the C-4 amino group in the 4-aminopyrimidinone underwent alkylation 
with alkyl, benzyl, and halogenated benzyl substituents.197 These synthetic efforts led to 
nineteen FLC-5FC hybrids in a straightforward five-step synthesis leading to analogs such 
as 71 (Fig. 1.20A). Unfortunately, these compounds displayed little activity with the 
exception of compound 71, that showed good antifungal activity against A. fumigatus, C. 
albicans, C. tropicalis, and C. parapsilosis with MIC values of 0.008-0.03 mM (4.2-15.7 
µg/mL) comparable to that of the parent FLC (MIC = 0.003-1.65 mM (1.83-50.3 µg/mL)) 
and 5FC (MIC = 0.03-1.98 mM (3.87-25.6 µg/mL)). Preliminary investigations into the 
mechanism of action utilized membrane-permeabilization experiments and molecular 
docking of compound 71 in the C. albicans CYP51 active site. Overall, the limited 
antifungal activity of this series suggested that FLC-5FC hybrids offer little promise as 
potential antifungal agents. 
 
The incorporation of 5FU into substituted benzimidazoles appeared in a preliminary study 
that involved the N-alkylation of 5FU by alkyl groups and/or benzimidazoles decorated 
with substituted aryl moieties to furnish hybrids such as 72 (Fig. 1.20B).198 Twenty-two 
5FU hybrids emerged in one to three synthetic steps, but unfortunately, these compounds 
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were inactive with the exception of 72 that showed excellent antifungal activity when tested 
against S. cerevisiae (MIC value of 1 µg/mL). This activity of 72 was better than that of 
the standard FLC (MIC = 16 µg/mL); however, compound 72 displayed poor antifungal 
activity when tested against C. albicans, C. mycoderma, and A. flavus. Molecular docking 
studies against DNA topoisomerase IA suggested some basis for the antifungal activity 
observed with analog 72. Based on their limited antifungal activity, the development of 
5FU hybrids as antifungal agents appeared to have limited prospects for success. 
 
Modification of pyrimidinone scaffolds appeared in a modest study using only zones-of-
inhibition to establish preliminary readouts of antifungal activity.199 In one such study, the 
synthesis of ten pyrimidines substituted with various groups (e.g., amino, cyano, 
thiophenyl, furanyl, pyridinyl, and arylsulfonamidoyl) using one to two simple synthetic 
steps furnished analogs such as 73-74 (Fig. 1.20C). None of the compounds displayed 
activity against A. flavus. Only two compounds, 73 and 74, were active against C. albicans 
(zone of inhibition 9-15 mm, comparable to that of the AmB standard (19 mm)). More 
detailed investigation of these compounds will be necessary to determine their potential 
value as antifungal agents. 
 
In summary, with only a few exceptions, the development of new antimetabolite 
derivatives as antifungal agents was unsuccessful. Only the synthesis and evaluation of 
dimeric analogs of 5FC led to promising antifungal activity. Other modifications, such as 
the hybridization of 5FC to FLC, the binding of 5FU to benzimidazoles, and modifications 
57 
of pyrimidines with various groups, led to analogs with little promise as potential 
antifungal agents. 
 
1.3.2. Design and preparation of novel synthetic scaffolds as antifungal agents 
1.3.2.1. Imidazole, aminothiazole, and their benzimidazole/benzothiazole derivatives 
In addition to making derivatives of FDA-approved imidazole-containing antifungal 
agents, investigators explored new compounds containing an imidazole group as a common 
pharmacophore. In one such study, a series of twenty-eight compounds were synthesized 
in two to four synthetic steps in which D-histidine provided the key imidazole ring. 
Acylation of the α-amino group of the histidine with biphenyl groups and esterification of 
the α-carboxylate group furnished the analogs 75-77 (Fig. 1.21A).200 Among these 
compounds, eighteen displayed excellent antifungal activity against two strains of C. 
albicans and one strain of C. tropicalis (MIC values of 0.03125-2 µg/mL comparable to 
that of ITC (MIC = 0.0625-0.5 µg/mL)). Additionally, seven compounds showed excellent 
activity against C. neoformans (MIC = 0.5-2 µg/mL), an outcome that was in line with the 
MIC of ITC (1 µg/mL). Analogs 75-77 were the most active, but unfortunately, all 
compounds, including 75-77, were inactive when tested against A. fumigatus. A detailed 
study of structure-activity relationships (SARs) revealed that compounds with (S) or L-
stereochemistry at the quaternary center were less active than their (R) or D-counterparts. 
Compounds 75a and 75b displayed the best antifungal activity and showed limited 
inhibition of five major human cytochrome P450 isoforms (CYP1A2, CYP2C9, CYP2C19, 
CYP2D6, and CYP3A4-M). Molecular docking of 75a in the active site of lanosterol 14α-
demethylase (CYP51A1) along with investigation of sterol composition of the fungal cell 
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suggested that 75a inhibited this specific enzyme. Further testing against a broad panel of 
fungi, testing against drug-resistant fungal clinical isolates, and cytotoxicity studies will 
ultimately determine the potential value of these imidazole analogs as antifungal agents. 
 
 
Fig. 1.21. Representative examples of compounds from seven new scaffolds tested as potential antifungals 
that contain A. imidazole, B. thiazole, C. benzimidazole, or D. benzothiazole in their structures. 
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Another study employed various four- to six-step syntheses to generate twenty-seven 
imidazole derivatives, represented by imidazoles 78-79 (Fig. 1.21A).200 In this series, 
investigators again used D-histidine as the framework on which to make modifications. 
Coupling of the α-amino group in the unnatural histidine to carboxylate groups in various 
heterocycles (e.g., thiophene, thiazole, isoxazole, pyrimidine, pyridine, furan, and oxazole) 
led to carboxamides such as the isoxazole-containing compounds 78-79 that displayed the 
best overall antifungal activity. These analogs displayed antifungal activity better than or 
equal to that of FLC and comparable to that of ITC when tested against two C. albicans 
(MIC values of 0.03125-2 µg/mL), C. tropicalis (MIC values of 0.03125-0.25 µg/mL), and 
C. neoformans (0.25-2 µg/mL). In general, analogs 78-79 showed good to poor activity 
against A. fumigatus, and analogs 78e and 79e showed excellent antifungal activity when 
tested against two strains of FLC-resistant C. albicans while exhibiting low inhibition of 
human cytochrome P450 isoforms, good metabolic profiles in human plasma stability 
experiments, and inhibition of CYP51 in sterol composition experiments. With low MIC 
values, a defined mechanism of action, and a good stability in human blood plasma, these 
compounds show good potential as antifungals and warrant additional exploration. 
 
Yet another study led to ten compounds that contained an internal imidazole ring modified 
at the 2-position with 4-ethyl pyridine and at the 1-position with an oxadiazole decorated 
with aromatic substituents. The synthesis of these compounds in three simple steps led to 
representative imidazoles 80-82 (Fig. 1.21A).201 When tested against four strains of C. 
albicans and three strains of C. tropicalis, imidazoles 80-82 in general exhibited poor 
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antifungal activity (MIC values of >1000 µg/mL) with the exception of three compounds 
that displayed MIC values of 2-125 µg/mL. These imidazoles inhibited ergosterol 
biosynthesis based on molecular docking in the active site of the cytochrome P450 
lanosterol 14α-demethylase of C. albicans. Because of their poor activity, these 
compounds are unlikely to undergo further development. 
 
Heterocycles other than imidazole served as attractive platforms for the development of 
new antifungal agents. SAR studies utilizing the 2-aminothiazole scaffold led to analogs 
modified at C-5 with benzyl, naphthyl, and cycloalkyl groups and acylated at the C-2 amino 
group with an array of carboxylic acids to acquire nineteen different carboxamides 
including 83-85 (Fig. 1.21B).202 Introduction of methyl groups at C-3 and C-4 led to other 
analogs with decreased activity. Compound 83, which was active against Histoplasma 
yeast, served as the leading scaffold from previous work203 and was used to generate sixty-
eight additional aminothiazole derivatives. When tested against Histoplasma capsulatum, 
twenty-nine of the compounds showed activity, and three 83-85, displayed MIC values of 
0.6-1.3 µM. The compounds were not active against C. neoformans. In cytotoxicity 
experiments using human hepatocyte (HepG2) cells compounds 83-85 were found to have 
low toxicity. A comparison with standard antifungal agents was not provided, and the 
absence of this information makes it difficult to evaluate the potential value of these 
compounds as antifungal agents. 
 
A separate publication also reported the two-step synthesis and evaluation of ten, related 
hydrazine-substituted thiazole derivatives.204 In this study, the 2-hydrazinothiazole core 
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contained an N-cyclopropylmethylene group and a variety of substituted phenyl groups at 
C-4 as in the representative examples 86-94 (Fig. 1.21B). When tested against three strains 
of C. albicans and fifteen strains of non-albicans Candida, hydrazinothiazoles 86-94, with 
a few exceptions, displayed excellent antifungal activity against fourteen of the strains 
(three C. albicans, two C. parapsilosis, two C. krusei, C. tropicalis, C. inconspicua, C. 
famata, C. guilliermondii, C. lusitaniae, C. sake, and C. dubliniensis) with MIC values of 
0.015-1.95 µg/mL that were comparable to that of NYT (MIC = 0.015-0.48 µg/mL). The 
compounds were inactive against C. kefyr, C. pulcherrima, C. glabrata, and C. lambica. 
Hydrazinothiazoles 88, 90, and 93 displayed good safety profiles in cytotoxicity 
experiments with mouse L929 fibroblast and African green monkey kidney VERO cells. 
Molecular docking studies suggested aspartic proteinase as a possible target. It is 
interesting that modifying the C-4 position in the presence of a C-2 hydrazino moiety 
provided potent antifungals in contrast to what was observed in the study discussed in the 
paragraph above. With their excellent antifungal activity and safety profile, these 
compounds warrant additional investigation. 
 
Because of the somewhat promising results seen with imidazoles and thiazoles, the bicyclic 
benzimidazoles and benzothiazoles also attracted attention as scaffolds on which to 
develop antifungal agents. A series of eighteen, substituted benzimidazoles were 
synthesized in nine synthetic steps in which the C-2 position contained aryl substituents 
and the C-6 position contained N-alkylpiperazines, as in the representative benzimidazoles 
95-97 (Fig. 1.21C).205 Benzimidazoles 95-97 displayed excellent to good activity against 
at least one of eleven fungal strains that included six strains of C. albicans, three non-
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albicans Candida (C. glabrata, C. krusei, and C. parapsilosis), and two Aspergillus spp. 
(A. nidulans and A. terreus) with MIC values of 0.975-7.8 µg/mL that were better than 
MIC values for FLC (MIC = 1.95-15.6 µg/mL). Fungistatic activity at 1× MIC and 
fungicidal activity at 2× MIC against C. albicans were observed with benzimidazoles 95 
and 96. Benzimidazole 95 was found to be safe at concentrations of ≥31.2 µg/mL in 
cytotoxicity experiments using A549 and BEAS-2B mammalian cell lines. Experimental 
results suggested a possible mechanism of action for these derivatives involving the 
induction of reactive oxygen species as the trigger for fungal inhibition in C. albicans. 
These benzimidazole derivatives show promise as antifungal agents and warrant further 
development. 
 
Another study reported a series of twenty-five benzothiazole derivatives containing D-
histidine in which the α-amino group underwent acylation by 1H-benzo[d]imidazole-2-
carboxylic acid and the α-carboxylate underwent esterification in three or four steps to give 
representative carboxylic esters (e.g., methyl, ethyl, propyl, isopropyl, and isobutyl), such 
as benzothiazoles 98-104 (Fig. 1.21D).206 Ten benzothiazoles displayed excellent 
antifungal activity when tested against two strains of C. albicans, one strain of C. 
neoformans, and one strain of C. tropicalis (MIC values of 0.125-2 µg/mL comparable to 
that of ITC (MIC = 0.125-1 µg/mL)). All compounds were inactive against A. fumigatus 
and compounds 101a-103a displayed little activity against two FLC-resistant strains of C. 
albicans (MIC = 8-32 µg/mL). Increased antifungal activity was observed with the addition 
of an electron-withdrawing group at C-6 and with the addition of bulky alkyl esters. Sterol 
composition studies and molecular docking into the CYP51 active site revealed that 101a 
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inhibits lanosterol 14α-demethylase in C. albicans. More studies including, in-depth 
mechanism of action, cytotoxicity, resistance, and testing against a broader panel of fungal 
species will be necessary to evaluate the potential of these compounds. In summary, the 
preparations of imidazole, thiazole, benzimidazole, and benzothiazole derivatives was 
successful in providing leading antifungal agents that warrant further investigation. 
 
1.3.2.2. Triazole derivatives 
As discussed in the preceding “azole derivatives - triazoles” section leading to FDA-
approved 1,2,4-triazole antifungal agents, the generation of amphiphilic molecules 
constitutes a strategy used to create effective antifungal agents. Amphiphiles will also be 
further discussed in the context of aminoglycosides and quinones in later sections of this 
review. In this section, we will take up a third category of amphiphiles based on the 1,2,3-
triazole pharmacophore. 
 
A recent study described modification of the C-1 position in a 1,2,3-triazole with either a 
hydrophobic, linear alkyl chain or with an ω-hydroxyalkyl chain as in triazole 105 (Fig. 
1.22).197 Four such 1,2,3-triazole derivatives were prepared in two-steps that involved the 
synthesis of appropriate alkyl azides and 1,3-cycloaddition reactions with cis-2-alkenoic 
acids. The addition of a terminal hydroxyl moiety abolished antifungal activity, and only 
the 1,2,3-triazoles with linear C8 and C10 alkyl chains displayed inhibition of C. albicans 
cell growth. Out of the four compounds synthesized, 1,2,3-triazole 105 with a C10 alkyl 
chain showed the best activity with 90% inhibition of C. albicans growth as well as 
inhibition of hyphal growth and germ tube germination in C. albicans. Even though the 
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compound was somewhat active, the concentration needed to inhibit 90% growth was very 
high (i.e., 60 µΜ (14.4 µg/mL)), a concentration that was comparable to the activity shown 
by the cis-2-dodecenoic acid from which 105 was derived. The high concentration needed 
to inhibit fungal growth dampen any enthusiasm for continued work in this series. 
 
 
Fig. 1.22. Representative examples of compounds from two new scaffolds tested as potential antifungals, 
which contain 1,2,3-triazole in their structure. 
 
Another series of eleven 1,2,3-triazole derivatives were synthesized in five steps using a 
similar 1,3-cycloaddition to the one described in the preceding paragraph.207 All 
compounds contained a 4,5-diphenyloxazol-2-one at C-1 of the triazole and various 
moieties (e.g., alkyl, aryl, acetyl, cyano, and heterocyclic groups) at C-4 and C-5 as 
illustrated by 1,2,3-triazoles 106-108 (Fig. 1.22). Three 1,2,3-triazoles 106-108 showed 
excellent activity against at least one of the following strains: C. glabrata, M. hiemalis, and 
T. cutaneum (MIC values of 0.125-2 µg/mL, that was better than that of ITC (MIC = 1-8 
µg/mL)). In general, little to no activity was observed against C. albicans, C. tropicalis, C. 
utilis, C. krusei, C. parapsilosis, A. fumigatus, and R. oryzae. Other studies revealed that 
most of the Candida strains were resistant to almost all of the compounds tested; therefore, 
these compounds possessed very limited promise as potential antifungal agents. 
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1.3.2.3. Tetrazole derivatives 
A number of tetrazoles are now in preclinical and clinical development as antifungal 
agents. Although promising, the synthesis of tetrazoles typically involves the reaction of 
an aryl nitrile with hydrazoic acid. The toxicity of hydrazoic acid and the risk of tetrazole 
explosions deterred interest in these pharmacophores until a recent protocol was developed 
for the preparation of 5-aryltetrazoles using a reaction of aryl nitriles with an arylamine, 
amine hydrochlorides, and sodium azide.208 However, prior to development of this 
methodology, twelve 5-aryltetrazole derivatives were synthesized via N-alkylation or 
Michael-type additions using nitriles, sodium azide and ammonium chloride in N,N-
dimethylformamide to generate the starting 5-aryltetrazoles. Position 2 of the 5-
aryltetrazoles was modified to contain benzoxazole, benzothiazole, or phenylsulfonyl 
moieties (109-112; Fig. 1.23).209 Excellent antifungal activity was observed with seven of 
the derivatives, 109-112, when tested against one strain of C. albicans (>98% growth 
inhibition at 0.0313 µg/mL, that was better than that of AmB (MIC = 0.5 µg/mL)). All 
compounds were inactive against Colletotrichum coccodes, F. sambucinum, F. oxysporum, 
and A. niger strains. In combination experiments using FLC, 110b and 111b showed 
antagonism in C. albicans. These two compounds were also found to be safe at 
concentrations of 16 µg/mL in cytotoxicity studies using the moth, Galleria mellonella. 
Preliminary mechanism of action studies tested compound 110b against C. albicans in the 
presence of sorbitol and indicated that compound 110b modified the cell wall architecture 
of C. albicans. Testing against a broader panel or resistant fungal clinical isolates in 
addition to resistance studies of compound 110b would be beneficial to establish the value 
of this scaffold as an antifungal. 
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Fig. 1.23. Representative examples of compounds from a new scaffold tested as potential antifungals, which 
contain tetrazole in their structure. 
 
1.3.2.4. Hydrazone derivatives 
Acylhydrazones derived from the addition of acyl hydrazides to aryl aldehydes provided 
scaffolds that were explored in an attempt to combat azole-resistant Candida spp. A series 
of fifty-one acylhydrazone derivatives were synthesized in two to three convergent steps, 
but unfortunately, only MIC80 values instead of MIC values for complete C. albicans 
growth inhibition were determined.210 Only four of the fifty-one compounds, all belonging 
to the N'-(2-hydroxybenzylidene)picolinohydrazide family, displayed some antifungal 
activity (MIC80 values of 1-8 µg/mL) when tested against azole-susceptible and azole-
resistant C. albicans and C. glabrata (Fig. 1.24; 113-116). Unfortunately, no standard 
antifungal agents were used as comparison points. In cytotoxicity studies using VERO and 
HepG2 cell lines, compounds 113 and 116 were non-toxic at up to levels that were 100× 
MIC. Acylhydrazone 115 was fungicidal against C. albicans, and 113 and 116 were 
fungistatic. Checkerboard assays (i.e., simultaneous testing of two different agents at 
variable concentrations) revealed that none of the compounds exhibited synergy in 
combination with FLC. As some compounds exhibited reasonable MIC80 values and 
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toxicity to mammalian cells, it is unclear why MIC values for complete growth inhibition 
were not determined. Expanded studies of the N-(2-hydroxybenzylidene)picolinohydrazide 
family will establish their potential as new antifungal agents. 
 
 
Fig. 1.24. Representative examples of compounds from four new scaffolds tested as potential antifungals, 
which contain hydrazone in their structure. 
 
The positive results seen with monohydrazones prompted studies of bishydrazones in 
which the hydrazone moieties were attached through an hydrophobic linker (117-121; Fig. 
1.24).211 In an initial study, the synthesis of seventeen bishydrazones required one or two 
synthetic steps and incorporated either N-arylhydrazines or N-aminoguanidine into various 
linkers containing two aldehyde groups or two acetyl groups to obtain eight unsymmetrical 
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N-(amidino)-N'-aryl bishydrazones 117-121 (Fig. 1.24) and nine symmetrical bis(N,N'-
amidinohydrazones). When tested against three azole-susceptible and four FLC-, ITC-, and 
VRC-resistant C. albicans strains, six compounds, namely the bishydrazones 117-121, 
displayed excellent activity against at least one of the strains tested with MIC values of 1-
2 µg/mL that was better than the MIC values for AmB (MIC = 2-3.9 µg/mL). Resistance 
studies revealed that, after thirteen passages, C. albicans did not develop resistance to 117b 
or 118b. Investigation into the mechanism of action of these two compounds showed an 
increase in intracellular reactive oxygen species (ROS) production in C. albicans at their 
1× and 2× MIC values. In cytotoxicity experiments, compounds 120b and 121b showed 
low toxicity when tested against A549 and BEAS-2B mammalian cell lines along with only 
moderate interaction with the human ether-à-go-go-related gene (hERG) potassium 
channel. Additional testing against a broad panel of fungal species should precede their 
further development as antifungal agents. 
 
Additionally, the synthesis of symmetrical bis(N,N'-arylhydrazones) linked by diaryl 
moieties used substituted arylhydrazines (e.g., methoxy, nitro, halogen, cyano, and 
multiples of the aforementioned groups) and either [1,1'-biphenyl]-3,4'-dicarbaldehyde, 
[1,1'-biphenyl]-4,4'-dicarbaldehyde, or 4,4'-diacetyl-1,1-biphenyl and led to thirty 
bis(N,N'-arylhydrazones) 122-125 (Fig. 1.24).212 Eight of the thirty derivatives, namely 
122-125, displayed excellent to good activity against at least one of the thirteen strains 
tested, including seven C. albicans, three non-albicans Candida (C. glabrata, C. krusei, 
and C. parapsilosis), and three Aspergillus spp. (A. flavus, A. nidulans, and A. terreus) with 
MIC values of 0.98-7.8 µg/mL comparable to that of CAS and VRC (MIC = 0.06 to >31.3). 
69 
Compound 123c was able to eliminate pre-formed C. albicans biofilms, but at a 
concentration above the MIC value. In cytotoxicity experiments, compounds 122a,b and 
123a were found to be safe at 31 µg/mL, while compounds 123c and 125a were safe at 
15.5 µg/mL against the A459 mammalian cell line. When tested against the BEAS-2B 
mammalian cell line, 123a was safe at 31 µg/mL, and compounds 122a,b, 123c, and 125a 
were safe at 15.5 µg/mL. Compound 123c also displayed low hemolytic activity, 
fungistatic activity, and no toxicity when tested in hERG binding studies. The positive 
outcomes seen in these bishydrazone derivatives warrant their further development as 
antifungal agents. 
 
A two-step synthesis consisting of Suzuki cross-coupling followed by a condensation with 
N-aminoguanidine was used to generate a series of ten mono- and bishydrazone derivatives 
(126-131; Fig. 1.24).213 These derivatives were linked via a thiophene or a furan group 
substituted at C-2 and 5 with iminoguanidines and various para-substituted phenyl groups 
(e.g., methyl, methoxy, fluoro, bromo, cyano, and iminoguanidine). Among these 
compounds, nine displayed excellent activity (MIC values of 0.25-1.56 µg/mL) against at 
least one of the following strains C. albicans, C. krusei, C. parapsilosis, A. fumigatus, F. 
oxysporum, M. canis, and T. mentagrophytes, and these MIC values were only slightly 
poorer than the corresponding activity of the parent VRC (MIC = 0.06-0.5 µg/mL). Six of 
these displayed excellent to good activity (MIC = 0.25-7.8 µg/mL) against at least one of 
the VRC-resistant C. albicans, C. parapsilosis, or F. oxysporum strains. Compounds 127a, 
129a, and 130a were shown to be fungistatic. Compounds 127a and 130a were also able 
to disperse pre-formed biofilm of C. albicans. Mechanism of action studies through 
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molecular docking showed that these compounds bind the CYP51 active site. With low 
toxicity and minimal hemolysis, these hydrazone and bishydrazone derivatives show great 
promise as antifungal agents, but additional mechanistic studies remain to be done to fully 
understand the scope of these molecules as antifungal agents. 
 
In general, hydrazone derivatives show great promise as antifungal agents. However, more 
mechanistic studies remain to be done to fully understand the scope of these molecules. 
 
1.3.2.5. Aromatic and heterocyclic derivatives 
Apart from the aforementioned studies, several reports described idiosyncratic aromatic 
and heterocyclic scaffolds as potential novel antifungal agents (132-158; Fig. 1.25). A two-
step synthesis led to thirty-six compounds with an imidazolin-2-one core, including twenty 
substituted benzimidazolones and sixteen substituted imidazopyridines with an array of 
substituents (e.g., acetyl, aryl, bromo, and nitro groups). These imidazolin-2-ones 132-135 
(Fig. 1.25) displayed relatively poor outcomes using percent inhibition of spore 
germination and mycelial growth of Botrytis cinerea, which is primarily a plant 
pathogen.214 Unfortunately, it took 50 µg/mL and 25 µg/mL for four of these imidazolin-
2-ones to display >90% inhibition of spore germination and mycelial growth, respectively. 
All other compounds were inactive, and additional efforts to imidazolin-2-ones as 
antifungal agents does not appear to hold much promise. 
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Fig. 1.25. Representative examples of compounds from six new scaffolds tested as potential antifungals, 
which contain an aromatic or heterocyclic group in their structure. 
 
Because imidazoles and pyrimidines were structural components of several antifungal 
agents, efforts to employ 4,5-dihydro-1H-imidazoles and the 1,4,5,6-
tetrahydropyrimidines, respectively, in a new generation of antifungal agents was a logical 
extension of these other studies. A report described an array of amidine derivatives, 
including symmetrical 4,5-dihydro-1H-imidazoles, such as 136 (Fig. 1.25), and 
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unsymmetrical 1,4,5,6-tetrahydropyrimidines, such as 137 (Fig. 1.25).215 Among these 
compounds, eighteen showed excellent antifungal activity with MIC values of ≤0.03-2 
µg/mL that were better than that of AmB (MIC = 0.13-32 µg/mL) against five fungal strains 
(i.e., C. albicans, C. krusei, C. glabrata, C. parapsilosis, and C. neoformans). However, 
when tested against HeLa cells, only two compounds, 136-137, displayed sufficiently low 
toxicity as well as excellent antifungal activity. Fungicidal activity at 4× MIC against C. 
albicans was observed for three other compounds in this series that were unfortunately 
toxic. Preliminary mechanism of action revealed that the compounds interacted with DNA 
and RNA and concomitantly inhibited cell wall biosynthesis in C. albicans, outcomes that 
possibly explain the observed toxicity toward mammalian cells. Further investigations will 
presumably focus on developing these compounds for cutaneous applications. 
 
Another study that focused principally on antibacterial activity tested twenty 
bispyrimidines against two fungal strains (C. albicans and A. niger).216 Five of these 
compounds 138-142 (Fig. 1.25) displayed better antifungal activity than FLC; however, 
because of inconsistencies between units used in the experimental procedures (reported to 
range between 1.562-50 µg/mL) and units in the MIC data presented in a table (reported in 
µmol/mL that would correspond to values >300 µg/mL), it is difficult to assess the potential 
value of these compounds as antifungal agents. 
 
The synthesis of fifty-one acetamides bearing an α-(2-oxo-morpholin-3-yl) group required 
two to five steps and constituted a new scaffold for evaluation for antifungal activity, 
exemplified by acetamides 143-144 (Fig. 1.25).217 This study focused on modifications of 
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the α-(2-oxo-morpholin-3-yl)acetamide at the nitrogen of the acetamide (e.g., N-aryl, 
alkyl, heteroaryl, or mono- or bicyclic groups), at the C-4 nitrogen of the 2-oxo-morpholin-
3-yl group (e.g., N-alkyl, cycloalkyl, phenyl, acyl, and sulfonyl moieties), and at the C-6 
position of the 2-oxo-morpholin-3-yl group (e.g., alkyl and phenyl groups). Of the fifty-
one compounds that were synthesized, twelve displayed minimum fungicidal activity 
(MFC) values of 6.25-12.5 µg/mL against one MCZ-tolerant C. albicans strain (MFC value 
for MCZ >100 µg/mL). Four of the twelve derivatives were selected for additional testing 
against C. glabrata, A. fumigatus, and A. flavus, and three displayed excellent antifungal 
activity against A. fumigatus (MIC values of ≤3.1-1.6 µg/mL). Compounds 143-144 were 
selected for further evaluation for their ADMET properties and in vivo efficacy in a C. 
albicans infection mouse model along with MOA investigation through a phenotype 
microarray assay. Because these compounds displayed only low antifungal activity, 
additional lead optimization studies will be required to improve the activity of analogs 
bearing this scaffold. 
 
Coumarin-based phosphoramidate derivatives, such as 145-147, were also investigated as 
potential antifungal agents (Fig. 1.25).218 A six-step synthesis provided twenty analogs, but 
unfortunately, most compounds were inactive against C. albicans, A. flavus, A. fumigatus, 
and C. neoformans with the exception of three compounds 145-147 that displayed excellent 
activity against A. flavus (MIC values of 1-2 µg/mL, that was superior to that of FLC (MIC 
= 32 µg/mL). The general lack of antifungal activity in these coumarin-based 
phosphoramidates suggest that additional SAR effort should focus on compounds for the 
potential treatment of aspergillosis. 
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Several reports described the synthesis and evaluation of thirty-four trans-stilbenes bearing 
a substituted phenyl or pyridyl ring at one terminus and bearing a phenyl ring with the 
unusual isonitrile moiety at the other terminus (148-158; Fig. 1.25).219-220 When tested 
against one strain of C. albicans, twenty-four compounds displayed excellent activity with 
MIC values of 0.5-8 µM (0.1-2 µg/mL) that were comparable of that to FLC (MIC = 0.5 
µM). These stilbene-like compounds 148-158 displayed excellent activity with MIC values 
in the 0.5-2 µM range. An evaluation of six of the fifteen most active compounds against 
twenty-one clinical fungal isolates, including six C. albicans, two C. krusei, one C. 
parapsilosis, two C. glabrata, two C. tropicalis, two C. gattii, one C. neoformans, one A. 
brasiliensis, two A. niger, and two A. fumigatus strains, revealed that most of the 
compounds showed excellent antifungal activity against the Candida and Cryptococcus 
spp., but displayed little to no activity against Aspergillus spp. Additional testing of the 
cytotoxicity of thirteen of the most active compounds using human epithelial colorectal 
(HRT-18) cells concluded that these compounds were non-toxic at concentrations up to 
256 µM. With their potent antifungal activity and excellent safety profiles, these stilbene-
like isonitrile derivatives should be examined for their mechanism of action and evaluated 
in resistance, anti-biofilm, and animal studies. 
 
1.3.2.6. Additional unrelated scaffolds 
Fortuitous testing of scaffolds, often developed for other purposes other than antifungal 
drug development, provides potentially valuable information that may guide new 
antifungal drug development. In a study focused on identifying anticancer activity, the 
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four-step synthesis and evaluation of twenty quinolines bearing a C-3 (2H-tetrazol-2-
yl)methyl) or a C-3 (1H-tetrazol-1-yl)methyl) group221 for antifungal activity against C. 
albicans and A. fumigatus led to several compounds 159-162 (Fig. 1.26) that displayed 
excellent to good activity against A. fumigatus with MIC values of 2.5-5 µg/mL that were 
better than that of FLC (MIC = 30 µg/mL). All other compounds exhibited poor antifungal 
activity against both strains tested. The quinoline core also appeared in another study in 
which thirty-one compounds were made in three to four synthetic steps to generate 
compounds with either pyrrolidinyl or ω-hydroxyalkylamino groups attached to the C-3, 
5, 6, or 8 positions of the quinoline ring (163-166; Fig. 1.26).222 Once again, these 
compounds also displayed low antifungal activity against C. albicans. Compound 163, 
however, displayed excellent activity against A. flavus with an MIC value of 2 µg/mL, that 
was better than that of AmB (MIC = 3.1 µg/mL). Compounds 164-166 also displayed good 
activity against the yeast, Rhodotorula bogoriensis with MIC values of 3.9-7.8 µg/mL, but 
these values are poorer than that of AmB (MIC = <0.2 µg/mL). In both of the preceding 
cases, a more detailed SAR study and evaluation of these quinolines would be required to 
determine if these compounds warrant progression as potential antifungal agents. 
 
76 
 
Fig. 1.26. Representative examples of compounds from four new scaffolds tested as potential antifungals, 
which contain different groups in their structure. 
 
A two-step synthesis and evaluation of five tricyclic compounds containing one 
heterocyclic moiety and five pentacyclic compounds containing two heterocyclic moieties 
(e.g., pyrazole, pyrazolecarbothioamide, dihydroisoxazole, dihydropyrimidinone, and 
dihydropyrimidinethione) interspersed with phenyl groups led to compounds 167-168 (Fig. 
1.26).223 Four out of the ten compounds displayed excellent activity against one azole-
susceptible C. albicans strain with MIC values of 0.5-2 µg/mL that were better than that of 
FLC (MIC = 4 µg/mL). Two compounds, 167-168, also displayed excellent to good activity 
against one azole-resistant C. albicans strain (MIC = 2-4 µg/mL) as well as synergy in both 
strains of C. albicans when tested in combination with FLC. Mechanism of action studies 
revealed that the compounds depressed ergosterol levels but did not overcome efflux pump 
resistance in C. albicans. At a minimum, additional SAR work on the leading compounds 
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167-168 and testing against a broad panel of fungal clinical isolates will determine if this 
pharmacophore warrants additional study. 
 
An investigation of a CYP51 inhibitor, called (R)-N-(1-(2,4-dichlorophenyl)-2-(1H-
imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide (VNI), led to fifteen, 
pentacyclic compounds, including 169-172, in a ten-step synthesis (Fig. 1.26).224 This 
study examined the influence of substituents (e.g., fluoro, chloro, trifluoromethyl, 
trifluoroethoxy, pyridinyl, fluoropyrimidinyl, and morpholino groups) in the terminal 
phenyl ring that had no substituents in the parent VNI on the activity of these compounds. 
When tested at 0.75 µM with 0.5 µM of CYP51 from a C. albicans strain, eight of the 
fifteen compounds, including 169-172, displayed 83-94% inhibition of the enzyme. When 
tested against three strains of A. fumigatus, compounds 169-172 displayed excellent 
antifungal activity with MIC values of 0.06-0.78 µg/mL that was comparable to that of 
VNI (MIC = 0.08-0.48 µg/mL). Additional, interesting data in support of compounds 169-
172 as potential antifungal agents included promising, half-life stability experiments in 
human, rat, and mouse microsomes and the co-crystallization of compound 171 with in the 
active site of CYP51B from A. fumigatus that confirmed the mechanism of action. These 
compounds warrant additional in-depth investigation. 
 
1.3.2.7. Additional scaffolds developed as inactive antifungals 
Reports describing work on unusual scaffolds that fail to produce significant differences in 
antifungal activity rarely reach the medicinal chemistry literature. These failures, 
nevertheless, provide important lessons that may point other investigators away from 
78 
unproductive, research avenues. Herein, we provide a brief review of eleven 
pharmacophores in which the synthesis and evaluation of a leading compound failed to 
generate useful antifungal agents (Fig. 1.27).225-235 We will arbitrarily organize this 
discussion by grouping these compounds into two categories: (1) those that show highly 
limited improvement in activity (Fig. 1.27A); and (2) those that show no improvement in 
activity (Fig. 1.27B). 
 
Twenty 3-amino-4-hydroxycoumarin derivatives were tested against C. albicans, A. flavus, 
A. fumigatus, and C. neoformans with both FLC and polyoxin B as standards. These 
analogs were inactive although in some instances they displayed a two- to four-fold 
improvement over the standards (173-174; Fig. 1.27A).225 A series of twenty-five 
imidazole[2,1-b]-1,3,4-thiadiazole derivatives were tested against two C. albicans, two C. 
neoformans, and one A. niger, as well as some bacterial strains.226 Three analogs (175-177; 
Fig. 1.27A) had excellent activity against the two C. neoformans strains with similar 
activity to AmB. Other analogs in the series, however, showed only good to poor activity 
against these same strains. All analogs were inactive against all other fungal and bacterial 
strains. In yet another study, the synthesis and evaluation of more than 100 1,3-thiazolidin-
4-one against twenty-two FLC-sensitive Candida spp. strains identified only nine 
compounds, 178-186 (Fig. 1.27), that displayed activity that was on a par with the controls 
(i.e., FLC, KTC, CLT, MCZ, TIO, and AmB).227 
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Fig. 1.27. Representative examples of compounds from eleven new scaffolds tested as potential antifungals 
against the fungal strains listed, which were found to A. show limited improvement or no activity when 
compared to standard antifungal agents, or B. to not be active at all. 
 
The synthesis and evaluation of four indole-triazole-amino acid conjugates against only 
one C. albicans strain (Fig. 1.27B) using a disk-diffusion assay identified an analog 187 
that achieved 84% inhibition at a very high concentration (i.e., 600 µg/mL).229 The 
evaluation of twenty-three spirooxindole analogs against not only human fungal pathogens 
but also phytopathogens (Fig. 1.27B) led to analogs, such as 188 that failed to show 
complete inhibition of fungal growth at 50 µg/mL against five dimorphic fungi, including 
two Fusarium spp.230 Another report described the synthesis and evaluation of twenty-eight 
quinoline analogs, such as 189-190 (Fig. 1.27B) using only their MIC50 and MIC80 values 
against one strain of C. albicans and one strain of C. neoformans.235 These analogs were 
inactive with the exception of two of them, 189-190, that showed 50% inhibition of fungal 
growth against C. neoformans at high concentrations of 15.6 µg/mL. The synthesis and 
evaluation of twenty-two thiazolyl-pyrazoline scaffold, including the representative 
example 191 (Fig. 1.27B), against ten fungal strains (six Candida spp., three Aspergillus 
spp., and one Fusarium spp.) produced inactive analogs with MIC values in the range of 
125-1000 µg/mL.231 The synthesis and evaluation of fourteen 8,9-dihydro-7H-
pyrimido[4,5-b] [1,4]diazepine analogs against one strain of C. albicans and one strain of 
C. neoformans (192-193; Fig. 1.27B) failed to produce a compound with antifungal 
activity.232 Two analogs, 192-193, showed 100% inhibition of C. albicans growth but only 
at the high concentrations of 15.6-31.3 µg/mL. The synthesis and evaluation of ten 
naphthalene-substituted thiosemicarbazone analogs (194-195; Fig. 1.27B) against ten 
fungal strains (i.e., six Candida spp., three Aspergillus spp., and one Fusarium spp.) failed 
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to produce an analog with significant antifungal activity.233 The synthesis and evaluation 
of thirty-seven chalcones (196-197; Fig. 1.27B) against C. albicans and C. neoformans 
identified two compounds that showed 80% inhibition at high concentrations (i.e., 7.8-15.6 
µg/mL).234 Finally, the synthesis and evaluation of twenty-one benzimidazole analogs 
(198; Fig. 1.27B) against four fungal strains (i.e., A. niger, C. albicans, F. oxysporum, and 
Fusarium solani) led only to completely inactive compounds.228 Conclusions must be 
tempered by the limited number of compounds, the equally limited number of strains, and 
the limited information about important pharmaceutical properties (e.g., cytotoxicity) for 
the compounds discussed in this section. 
 
1.3.3. Repositioning of FDA-approved drugs or their derivatives used for other 
medicinal purposes as antifungal agents 
The repurposing of existing drugs developed for non-fungal-related diseases as new 
antifungal agents is an attractive pursuit given the extraordinary costs associated with new 
drug development. In recent studies, investigators identified antibacterial agents, such as 
aminoglycoside-based amphiphiles as potential antifungal agents. In addition, other 
investigators found that the organoselenium drug, ebselen, used in clinical trials for 
chemotherapy-induced hearing loss (NCT01451853),236 Ménière’s disease 
(NCT02603081), and cerebral ischemia,237 possessed potential antifungal activity. This 
section of the review endeavors to provide a summary of our current understanding of 
efforts along these lines. 
 
1.3.3.1. Aminoglycoside amphiphiles 
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Recent years saw the expansion of amphiphilic aminoglycosides from their traditional role 
as antibacterial agents to a potentially new, important role as antifungal agents. Apart from 
efforts involving the testing of natural products in the aminoglycoside family, efforts are 
underway to develop semisynthetic analogs designed to improve activity, identify 
selectivity, and decrease cytotoxicity. Seven general approaches focus on developing 
aminoglycoside amphiphiles as antifungal agents: (i) modification of the C-1, 3, 2', and 6' 
amino groups in nebramine (NEB) with linear alkyl chains, imidazoles, or triazoles (Fig. 
1.28); (ii) alkylation of the C-2, 3, 2', and 3' hydroxyl groups of trehalose with linear alkyl 
chains (Fig. 1.28); (iii) alkylation of the C-6" and 4" hydroxyl groups of kanamycin A 
(KANA) (Fig. 1.29); (iv) alkylation of the C-6" hydroxyl group of tobramycin (TOB) (Fig. 
1.29); (v) modification of the C-6" hydroxyl group of kanamycin B (KANB) with a 
thioalkoxide group (Fig. 1.29); (vi) modification of the C-6" hydroxyl group of tobramycin 
(TOB) with C18 lipid chains with varied levels of unsaturation and configuration of the 
double bonds (Fig. 1.30); and (vii) linking of neomycin B (NEO) to mono- or 
bisbenzimidazoles (Fig. 1.31). 
 
Alkylation of the hydroxyl groups in NEB-derived cationic amphiphiles led to alkoxy 
analogs with chains that varied in length from C5-C7. Modifications at the C-1, 3, 2', and 6' 
amino groups furnished either the corresponding imidazoles or 1,2,3-triazoles in three or 
four steps as in the imidazole 199 (Fig. 1.28).238 Testing of eight NEB-based analogs 
against nine fungal strains (i.e., three C. albicans, one C. parapsilosis, four C. glabrata, 
and one S. cerevisiae) indicated that three analogs with alkoxy groups and primary amines 
displayed better antifungal activity than analogs with alkoxy groups and imidazoles; 
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however, these alkoxy- and amine-substituted analogs also displayed high hemolytic 
activity. Two of the eight compounds displayed no antifungal activity, including one that 
contained alkoxy and 1,2,3-triazole groups and the other that contained imidazoles but no 
alkoxy groups. Alkoxy and imidazole-based analogs such as 199 showed chain-length 
dependence with respect to antifungal activity in which analogs with C7 and C6 alkoxy 
groups and imidazoles displayed selective and excellent antifungal activity against the four 
C. glabrata strains tested with MIC values of 0.5-1 µg/mL that were better than that of 
FLC (MIC = 8 to >64 µg/mL). The analogs with C5 alkoxy groups and imidazoles only 
displayed good to poor activity (MIC values of 4-16 µg/mL). Compound 199 displayed 
good activity against S. cerevisiae, but was inactive against C. albicans and C. parapsilosis 
and displayed improved hemolytic activity up to 128 µg/mL relative to the standard AmB 
where ca. 80% hemolysis was seen at 4 µg/mL. Combination studies displayed synergistic 
activity between compound 199 and FLC in C. albicans and C. glabrata. Although these 
compounds do not display broad spectrum antifungal activity, their selectivity, low 
hemolytic activity, and synergy with FLC warranted continued investigation. 
 
 
Fig. 1.28. Representative examples of compounds from two new scaffolds tested as potential antifungals, 
which are derivatives of nebramine (NEB) (199) or trehalose (200-201). 
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Alkylation of the C-2, 3, 2', and 3' hydroxyl groups in trehalose furnished six alkoxy 
analogs (e.g., C4-C10) in eight synthetic steps including the analogs 200-201 (Fig. 1.28).239 
When tested against two FLC-susceptible C. albicans, one FLC-resistant C. albicans, and 
one C. glabrata strains, analogs 200-201 with C5 and C6 alkyl chains displayed excellent 
to good antifungal activity with MIC values of 1-4 µg/mL that were better than that of FLC 
(MIC = 0.25-64 µg/mL). As observed with NEB analog 199, the antifungal activity of these 
derivatives depended on the length of the alkyl chains, and analogs with C5 and C6 alkyl 
chains exhibited better antifungal activity than those with either shorter or longer chains 
than five or six carbons (i.e., C4, C8, and C10 analogs were completely inactive).  The analog 
with a C7 chain displayed good activity only against the FLC-resistant C. albicans and the 
C. glabrata strains. Unlike the NEB analog 199, the trehalose analogs 200-201 were broad-
spectrum antimicrobial agents that displayed activity against Gram-positive and Gram-
negative bacterial species, but unfortunately, the trehalose 200-201 also displayed high 
hemolytic activity at 4 µg/mL in rat red blood cells. Membrane-permeabilization assays 
with the trehalose derivative 200 using fluorescent microscopy in C. albicans showed that 
the mechanism of action was, as expected, membrane disruption, an outcome consistent 
with their lack of selectivity and high hemolytic activity. Although the most active 
compounds displayed unacceptably high hemolytic activity, their broad-spectrum activity 
made these analogs attractive for potential development as topical antibacterial or 
antifungal agents. 
 
Alkylation of KANA at its C-4" and 6" hydroxyl groups produced twenty-two analogs in 
a three-step sequence including the trisaccharide analogs 202-204 (Fig. 1.29).240 Just as in 
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the cases discussed previously, these analogs displayed chain-length dependent antifungal 
activity, but in this particular case, the optimal chain length for these KANA analogs was 
eight carbons. These analogs 202-204 showed poor to no antifungal activity against A. 
flavus and F. graminearum with MIC values of 31.3 to >500 µg/mL that was less than that 
of VRC (MIC = 1-32 µg/mL), but combination studies against one strain of azole-resistant 
C. albican, using either 202 or 204 displayed synergy in combination with CLT, FLC, ITC, 
POS, or VRC. In cytotoxicity experiments, compounds 202-204 displayed little to no 
cytotoxicity using a human cervical cancer cell line (HeLa) at concentrations ranging from 
1-1000 µg/mL. Because of these synergistic effects in combination with other azoles and 
their good safety profile, these compounds may find application in therapies to combat 
azole resistance. 
 
 
Fig. 1.29. Representative examples of compounds from five new scaffolds tested as potential antifungals, 
which are derivatives of KANA, KANB, or TOB. 
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A continued search for new, broad spectrum and potent amphiphilic Aminoglycosides led 
to the substitution of the C-6" hydroxyl group in KANB by thioalkoxy groups to give the 
analogs 205-207 (Fig. 1.29).241 A three-step synthesis furnished seven KANB derivatives 
along these lines, and once again, activity proved to be chain-length dependent. Analogs 
205-207 with C12 and C14 possessed the optimal alkyl chain lengths. Six derivatives 
displayed excellent to good activity when tested against one strain of A. nidulans with MIC 
values of ≤1.95-3.9 µg/mL that were better than that of FLC (MIC >62.5 µg/mL). When 
tested against two strains of azole-susceptible C. albicans and five strains of azole-resistant 
C. albicans, four out of the seven derivatives displayed good activity against at least one 
or all of the C. albicans strains tested with MIC = 3.9-7.8 µg/mL that was better than that 
of FLC (MIC = 15.6 to >125 µg/mL). Thioalkoxy analogs 205-206 displayed synergy in 
combination with POS against all seven C. albicans strains tested as well as fungicidal 
activity against azole-resistant C. albicans. These KANB derivatives displayed limited 
chain length-dependent hemolysis: 40% at 4× MIC for C12 and 15% at 1× MIC for C14 
chain lengths. In cytotoxicity experiments using the A549 and BEAS-2B mammalian cell 
lines, four of these KANB derivatives were found to be safe at concentrations as high as 
62.5 µg/mL. The mechanism of action was investigated using a membrane-
permeabilization assay, and compounds 205-206 disrupted the fungal membrane of azole-
resistant C. albicans. Consequently, the promising activity and properties seen in these 
KANB derivatives warrants their continued development as antifungal agents. 
 
In another study, the alkylation of the C-6" hydroxyl group of TOB with C18 lipid chains 
varying in degrees of unsaturation and stereochemistry led in three steps to six analogs 
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such as the TOB carboxamide 208 (Fig. 1.29).242 Testing against nineteen fungal strains 
(i.e., three azole-susceptible, four azole-resistant, and two echinocandin-resistant C. 
albicans, one C. parapsilosis, one C. tropicalis, one C. dubliniensis, one C. guilliermondii, 
four C. glabrata, and two C. neoformans) indicated that all six TOB derivatives displayed 
activity (MIC values of 4-8 µg/mL) that was comparable or better than that of the standards, 
FLC (MIC = 0.25 to >64 µg/mL) and CAS (MIC = 0.25-64 µg/mL)). A high degree of cis-
unsaturation, but not trans-unsaturation, in the C18 lipid chains correlated with the desired, 
low hemolytic activity and increased specificity for the fungal cell membrane. In 
cytotoxicity experiments using HEK-293, HepG2, and a mouse embryonic fibroblast 
(3T9MEF) cell line, compound 208 possessed the best safety profile at concentrations up 
to 216 µg/mL for the HepG2 cell line, and >256 µg/mL for the other cell lines. Mechanism 
of action studies revealed that compound 208 disrupted fungal cell membranes without 
disturbing comparable mammalian membranes. The increased antifungal activity, 
selectivity for fungal cells, and increased safety profile of compound 208 warrants its 
further development as an antifungal agent. 
 
The conversion of the C-6" hydroxyl group of TOB to a thioalkoxy group furnished the 
analogs 209-210 (Fig. 1.29) that possessed broad-spectrum antifungal activity.243 The most 
potent compounds, namely 209-210, possessed C12 and C14 chain lengths, respectively, and 
were active against C. neoformans, A. nidulans, and F. graminearum with MIC values of 
1.95-7.8 µg/mL that were comparable or better than that of FLC (MIC <0.195 to >125 
µg/mL). The thioalkoxy TOB analog 210 also displayed good antifungal activity against 
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the four azole-susceptible and three azole-resistant C. albicans strains tested (MIC = 3.9-
7.8 µg/mL). 
 
As expected, mechanism of action studies revealed that 209-210 induced apoptosis through 
a mechanism involving the disruption of fungal cell membranes. Analogs 209-210 were 
fungicidal against azole-resistant C. albicans, displayed 50% hemolytic activity of mouse 
erythrocytes at 4- to 32-fold and 8- to 32-fold higher levels than their MIC values, 
respectively, and showed no toxicity against human lung cancer A549 or bronchial 
epithelial BEAS-2B cell lines. Checkerboard assays revealed that 209-210 exhibited 
synergy in combination with FLC, ITC, POS, and VRC.244 An additional study 
investigating the effect of the linker (e.g. thioether, sulfone, triazole, amide, and ether 
group) at the 6"-OH position of TOB demonstrated that the introduction of a 1,2,3-triazole 
bearing a C12 alkyl chain at C-6" in analog 211 was the most active compound (Fig. 
1.29).245 Overall, the introduction of alkyl chains at the C-6" position of TOB proved a 
successful strategy for developing, new, promising antifungal agents. 
 
Modification at the C-4" and 6" positions of amphiphilic aminoglycosides as well as 
modification of the 6'-position of aminoglycosides provided various KANA and one TOB 
derivatives. Acylation, for example of the C-6' position KANA and TOB furnished 
carboxamides 212-214 with acyl chains that varied in length from C6-C18 (Fig. 1.30).246 
Overall, the KANA and TOB derivatives displayed poor activity when tested against A. 
flavus; however, analogs 212-214 displayed good activity when tested against nine other 
fungal strains comprising three C. albicans, one F. graminearium, one C. neoformans, one 
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Rhodotorula pilimanae, one Candida rugosa, one azole-resistant C. parapsilosis, and one 
C. tropicalis with MIC values of 4-8 µg/mL that were comparable or better than that of 
VRC (MIC = 0.125 to  ≥256 µg/mL). Analogs containing long acyl chains (C16-C18), such 
as 213, caused increased membrane permeabilization relative to analogs with short acyl 
chains; however, because there was an increase in toxicity in HeLa cells as the chain length 
increased, it will be important to balance the increase in membrane permeability against 
hemolysis in assessing these compounds as potential antifungal agents. 
 
 
Fig. 1.30. Representative examples of compounds from a new scaffold tested as potential antifungals, which 
are derivatives of KANA or TOB. 
 
Finally, a study of the conversion of alkylated NEO to mono- or bisbenzimidazole analogs 
led to eleven NEO derivatives, including a representative NEO analog 215 (Fig. 1.31) that 
displayed an interesting pattern of antifungal activity.247-249 Testing against thirteen fungal 
strains (i.e., four azole-susceptible C. albicans, three FLC- and ITC-resistant C. albicans, 
one C. glabrata, one C. krusei, one C. parapsilosis, one A. flavus, one A. nidulans, and one 
A. terreus) showed that four of the eleven compounds displayed excellent activity against 
at least one of the thirteen strains. Three of the analogs displayed excellent activity against 
seven to twelve of the thirteen strains with MIC values of 0.12-1.95 µg/mL that were better 
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than that of FLC (MIC = 1.95 to >125 µg/mL). In an outcome similar to that seen with 
compounds 202-204 that displayed no antifungal activity, these NEO analogs were inactive 
against A. flavus. Analog 215 displayed fungicidal activity at 1× MIC against C. albicans 
and displayed an inhibitory effect against biofilms of two C. albicans strains that was better 
than or comparable to that of VRC. In cytotoxicity experiments using the A549 and BEAS-
2B human cell lines, four out of the eleven NEO derivatives displayed no toxicity at 
concentrations up to 31 µg/mL for A549, and two of the compounds, including compound 
215, were nontoxic at 15.6 µg/mL in BEAS-2B, a value that was about 10× MIC. This 
NEO analog 215 also displayed little to no hemolytic activity in murine red blood cells up 
to 15.6 µg/mL. In a study of sterol composition, compound 215 had no effect on ergosterol 
biosynthesis and instead, the mechanism of action appeared to be the induction of ROS. 
With low MIC values, toxicity, and hemolysis, these NEO derivatives warrant additional 
study. 
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Fig. 1.31. A representative example of compounds from a new scaffold tested as a potential antifungal, which 
is a derivative of NEO. 
 
1.3.3.2. Probes for determination of mechanism of action of amphiphilic 
aminoglycosides and azoles 
Fluorescent probes provide a valuable window for investigating the mechanism of action 
of amphiphilic aminoglycosides and azole derivatives.246, 250-251 To examine visually the 
mechanism of action of amphiphilic AGs, NEA and TOB were alkylated to afford 216 and 
218, respectively, and subsequently modified either with a fluorescent nitrobenzoxidiazole 
to yield 217 or with a 7-diethylaminocoumarin to yield 219 (Fig. 1.32A).250 The availability 
of these fluorescent analogs facilitated mechanism-of-action studies that established the 
importance of fungal, plasma-membrane permeabilization for compounds 217 and 219. 
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Fig. 1.32. Representative examples of compounds from four new scaffolds tested as potential antifungals, 
which are A. amphiphilic aminoglycosides or B. azole derivatives. 
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The inclusion of a 1-pyrenylbutanoyl fluorescent group at the C-6' position of KANA 
yielded compound 220 that displayed antifungal activity and facilitated studies of 
mechanism of action (Fig. 1.32A).246 Not all fluorescent tags were useful, and the 
introduction of either a fluorescein or a 2-phenyl-4-quinolinecarbonyl tag at that same 
position led to inactive compounds that were ineffective probes. Probe 220 indicated that 
the mechanism of action of these analogs in F. graminearum and C. albicans was 
membrane permeabilization. Additional kinetic membrane-permeabilization studies246 
using 220 and propidium iodide showed that the rate of membrane permeabilization for the 
KANA derivatives from fastest to slowest was fungi, bacteria, and then mammalian cells. 
 
In another study, the synthesis of fluorescent FLC analogs yielded five azole derivatives, 
such as 221-223, that were active against Candida spp. (Fig. 1.32B).251 In mechanism of 
action studies, aminocoumarin-based FLC derivative 221 localized to the endoplasmic 
reticulum, and compounds 222 and 223 localized in the mitochondria of the Candida spp. 
Overall, fluorescent probes provided a direct means for investigating the antifungal 
mechanism of action of amphiphilic aminoglycosides and azole derivatives. 
 
1.3.3.3. Additional amphiphilic molecules - Quinone amphiphiles 
In addition to the amphiphilic AGs, a synthesis of six quinone-based amphiphiles in two to 
three steps led to dimeric quinones containing a 1,2,3-triazole. The triazole possessed alkyl 
groups with varying chain lengths (C1-C10) at the N-1 position, as illustrated by the 
representative analogs 224-225 (Fig. 1.33).252 Alkylation at the N-3-position with a C6 alkyl 
chain connected the two quinone-based moieties. When tested against one strain of azole-
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susceptible C. albicans, one strain of azole-resistant C. albicans, one strain of C. 
neoformans, and one strain of R. pilimanae, compounds 224-225 displayed excellent to 
good activity with MIC values of 2.0-3.91 µg/mL that were better than that of FLC (MIC 
= 1.56 to >250 µg/mL). Compounds 224-225 exhibited only slight activity against A. 
flavus, and the other four analogs were inactive. In both C. albicans and F. graminearum, 
the mechanism of action of 225 was cell membrane disruption. In cytotoxicity experiments 
using the human ovarian cancer SKOV3 cell line, five compounds displayed good safety 
profiles. The quinone-based amphiphiles 224-225 warrant further investigation. 
 
 
Fig. 1.33. Representative examples of compounds from a new scaffold tested as potential antifungals, which 
are quinone derivatives. 
 
1.3.3.4. Ebselen derivatives 
Ebselen is an organoselenium compound that has a structurally similar sulfur analog called 
ebsulfur. Because ebselen has several therapeutic applications and a reasonable safety 
profile in clinical trials,236 several studies investigated the antifungal properties of these 
compounds, such as the analogs 226-228 (Fig. 1.34).253 A study of thirty-two ebsulfur 
derivatives made three modifications: (1) substitution of the N-phenyl of ebselen by mono- 
and disubstituted phenyl, naphthyl, and nitrogen-containing aromatic heterocycles that 
slightly increased antifungal activity; (2) substitution of the N-phenyl with linear and 
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branched alkyl chains or with alkyl chains with terminal phenyl or adamantyl groups that 
dramatically increased activity; and (3) oxidized sulfoxide derivatives that led to a 
complete loss of activity. When tested against the same thirteen strains as those described 
above for the NEO derivative 215, ten of the thirty-two compounds displayed excellent 
activity against at least ten of the thirteen strains. Seven of these compounds displayed 
excellent activity against all thirteen strains tested with MIC values of ≤0.02-1.95 µg/mL 
that were better than that of FLC (MIC = 1.95 to >125 µg/mL). Compound 226 displayed 
fungistatic activity at 4× MIC against C. albicans. Two ebsulfur derivatives were tested 
against murine red blood cells, and one was found to be safe at up to 15.6 µg/mL and the 
other at 3.9 µg/mL. In cytotoxicity experiments using HEK-293 and a murine macrophage 
(J774A.1) cell line, compounds 226-228 were comparable to ebselen with IC50 of 10 
µg/mL that represented at least a 10-fold difference between the toxic dose to the 
mammalian cells and the fungal MIC values of the most active compounds. Preliminary 
mechanism of action studies suggested an induction of ROS production in C. albicans. Due 
to their excellent antifungal activity, additional studies of these compounds appear to offer 
promising outcomes. 
 
 
Fig. 1.34. Representative examples of compounds from a new scaffold tested as potential antifungals, which 
are ebselen derivatives. 
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1.3.4. Repositioning antifungals as anticancer agents 
The converse of studying non-antifungal-related drugs as antifungal agents involves 
studies in which antifungal agents are repurposed for other ailments, such as cancer254 or 
bacterial infections.255 For example, a study of ITC as a source of antineoplastic agents led 
to analogs such as 229 (Fig. 1.35).254 Synthesis of a series of twenty-four ITC derivatives 
in a convergent, fourteen-step synthesis led to ITC derivatives with modifications at 
various stereogenic centers and to ITC derivatives in which nitro or amine groups replaced 
the triazolone. The most active compound that showed promise as an antineoplastic agent 
was compound 229 that incidentally displayed no antifungal activity due to the lack of the 
essential, triazole moiety. Although the ultimate outcome of repurposing studies such as 
this one may be unclear, it seems reasonable to conclude that scaffolds that show success 
in providing antifungal drugs may also offer avenues for success in other areas of drug 
discovery. 
 
 
Fig. 1.35. Representative examples of ITC derivatives investigated as potential anticancer agents. 
 
1.3.5. New scaffolds for synergy with azoles 
In addition to the aminoglycoside amphiphiles including NEB (199; Fig. 1.28), KANA 
(202 and 204; Fig. 1.29), KANB (205-206; Fig. 1.29), and TOB (209-210; Fig. 1.29), and 
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in addition to derivatives of 5FC (70; Fig. 1.20A), tetrazole (110b and 111b; Fig. 1.23), 
chalcone (167-168; Fig. 1.26), and hydrazone (113-116; Fig. 1.24), the repurposing of new 
scaffolds and investigations of synergistic effects in combination studies with FDA-
approved azoles may have a promising future. For example, a combination study of the 
antifungal activity of the antipsychotic drug, bromperidol 230 (Fig. 1.36) and its derivatives 
containing C-4 substituted phenyl groups, with a variety of FDA-approved azole antifungal 
agents led to interesting results.256 Testing in combination with FLC, ITC, KTC, POS, and 
VRC against seven strains of C. albicans, one C. glabrata, and one A. terreus indicated 
that one of the bromperidol compounds 230 showed the good synergy with POS with a 16-
fold reduction of MIC values for both compounds. Synergy was also observed with 
compound 230 and POS with a 32-fold reduction in both MIC values. Time-kill assays of 
an azole-resistant C. albicans strain with compound 230 and POS or VRC revealed 
fungistatic activity at 8× MICcombo concentrations. The combination of compound 230 and 
POS or VRC showed an additive effect in fungal biofilms of an azole-resistant C. albicans 
with sessile MIC (SMIC) values of POS or VRC decreased from >32 to 0.5 µg/mL. In 
cytotoxicity experiments using BEAS-2B, HEK-293, and J774A.1 cell lines, compound 
230 was not toxic at up to 8 µg/mL alone, and similar cytotoxicity was observed with POS 
and VRC with 8 µg/mL of compound 230. Bromperidol at 32 µg/mL in combination with 
VRC at any concentration displayed no cytotoxicity and appeared to warrant further study 
as a useful combination therapy. 
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Fig. 1.36. Representative examples of compounds from two new scaffolds tested as potential antifungals, 
which were used in combination with FDA-approved azoles. 
 
In an attempt to find new solutions to the treatment of drug-resistant Candida fungal 
infections, the repositioning of the antihistamines, TERF and EBA, for antifungal 
combination synergy studies involved ninety-one different combinations with seven 
different azoles (TERF and EBA; Fig. 1.36).257 Testing of these combinations of either 
TERF or EBA with either CLT, ITC, KTC, MCZ, POS, or VRC against thirteen strains of 
Candida spp. comprising seven C. albicans (four of which were resistant to most triazoles), 
four C. glabrata, one C. krusei, and one C. parapsilosis led to interesting synergistic 
outcomes. Out of the ninety-one combinations, fifty-one of them were synergistic. The best 
combination was POS and EBA in which time-kill assays were fungistatic at 4× MIC 
against C. albicans and C. glabrata. When tested against fungal biofilms of one strain of 
azole-sensitive C. albicans, one azole-resistant C. albicans, and one azole-resistant C. 
glabrata, the combination of POS and EBA displayed synergy as shown by C. glabrata 
SMIC90 values of >32 µg/mL and ≥25 µg/mL alone to 0.06 µg/mL and 6.3 µg/mL in 
combination for POS and EBA, respectively. In cytotoxicity experiments using A549, 
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BEAS-2B, HEK-293, and human skin keratinocyte (HaCaT) mammalian cell lines, no 
significant difference was observed in the safety profile of POS and EBA when tested alone 
or in combination. EBA was found to be safe at up to 6.3 µg/mL in HaCaT cells and 3.1 
µg/mL in all other cell lines, while POS was found to be safe at 4 µg/mL for both A549 
and HEK-293 and safe to up to 8 µg/mL for the other cell lines. The combination of EBA 
and POS warrants further investigation. 
 
In another combination study, modifications of isoquinolones and phthalazinones based on 
a previously identified leading compound 231a,b (Fig. 1.36)258 led to three types of 
derivatives: (1) modifications of the bicyclic core including replacement of the phenyl 
group with a heterocycle containing various substituents; (2) introduction of a methoxy 
group at the 2-position of the N-phenyl ring that was essential for activity; and (3) 
modification of the C-4-position with a glycine derivative to afford compound 231a. 
Testing against two strains of C. albicans in combination with 0.25 µg/mL of FLC 
produced interesting results in which nine combinations displayed excellent EC50 values 
of 0.001-0.23 µM. Additionally, testing of compounds 231a,b in combination with FLC 
against five strains of FLC-resistant C. albicans (EC50 = 11-170 µM) displayed good to 
poor activity, and testing against C. glabrata or C. neoformans var. grubii showed no 
antifungal activity. Even though the compounds did not kill the FLC-susceptible or FLC-
resistant C. albicans strains, compounds 231a,b displayed fractional inhibitory 
concentration indices (FICI) of 0.12-0.17 in combination with FLC, indicating synergy 
(Note: FICI values are used to determine the interaction between two drugs for the purpose 
of being used in combination. A FICI value <0.5 indicates synergy). These compounds 
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also displayed antifungal activity in combination with ISA. Cytotoxicity experiments with 
all twelve derivatives against 3T3 mammalian fibroblasts revealed that they were safe at 
up to 10 µM. The isoquinolone and phthalazinone derivatives displayed excellent 
antifungal activity in combination with FLC and warrant additional study as potential 
antifungal agents. 
 
1.3.6. Isolation and/or derivatization of novel natural products with antifungal 
activity  
1.3.6.1. Isolated natural products 
Natural products served as starting points for the development of antifungal agents in the 
past and will undoubtedly continue to serve as sources of new scaffolds for future, 
antifungal drug discovery. Unfortunately, in recent years, no new natural products emerged 
with particularly promising, antifungal activities. For example, the testing of twelve natural 
products, such as the terpenoid 232 (Fig. 1.37)259 from the Chinese liverwort, Tritomaria 
quinquedentate, for antifungal activity against five C. albicans strains showed that 
compound 232 possessed a high MIC80 of 16 µg/mL against one drug efflux pump-
deficient strain of C. albicans. However, this natural product also targeted ERG6 and 
ERG11, decreased the amount of ergosterol in C. albicans, and inhibited yeast-to-hyphal 
formation. Although interesting, the high MIC80 value is unlikely to spark much interest in 
these terpenoids as potential antifungal agents. 
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Fig. 1.37. Representative examples of compounds from two new scaffolds tested as potential antifungals, 
which are isolated natural products. 
 
Similarly, a diterpenoid, 233, isolated from the evergreen tree, Polyalthia longifolia var. 
pendula displayed minimal activity (MIC90 value of 50 µM (equivalent to 17.2 µg/mL) to 
805 µM) when tested against two strains of C. albicans, one C. glabrata, one C. 
neoformans, one A. fumigatus, one A. niger, one F. oxysporum, and one Neurospora crassa 
(Fig. 1.37).260 At concentrations of up to 1200 µM, low hemolytic activity was observed 
for compound 233. This compound also inhibited yeast-to-hyphal transition in C. albicans. 
Membrane-permeabilization assays with the isolated compound 233 using fluorescent 
microscopy in C. albicans showed that the mechanism of action was the anticipated, 
membrane disruption. An increase in intracellular ROS generation was also observed with 
this compound. This minimal activity and the lack of information regarding cytotoxicity 
suggests discontinuing additional studies of antifungal activity of these compounds. 
 
1.3.6.2. Natural product derivatives 
Semisynthetic natural products often offer a more promising avenue to new antifungals 
than natural products themselves. For example, two analogs 234-235 of sampangine with 
simplified structures were synthesized in five steps and were more active and more water 
soluble than those of the parent natural product (Fig. 1.38).261 When tested against C. 
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parapsilosis, C. neoformans, A. fumigatus, T. rubrum, and M. gypseum, these compounds 
234-235 displayed antifungal activity (MIC80 values of 0.125-4 µg/mL) that were 4- to 
512-fold better than that of sampangine (MIC80 values of 2 to >64 µg/mL). When tested 
against four FLC-resistant strains of C. albicans, these compounds displayed MIC80 values 
of 0.5-1 µg/mL in contrast with FLC that had an MIC80 value that was >1024 µg/mL. In 
anti-biofilm studies, compounds 234-235 inhibited C. albicans biofilms by 30% at 1 µg/mL 
and inhibited yeast-to-hyphal formation. In cytotoxicity experiments using C. elegans 
worms, these compounds were non-toxic at concentrations of 128 µg/mL. In summary, 
these sampangine derivatives showed promise as antifungal agents and optimization of the 
leading compounds led to a series of 32 sampangine derivatives in five to eight synthetic 
steps, exemplified by 236-237 (Fig. 1.38).262 When tested against the same seven strains 
as those described above for 234-235, six of the 32 compounds displayed MIC80 values of 
0.25-2 µg/mL, similar to or better than that of FLC (MIC80 = 0.25 to >64 µg/mL) against 
at least six of the seven strains tested. Compounds 236 and 237 additionally displayed 
MIC80 values of 0.25-1 µg/mL against five FLC-resistant strains of C. albicans as well as 
anti-biofilm activity in C. albicans biofilms at concentrations of 6.4-12.8 µg/mL. Both 
compounds also inhibited yeast-to-hyphal formation at 0.4 µg/mL. In cytotoxicity 
experiments using C. elegans, no toxicity was observed at concentrations up to 100 µg/mL. 
Additional studies of cytotoxicity experiments using mammalian cells and potential 
development of resistance to these compounds will further define the very promising 
activity of these potential antifungal agents. 
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Fig. 1.38. Representative examples of compounds from four new scaffolds tested as potential antifungals, 
which are derivatives of isolated natural products. 
 
Investigations focused on derivatives of the natural product, α-mangostin, led to thirty-
two, semisynthetic α-mangostin derivatives such as 238 (Fig. 1.38)263. Analog 238, 
displayed excellent to good antifungal activity when tested against one strain of drug-
resistant C. albicans, five drug-susceptible C. albicans, four F. solani, two F. oxysporum, 
one A. brasiliensis, two A. flavus, and two A. fumigatus with MIC values of 0.78-6.25 
µg/mL that were similar to or better than that of CAS (MIC = 0.10 to >50 µg/mL). In 
combination studies with TRB, compound 238 displayed synergy against C. albicans and 
fungicidal activity at 4× MIC against drug-resistant C. albicans. In a drug-resistance 
development study, C. albicans DF2672R failed to develop drug resistance after twenty-
seven passages. In cytotoxicity experiments using human corneal fibroblasts, this 
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compound was non-toxic at concentrations up to IC50 of 64.1 µg/mL. The mechanism of 
action of compound 238 was increased membrane permeabilization and compound 238 
was efficacious in a C. albicans murine model of fungal keratitis. Clearly, this compound 
displayed activities that warrant additional development. 
 
Finally, a three-step synthesis led to twenty-four derivatives of the natural product, 
aureobasidin A such as analog 239 (Fig. 1.38).264 Six analogs displayed excellent 
antifungal activity when tested against C. albicans and A. fumigatus with MIC values of 
<0.025-2.5 µg/mL that were better than that of aureobasidin A (MIC <0.05 to >25 µg/mL). 
Testing of the most active compound 239 against an additional thirty-four fungal strains 
comprising six C. albicans, eight non-albicans Candida, Cryptococcus spp., Issatchenkia 
spp. (often designated as C. krusei), Saccharomyces spp., ten Aspergillus spp., Emericella 
spp. (sexual form of Aspergillus), Fusarium spp., Rhizopus spp., Sporothrix spp., and three 
Trichophyton spp. showed excellent antifungal activity against thirty-one out of the thirty-
four strains with MIC = 0.008-2 µg/mL, that was comparable to that of AmB (MIC = 0.004-
1 µg/mL). Compound 239 clearly warrants additional study as an antifungal agent in order 
to understand its mechanism of action, potential for drug resistance, and cytotoxicity. 
 
Overall, many families of compounds have been investigated as potential antifungal agents. 
Many were found to be promising, while others have informed us of directions that are less 
desirable. Table 1.3 presents a general summary of all data that were discussed throughout 
this review. 
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Table 1.3. Activity of the representative compounds amongst the series prepared. 
Family Cpd # Candida spp. 
Aspergill
us spp. 
Cryptococc
us spp. Other Family Cpd # 
Candid
a spp. 
Aspergil
lus spp. 
Cryptococ
cus spp. Other 
Currently used antifungal Novel Scaffolds 
Imidazoles 1-4 ? ×  × Imidazoles 75-77  ×   
 5-9      78-79  ~ to ×   
 10-12 ?     80-82  to ×    
 13  to ~  to ~   to ~ Thiazoles 83-85   ×  
Triazoles 14-22      86-94  to ×    
 23-26     Benzimidazoles 95-97  to ~  to ~   
 27-28 × × × × Benzothiazoles 98-104  ×   
 29-37  to ~    1,2,3-Triazoles 105 ×    
 38-39 × × × ×  106-108  to × ×   
 40-41  × ×  Tetrazoles 109-112  ×  × 
 42-62  ~   Hydrazones 113-116 ×    
Polyenes 63 ~     117-121     
 64  to ~     122-125  to ~  to ~   
 65      126-131     
 66-67     Aromatic and heterocyclic 132-135    × 
 68  to ×   to ~  to ~  136-137     
Echinocandins CD101      138-142  to ×?  to ×?   
Allylamines 69    ~  143-144     
Antimetabolites 70      145-147 ×  ×  
 71 ~ to × ~ to ×    148-158  ×   
 72 × ×   Additional scaffolds 159-162 ×  to ~   
 73-74 ~ ×    163-166 ×   ~ 
Natural Products  167-168     
Isolated 232 ×     169-172     
 233 × × × × Repositioning 
Derivatives 234-237 ~ ~ ~ ~ AG amphiphiles 199  to ×   ~ 
 238  to ~  to ~   to ~  200-201  to ~    
 239      202-204  ×  × 
       205-207 ~  to ~   
       208 ~  ~  
       209-210 ~  to ~  to ~  to ~ 
       211  to ×  to ×   
       212-214 ~ × ~ ~ 
       215   to ×   
      Quinone amphiphiles 224-225  to ~ ×  to ~  to ~ 
      Ebselen 226-228     
 Indicates MIC values of ≤2 µg/mL for the best representative compounds amongst the series prepared. 
 to ~ Indicates MIC values of ≤2-8 µg/mL for the best representative compounds amongst the series prepared 
 to × Indicates MIC values of ≤2 to ≥15.6 µg/mL for the best representative compounds amongst the series prepared. 
~ Indicates MIC values of 3.9-8 µg/mL for the best representative compounds amongst the series prepared. 
~ to × Indicates MIC values of 3.9 to ≥15.6 µg/mL for the best representative compounds amongst the series prepared. 
× Indicates MIC values of ≥15.6 µg/mL for the best representative compounds amongst the series prepared. 
? Indicates: (i) MIC data were provided without comparable MIC values for the standards from which the compounds were derived or (ii) inconsistencies between units used in the manuscript for the MIC values. 
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1.4. OVERALL CONCLUSION AND PERSPECTIVE 
The first antifungal drug to enter the clinic was AmB in 1959, and the most recent class of 
antifungals to succeed in the clinic were the echinocandins, beginning with CFG in 2001. 
The history of antifungal drugs may be short in comparison with agents for other infectious 
diseases, but antifungal agents currently advancing in preclinical development and in 
clinical trials represent promising antifungal scaffolds. We share not only our enthusiasm 
for the recent progress in this area but also our excitement as we learn of the advances that 
colleagues across the world make in developing new agents as medicines. 
 
For the compounds currently in preclinical studies, the wealth of preliminary studies 
heralds a growing interest in antifungal development. Although only a few compounds 
appear to pass the earliest stages of development that are generally limited to MIC values 
or even just disk diffusion assays, we encourage the use of dilution assays, multiple fungal 
strains, studies of the potential for drug resistance, hemolysis studies and, of course, animal 
studies. Those that venture into the investigation of the mechanism of action often explore 
known mechanisms and we also encourage our colleagues to look for novel mechanisms 
of action for the new scaffolds under development. 
 
There are scaffolds, as indicated in this review, that show considerable promise and warrant 
further investigation, particularly using the few available, animal models that will evaluate 
the true potential of these antifungal agents. There are mouse models for disseminated 
candidiasis and aspergillosis that mimic the natural progression of disease in humans. For 
candidiasis, the mice can be infected through gastrointestinal colonization as well as by 
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intravenous or intraperitoneal injections. To replicate lung disease in aspergillosis, mice 
are infected with spores using an inhalation inoculation. For more specific disease models, 
mouse models of disseminated infections have been modified to replicate mucosal Candida 
infections, neonatal Candida infections, and fungal biofilms. 
 
Fungal resistance is on the rise. We encourage colleagues to pursue in-depth studies leading 
to the development of antifungal agents that address this need. While once a minor problem 
in healthcare, fungal resistance will soon become a major healthcare crisis that will demand 
our full attention. We hope this review provides a thoughtful summary of the most recent 
chemical discoveries in the period covering from 2015-2019 and serves as a call-to-action 
for current and new investigators who desire to help in the fight against fungal diseases. 
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Chapter 2 
 
Synergistic combinations of azoles and antihistamines against Candida species in 
vitro 
 
2.1. ABSTRACT 
Fungal infections are a major cause of skin and mucosal membrane disease. 
Immunocompromised individuals, such as those undergoing chemotherapy, are most 
susceptible to fungal infections. With a growing population of immunocompromised 
patients, there are many reports of increasing numbers of infections and of fungal strains 
resistant to current antifungals. One way to treat drug-resistant infections is to administer 
combinations of drugs to patients. Azoles are the most prescribed antifungals, as they are 
broad-spectrum and orally bioavailable. Terfenadine (TERF) and ebastine (EBA) are 
second-generation antihistamines, with EBA being used in many countries. In this study, 
we explored combinations of seven azole antifungals and two antihistamines (TERF and 
EBA) against a panel of thirteen Candida fungal strains. We found fifty-five out of ninety-
one combinations tested of TERF and EBA against the various fungal strains to be 
synergistic with the azoles. To evaluate the efficiency of these combinations to inhibit 
fungal growth, we performed time-kill assays. We also investigated the ability of these 
combinations to disrupt biofilm formation. Finally, we tested the specificity of the 
combinations towards fungal cells by mammalian cytotoxicity assays. These findings 
suggest a potential new strategy for targeting drug-resistant Candida infections. 
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2.2. INTRODUCTION 
Candida spp. are a normal part of the skin and gastrointestinal microbiome. However, 
patients who are being treated with broad-spectrum antibiotics, corticosteroids, or 
immunosuppressants as well as patients with conditions, such as HIV, that compromise the 
immune system are more susceptible to fungal infections. In addition, patients with 
diabetes and severe burn wounds are at an increased risk for fungal infections.265-268 On the 
skin and mucosal membranes, Candida spp. can cause cutaneous infections, which when 
untreated can lead to invasive infections affecting the eyes, heart, and brain with a high 
mortality rate.269-272 In addition, Candida spp. are the primary cause of oral thrush and 
vulvovaginal infections.273-275 
 
As Candida spp. are eukaryotes, development of antifungal drugs has exploited differences 
in cell membrane structure. There are four classes of drugs used to treat Candida infections. 
These classes include the azoles, the polyenes, the echinocandins, and the allylamines. The 
polyenes are broad-spectrum antifungals and include nystatin (NYT) topical cream and 
amphotericin B (AmB), which is only delivered intravenously. The echinocandins are 
narrow-spectrum antifungals, and the only approved member of this antifungal family for 
topical application is micafungin. Terbinafine is the primary example of an allylamine and 
can be given orally or as a nail lacquer. The azoles are broad-spectrum antifungals that are 
used to treat Candida infections by inhibiting ergosterol biosynthesis. 
 
The azoles are comprised of imidazoles and triazoles. The imidazoles, examples including 
clotrimazole (CLT), miconazole (MCZ), and ketoconazole (KTC), are used to treat skin 
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infections while the triazoles, fluconazole (FLC), itraconazole (ITC), posaconazole (POS), 
and voriconazole (VRC), are used for invasive infections (Fig. 2.1A). For cutaneous 
infections, treatment with azoles can range from a few days to a few months depending on 
the severity of the infection and species causing the infection. Treatment can also be 
extended due to fungal resistance, as there are reports of infections resistant to azoles, 
especially in non-albicans Candida strains.276-278 With topical treatments, skin irritation 
can occur as a result of the azoles.279 
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Fig. 2.1. Structures of: A. azole antifungals clotrimazole (CLT), fluconazole (FLC), ketoconazole (KTC), 
itraconazole (ITC), miconazole (MCZ), posaconazole (POS), and voriconazole (VRC), B. haloperidol, an 
antipsychotic, and C. antihistamine agents ebastine (EBA) and terfenadine (TERF). 
 
Previous studies have shown the antipsychotic haloperidol (Fig. 2.1B) and its derivatives 
to act synergistically with azole antifungals in vitro.256, 280 Some antihistamines such as 
terfenadine (TERF) and ebastine (EBA) have a 4-piperidinol group as well as an 
acetophenone moiety similar to haloperidol (Fig. 2.1C), but are not able to cross the blood-
brain barrier to cause drowsiness, which is an adverse effect of haloperidol.281 Interestingly, 
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studies have explored TERF for additional drug activities, including antibacterial and 
antitumor activity.282-284 
 
Based on similarity in structure between TERF, EBA, and haloperidol, we predicted that 
TERF and EBA would also act synergistically with azole antifungals. The goal of this study 
is to explore novel combinations of antifungals and antihistamine drugs to discover 
synergistic antifungal combinations for potential use as topical antifungal treatments. 
Checkerboard assays were used to calculate the fractional inhibitory concentration indexes 
(FICI) of combinations. In order to be considered synergistic, a minimum of 4-fold 
decrease of both individual MIC values while in combination needs to be achieved. With 
synergistic combinations, the addition of the second drug in this case decreases the MIC of 
the initial drug. In the case of azole-resistant Candida strains, this both improves the 
efficaciousness of the azole antifungal as well as lowers the dose of needed, which 
decreases the potential for side-effects. With additive combinations, both drugs exert their 
effect, however, MIC values remain the same in combination. We investigated two 
antihistamines, TERF and EBA, by checkerboard dilution assays with seven azole 
antifungal drugs, CLT, KTC, MCZ, ITC, POS, FLC, and VRC against a panel of 13 
Candida spp. We then evaluated combinations with successful FICI scores in time-kill 
assays, biofilm disruption assays, and mammalian cytotoxicity assays to assess the 
cytotoxicity of the drug combinations with planktonic fungal cells, sessile fungal cells, and 
mammalian cells, respectively. 
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2.3. RESULTS 
2.3.1. Determination of synergistic azole antifungal and antihistamine combinations 
by checkerboard assays 
In order to establish the concentration ranges to use for combination studies of azoles and 
antihistamines, we first determined the minimal inhibitory concentration (MIC) values of 
seven azole antifungals (three imidazoles: CLT, KTC, and MCZ; as well as four triazoles: 
ITC, POS, FLC, and VRC) and two antihistamine agents (TERF and EBA) individually 
against thirteen yeast strains (strains A-M), of which one strain is annotated as FLC 
sensitive (strain E) and all other are considered FLC resistant (Tables 2.1 and 2.2). Many 
of the strains were susceptible to the imidazole antifungals CLT, KTC, and MCZ (Table 
2.1), but showed reduced susceptibility to the triazole antifungals ITC, POS, FLC, and 
VRC (Table 2.2). The antihistamines did not show any antifungal activity against the 
thirteen strains tested. 
 
We next investigated the potential synergy of azole and antihistamine combinations by 
using checkerboard assays (Tables 2.1 and 2.2). Combinations were considered synergistic 
(SYN) if they displayed FICI ≤ 0.5, additive (ADD) if 0.5 < FICI ≤ 2, and antagonistic 
(ANT) if FICI ≥ 4. Under this definition, both drugs need to have at least a four-fold 
decrease in MIC value when used in combination as compared to their MIC alone to be 
considered a synergistic combination. As the antihistamines showed no activity against the 
fungal strains tested, and many fungal strains were resistant to multiple azole antifungals, 
there are drugs with MIC values greater than the maximum concentration of drugs tested. 
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In these cases, the maximum concentration of drug tested was considered the MICalone, 
which results in increased FICI values. 
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Table 2.1. Combinational effect of imidazoles with antihistamine compounds against thirteen fungal strains. 
TERF EBA 
Azole Strain MIC alone 
(µg/mL) 
MIC combo 
(µg/mL) 
FICI Interp. Azole Strain MIC alone 
(µg/mL) 
MIC combo 
(µg/mL) 
FICI Interp. 
  Azole Cpd Azole Cpd     Azole Cpd Azole Cpd   
CLT A 16 >42.7 1 21.4 0.56 ADD CLT A 16 >25 16 25 2.00 ADD 
 B 1 >42.7 0.5 42.7 1.50 ADD  B 1 >25 1 25 2.00 ADD 
 C 16 >42.7 0.063 10.7 0.25 SYN  C 8 >25 32 25 5.00 ANT 
 D 4 >42.7 0.008 21.4 0.50 SYN  D 4 >25 >4 >25 2.00 ADD 
 E 1 >42.7 0.008 21.4 0.51 ADD  E 0.5 >25 1 0.39 2.00 ADD 
 F 16 >42.7 4 10.7 0.50 SYN  F 16 >25 8 12.5 1.00 ADD 
 G 16 >42.7 0.5 10.7 0.28 SYN  G 16 >25 8 1.6 0.56 ADD 
 H 4 >42.7 0.5 5.3 0.25 SYN  H 4 >25 1 6.3 0.50 SYN 
 I 4 >42.7 1 2.7 0.31 SYN  I 4 >25 8 25 3.00 ADD 
 J 4 >42.7 2 5.3 0.62 ADD  J 8 >25 8 25 2.00 ADD 
 K 4 >42.7 0.031 42.7 1.01 ADD  K 4 >25 8 25 3.00 ADD 
 L 0.25 >42.7 0.13 42.7 1.50 ADD  L 0.25 >25 0.25 25 2.00 ADD 
 M 0.25 >42.7 0.25 42.7 2.00 ADD  M 0.25 >25 0.016 3.1 0.19 SYN 
KTC A 32 >42.7 1 21.4 0.53 ADD KTC A 32 >25 32 25 2.00 ADD 
 B 0.25 >42.7 0.25 21.3 1.50 ADD  B 0.25 >25 0.13 0.8 0.55 ADD 
 C 32 >42.7 0.25 10.7 0.26 SYN  C 32 >25 >32 >25 2.00 ADD 
 D 16 >42.7 0.063 10.7 0.25 SYN  D >32 >25 >32 >25 2.00 ADD 
 E 32 >42.7 0.063 10.7 0.25 SYN  E >32 >25 >32 >25 2.00 ADD 
 F 16 >42.7 4 42.7 1.25 ADD  F 16 >25 16 25 2.00 ADD 
 G 32 >42.7 16 10.7 0.75 ADD  G 32 >25 32 >25 2.00 ADD 
 H 32 42.7 16 1.3 0.53 ADD  H 32 >25 0.25 1.6 0.07 SYN 
 I 32 >42.7 2 2.7 0.13 SYN  I 32 >25 4 3.1 0.25 SYN 
 J 8 >42.7 2 10.7 0.50 SYN  J 8 >25 8 25 2.00 ADD 
 K 32 >42.7 2 5.3 0.19 SYN  K 32 >25 4 12.5 0.63 ADD 
 L 2 >42.7 2 42.7 2.00 ADD  L 2 >25 2 25 2.00 ADD 
 M 0.1 >42.7 0.1 42.7 2.00 ADD  M 0.1 >25 0.05 1.6 0.56 ADD 
MCZ A >32 >42.7 1 21.4 0.53 ADD MCZ A >32 >25 >32 >25 2.00 ADD 
 B 2 >42.7 0.13 42.7 1.07 ADD  B 2 >25 2 25 2.00 ADD 
 C 16 >42.7 0.5 10.7 0.28 SYN  C 16 >25 >16 >25 2.00 ADD 
 D 8 >42.7 0.13 10.7 0.27 SYN  D 8 >25 >16 >25 3.00 ADD 
 E 4 >42.7 0.032 10.7 0.26 SYN  E 4 >25 2 1.6 0.56 ADD 
 F >32 >42.7 >32 >42.7 2.00 ADD  F >32 >25 >32 >25 2.00 ADD 
 G 8 >42.7 0.5 10.7 0.31 SYN  G 8 >25 8 >25 2.00 ADD 
 H 8 42.7 0.06 10.7 0.26 SYN  H 4 >25 0.016 1.6 0.07 SYN 
 I 32 >42.7 0.063 10.7 0.25 SYN  I 32 >25 >32 >25 2.00 ADD 
 J 2 >42.7 0.25 10.7 0.38 SYN  J 4 >25 4 25 2.00 ADD 
 K 16 >42.7 0.25 5.3 0.14 SYN  K 16 >25 16 25 2.00 ADD 
 L 4 >42.7 1 42.7 1.25 ADD  L 4 >25 >4 >25 2.00 ADD 
 M 1 >42.7 1 >42.7 2.00 ADD  M 1 >25 0.13 3.1 0.25 SYN 
Strains: A = C. albicans ATCC MYA-1003, B = C. albicans ATCC 10231, C = C. albicans ATCC MYA-1237, D = C. albicans, 
ATCC MYA-2310, E = C. albicans ATCC MYA-2876, F = C. albicans ATCC 64124, G = C. albicans ATCC 90819, H = C. glabrata 
ATCC 2001, I = C. glabrata clinical isolate 1 (CG1), J = C. glabrata clinical isolate 2 (CG2), K = C. glabrata clinical isolate 3 (CG3), 
L = C. krusei ATCC 6258, M = C. parapsilosis ATCC 22019. 
Abbreviations used: cpd = compound, CLT = clotrimazole, EBA = ebastine, KTC = ketoconazole, MCZ = miconazole, MIC = 
minimum inhibitory concentration, TERF = terfenadine. 
The FICI cutoff values for determining synergy are: synergistic (SYN) if FICI ≤ 0.5, additive (ADD) if 0.5 < FICI ≤ 4, antagonistic 
(ANT) if FICI > 4. 
Note: Where the highest concentration of a compound or azole drug alone did not achieve optical growth inhibition, the MICalone 
value used in the FICI calculation is the highest concentration tested of that compound or azole drug. Combinations were tested in 
duplicate.  
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Table 2.2. Combinational effect of triazoles with antihistamine compounds against thirteen fungal strains. 
TERF EBA 
Azole Strain MIC alone 
(µg/mL) 
MIC combo 
(µg/mL) 
FICI Interp. Azole Strain MIC alone 
(µg/mL) 
MIC combo 
(µg/mL) 
FICI Interp. 
  Azole Cpd Azole Cpd     Azole Cpd Azole Cpd   
FLC A >32 >42.7 >32 >42.7 2.00 ADD FLC A >32 >25 >32 >25 2.00 ADD 
 B >32 >42.7 32 42.7 2.00 ADD  B >32 >25 >32 >25 2.00 ADD 
 C >32 >42.7 4 21.3 0.63 ADD  C >32 >25 >32 >25 2.00 ADD 
 D >32 >42.7 4 21.3 0.63 ADD  D >32 >25 >32 >25 2.00 ADD 
 E >32 >42.7 4 21.3 0.63 ADD  E >32 >25 >32 >25 2.00 ADD 
 F >32 >42.7 >32 >42.7 2.00 ADD  F >32 >25 >32 >25 2.00 ADD 
 G >32 42.7 8 21.3 0.75 ADD  G >32 >25 >32 >25 2.00 ADD 
 H >32 42.7 16 5.3 0.62 ADD  H >32 >25 8 12.5 0.75 ADD 
 I >32 >42.7 32 42.7 2.00 ADD  I >32 >25 >32 >25 2.00 ADD 
 J >32 >42.7 >32 >42.7 2.00 ADD  J >32 >25 >32 >25 2.00 ADD 
 K >32 >42.7 >32 >42.7 2.00 ADD  K >32 >25 >32 >25 2.00 ADD 
 L >32 >42.7 1 42.7 1.03 ADD  L >32 >25 >32 >25 2.00 ADD 
 M 8 >42.7 8 42.7 2.00 ADD  M 8 >25 2 3.1 0.37 SYN 
ITC A >32 >42.7 0.13 42.7 1.00 ADD ITC A >32 >25 >32 >25 2.00 ADD 
 B 1 >42.7 0.03 42.7 1.03 ADD  B 1 >25 0.5 1.6 0.56 ADD 
 C >32 >42.7 1 21.4 0.53 ADD  C >32 >25 >32 >25 2.00 ADD 
 D >32 >42.7 0.13 10.7 0.25 SYN  D >32 >25 >32 >25 2.00 ADD 
 E >32 >42.7 0.5 10.7 0.27 SYN  E >32 >25 >32 >25 2.00 ADD 
 F >32 >42.7 >32 >42.7 2.00 ADD  F >32 >25 >32 >25 2.00 ADD 
 G >32 >42.7 2 21.4 0.56 ADD  G >32 >25 >32 >25 2.00 ADD 
 H >32 42.7 1 5.3 0.16 SYN  H >32 >25 2 6.3 0.31 SYN 
 I >32 >42.7 1 5.3 0.16 SYN  I >32 >25 >32 >25 2.00 ADD 
 J >32 >42.7 1 42.7 1.03 ADD  J >32 >25 >32 >25 2.00 ADD 
 K >32 >42.7 1 21.4 0.53 ADD  K >32 >25 >32 >25 2.00 ADD 
 L 4 >42.7 0.13 42.7 1.03 ADD  L 4 >25 4 25 2.00 ADD 
 M 1 >42.7 0.25 2.7 0.31 SYN  M 1 >25 0.06 3.1 0.18 SYN 
POS A >32 >42.7 0.25 21.3 0.51 ADD POS A >32 >25 >32 >25 2.00 ADD 
 B 1 >42.7 0.25 5.3 0.37 SYN  B 1 >25 0.125 3.1 0.25 SYN 
 C >32 >42.7 0.063 21.3 0.50 SYN  C >32 >25 >32 >25 2.00 ADD 
 D >32 >42.7 0.063 10.7 0.25 SYN  D >32 >25 >32 >25 2.00 ADD 
 E >32 >42.7 0.125 10.7 0.25 SYN  E >32 >25 >32 >25 2.00 ADD 
 F >32 >42.7 2 10.7 0.31 SYN  F >32 >25 1 12.5 0.53 ADD 
 G >32 >42.7 0.5 10.7 0.27 SYN  G >32 >25 >32 >25 2.00 ADD 
 H >32 42.7 1 1.3 0.06 SYN  H >32 >25 0.5 0.78 0.05 SYN 
 I >32 >42.7 2 21.4 0.56 ADD  I >32 >25 >32 >25 2.00 ADD 
 J >32 >42.7 1 21.4 0.53 ADD  J >32 >25 >32 >25 2.00 ADD 
 K >32 >42.7 0.5 21.4 0.52 ADD  K >32 >25 >32 >25 2.00 ADD 
 L 0.5 42.7 0.125 5.3 0.37 SYN  L 2 >25 0.5 3.1 0.37 SYN 
 M 0.25 >42.7 0.032 1.3 0.16 SYN  M 0.5 >25 0.008 3.1 0.14 SYN 
VRC A >32 >42.7 4 21.3 0.62 ADD VRC A >32 >25 >32 >25 2.00 ADD 
 B 1 >42.7 0.5 42.7 1.50 ADD  B 0.5 >25 0.5 >25 2.00 ADD 
 C >32 >42.7 0.063 21.3 0.50 SYN  C >32 >25 >32 >25 2.00 ADD 
 D >32 >42.7 0.25 10.7 0.26 SYN  D >32 >25 >32 >25 2.00 ADD 
 E >32 >42.7 0.063 10.7 0.25 SYN  E >32 >25 >32 >25 2.00 ADD 
 F >32 >42.7 16 10.7 0.75 ADD  F >32 >25 >32 >25 2.00 ADD 
 G >32 >42.7 0.5 5.3 0.14 SYN  G >32 >25 >32 >25 2.00 ADD 
 H >32 42.7 1 1.3 0.06 SYN  H >32 >25 0.5 1.56 0.08 SYN 
 I >32 >42.7 4 5.3 0.25 SYN  I >32 >25 >32 >25 2.00 ADD 
 J 8 >42.7 2 21.4 0.75 ADD  J 8 >25 4 12.5 1.00 ADD 
 K >32 >42.7 8 5.3 0.37 SYN  K >32 >25 >32 >25 2.00 ADD 
 L 0.5 42.7 0.5 42.7 2.00 ADD  L 1 >25 1 25 2.00 ADD 
 M 0.063 >42.7 >0.063 >42.7 2.00 ADD  M 0.065 >25 0.033 3.1 0.62 ADD 
Strains: A = C. albicans ATCC MYA-1003, B = C. albicans ATCC 10231, C = C. albicans ATCC MYA-1237, D = C. albicans, 
ATCC MYA-2310, E = C. albicans ATCC MYA-2876, F = C. albicans ATCC 64124, G = C. albicans ATCC 90819, H = C. glabrata 
ATCC 2001, I = C. glabrata clinical isolate 1 (CG1), J = C. glabrata clinical isolate 2 (CG2), K = C. glabrata clinical isolate 3 (CG3), 
L = C. krusei ATCC 6258, M = C. parapsilosis ATCC 22019. 
Abbreviations used: cpd = compound, EBA = ebastine, FLC = fluconazole, ITC = itraconazole, MIC = minimum inhibitory 
concentration, POS = posaconazole, TERF = terfenadine, VRC = voriconazole. 
The FICI cutoff values for determining synergy are: synergistic (SYN) if FICI ≤ 0.5, additive (ADD) if 0.5 < FICI ≤ 4, antagonistic 
(ANT) if FICI > 4. 
Note: Where the highest concentration of a compound or azole drug alone did not achieve optical growth inhibition, the MICalone 
value used in the FICI calculation is the highest concentration tested of that compound or azole drug. Combinations were tested in 
duplicate. 
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The combination with the best FICI score was POS and EBA against C. glabrata (strain 
H) with a FICI value of 0.05. Strain H is resistant to both POS and EBA alone, having MIC 
values of >32 and >25 µg/mL, respectively. In combination, 0.5 µg/mL of POS and 0.78 
µg/mL of EBA inhibited the growth of strain H, which is a 64-fold decrease in POS and a 
thirty-two-fold decrease in EBA. Other combinations with FICI values lower than 0.10 
included POS and TERF as well as KTC, MCZ, and VRC with EBA, all against C. glabrata 
(strain H). While strain H appears more susceptible to both antihistamines and these POS 
and EBA combinations, this is interesting as C. glabrata is a species that has intrinsic 
resistance to many azoles.285 With strain H, there were a total of five SYN combinations 
with TERF and six with EBA. In contrast, the clinical isolates of C. glabrata (CG1-CG3; 
strain I-K) displayed reduced susceptibility, but we observed six SYN combinations with 
strain I (five with TERF, one with EBA), two SYN with strain J (two with TERF), and 
three SYN with strain K (three with TERF). It is also notable that five of seven azoles 
exhibited SYN with EBA with the other non-albicans Candida, C. parapsilosis (strain M). 
While multiple combinations with EBA produced very low FICI values, overall, TERF 
displayed more SYN across all the azole antifungals and all fungal strains. 
 
In total, we observed forty-one SYN combinations with TERF and fourteen with EBA. It 
appears that the synergistic effect of EBA is more strain-dependent. In addition, POS 
appears to have the best effect with EBA against many strains. For both TERF and EBA, 
combinations with POS and ITC appear to be very effective against C. krusei (strain L), C. 
parapsilosis (strain M), and C. glabrata (strain H). TERF and azole combinations exhibited 
much SYN with C. albicans strains, especially in strains C, D, E, and G, all of which are 
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resistant to most triazoles. In contrast to TERF, EBA appeared to be best with C. 
parapsilosis (strain M). For a summary of FICI scores, we presented the checkerboard 
results in heat map style in Tables 2.3 and 2.4. 
 
Table 2.3. FICI values of azole and TERF combinations against a panel of thirteen fungal strains. 
 strain 
Imidazole Triazole 
CLT KTC MCZ FLC ITC POS VRC 
Candida 
albicans 
spp. 
A 0.56 0.53 0.53 2.00 1.00 0.51 0.62 
B 1.50 1.50 1.07 2.00 1.03 0.37 1.50 
C 0.25 0.26 0.28 0.63 0.53 0.50 0.50 
D 0.50 0.25 0.27 0.63 0.25 0.25 0.26 
E 0.51 0.25 0.26 0.63 0.27 0.25 0.25 
F 0.50 1.25 2.00 2.00 2.00 0.31 0.75 
G 0.28 0.75 0.31 0.75 0.56 0.27 0.14 
non-albicans 
Candida 
spp. 
H 0.25 0.53 0.26 0.62 0.16 0.06 0.06 
I 0.31 0.13 0.25 2.00 0.16 0.56 0.25 
J 0.62 0.50 0.38 2.00 1.03 0.53 0.75 
K 1.01 0.19 0.14 2.00 0.53 0.52 0.37 
L 1.50 2.00 1.25 1.03 1.03 0.37 2.00 
M 2.00 2.00 2.00 2.00 0.31 0.16 2.00 
Strains: A = C. albicans ATCC MYA-1003, B = C. albicans ATCC 10231, C = C. albicans ATCC MYA-1237, D = C. albicans, 
ATCC MYA-2310, E = C. albicans ATCC MYA-2876, F = C. albicans ATCC 64124, G = C. albicans ATCC 90819, H = C. 
glabrata ATCC 2001, I = C. glabrata clinical isolate 1 (CG1), J = C. glabrata clinical isolate 2 (CG2), K = C. glabrata clinical 
isolate 3 (CG3), L = C. krusei ATCC 6258, M = C. parapsilosis ATCC 22019. 
The FICI cutoff values for determining synergy are: synergistic (SYN) if FICI ≤ 0.5, additive (ADD) if 0.5 < FICI ≤ 4, antagonistic 
(ANT) if FICI > 4. 
 Indicates synergy (SYN, both drugs showed ≥4-fold reduction in MIC value). 
 Indicates additive effect (ADD). 
 
Table 2.4. FICI values of azole and EBA combinations against a panel of thirteen fungal strains. 
 strain 
Imidazole Triazole 
CLT KTC MCZ FLC ITC POS VRC 
Candida 
albicans spp. 
A 2.00 2.00 2.00 2.00 2.00 2.00 2.00 
B 2.00 0.55 2.00 2.00 0.56 0.25 2.00 
C 5.00 2.00 2.00 2.00 2.00 2.00 2.00 
D 2.00 2.00 3.00 2.00 2.00 2.00 2.00 
E 2.00 2.00 0.56 2.00 2.00 2.00 2.00 
F 1.00 2.00 2.00 2.00 2.00 0.53 2.00 
G 0.56 2.00 2.00 2.00 2.00 2.00 2.00 
non-albicans 
Candida spp. 
H 0.50 0.07 0.07 0.75 0.31 0.05 0.08 
I 3.00 0.25 2.00 2.00 2.00 2.00 2.00 
J 2.00 2.00 2.00 2.00 2.00 2.00 1.00 
K 3.00 0.63 2.00 2.00 2.00 2.00 2.00 
L 2.00 2.00 2.00 2.00 2.00 0.37 2.00 
M 0.19 0.56 0.25 0.37 0.18 0.14 0.62 
Strains: A = C. albicans ATCC MYA-1003, B = C. albicans ATCC 10231, C = C. albicans ATCC MYA-1237, D = C. albicans, 
ATCC MYA-2310, E = C. albicans ATCC MYA-2876, F = C. albicans ATCC 64124, G = C. albicans ATCC 90819, H = C. 
glabrata ATCC 2001, I = C. glabrata clinical isolate 1 (CG1), J = C. glabrata clinical isolate 2 (CG2), K = C. glabrata clinical 
isolate 3 (CG3), L = C. krusei ATCC 6258, M = C. parapsilosis ATCC 22019. 
The FICI cutoff values for determining synergy are: synergistic (SYN) if FICI ≤ 0.5, additive (ADD) if 0.5 < FICI ≤ 4, antagonistic 
(ANT) if FICI > 4. 
 Indicates synergy (SYN, both drugs showed ≥4-fold reduction in MIC value). 
 Indicates additive effect (ADD). 
 Indicates antagonistic effect (ANT, both drugs show ≥4-fold increase in MIC value). 
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2.3.2. Time-dependent killing of fungi with POS and EBA combinations 
To examine the efficiency of azole and antihistamine combinations at inhibiting the growth 
of fungi, we tested the POS and EBA combination against two yeast strains, C. albicans 
ATCC 10231 (strain B) and C. glabrata ATCC 2001 (strain H). As EBA is approved in 
many countries and as of all the azoles tested POS exhibited the most synergy and had the 
lowest FICI score with C. glabrata (strain H), we selected POS and EBA combinations as 
representatives for the time-kill assays as well as for the cytotoxicity and biofilm studies. 
To study the synergistic effect of POS and EBA, we tested POS and EBA alone at sub-
inhibitory concentrations and compared these to POS and EBA combinations. The specific 
experiments included no drug (growth control), POS alone at concentration used in 
MICcombination, EBA alone at concentration used in MICcombination, POS with EBA at 
MICcombination, and POS with EBA at 4× the MICcombination, and the polyenes nystatin (NYT) 
and AmB at 1× MIC as fungicidal controls. Both strains B and H showed similar profiles 
in the relative amounts of colony forming units (CFU) over time (Fig. 2.2). EBA alone did 
not inhibit fungal growth. The sub-inhibitory concentration of POS partially inhibited the 
growth of strains B and H; only reaching 108 CFU/mL at 24 h as compared to 1013 for each 
the growth control. In combination at 1× MIC, POS and EBA strongly inhibited fungal 
growth, limiting the growth to 106 CFU/mL through the 24 h time period, but inhibition 
was not complete. However, at 4× MIC, counts remained between 104 and 105 CFU/mL 
throughout the 24-hour time frame, indicating complete inhibition of fungal growth and 
between 102 and 103 decrease as compared to POS alone. The POS and EBA combination 
shows a fungistatic effect while NYT and AmB showed fungicidal activity by decreasing 
the initial inoculum of 105 to 101-102 CFU/mL by 24 h. 
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Fig. 2.2. Representative time-kill curves for POS and EBA against A. C. albicans ATCC 10231 (strain B) 
and B. C. glabrata ATCC 2001 (strain H). Fungal strains were treated with no drug (black circles), EBA 
(white circle), POS (inverted black triangle), 1× MIC (white triangle), 4× MIC (black square), AmB at 1× 
MIC (grey square), and NYT at 1× MIC (white square). We further verified the number of CFU/mL at the 
24-hour end point by adding resazurin to the cultures. Actively replicating fungal cells metabolize resazurin, 
which is a blue-purple color, to produce resorufin, which has a pink-orange color. In cultures where there is 
little to no active cells, the culture remains a blue-purple. Where there is a low number of CFU, the culture 
appears a red color, and where there are many cells, the culture appears pink to orange. Time-points were 
plated in duplicate. 
 
2.3.3. Determination of biofilm disruption activity by POS and EBA combinations 
To evaluate the ability of POS and EBA combinations to disrupt biofilms (sessile MIC 
values (SMIC)), a cell viability assay using the water-soluble dye XTT in checkerboard 
format was performed (Table 2.5 and Fig. 2.3A-F). Two C. albicans strains, ATCC 10231 
(strain B) and ATCC 64124 (strain F), and one C. glabrata strain, ATCC 2001 (strain H), 
were chosen as representative strains. As free-floating planktonic cells, strain B is generally 
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sensitive to azole antifungals, while both strains F and H are resistant. Against the biofilms, 
neither POS nor EBA showed any activity (SMIC90 for POS >32 µg/mL and SMIC90 for 
EBA  ≥25 µg/mL against strains B, F, and H). When tested in combination, POS with EBA 
had no activity against both C. albicans strains (B and F). However, POS with EBA showed 
synergy against C. glabrata (strain H) (SMIC90 combo for POS = 0.06 µg/mL and SMIC90 
combo for EBA = 6.3 µg/mL). Similarly, both AmB and NYT had no activity against C. 
albicans (strain B), but had an SMIC90 of 4 µg/mL against C. glabrata (strain H), while C. 
albicans (strain F) biofilm had an SMIC90 of 32 µg/mL for AmB and >32 µg/mL for NYT 
(Table 2.6 and Fig. 2.3 
G-I). 
 
Table 2.5. Disruption of biofilm by POS and EBA combination against three fungal strains  
Strain SMIC90 alone (µg/µL) SMIC90 combo (µg/µL) FICI Interpretation 
Azole Cpd Azole Cpd 
B >32 >25 >32 >25 2.00 ADD 
F >32 >25 >32 >25 2.00 ADD 
H >32 25 0.06 6.3 0.25 SYN 
Strains: B = C. albicans ATCC 10231, F = C. albicans ATCC 64124, H = C. glabrata ATCC 2001. 
Abbreviations used: cpd = compound,  EBA = ebastine, POS = posaconazole, SMIC = sessile minimum inhibitory concentration. 
The FICI cutoff values for determining synergy are: synergistic (SYN) if FICI ≤ 0.5, additive (ADD) if 0.5 < FICI ≤ 4, antagonistic 
(ANT) if FICI > 4. 
Note: In cases where the highest concentration of EBA or azole alone did not achieve complete growth inhibition, the MICalone value 
used in the FICI calculation is the highest concentration tested of compound EBA or azole drugs. Combinations were tested in duplicate. 
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Fig. 2.3. Duplicate 96-well plates showing the anti-biofilm activity of the POS and EBA combinations against 
A-B. C. albicans ATCC 10231 (strain B), C-D. C. albicans ATCC 64124 (strain F), and E-F. C. glabrata 
ATCC 2001 (strain H). For comparison to fungicidal control, SMIC of the polyenes AmB and NYT tested 
in quadruplicate are shown against G. C. albicans ATCC 10231 (strain B), H. C. albicans ATCC 64124 
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(strain F), and I. C. glabrata ATCC 2001 (strain H). The corresponding data are presented in Table 2.6. SC 
indicates sterile controls where no fungal cells were added to the wells.  
 
Table 2.6. SMIC values for polyenes against biofilms of three fungal strains  
strain Polyene SMIC90 (µg/mL) 
B AmB >32 
NYT >32 
F AmB 32 
NYT >32 
H AmB 4 
NYT 4 
Strains: B = C. albicans ATCC 10231, F = C. albicans ATCC 64124, H = C. glabrata ATCC 2001. 
Note: Compounds were tested in duplicate. 
 
2.3.4. Evaluation of mammalian cytotoxicity of POS and EBA combinations 
To examine whether the activity of POS and EBA combinations is specific to fungal 
strains, we used a resazurin cell viability assay to assess the cytotoxic effect of POS and 
EBA alone and in combination against mammalian cells (Fig. 2.4). For these assays, we 
used four human cell lines, including lung carcinoma epithelial cells (A549), bronchial 
epithelial cells (BEAS-2B), embryonic kidney cells (HEK-293), and of course, the 
keratinocytes (HaCaT), which are most relevant for skin infections. We tested POS within 
the concentration range of 0.06-16 µg/mL. With POS alone, the maximum concentration 
with no observed toxicity was 4 µg/mL for HEK-293 and A549, whereas it was 8 µg/mL 
for HaCaT and BEAS-2B. For EBA alone, we used concentrations ranging from 0.1-25 
µg/mL. Complete cell survival was observed up to 6.3 µg/mL for HaCaT and 3.1 µg/mL 
for all other cell lines. A cytotoxic effect began at 6.3 µg/mL with cell survival of 78 ± 8%, 
69 ± 5%, and 70 ± 7% for A549, BEAS-2B, and HEK-293, respectively. At the highest 
concentration of EBA, 25 µg/mL, we observed near 0% cell survival for all cell lines. 
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Fig. 2.4. Representative cytotoxicity assays against four mammalian cell lines: A. HaCaT, B. A549, C. 
BEAS-2B, and D. HEK-293. Treatments included POS alone (black bars), POS + 3.1 µg/mL EBA (pale gray 
bars), and EBA alone (dark gray bars). The positive control consisted of cells treated with Triton X-100® 
(TX, 12.5% v/v). The negative control consisted of cells treated with DMSO (no drug). Combinations were 
tested in duplicate. 
 
To examine the effect of POS and EBA combinations on cytotoxicity, we varied the 
concentration of POS with a constant amount of EBA. Since all cell lines showed no 
toxicity at 3.1 µg/mL of EBA, we assessed POS with all cell lines in combination with 3.1 
µg/mL of EBA (Fig. 2.4C). Cell survival rates of POS + 3.1 µg/mL of EBA was not 
significantly different as compared to POS alone for all 4 cell lines.  
 
2.4. DISCUSSION 
Candida infections primarily affect immunocompromised patients, but they also occur in 
otherwise healthy adults. It is estimated that 75% of all women will have at least one 
vulvovaginal infection during their life. Approximately half of vaginal infections are 
caused by Candida species.286 Out of the cases of candidiasis, a study in China reported 
that 80.5% of vaginal candidiasis cases over an eight-year period were caused by C. 
albicans, while 18%, 1.2%, and 0.1% were caused by C. glabrata, C. krusei, and C. 
tropicalis, respectively.273 We found 55 synergistic combinations of azole antifungals and 
antihistamines. While these combinations did not reverse FLC resistance, there appeared 
to be an adjuvant effect with other azole antifungals. While both EBA and TERF showed 
synergy with azoles against C. albicans strains, each also showed synergy against non-
albicans Candida strains, which have intrinsic resistance to azole antifungals.277-278, 286 
Furthermore, as many skin diseases have similar symptoms, diagnosis of fungal infections 
without a diagnostic test can be difficult.287 Due to this difficulty and the associated 
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irritation from fungal infections, CLT is also formulated with hydrocortisone or 
betamethasone, a highly potent fluorinated corticosteroid.288 However, corticosteroids used 
for prolonged periods and in occlusive environments such as where fungal infections 
normally occur, can have serious side effects including severe allergic reactions and skin 
atrophy.289-290 In addition, as dermatophyte species cause the majority of cutaneous fungal 
infections and dermatophytes show lower susceptibility to azoles than yeasts, the azole and 
antihistamine combinations could be explored with dermatophytes.291-292 If combinations 
of azoles and antihistamines were shown to be efficacious in animal models and further 
testing, a topical cream containing an azole and an antihistamine could be an alternative 
product for the CLT corticosteroid topical cream. 
 
In addition to checkerboard assays, we used time-kill studies to further verify the 
synergistic interactions between the azoles and antihistamines. We chose two fungal strains 
and the POS and EBA combination to observe the inhibitory effect of the drug combination 
over time. The results from the time-kill study do substantiate the synergy observed in the 
checkerboard assays as the addition of EBA to a sub-inhibitory concentration of POS 
decreases fungal counts while EBA alone has no effect on fungal growth. Additionally, as 
azoles are fungistatic against Candida spp., we looked at time-kill dynamics to evaluate 
whether the combinations of azoles and antihistamines remained fungistatic. As the 
number of CFU/mL remained constant for POS and EBA in combination at 4× MIC while 
the fungicidal controls, AmB and NYT, decreased counts to ≤102 CFU/mL, this suggests 
that the POS and EBA combinations are fungistatic. 
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Many fungal strains in vivo can form biofilms, especially on implanted medical devices 
such as joint replacements and urinary catheters.293-294 Treatment of infections where 
biofilms occur is more challenging as the biofilms protect fungal cells from the antifungal 
drugs. In biofilms, fungal cells secrete an oligosaccharide layer that can prevent antifungal 
drugs from penetrating the biofilm and acting on the fungal cells. Biofilms remaining intact 
after treatment increases the risk of reoccurring infections.176, 295 As an additional measure 
to evaluate the effectiveness of the POS and EBA combinations, we used a biofilm 
disruption assay to look at the outcome on sessile cells. While we did not observe synergy 
against C. albicans biofilms, which are believed to be a cause of recurrent mucosal 
infections, we did observe synergy against C. glabrata (strain H) biofilm.296-297 The 
concentration of POS and EBA used to achieve SMIC90 against strain H had similar 
concentrations of POS and about 100-fold less concentration of EBA as compared to the 4 
µg/mL of AmB and NYT needed to also achieve SMIC90. The difference in results between 
fungal species may be due to differences in the oligosaccharide composition of the biofilms 
or differences in regulation of efflux pumps.298-299 
 
Since we corroborated the synergistic interaction with POS and EBA, we then assessed 
cytotoxicity. We found that EBA at 3.1 µg/mL in combination with POS has a similar cell 
survival rates as POS alone, which is non-toxic to the mammalian cells up to at least 16 
µg/mL. The concentration of POS alone at which a cytotoxic effect was beginning to be 
observed, 16 µg/mL, was at significantly higher concentrations of POS than the MIC 
values for POS alone against sensitive fungal strains, as the MIC values for POS ranged 
from 0.25-1.0 µg/mL. In synergistic combinations, the MIC values for POS ranged from 
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0.008-0.5 µg/mL, while MIC values for EBA in synergistic combinations with POS ranged 
from 0.78-3.1 µg/mL. As the MIC values for POS and EBA in synergistic combinations 
are the same as or lower than the concentrations of drugs in combination where no 
cytotoxic effect was observed, it suggests that POS and EBA combinations would be safe 
to use. 
 
The known targets for EBA and TERF are the histamine H1 receptors.103 In addition, 
TERF, and to a lesser extent EBA, is known to inhibit the human cardiac hERG potassium 
channel at high concentrations. While fungi also have potassium channels, there is no 
known orthologue to hERG in fungi.300 The mechanism of action of the antifungal activity 
is uncertain for TERF and EBA. However, other groups have proposed mechanisms of 
action for TERF with regards to the other activities it exhibits. While we did not test TERF 
for cytotoxicity, reports show that TERF and its derivative have strong antitumor activity, 
suggesting that TERF would be cytotoxic at the concentrations tested.301-303 In vitro, TERF 
sensitized cancer cells to doxorubicin by a proposed mechanism of inhibiting P-
glycoprotein.282 Other studies have proposed TERF as a CYP2J2, inhibitor, which also 
plays a role in apoptosis and inhibiting cancer cells.283 Furthermore, TERF and its 
derivatives show antibacterial activity against Staphylococcus aureus, which may be 
partially due to inhibition of type II topoisomerases.284 Less work has been done to identify 
secondary targets of EBA, but one study showed in silico evidence as an ATPase 
inhibitor.304 As TERF and EBA are structurally similar, we expect that both compounds 
would have similar targets, but the specific targets for each remains unclear. This will be 
the topic of future studies outside of the scope of the current work. 
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In sum, we evaluated the effectiveness of combinations of seven azole antifungals and two 
antihistamines, EBA and TERF, against a wide panel of fungal strains. We found that both 
TERF and EBA exhibited synergy in combination with azole antifungals. The majority of 
synergy was observed with POS and VRC and specific strains of Candida. More 
synergistic combinations were observed with TERF than EBA, however, the POS and EBA 
combination with C. glabrata (strain H) had the lowest FICI value. By time-kill studies we 
found that POS and EBA at 1× MIC were fungistatic. The POS and EBA combination was 
also found to be synergistic against biofilms of C. glabrata (strain H), but not against those 
of C. albicans (strains B and F). Finally, we showed that POS and EBA combinations were 
not toxic to mammalian cells. 
 
2.5. EXPERIMENTAL 
2.5.1. Antifungal and antihistamine agents used for combination studies 
The antifungal agents fluconazole (FLC), itraconazole (ITC), posaconazole (POS), and 
voriconazole (VRC) were purchased from AK Scientific (Union City, CA, USA). The 
remaining antifungal agents amphotericin B (AmB), clotrimazole (CLO), ketoconazole 
(KTC), miconazole (MCZ), and nystatin (NYT) were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). The antihistamines used were terfenadine (TERF, Sigma-Aldrich, St. 
Louis, MO, USA) and ebastine (EBA, VWR, Atlanta, GA, USA). All compounds (>98% 
purity) were dissolved in DMSO and stored at -20 °C (Sigma-Aldrich, St. Louis, MO, 
USA) for use in assays. It is to note that all other chemicals used for the various experiments 
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were purchased from Sigma-Aldrich (St. Louis, MO, USA) and used without any further 
purification. 
 
2.5.2. Fungal strains, mammalian cell lines, and their culture conditions 
The Candida albicans strains ATCC MYA-1003 (strain A), ATCC MYA-1237 (strain C), 
ATCC MYA-2310 (strain D), and ATCC 90819 (strain G) were purchased from the 
American Type Culture Collection (ATCC, Manassas, VA, USA). The remaining C. 
albicans strains, including ATCC 10231 (strain B), ATCC MYA-2876 (strain E), and 
ATCC 64124 (strain F) were a generous gift from Dr. Jon Y. Takemoto (Utah State 
University, Logan, UT, USA). The non-albicans Candida fungi C. glabrata ATCC 2001 
(strain H), C. krusei ATCC 6258 (strain L), and C. parapsilosis ATCC 22019 (strain M) 
were also purchased from ATCC. The C. glabrata clinical isolates, CG1 (strain I), CG2 
(strain J), and CG3 (strain K) were a wonderful gift from Dr. Nathan P. Wiederhold (The 
University of Texas, San Antonio, TX, USA). All Candida strains were grown at 35 °C on 
potato dextrose agar plates (PDA, catalog # 110130, EMD Millipore, Billerica, MA, USA). 
Liquid cultures of the yeast strains were grown in yeast extract peptone dextrose (YEPD) 
broth at 35 °C. 
 
The human embryonic kidney cell line HEK-293 and the human lung carcinoma epithelial 
cells A549 were purchased from ATCC. The human bronchial epithelial cells BEAS-2B 
were a generous gift from Prof. David K. Orren (University of Kentucky, Lexington, KY). 
Immortalized human keratinocytes HaCaT were an amiable gift from Prof. Hollie Swanson 
(University of Kentucky, Lexington, KY). All mammalian cells were cultured in 
131 
Dulbecco’s Modified Eagle’s Medium (DMEM, catalog # 11965-092, Thermo Fisher 
Scientific, Waltham, MA) supplemented with 10% fetal bovine serum (FBS; from ATCC) 
and 1% penicillin/streptomycin (from ATCC) at 37 °C with 5% CO2. 
 
2.5.3. Determination of minimum inhibitory concentration (MIC) values 
MIC values were recorded for all antifungals and antihistamines in order to determine the 
concentration range of compounds to be used in the checkerboard assays. All antifungal 
agents were screened in the range of 0.063-32 µg/mL. The antihistamines, EBA and TERF, 
are less soluble in ddH2O and therefore were tested starting at the maximal concentration 
where no precipitation was observed, 42.7 µg/mL for TERF (0.08-42.7 µg/mL) and 25 
µg/mL for EBA (0.05-25 µg/mL). Compound stocks for all antifungal agents and EBA 
were dissolved in DMSO at a concentration of 5 mg/mL while TERF was dissolved in 
DMSO at 10 mg/mL. 
 
The MIC assays were done using the broth microdilution method as described in CLSI  
document M27-A3 with minor modifications.305 Inocula were prepared by picking a colony 
from a PDA plate stored at 4 °C. The colonies were grown in YEPD medium overnight at 
35 °C with shaking at 200 rpm. In a 96-well plate compounds were diluted lengthwise 
along the plate in serial 2-fold dilutions in the RPMI 1640 medium. The yeast cultures were 
diluted in RPMI 1640 medium to an OD600 within the range of 0.12 and 0.15 (~1×106 
cells/mL). The fungal cells were further diluted by taking 25 µL of fungal cells and adding 
them to 10 mL of RPMI 1640 medium before adding 100 µL to plate (200 µL total volume). 
The plates were incubated at 35 °C for 48 h. Visual inspection of the wells for no growth 
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was used to determine the MIC. All compounds were tested in duplicate with the maximum 
concentration of DMSO <1% (Tables 2.1 and 2.2). 
 
2.5.4. Combination studies of azoles and antihistamines by checkerboard assays 
Checkerboard assays were done as previously described to determine the fractional 
inhibitory concentration index (FICI) (Tables 2.1 and 2.2 and 2.3-2.4).305-306 2-fold 
dilutions of the azole drug were made in RPMI 1640 medium lengthwise along the plate. 
(Note: In order to confirm that diluting in RPMI 1640 medium gave the same MIC and 
FICI results as performing the experiments by doing the serial 2-fold dilutions in DMSO, 
we selected 4 azoles to test in combination with TERF and EBA against C. glabrata ATCC 
2001 (strain H) (Table 2.7). We found that both serial 2-fold dilution methods gave the 
same results). For the antihistamine, 2-fold serial dilutions were made in sterile tubes with 
RPMI 1640 medium, then aliquoted into the plate. The drug concentration used in the 
checkerboards was 2- or 4-fold higher concentrations than the measured individual MIC 
values. The maximum drug concentration tested for the azoles was 32 µg/mL, while 25 
µg/mL was maximal for EBA, and 42.7 µg/mL for TERF. The maximal amount was used 
in the checkerboard assays if complete inhibition was not observed in the MIC assays. 
Inocula were prepared diluting overnight cultures in RPMI 1640 medium to an OD600 
between 0.12 and 0.15 (~1×106 cells/mL). Cells were then further diluted by taking 25 µL 
of cell suspension and adding to 10 mL of RPMI 1640 medium. After the drugs were added 
to the plate with 100 µL of medium, 100 µL of fungal cells were added. Plates were 
incubated at 35 °C for 48 h and visual inspection was used to determine wells with no 
growth. All experiments were carried out in duplicate. The FICI was calculated based on 
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the formula below. The combinational effect of the 2 tested compounds were considered 
synergistic (SYN) if FICI ≤ 0.5, additive (ADD) if 0.5 < FICI ≤ 4, and antagonistic if FICI 
> 4 (Tables 2.1 and 2.2 and 2.3-2.4).307 
 
FICI = 𝑀𝑀𝑀𝑀𝑀𝑀 𝑜𝑜𝑜𝑜 𝑎𝑎𝑎𝑎𝑜𝑜𝑎𝑎𝑎𝑎𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
𝑀𝑀𝑀𝑀𝑀𝑀 𝑜𝑜𝑜𝑜 𝑎𝑎𝑎𝑎𝑜𝑜𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑐𝑐𝑎𝑎𝑎𝑎
+  𝑀𝑀𝑀𝑀𝑀𝑀 𝑜𝑜𝑜𝑜 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎ℎ𝑎𝑎𝑖𝑖𝑎𝑎𝑎𝑎𝑖𝑖𝑎𝑎𝑎𝑎𝑎𝑎𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
𝑀𝑀𝑀𝑀𝑀𝑀 𝑜𝑜𝑜𝑜 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎ℎ𝑎𝑎𝑖𝑖𝑎𝑎𝑎𝑎𝑖𝑖𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑐𝑐𝑎𝑎𝑎𝑎
 
 
Table 2.7. Selected combinations of azoles and antihistamines against C. glabrata ATCC 2001 (strain H). 
TERF EBA 
Azole MIC alone 
(µg/mL) 
MIC combo 
(µg/mL) 
FICI Interp. Azole MIC alone 
(µg/mL) 
MIC combo 
(µg/mL) 
FICI Interp. 
 Azole Cpd Azole Cpd    Azole Cpd Azole Cpd   
CLT 4 >42.7 0.5 5.3 0.25 SYN CLT 4 >25 1 6.3 0.50 SYN 
 4 >42.7 0.5 2.7 0.19 SYN  4 >25 0.25 1.6 0.13 SYN 
MCZ 8 42.7 0.06 10.7 0.26 SYN MCZ 4 >25 0.016 1.6 0.07 SYN 
 4 >42.7 0.13 2.7 0.10 SYN  4 >25 0.063 3.1 0.14 SYN 
POS >32 42.7 1 1.3 0.06 SYN POS >32 >25 0.5 0.78 0.05 SYN 
 >32 >42.7 0.5 2.7 0.08 SYN  >32 >25 0.25 1.6 0.07 SYN 
VRC >32 42.7 1 1.3 0.06 SYN VRC >32 >25 0.5 1.6 0.08 SYN 
 >32 >42.7 0.5 2.7 0.08 SYN  >32 >25 0.25 1.6 0.07 SYN 
a The non-bold data are the same as in Tables 1 and 2 (from experiments performed by diluting in RPMI medium), whereas 
the data in bold are those resulting from experiments performed by diluting in DMSO. When compared, it is clear that both 
methods result in the same MIC values. 
Note: Combinations were tested in duplicate. 
 
2.5.5. Time-kill assays 
Time-kill assays were used to assess the inhibitory efficiency of the POS and EBA 
combination against two yeast strains, C. albicans ATCC 10231 (strain B) and C. glabrata 
ATCC 2001 (strain H). The protocol for time-kill assays followed methods previously 
described with minor modifications.244, 308 Yeast cultures were grown overnight in YEPD 
medium at 35 °C with shaking at 200 rpm. A working stock of fungal cells was made by 
diluting cultures in 1640 medium to an OD600 of 0.125 (~1×106 CFU/mL). From the 
working stock, 100 µL of cells was added to 4.9 mL of RPMI 1640 medium in sterile 
culture tubes, making the starting fungal cell concentration ~1×105 CFU/mL. Drug was 
then added to the fungal cells. The treatment conditions included sterile control, growth 
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control, EBA, POS, EBA and POS combination at 1× MIC, EBA and POS combination at 
4× MIC, as well as AmB and NYT at their respective 1× MIC as fungicidal controls. The 
concentration of EBA and POS alone were the same concentration used in the combination 
at 1× MIC treatment. Treated fungal cultures were incubated in the culture tubes at 35 °C 
with 200 rpm shaking for 24 h. Samples were aliquoted from the different treatments at 
regular time points (0, 3, 6, 9, 12, and 24 h) and plated in duplicate. For each time point, 
cultures were vortexed, 100 µL of culture was aspirated, and 10-fold serial dilutions were 
made in sterile ddH2O. From the appropriate dilutions, 100 µL of fungal suspension was 
spread on PDA plates and incubated at 35 °C for 48 h before colony counts were 
determined. Only plates containing between 30 and 300 colonies were counted making 30 
CFU/mL the limit of detection. At 24 h, 50 µL of 1 mM resazurin in phosphate buffered 
saline (PBS) was added to the treatments and incubated at 35 °C with 200 rpm shaking for 
2 h in the dark for visual inspection. As resazurin (blue-purple) is metabolized by the cells 
to produce resorufin (pink-orange), the addition of resazurin is used as a qualitative 
measure to confirm the relative growth of the fungal cells in the different treatment 
conditions (Fig. 2.2). Experiments were performed in duplicate. 
 
2.5.6. Biofilm disruption assays 
Biofilm disruption assays were performed to assess the effectiveness of the POS and EBA 
combination against sessile yeast cells for 3 representative yeast strains, C. albicans ATCC 
10231 (strain B), C. albicans ATCC 64124 (strain F), and C. glabrata ATCC 2001 (stain 
H). Biofilm assays were performed in 96-well plates using XTT [2,3-bis(2-methoxy-4-
nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] to measure the viability of the 
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biofilm as previously described.309 An overnight culture of yeast was grown at 35 °C in 
YEPD medium with shaking at 200 rpm. The overnight culture was diluted in RPMI 1640 
medium to an OD600 between 0.12 and 0.15 to make a working stock. Working stock was 
transferred to the 96-well plate in 100 µL aliquots, leaving one column empty for the sterile 
control. The plates were incubated at 37 °C for 24 h to allow formation of the biofilm. The 
medium and planktonic cells from the plate were then aspirated. Wells were washed with 
100 µL of PBS 3 time to remove any remaining planktonic cells off of the biofilm. After 
washing, RPMI 1640 medium and drug were added to the plate, in a similar fashion to that 
described in the checkerboard assays. POS was tested in the concentration range of 0.06-
32 µg/mL with EBA at concentrations of 0.39-25 µg/mL in checkerboard format. As 
controls, the AmB and NYT SMIC were also tested in the range of 0.06-32 µg/mL (Table 
2.6). Plates were incubated at 37 °C for 24 h. Finally, the plates were washed 3 times with 
PBS before adding 100 µL of XTT dye. The XTT was prepared by dissolving XTT at 0.5 
mg/mL concentration in sterile PBS. Before adding to a plate, 1 µL of 10 mM menadione 
in acetone was added to 10 mL of the 0.5 mg/mL solution of XTT. After addition of XTT 
(containing menadione), the plates were incubated at 3 h at 37 °C in the dark. 80 µL of 
liquid from each well was transferred to a new plate. Plates were then read with a 
SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, CA, USA) for absorbance at 
450 nm. For these experiments, we determined the SMIC90, which is defined as the drug 
concentration required to inhibit the metabolic activity of biofilm by 90% compared to the 
growth control. The SMIC90 values were used to calculate the FICI as described above 
(Table 2.5). The plates used to determine the SMIC90 are provided in Fig. 2.3. Each assay 
was performed in duplicate. 
136 
 
2.5.7. Mammalian cytotoxicity assays 
To examine whether the inhibitory effect of the antifungal and antihistamine combinations 
is specific to fungal cells, the combinations were tested with four mammalian cell lines: 
A459, BEAS-2B, HEK-293, and HaCaT. POS and EBA alone were tested against each cell 
line to measure their cytotoxic effect by using a resazurin cell viability assay as previously 
described with minor modifications.310 The assays were done in 96-well plates. A549 and 
BEAS-2B cells were plated at a density of 3×103 cells/mL, HaCaT were plated at 2×104 
cells/mL, and HEK-293 cells were plated at 1×104 cells/mL as determined by using a 
hemacytometer. POS was tested in concentrations ranging from 0.06 to 16 µg/mL and EBA 
was tested in the range of 0.10 to 25 µg/mL. In order to test the cytotoxic effect of the azole 
and antihistamine combinations, the highest concentration of EBA that did not show any 
cytotoxic effect when used alone (3.1 µg/mL of EBA for all cell lines) was used with 
varying concentrations of POS (Fig. 2.4). It is important to note that testing xenobiotics at 
sub-IC50 concentrations can result in increase in cell growth, resulting in >100% cell 
survival in the treatment groups.244, 311-314 In instances where >100% cell survival was 
observed, as custom in this field of research, we displayed the data as 100% cell survival. 
All assays were done in quadruplicate. 
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Chapter 3 
 
Distorted gold(I)-phosphine complexes as antifungal agents 
 
3.1. ABSTRACT 
Fungi cause serious nosocomial infections including candidiasis and aspergillosis, some of 
which display reduced susceptibility to current antifungals. Inorganic compounds have 
been found beneficial against various medical ailments, but have yet to be applied to fungal 
infections. Here, we explore the activity of linear and square-planar gold(I)-phosphine 
complexes against a panel of twenty-eight fungal strains including Candida spp., 
Cryptococcus spp., Aspergillus spp., and Fusarium spp. Notably, two square-planar gold(I) 
complexes with excellent broad-spectrum activity display potent antifungal effects against 
strains of Candida auris, an emerging multidrug-resistant fungus that presents a serious 
global health threat. To characterize the biological activity of these gold(I) complexes, we 
used a series of time-kill studies, cytotoxicity, and hemolysis assays, as well as whole cell 
uptake and development of resistance studies. 
 
3.2. INTRODUCTION 
Fungal infections are deadly for patients with conditions that weaken the immune system,13 
as demonstrated by mortality rates exceeding 50% for systemic fungal infections.12 Those 
most affected include patients (i) with acquired immune deficiency syndrome, (ii) having 
received recent chemotherapy, (iii) having had an organ transplant, as well as (iv) with 
underlying lung disease such as chronic obstructive pulmonary disorder and asthma.12-13 
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These systemic fungal infections are primarily caused by only a few fungal genera, 
specifically Candida72 and Aspergillus.315 
 
For treatment of fungal infections, there are three classes of antifungal agents that can be 
used. One class, the polyenes, includes the widely used antifungal therapy, amphotericin B 
(AmB). While effective in treating a broad spectrum of infections, treatment is often 
associated with severe side effects. The second class, the azoles, specifically fluconazole 
(FLC) and voriconazole (VRC), are a first line of defense against fungal infections, but can 
cause drug-drug interactions. The third class is the echinocandins, which includes 
caspofungin (CFG). The echinocandins, are narrow-spectrum and can only be administered 
by intravenous catheter. What is of concern is the ability of fungi to be intrinsically resistant 
to antifungal agents. Examples include Candida glabrata316 to the echinocandins and the 
emerging pathogen, Candida auris, which in some cases is resistant to all three drug 
classes.317-318 C. auris is currently attracting attention due to recent outbreaks of resistant 
C. auris infections in the USA.1-3 In addition, infections can develop decreased 
susceptibility to antifungal agents during treatment. With a limited armament of antifungal 
agents, there is a need for new classes of agents. 
 
In agriculture, metal salts (e.g., copper salts319) are widely used as fungicides to improve 
food production. As medicines, inorganic compounds have been predominantly developed 
as anticancer agents (e.g., cisplatin).320 These metal complexes typically consist of either 
platinum, ruthenium, silver, or copper. As anticancer agents, these compounds have been 
successful, but typically have problems with toxicity321 and associated acquired 
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resistance.322 More recently gold(I) phosphine and gold(III) complexes have gained 
attention as anticancer agents323 as well as antimicrobials.324-325 
 
The arthritis drug, auranofin (Fig. 3.1), is an exemplary gold complex that has been used 
in the clinic since 1983. It can be administered orally and has been shown to be well-
tolerated at a 6 mg daily dose in patients (www.fda.gov/drugsatfda). Auranofin is believed 
to block inflammation in arthritis by regulating the secretion levels of various cytokines.326 
In recent years, reports looking at repurposing auranofin as an antimicrobial agent against 
bacteria327-330 and fungi have been published.280, 331-333 In fact, auranofin is currently in 
clinical trials for cancer, HIV, amoebiasis, and tuberculosis.334-335 As an anticancer and 
antimicrobial agent, auranofin acts to inhibit thioredoxin reductase.336-337 With no known 
inorganic antifungals on the market, auranofin speaks to the promise of using gold 
scaffolds to investigate and develop novel antifungal agents. 
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Fig. 3.1. Structure of auranofin. 
 
Our group has a long-standing interest in the development of antifungal agents. In the past, 
we have used different strategies to develop antifungals, including the development of 
azole analogues,183-184, 338 combinations of antifungal drugs,244, 256-257 and synthesis and 
biological evaluation of new scaffolds.205, 211-212, 245, 253 We previously developed gold 
complexes as potential anticancer agents.339-340 We were intrigued to see if the applications 
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of gold complexes could be expanded to include antifungal activity. Herein, we present the 
antifungal activity of six distorted gold(I)-phosphine complexes, 1-6 (Fig. 3.2) not derived 
or related in structure to auranofin, against yeast, molds, and yeast biofilms. We then 
confirm the activity of the two best complexes, 4 and 6, in time-kill studies. To evaluate 
the efficacy of complexes 4 and 6, we use both cytotoxicity studies against four mammalian 
cell lines as well as hemolysis assay with both murine and human red blood cells. We also 
present whole cell uptake assays and development of resistance studies. The gold 
complexes with square-planar geometry appear to show great promise for future 
development as antifungal agents. As there are currently no metal complexes that have 
been thoroughly investigated for antifungal activity, our distorted gold(I)-phosphine 
complexes are innovative in the field of antifungal development. 
 
 
Fig. 3.2. Synthetic schemes showing the preparation of the Au complexes 1-6. 
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3.3. RESULTS AND DISCUSSION 
3.3.1. Design, chemical synthesis, and X-ray crystallography 
For this study we wanted to create gold(I) complexes that could be easily prepared in a 
single synthetic step (Fig. 3.2). The reaction of three commercially available phosphorus 
ligands with AuCl(THT) (prepared by the reaction of tetrahydrothiophene and 
tetrachloroauric acid (HAuCl4•3H2O))341 in chloroform at room temperature afforded 
mixtures of linear gold(I) complexes 1, 3, and 5 and their square-planar gold(I) complex 
counterparts 2, 4, and 6 in 23-37% yield, which could be easily separated by silica gel flash 
chromatography. To expand the availability of chiral gold(I) complexes, which are limited 
and underexplored for biological applications, we used both the achiral 
bis(diphenylphosphino)benzene ligand and chiral ligands such as the 1,2-bis[(2S,5S)-2,5-
dimethylphospholano]benzene and 1,2-bis[(2R,5R)-2,5-dimethylphospholano]benzene. 
The structures of compounds 1-6 were confirmed by 1H, 13C, and 31P NMR spectroscopy, 
mass spectrometry, as well as RP-HPLC for purity determination. Additionally, the 
structures of compounds 3, 4, 5, and 6 were confirmed by X-ray crystallography. Single 
crystals of complexes were grown by vapor diffusion (Fig. 3.3). Crystal structures for the 
known compounds 1342 and 2343 had already been solved. The structures of complexes 3 
and 5 were consistent with linear geometry for classical gold(I) complexes. Furthermore, 
complexes 4 and 6 were characterized by a distorted square-planar arrangement around the 
gold(I) center as observed in gold complexes with bisphosphine ligands. In all cases, the 
gold(I) center is coordinated to bidentate ligands with phosphorus donors; 3 and 5 have 
one chloride ion bound to the gold(I) center, while 4 and 6 have all donors as phosphorus 
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atoms. Typically, Au–P distances vary from 2.229-2.239 Å and Au–Cl distances are in the 
range of 2.286-2.292 Å. 
 
 
Fig. 3.3. X-ray crystal structures of compounds A. 3, B. 4, C. 5, and D. 6. Ellipsoids are drawn at 50% 
probability level. Hydrogen atoms bound to carbon atoms are omitted for clarity. For compounds 4 and 6, 
the molecules co-crystallized with a molecule of CHCl3. 
 
3.3.2. Determination of minimum inhibitory concentration (MIC) values of 
compounds 1-6 against twenty-eight fungal strains 
For all biological studies, we used auranofin as a control as it is one of the only metal 
complexes that is an FDA-approved drug, is well-tolerated in patients, and has some 
reported antimicrobial activity, and may have a similar cellular target at the gold(I)-
phosphine complexes. As there are currently no metal complexes that have been thoroughly 
investigated for antifungal activity, our distorted gold(I)-phosphine complexes are 
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innovative in the field of antifungal development. For most biological assays, we also used 
the current FDA-approved antifungal AmB as a positive control. 
 
Compounds 1-6 were first tested in MIC value determination assays against a panel of 
twenty fungal strains (Table 3.1). The panel consisted of seven Candida albicans (strains 
A-G), five non-albicans Candida (one C. glabrata (strain H), one C. krusei (strain I), one 
C. parapsilosis (strain J), and two C. auris (strains K and L)), four Cryptococcus 
neoformans (strains M-P), three Aspergillus (strains Q-S), as well as one Fusarium 
graminearum (strain T). These strains were chosen as they represent pathogens causing 
systemic infections. Furthermore, this panel includes many (five out of seven) C. albicans 
strains designated as fluconazole-resistant by the American Type Culture Collection 
(ATCC, see legend of Table 3.1). We observed that auranofin had no antifungal activity 
against Candida spp., while it displayed MIC values of 0.06 to 7.8 µg/mL against all four 
C. neoformans and two of the three Aspergillus strains tested, which agrees with other 
reports of its activity.332 We found that compounds 4 and 6 displayed excellent activity 
against Candida spp. and Cryptococcus spp. with MIC values against seventeen strains in 
the range of 0.06 to 1.95 µg/mL, which were generally better than MIC values for AmB. 
Compounds 4 and 6 also displayed good to excellent activity (MIC values of 1.95 to 7.8 
µg/mL) against all filamentous fungi, the Aspergillus spp. and Fusarium spp., which was 
much better than that of AmB (MIC values 7.8-31.3 µg/mL). Compound 3, on the other 
hand, was found to be completely inactive against all fungal strains tested, except for C. 
neoformans (strain M). Compounds 1, 2, and 5 were inactive against both Aspergillus spp. 
and Fusarium spp. and most of the non-albicans Candida strains tested, whereas they 
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displayed some activity in the range of 0.12 to 7.8 µg/mL against a few strains of C. 
albicans and C. neoformans. From these data, we concluded that linear gold(I) complexes 
(i.e., 1, 3, and 5) and achiral square-planar gold(I) complexes (i.e., 2) were poor antifungals 
that should not be further pursued, whereas the chiral square-planar gold(I) complexes (i.e., 
4 and 6) showed great promise as antifungals and deserved further investigation. 
 
Table 3.1. MIC values in µg/mL (Note: MIC values are also provided in µM into parentheses) for compounds 1-6, auranofin, and AmB 
against various fungal strains. 
 Compound # 
Strains 1 2 3 4 5 6 Auranofin AmB 
Candida 
albicans 
A 3.9 (4.3) 15.6 (13.9) 31.3 (40.6) 0.98 (1.2) 3.9 (5.1) 0.49 (0.6) >31.3 (>46.1) 0.98 (1.1) 
B 15.6 (17.1) 15.6 (13.9) >31.3 (40.6) 1.95 (2.3) 31.3 (40.6) 0.98 (1.2) >31.3 (>46.1) 1.95 (2.1) 
C 0.49 (5.4) 15.6 (13.9) >31.3 (40.6) 0.98 (1.2) 15.6 (20.2) 0.98 (1.2) >31.3 (>46.1) 3.9 (4.2) 
D 7.8 (8.6) 7.8 (6.9) 31.3 (40.6) 0.98 (1.2) 7.8 (10.1) 0.49 (0.6) >31.3 (>46.1) 7.8 (8.4) 
E 7.8 (8.6) 7.8 (6.9) 31.3 (40.6) 0.98 (1.2) 15.6 (20.2) 0.49 (0.6) >31.3 (>46.1) 3.9 (4.2) 
F 7.8 (8.6) 7.8 (6.9) 31.3 (40.6) 0.98 (1.2) 15.6 (20.2) 0.49 (0.6) >31.3 (>46.1) 3.9 (4.2) 
G 7.8 (8.6) 7.8 (6.9) 31.3 (40.6) 0.98 (1.2) 7.8 (10.1) 0.49 (0.6) >31.3 (>46.1) 0.98 (1.1) 
Non-albicans 
Candida 
H 7.8 (8.6) 7.8 (6.9) >31.3 (>40.6) 1.95 (2.3) 15.6 (20.2) 0.98 (0.6) >31.3 (>46.1) 3.9 (4.2) 
I 15.6 (17.1) 15.6 (13.9) >31.3 (>40.6) 1.95 (2.3) 31.3 (40.6) 0.98 (0.6) 31.3 (46.1) 3.9 (4.2) 
J 15.6 (17.1) 7.8 (6.9) >31.3 (>40.6) 0.98 (1.2) 15.6 (20.2) 0.49 (0.6) >31.3 (>46.1) 3.9 (4.2) 
 K >31.3 (>34.3) >31.3 (>27.8) >31.3 (>40.6) 3.9 (4.6) >31.3 (>40.6) 1.95 (2.3) >31.3 (>46.1) 1.95 (2.1) 
 L >31.3 (>34.3) >31.3 (>27.8) >31.3 (>40.6) 7.8 (9.2) >31.3 (>40.6) 1.95 (2.3) >31.3 (>46.1) 1.95 (2.1) 
Cryptococcus M 0.98 (1.1) 3.9 (3.5) 1.95 (2.5) 0.98 (1.2) 0.12 (0.2) 0.25 (0.3) ≤0.06 (≤0.1) >31.3 
(>33.9) 
 N 3.9 (4.3) 3.9 (3.5) >31.3 (>40.6) 0.98 (1.2) 15.6 (20.2) 0.49 (0.6) 3.9 (5.7) 0.98 (1.1) 
 O 3.9 (4.3) 3.9 (3.5) 31.3 (40.6) 0.98 (1.2) 7.8 (10.1) 0.49 (0.6) 7.8 (11.5) 1.95 (2.1) 
 P 15.6 (17.1) 3.9 (3.5) >31.3 (>40.6) 0.98 (1.2) 7.8 (10.1) 0.49 (0.6) 3.9 (5.7) 0.98 (1.1) 
Aspergillus Q >31.3 (>34.3) >31.3 (>27.8) >31.3 (>40.6) 3.9 (4.6) >31.3 (>40.6) 3.9 (4.6) 3.9 (5.7) 15.6 (16.9) 
 R >31.3 (>34.3) >31.3 (>27.8) >31.3 (>40.6) 1.95 (2.3) >31.3 (>40.6) 3.9 (4.6) 7.8 (11.5) 7.8 (8.4) 
 S >31.3 (>34.3) >31.3 (>27.8) >31.3 (>40.6) 7.8 (9.2) >31.3 (>40.6) 7.8 (9.2) >31.3 (>46.1) 31.3 (33.8) 
Fusarium T >31.3 (>34.3) 31.3 (27.8) >31.3 (>40.6) 3.9 (4.6) >31.3 (>40.6) 3.9 (4.6) >31.3 (>46.1) 7.8 (8.4) 
Candida albicans strains: A = C. albicans ATCC MYA-1003(R), B = C. albicans ATCC 10231(R), C = C. albicans ATCC MYA-
1237(R), D = C. albicans ATCC MYA-2310(S), E = C. albicans ATCC MYA-2876(S), F = C. albicans ATCC 64124(R), G = C. 
albicans ATCC 90819(R). NOTE: (S) and (R) are indicating strains that are reported to be sensitive (S) and resistant (R) to fluconazole 
by the ATCC. 
Non-albicans Candida strains: H = C. glabrata ATCC 2001, I = C. krusei ATCC 6258, J = C. parapsilosis ATCC 22019, K = C. 
auris AR Bank # 0384, L = C. auris AR Bank # 0390. 
Cryptococcus strains: M = C. neoformans ATCC MYA-85, N = C. neoformans CN1, O = C. neoformans CN2, P = C. neoformans 
CN3. 
Aspergillus strains: Q = A. nidulans ATCC 38163, R = A. terreus ATCC MYA-3633, S = A. flavus ATCC MYA-3631. 
Fusarium strain: T = F. graminearum 053. 
Abbreviations: AmB = amphotericin B; MIC = minimum inhibitory concentration. 
Note: Compounds were tested in duplicate. 
 MIC ≤1.95 µg/mL (excellent antifungal activity) 
 MIC = 3.9 - 7.8 µg/mL (good antifungal activity) 
 MIC ≥15.6 µg/mL (poor antifungal activity) 
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As C. auris is an emerging drug-resistant pathogen, we included two C. auris strains in our 
initial panel (strains K and L) (Table 3.1). As compounds 4 and 6 displayed good and 
excellent activity against these two C. auris strains, respectively, we expanded our panel 
and tested compounds 4 and 6, and AmB with an additional eight C. auris strains (strains 
I-VIII) from the Centers for Disease Control (CDC) Antibiotic Resistance Bank51 (Table 
3.2). We observed that both compounds 4 and 6 had excellent antifungal activity (MIC 
values 0.98 to 1.95 µg/mL) against almost all C. auris strains. 
 
Table 3.2. MIC values in µg/mL (Note: MIC values are also provided in µM into parentheses) for 
compounds 4, 6, and AmB against a panel of C. auris strains. 
 Compound # 
Strains 4 6 AmB CFG FLC† VRC† 
I 0.98 (1.2) 0.98 (1.2) 1.95 (2.1) <0.98 (<0.9) 0.49 (1.6) 0.06 (0.2) 
II 1.95 (2.3) 0.98 (1.2) 0.98 (1.1) <0.98 (<0.9) 0.49 (1.6) 0.06 (0.2) 
III 1.95 (2.3) 3.9 (4.6) 1.95 (2.1) 1.95 (1.8) 62.5 (204.1) 1.95 (5.6) 
IV 1.95 (2.3) 1.95 (2.3) 1.95 (2.1) <0.98 (<0.9) >62.5 (>204.1) 3.9 (11.2) 
V 1.95 (2.3) 3.9 (4.6) 1.95 (2.1) 7.8 (7.1) >62.5 (>204.1) 3.9 (11.2) 
VI 1.95 (2.3) 1.95 (2.3) 1.95 (2.1) 31.3 (28.6) 0.98 (3.2) 0.06 (0.2) 
VII 1.95 (2.3) 1.95 (2.3) 1.95 (2.1) 31.3 (28.6) >62.5 (>204.1) 0.49 (1.4) 
VIII 1.95 (2.3) 1.95 (2.3) 1.95 (2.1) 7.8 (7.1) >62.5 (>204.1) 0.98 (2.8) 
K* 3.9 (4.6) 1.95 (2.3) 1.95 (2.1) 1.95 (1.8) 31.3 (102.2) 0.24 (0.7) 
L* 7.8 (9.2) 1.95 (2.3) 1.95 (2.1) 7.8 (7.1) >62.5 (>204.1) 0.49 (1.4) 
C. auris strains: I = C. auris AR Bank # 0381, II = C. auris AR Bank # 0382, III = C. auris AR Bank 
# 0383, IV = C. auris AR Bank # 0385, V = C. auris AR Bank #  0386, VI = C. auris AR Bank # 0387, 
VII = C. auris AR Bank # 0388, VIII = C. auris AR Bank # 0389, K = C. auris AR Bank # 0384, L = 
C. auris AR Bank # 0390. 
Abbreviations: AmB = amphotericin B; CFG = caspofungin; FLC = fluconazole; MIC = minimum 
inhibitory concentration; VRC = voriconazole. 
*Note: values presented for strains K and L, which are new to this manuscript, are also presented in 
Table 3.1, but are also displayed here for ease of comparison.  
†MIC-2 values are presented for azoles. MIC-0 values are presented for all other compounds.  
Note: Compounds were tested in duplicate. 
 MIC ≤1.95 µg/mL (excellent antifungal activity) 
 MIC = 3.9 - 7.8 µg/mL (good antifungal activity) 
 MIC ≥15.6 µg/mL (poor antifungal activity) 
 
3.3.3. Time-kill assays for compounds 4 and 6 
With the very promising antifungal activity results for compounds 4 and 6, we next 
examined their killing kinetics. Time-kill assays were done with four representative 
Candida strains, one C. albicans (strain B), one C. glabrata (strain H), and two C. auris 
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(strains K and L) (Fig. 3.4). Compounds 4 and 6 were tested at both their 1× and 2× MIC 
values, and AmB at 1× MIC was used as a known fungicidal control. Both compounds 
significantly decreased fungal colony forming units (CFU) by 102 CFU/mL by the 3 h time 
point and did not increase over the 24 h time period, which indicated that compounds 4 and 
6 are fungicidal. This pattern was very similar to AmB. With C. albicans (strain B), 
compound 4 at 1× MIC reached the limit of detection at 9 h and compound 6 at 2× MIC at 
3 h. With C. glabrata (strain H), both compounds at 2× MIC were at the limit of detection 
by 24 h. For C. auris (strain K), compound 4 failed to reach the limit of detection by 24 h, 
but compound 6 at 1× MIC reached the limit at 6 h. However, with C. auris (strain L) both 
compounds 4 and 6 at 1× MIC reached the limit of detection by 3 h and remained under 
the limit of detection, while AmB reached the limit of detection at 9 h before the CFU/mL 
began to return to the original yeast cell concentration. 
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Fig. 3.4. Representative time-kill curves for compounds 4, 6, and AmB against A. C. albicans ATCC 10231 
(strain B) and B. C. glabrata ATCC 2001 (strain H), C. C. auris AR Bank # 0384 (strain K), and D. C. auris 
AR Bank # 0390 (strain L). Fungal strains were treated with no drug (black circles), compound 4 at 1× MIC 
(black triangle), compound 4 at 2× MIC (white triangle), compound 6 at 1× MIC (black square), compound 
6 at 2× MIC (white square), and AmB at 1× MIC (white circle). At the 24-hour end point, resazurin was 
added to the cultures to qualitatively measure the CFU/mL. Resazurin, which is a blue-purple color, is 
metabolized by viable cells to produce resorufin, which has a pink-orange color. Cultures with little to no 
cells remain a blue-purple color while dense cultures appear pink or orange. Time-points samples were done 
in duplicate. 
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3.3.4. Prevention of biofilm formation and disruption of pre-formed biofilm assays 
for compounds 4 and 6 
Biofilms are well-known in the world of bacteria to cause difficult to treat and reoccurring 
infections by a multitude of species including Staphylococcus aureus, Escherichia coli, 
and Pseudomonas aeruginosa.344-345 There is an extensive number of fungal strains known 
to form biofilms, but biofilm formation on catheters, prostheses, and other medical devices 
in healthcare associated infections are mainly limited to Candida spp.346-349 The ability of 
compounds 4 and 6 to both prevent and disrupt biofilm formation is important for 
prophylactic treatment and to stop the spread of a fungal infection. However, it is regarded 
that it is more challenging to disrupt a pre-formed biofilm as the large, sugary extracellular 
matrix that is the key characteristic of biofilms, can prevent many drugs from reaching the 
fungal cells.350 Furthermore, in biofilms, fungal cells can upregulate efflux pumps to 
prevent the action of any drugs that do reach the fungal cells through the extracellular 
matrix.351 We measured the ability of compounds 4 and 6, auranofin, and AmB to both 
prevent biofilm formation and to disrupt pre-formed biofilms of C. albicans (strain B), C. 
glabrata (strain H), and C. auris (strains K and L) (Table 3.3 and Figs. 3.5 and 3.6). As the 
biofilm assay is a colorimetric assay and it is difficult to achieve 100% disruption of 
biofilms, we report the sessile MIC90 (SMIC90), which is the concentration of compound 
at which there is a 90% decrease in metabolic activity as compared to untreated biofilm. 
Both compounds 4 and 6 showed similar results with both fungal strains tested. SMIC90 
values in prevention of biofilm formation assays were 1- to 2-fold higher than with 
planktonic cells. When tested against a pre-formed biofilm, compound 4 had a SMIC90 of 
7.8 µg/mL with both strains and compound 6 had a SMIC90 of 3.9 µg/mL with both strains. 
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These SMIC90 results were 4-fold higher than the MIC results for the same Candida strains 
with planktonic cells. Interestingly, auranofin with C. albicans (strain B) achieved the same 
SMIC90 as compound 4, but was inactive against C. glabrata (strain H). These values for 
auranofin are similar to a value reported for auranofin against the biofilm of one C. albicans 
strain.331 In contrast, AmB had SMIC90 values of 7.8 µg/mL and 31.3 µg/mL against C. 
glabrata (strain H) and C. albicans (strain B), respectively, which were 2- and 32-fold 
higher than its MIC values against the same strains in liquid culture. 
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Fig. 3.5. Prevention of biofilm formation of A. C. albicans ATCC 10231 (strain B), B. C. glabrata ATCC 
2001 (strain H), C. C. auris AR Bank # 0384 (strain K), and D. C. auris AR Bank # 0390 (strain L) treated 
at 0 h with auranofin, 6, 4, and AmB. Compounds were tested in duplicate. XTT dye is metabolized by fungal 
cells to produce an orange color. The corresponding data are presented in Table 3.3. 
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Fig. 3.6. Disruption of pre-formed biofilms of A. C. albicans ATCC 10231 (strain B), B. C. glabrata ATCC 
2001 (strain H), C. C. auris AR Bank # 0384 (strain K), and D. C. auris AR Bank # 0390 (strain L) treated 
at 24 h with auranofin, 6, 4, and AmB. Compounds were tested in duplicate. XTT dye is metabolized by 
fungal cells to produce an orange color. The corresponding data are presented in Table 3.3. 
 
It is promising that both compounds 4 and 6 have good activity against biofilms of Candida 
spp. There have been reports that compared planktonic and sessile MIC values of other 
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FDA-approved antifungal agents, which demonstrate the reduced susceptibility of biofilms 
to antifungal agents.348, 352 Of the currently used antifungal agents, AmB and echinocandins 
have the best efficacy with biofilms with SMIC90 in the range of 0.5-128 µg/mL (4- to 128-
fold increase from MIC) and 0.03-8 µg/mL (2- to 16-fold increase from MIC), respectively. 
For the azoles, itraconazole and posaconazole have some efficacy against biofilms with 1- 
to 256-fold increases in MIC against biofilms. However, VRC and FLC have no efficacy 
with SMIC90 exceeding 512 µg/mL. Additionally, new investigational antifungal 
molecules that have been reported to be active against C. albicans biofilms, include azole 
derivatives and benzimidazole containing compounds. For the azole derivatives, seven 
econazole derivatives were reported with minimum biofilm inhibiting concentrations at or 
near 8 µg/mL178 (2- to 16-fold increase in MIC) and alkylated azole derivatives displayed 
SMIC80 values of 15.6-31.3 µg/mL.184 Other investigational molecules with activity 
against biofilms included three neomycin B-benzimidazole hybrid molecules with SMIC80 
values of 7.8-15.6 µg/mL247 (2- to 4-fold increase in MIC). Candida biofilms are known 
to be key virulence factors in mucosal membrane infections (i.e., thrush and vulvovaginal 
infections)353-355 and Candida clinical isolates from bloodstream infections can form 
biofilms as well. Of the bloodstream isolates, it is estimated that approximately 20% of C. 
albicans strains were able to form biofilm in vitro, with that percentage increasing to near 
70% for non-albicans Candida.167, 356-357 With few other antifungals displaying antibiofilm 
activity, the 4-fold difference that we observed is highly promising. 
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Table 3.3. Prevention of biofilm formation and disruption of a pre-formed 
biofilm by compounds 4, 6, auranofin, and AmB against four fungal strains. 
  Biofilm prevention Pre-formed biofilm 
Strain Compound SMIC90 (µg/mL) SMIC90 (µg/mL) 
B 4 3.9 7.8 
 6 0.98 3.9 
 Auranofin 7.8 7.8 
 AmB 0.98 31.3 
H 4 3.9 7.8 
 6 1.95 3.9 
 Auranofin 31.3 >31.3 
 AmB 0.98 7.8 
K 4 3.9 7.8 
 6 3.9 7.8 
 Auranofin >31.3 >31.3 
 AmB 1.95 1.95 
L 4 3.9 15.6 
 6 3.9 7.8 
 Auranofin >31.3 >31.3 
 AmB 1.95 7.8 
Strains: B = C. albicans ATCC 10231, H = C. glabrata ATCC 2001, K = 
C. auris AR Bank # 0384, L = C. auris AR Bank # 0390. 
Note: Compounds were tested in duplicate. 
 
3.3.5. Mammalian cytotoxicity assays for compounds 4 and 6 
For the gold complexes to progress further into the drug development process, the gold 
complex activity should be specific to fungal cells and not be toxic to mammalian cells. 
Therefore, we tested compounds 4 and 6 as well as the control auranofin against four 
mammalian cell lines: human adenocarcinoma (A549), bronchial epithelial (BEAS-2B), 
human embryonic kidney (HEK-293), and murine macrophage (J774A.1) (Fig. 3.7). 
Excluding auranofin with J774A.1, we observed <50% cell survival at 7.8 µg/mL with no 
cell survival at 15.6 µg/mL for both compounds 4 and 6 and auranofin. Auranofin, 
displayed IC50 values of 0.5-3.0 µM against A549, BEAS-2B, and HEK-293 cell lines, 
which agrees with other published values against cisplatin-sensitive cell lines.339 For 
J774A.1, the IC50 value for auranofin was significantly higher at 16.2 µM. As J774A.1 is 
a macrophage cell line, auranofin may have had an anti-inflammatory effect that stimulated 
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cell metabolism, which could account for the higher IC50 value. There is interest in 
repurposing auranofin as an antimicrobial, however, auranofin does not appear to be 
promising as an antifungal. Auranofin displayed poor activity against Candida spp. (MIC 
>31.3 µg/mL) and only good activity against two Aspergillus spp. (MIC = 3.9 and 7.8 
µg/mL). For compound 4, IC50 values were very similar for BEAS-2B, HEK-293, and 
J774A.1 (1.5-2.0 µM) and somewhat higher for A549 (4.5 µM). The MIC values for 
compounds 4 and 6 against eighteen of the Candida spp. are in the range of 0.49-1.95 
µg/mL, which are concentrations at which there is toxicity observed for the mammalian 
cells. Overall, compounds 4 and 6 displayed somewhat better selectivity to kill fungi over 
mammalian cells than the FDA approved drug, auranofin. Despite this result, there is room 
to improve these gold complexes to increase the therapeutic window by reducing 
mammalian cell toxicity. 
 
Reports have suggested that gold complexes bind to thioredoxin reductase in bacteria and 
mammalian cells,336-337 but there is some evidence to suggest that gold complexes could 
inhibit mitochondrial function in fungi.333 Future studies for the gold complexes, out of 
scope for this proof-of-concept work, should seek to answer whether these square planar 
gold complexes bind thioredoxin reductase or mitochondrial enzymes, which if so, could 
lead to more in depth structure activity studies to decrease cytotoxicity. For other reported 
gold complexes which were investigated for anti-cancer activity, IC50 values for complexes 
comprised of (1R,2R)-(+)-1,2-diaminocyclohexane ligands ranged from 1.2-14.8 µM 
against cancer cell lines, and were >100 µM against a human normal lung fibroblast cell 
line, MRC5.339 Another square-planar gold(I)-phosphine complex displayed IC50 values of 
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0.3-9.2 µM.358 In this report, IC50 values ranged from 0.55-0.83 µM against two cancer cell 
lines for both compounds 4 and 6. Interestingly, an achiral version of these complexes was 
reported to be insoluble. Furthermore, in a preliminary study with a xenograft model, 
compounds 4 and 6 were tolerated in mice at a dose of 2 mg/kg (100% survival) or 8 mg/kg 
(83% and 67% survival, respectively), which suggests an acceptable level of toxicity at 
lower doses. 
 
Table 3.4. IC50 (µM) for mammalian cell lines. 
Compound # A549 BEAS-2B HEK-293 J774A.1 
4 4.5 ± 0.6 2.0 ± 0.3 1.9 ± 0.7 1.5 ± 0.1 
6 2.5 ± 0.2 4.9 ± 0.3 5.7 ± 0.5 1.5 ± 0.1 
Auranofin 0.5 ± 0.1 1.3 ± 0.1 3.0 ± 0.2 16.2 ± 0.9 
Note: Compounds were tested in quadruplicate. 
 
 
Fig. 3.7. Evaluation of cytotoxicity for compound 4 (orange), compound 6 (blue), and auranofin (white) with 
A. A549, B. BEAS-2B, C. HEK-293, and D. J774A.1 cell lines. Controls include treatment with Triton-X® 
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(TX, 1% v/v, positive control) and 0.5% DMSO (negative control). Note: values >100% were normalized to 
100%. Compounds were tested in quadruplicate. 
 
3.3.6. Measurement of hemolysis for compounds 4 and 6 
To expand upon the cytotoxicity results, we obtained both murine and human red blood 
cells (RBCs) to evaluate the hemolytic activity of compounds 4 and 6 as compared to both 
auranofin and AmB, as well as to the detergent, Triton-X® (positive control) (Fig. 3.8). 
Some drugs, especially those containing both hydrophobic and hydrophilic components, 
can disrupt cell membranes to cause hemolysis.359 Examples of drugs that are known to be 
hemolytic include AmB as well as cisplatin. With AmB, to minimize hemolytic activity a 
lipid formulation has been developed.360 The results are similar for both murine and human 
RBCs, however, the murine RBCs appear more prone to hemolysis as compounds 4 and 6 
displayed 13% and 60% hemolysis, respectively, at 3.9 µg/mL and less than 5% with 
human RBCs. We observed that both compounds 4 and 6 displayed hemolytic activity at 
7.8 µg/mL. AmB exhibited somewhat better values with 30-60% hemolysis at 7.8 µg/mL 
and 100% hemolysis at 15.6 µg/mL. In contrast, auranofin displayed no hemolytic activity 
at 15.6 µg/mL. With MIC values for compounds 4 and 6 typically in the range of 0.49-1.95 
µg/mL for Candida spp., there is a 1- to 2-fold therapeutic window, which is not perfect 
when comparing to the desired 10-fold therapeutic window. 
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Fig. 3.8. Hemolytic activity of compound 4 (orange), compound 6 (blue), auranofin (white), and AmB (grey) 
against A. human and B. murine red blood cells. Positive control is Triton-X® (TX, 1% v/v). Compounds 
were tested in quadruplicate. 
 
3.3.7. Whole cell uptake assay for compounds 4 and 6 
To gain some insight into whether compounds 4 and 6 have an intracellular or extracellular 
target, the uptake of gold into the cell was measured using Inductively Coupled Plasma 
Optical Emission Spectroscopy (ICP-OES, Fig. 3.9). Uptake was measured with 100 
million yeast cells (Note: this is 2-3× more cells than in MIC and time-kill studies) after 
30 minutes treatment with 10 µM (~5× MIC for compounds 4 and 6 against strain B and 
H, respectively; ~10× MIC for compounds 4 and 6 against strain H and B, respectively) 
compound. These conditions were chosen to have a significant number of cells for analysis, 
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a saturating amount of compound (note that 10 µM was required to achieve saturation), 
and at a time-point within the doubling time of the yeast. Both compounds exhibited very 
similar uptake by C. albicans (strain B) and C. glabrata (strain H) of ~17 pmol/million 
cells. However, the uptake when 5× MIC was used was higher than when 10× MIC was 
used. With the values for gold uptake in the pmol/million cells range, there appears to be a 
relatively low amount of gold uptake per cell, but there are no reports of similar uptake 
studies in yeast to compare to. However, we do observe uptake and these values correspond 
to approximately 15% and 20% of total gold content for compounds 4 and 6, respectively. 
It is possible that by the 30-minute end point there is some lysis of the fungal cells, 
especially with 10× MIC, which would decrease uptake values. These results do suggest 
that the compounds enter the yeast cell by facilitated diffusion or active transport as with 
passive diffusion higher dosing of compound (e.g., saturating amount) corresponds to 
greater cell uptake. We previously published gold(III) complexes that we investigated as 
anticancer agents, where we measured gold uptake in OVCAR8 cells.339 We found that 
gold(III) complexes that included a single chloride anion had improved uptake over similar 
complexes with perchlorate anions, with relative uptake of ~300-400 and ~200 
pmol/million cells, respectively. These values were significantly lower than the ~1300 
pmol/million cells uptake of auranofin in the OVCAR8 cell. The uptake values for 
compounds 4 and 6 in fungi appear significantly lower than the values measured for other 
complexes with the mammalian cells, but are similar when the difference in cell volume 
and incubation time between yeast and mammalian cells is considered.361-362 Therefore, it 
is still unclear, but within reason for the gold complexes to have an intracellular target. 
Conceivably, the structurally complex cell wall of fungus composed of chitin, glucans, and 
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glycoproteins may contribute to the limited uptake of the cationic gold complexes 
investigated. Further studies will focus on developing neutral complexes and complexes 
that benefit from active transport. 
 
 
Fig. 3.9. Whole cell uptake of 10 µM of compound 4 (orange) and compound 6 (blue) by A. C. albicans 
ATCC 10231 (strain B) and B. C. glabrata ATCC 2001 (strain H) after 30 min treatment. Compounds were 
tested in duplicate. 
 
3.3.8. Development of fungal resistance for compounds 4 and 6 
Fungal drug resistance can be caused by mutation of the target protein (observed with 
azoles and echinocandins),83-84 overexpression of the target protein (observed with 
azoles),73-74 the use of efflux pumps (observed with azoles),86-90 or increased filamentation 
to decrease drug uptake (observed with AmB).127, 131 In order to assess the potential for the 
development of fungal resistance, we determined MIC values of compounds 4 and 6 as 
well as AmB as a control over fifteen serial passages with C. albicans (strain B) and C. 
glabrata (strain H) (Fig. 3.10). We observed no significant changes in MIC values for our 
compounds over the course of this study. The gold complexes are likely to display different 
mechanisms of action in fungi that can circumvent resistance pathways. 
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Fig. 3.10. Changes in MIC values of A. C. albicans ATCC 10231 (strain B) and B. C. glabrata ATCC 2001 
(strain H) treated with compound 4 (orange), compound 6 (blue), and AmB (grey) over fifteen serial passages. 
MICs were done in duplicate. 
 
3.4. CONCLUSIONS 
In summary, we synthesized three linear gold(I)-phosphine complexes and three 
corresponding square-planar gold(I) complexes and explored their antifungal activity. Two 
square-planar complexes, 4 and 6, displayed excellent antifungal activity against a panel 
of twenty-one Candida strains which included C. albicans, C. glabrata, C. krusei, C. 
parapsilosis, and C. auris as well as four C. neoformans Furthermore, these square-planar 
complexes displayed good activity against four filamentous strains of Aspergillus spp., and 
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Fusarium spp. In addition, compounds 4 and 6 displayed good activity against Candida 
spp. biofilms. When tested against mammalian cells, the gold complexes displayed limited 
improvement in selectivity index over the FDA-approved drugs AmB and auranofin. 
Finally, by development of resistance studies of compounds 4 and 6 in Candida spp., it 
was found that Candida spp. have a low chance of developing resistance to these gold 
complexes. Future studies will work to decrease the toxic effect to mammalian cells and to 
substantiate the mechanism of action of the gold complexes in fungi. 
 
3.5. EXPERIMENTAL 
3.5.1. Chemistry 
3.5.1.1. Materials and instrumentation 
Tetrahydrothiophene (THT) was from Sigma-Aldrich and used without further purification 
or drying. Tetrachloroauric acid (HAuCl4•3H2O) was purchased from Oakwood and used 
as received. THT and HAuCl4•3H2O were used to prepare AuCl(THT) as previously 
reported.341 All phosphorus ligands used: 1,2-bis(diphenylphosphino)benzene, 1,2-
bis[(2S,5S)-2,5-dimethylphospholano]benzene, and 1,2-bis[(2R,5R)-2,5-
dimethylphospholano]benzene were purchased from Sigma-Aldrich and used as received. 
ACS grade solvents were purchased from Pharmco-Aaper and used without further 
purification or drying. Deuterated solvents were purchased from Cambridge Isotope 
Laboratories and used as received. Silica gel for column chromatography (Silicycle, P/N: 
R10030B SiliaFlashF60, Size: 40-63 µm, Canada) was purchased from Silicycle. 
Aluminum backed silica-gel plates (20 × 20 cm2) were purchased from Silicycle (TLA-
R10011B-323) and utilized for analytical thin-layer chromatography (TLC). 
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All reactions were insensitive to air or moisture, as a result, they were carried out under 
standard atmospheric conditions without air-sensitive techniques or drying agents. 
Reactions were carried out in round-bottom flasks or scintillation vials equipped with 
Teflon-coated magnetic stir bars for stirring non-homogenous reaction mixtures. Reactions 
were monitored by NMR and TLC, and the TLC plates visualized under short-wavelength 
light (254 nm) or stained with iodine on Silica. All compound purification was performed 
using silica-gel chromatography, employing CombiFlash Rf+ Lumen, Teledyne ISCO. 
Filtrations were carried out using medium-porosity ceramic funnels. Removal of solvents 
in vacuo was performed using a Büchi rotary evaporator and further drying was achieved 
by Schlenk line at ~120 mTorr using a dynamic vacuum pump. 
 
1H, 13C (1H-decoupled), and 31P (1H-decoupled) NMR spectra were recorded on a Varian 
Unity 400 MHz NMR spectrometer with a Spectro Spin superconducting magnet at the 
University of Kentucky NMR facility in the Department of Chemistry. Chemical shifts in 
1H and 13C NMR spectra were internally referenced to solvent signals (1H NMR: CDCl3 at 
δ = 7.26 ppm; 13C NMR: CDCl3 at δ = 77.16 ppm), and those in 31P NMR spectra, which 
were run in CDCl3, were externally referenced to 85% H3PO4 in D2O at δ = 0 ppm. 
 
High-resolution mass spectra (HRMS) were obtained using a direct flow injection 
(injection volume = 1 µL) method with ElectroSpray Ionization (ESI) on a Waters Q-TOF 
Premier instrument in the positive mode. The optimized conditions were as follows: 
capillary = 3000 kV, cone = 35, source temperature = 120 °C, and desolvation temperature 
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= 350 °C. Mass spectrometry experiments and analysis were conducted at the Chemical 
Instrumentation Center at Boston University. 
 
In addition to spectroscopic characterization, the purity of all compounds was assessed by 
RP-HPLC using an Agilent Technologies 1100 series HPLC instrument and an Agilent 
Phase Eclipse Plus C18 column (4.6 mm × 100 mm; 3.5 µm particle size). All compounds 
were found to be ≥97% pure. 
 
3.5.1.2. Synthesis and characterization of compounds 1-6 
Synthesis of the known compounds [1,2-bis(diphenylphosphino)benzene]digold(I) 
(1)342 and bis-[1,2-bis(diphenylphosphino)benzene]gold(I) (2)343 
Under normal atmospheric conditions, in a 25 mL round bottom flask was placed 
AuCl(THT) (58.7 mg, 0.183 mmol). CHCl3 (10.0 mL) was added and the solution (white 
suspension) was stirred at room temperature for 2-3 min. To the solution was added 1,2-
bis(diphenylphosphino)benzene (80.2 mg, 0.180 mmol). The solution turned yellow 
instantly. The solution was stirred for about 1 h and monitored by TLC using 
5:95/MeOH:CH2Cl2 as an eluent. Separation of compounds 1 and 2 was achieved via flash 
chromatography using CombiFlash Rf+ Lumen with 5:95/MeOH:CH2Cl2. 
 
Characterization of compound 1: White solid (37 mg, 23%); Rf 0.8 in 5:95/MeOH:CH2Cl2; 
1H NMR (400 MHz, CDCl3, Fig. 3.A1 “Disclaimer: All figures are presented for Chapter 
3 are presented in Appendix A and are listed as Fig. 3.A#”) δ 7.56-7.46 (m, 6H), 7.46-7.35 
(m, 16H), 7.25-7.16 (m, 2H); 13C NMR (101 MHz, CDCl3, Fig. 3.A2) δ 137.12, 137.05, 
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136.97, 134.81, 134.74, 134.67, 132.35, 131.90, 131.87, 131.84, 129.60, 129.54, 129.48, 
128.91, 128.60, 128.28; 31P NMR (162 MHz, CDCl3, Fig. 3.A3) δ 24.60; HRMS (ESI) 
(m/z): calcd. for C30H24Au2Cl2P2 [M-Cl]+: 875.0373, found: 875.0408 ∆ = 3.9998 (Fig. 
3.A4). Purity was demonstrated to be 97% by RP-HPLC: Rt = 8.82 min using the following 
method: Flow rate: 1 mL/min; λ = 260 nm; Eluent A = H2O with 0.1% TFA; Eluent B = 
MeCN with 0.05% formic acid; Elution program: 0 to 100% B over 10 min followed by 
100 to 0% B over 5 min and 4 additional min at 0% B (Fig. 3.A5). 
 
Characterization of compound 2: Yellow solid (68 mg, 36%); Rf 0.2 in 
5:95/MeOH:CH2Cl2; 1H NMR (400 MHz, CDCl3, Fig. 3.A6) δ 7.57-7.25 (m, 20H), 7.13-
6.87 (m, 28H); 13C NMR (101 MHz, CDCl3, Fig. 3.A7) δ 142.13, 134.52, 134.37, 132.56, 
132.44, 132.37, 132.33, 132.29, 132.25, 132.21, 132.18, 131.72, 130.40, 129.13, 129.11, 
129.08, 129.06, 129.03, 129.01, 128.89, 128.86, 128.74; 31P NMR (162 MHz, CDCl3, Fig. 
3.A8) δ 21.17; HRMS (ESI) (m/z): calcd. for C60H48AuClP4 [M-Cl]+: 1089.2372, found: 
1089.2357 ∆ = 1.3771 (Fig. 3.A9). Purity was demonstrated to be 100% by RP-HPLC: Rt 
= 10.78 min using the following method: Flow rate: 1 mL/min; λ = 260 nm; Eluent A = 
H2O with 0.1% TFA; Eluent B = MeOH with 0.1% TFA; Elution program: 0 to 100% B 
over 5 min, stay at 100% B for 10 min, followed by 100 to 0% B over 4 min (Fig. 3.A10). 
 
Synthesis of [1,2-bis[(2S,5S)-2,5-dimethylphospholano]benzene]digold(I) (3) and bis-
[1,2-bis[(2S,5S)-2,5-dimethylphospholano]benzene]gold(I) (4) 
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Compounds 3 and 4 were synthesized and separated following the procedure described for 
the preparation of compounds 1 and 2 using AuCl(THT) (64.6 mg, 0.202 mmol) and 1,2-
bis[(2S,5S)-2,5-dimethyl-1-phospholano]benzene (58.6 mg, 0.191 mmol). 
 
Characterization of compound 3: White solid (47 mg, 32%); Rf 0.8 in 5:95/MeOH:CH2Cl2; 
1H NMR (400 MHz, CDCl3, Fig. 3.A11) δ 7.73-7.64 (m, 4H), 3.60 (sextet, J = 7.6 Hz, 2H), 
2.99-2.85 (m, 2H), 2.53-2.38 (m , 2H), 2.30-2.13 (m, 2H), 1.92-1.77 (m, 2H), 1.57-1.44 
(m, 2H), 1.37 (dd, J = 20.6, 6.7 Hz, 6H), 1.06 (dd, J = 17.2, 7.2 Hz, 6H); 13C NMR (101 
MHz, CDCl3, Fig. 3.A12) δ 134.45, 134.39, 134.33, 132.19, 131.61, 131.58, 131.56, 37.20, 
37.03, 37.01, 36.97, 36.84, 36.79, 36.61, 35.56, 35.54, 33.99, 33.92, 33.85, 19.59, 19.56, 
19.52, 19.47, 19.42; 31P NMR (162 MHz, CDCl3, Fig. 3.A13) δ 43.96; HRMS (ESI) (m/z): 
calcd. for C18H28Au2Cl2P2 [M-Cl]+: 735.0686, found: 735.0671 ∆ = 2.0406 (Fig. 3.A14). 
Purity was demonstrated to be 97% by RP-HPLC: Rt = 7.94 min using the following 
method: Flow rate: 1 mL/min; λ = 260 nm; Eluent A = H2O with 0.1% TFA; Eluent B = 
MeCN with 0.05% formic acid; Elution program: 0 to 100% B over 10 min followed by 
100 to 0% B over 5 min and 4 additional min at 0% B (Fig. 3.A15). 
 
Characterization of compound 4: Yellow solid (44 mg, 27%); Rf 0.4 in 
5:95/MeOH:CH2Cl2; 1H NMR (400 MHz, CDCl3, Fig. 3.A16) δ 7.75-7.67 (m, 4H), 7.60-
7.54 (m, 4H), 2.71-2.46 (m, 8H), 2.35-2.13 (m, 8H), 1.87-1.72 (m, 4H), 1.62-1.49 (m, 4H), 
1.19 (td, J = 10.6, 6.9 Hz, 12H), 0.81-0.71 (m, 12H); 13C NMR (101 MHz, CDCl3, Fig. 
3.A17) δ 142.52, 142.36, 142.20, 133.34, 133.31, 133.29, 130.67, 40.56, 40.48, 40.40, 
37.71, 37.65, 37.59, 36.06, 35.84, 21.47, 21.41, 21.36, 14.49; 31P NMR (162 MHz, CDCl3, 
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Fig. 3.A18) δ 38.34; HRMS (ESI) (m/z): calcd. for C36H56AuClP4 [M-Cl]+: 809.2998, 
found: 809.3016 ∆ = 2.2241 (Fig. 3.A19). Purity was demonstrated to be 98% by RP-
HPLC: Rt = 10.81 min using the following method: Flow rate: 1 mL/min; λ = 260 nm; 
Eluent A = H2O with 0.1% TFA; Eluent B = MeCN with 0.05% formic acid; Elution 
program: 0 to 100% B over 10 min followed by 100 to 0% B over 5 min and 4 additional 
min at 0% B (Fig. 3.A20). 
 
Synthesis of the known compounds[1,2-bis[(2R,5R)-2,5-
dimethylphospholano]benzene]digold(I) (5)363 and of bis-[1,2-bis[(2R,5R)-2,5-
dimethylphospholano]benzene]gold(I) (6) 
Compounds 5 and 6 were synthesized and separated following the procedure described for 
the preparation of compounds 1 and 2 using AuCl(THT) (61.9 mg, 0.193 mmol) and 1,2-
bis[(2R,5R)-2,5-dimethylphospholano]benzene (60.1 mg, 0.196 mmol). 
 
Characterization of compound 5: White powder (35 mg, 35%); Rf 0.8 in 
5:95/MeOH:CH2Cl2; 1H NMR (400 MHz, CDCl3, Fig. 3.A21) δ 7.73-7.64 (m, 4H), 3.61 
(sextet, J = 7.7 Hz, 2H), 2.99-2.86 (m, 2H), 2.54-2.38 (m, 2H), 2.30-2.12 (m, 2H), 1.92-
1.76 (m, 2H), 1.56-1.44 (m, 2H), 1.37 (dd, J = 20.6, 6.8 Hz, 6H), 1.06 (dd, J = 17.2, 7.2 
Hz, 6H); 13C NMR (101 MHz, CDCl3, Fig. 3.A22) δ 134.62, 134.56, 134.49, 131.75, 
131.72, 131.70, 37.37, 37.20, 37.19, 37.16, 37.02, 36.99, 36.81, 35.73, 35.71, 35.69, 34.17, 
34.10, 34.03, 19.73, 19.71, 19.68, 19.63, 19.57; 31P NMR (162 MHz, CDCl3, Fig. 3.A23) 
δ 43.96; HRMS (ESI) (m/z): calcd. for C18H28Au2Cl2P2 [M-Cl]+: 735.0686, found: 
735.0697 ∆ = 1.4965 (Fig. 3.A24). Purity was demonstrated to be 97% by RP-HPLC: Rt = 
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7.86 min using the following method: Flow rate: 1 mL/min; λ = 260 nm; Eluent A = H2O 
with 0.1% TFA; Eluent B = MeCN with 0.05% formic acid; Elution program: 0 to 100% 
B over 10 min followed by 100 to 0% B over 5 min and 4 additional min at 0% B (Fig. 
3.A25). 
 
Characterization of compound 6: Yellow powder (71 mg, 37%); Rf 0.2 in 
5:95/MeOH:CH2Cl2; 1H NMR (400 MHz, CDCl3, Fig. 3.A26) δ 7.74-7.66 (m, 4H), 7.60-
7.53 (m, 4H), 2.71-2.44 (m, 8H), 2.35-2.13 (m, 8H), 1.86-1.72 (m, 4H), 1.61-1.48 (m, 4H), 
1.18 (td, J = 10.5, 6.8 Hz, 12H), 0.80-0.71 (m, 12H); 13C NMR (101 MHz, CDCl3, Fig. 
3.A27) δ 142.34, 133.32, 133.29, 133.27, 130.66, 40.54, 40.46, 40.39, 37.69, 37.63, 37.56, 
36.04, 35.82, 21.45, 21.39, 21.34, 14.47; 31P NMR (162 MHz, CDCl3, Fig. 3.A28) δ 38.24; 
HRMS (ESI) (m/z): calcd. for C36H56AuClP4 [M-Cl]+: 809.2998, found: 809.3025 ∆ = 
3.3362 (Fig. 3.A29). Purity was demonstrated to be 97% by RP-HPLC: Rt = 10.81 min 
using the following method: Flow rate: 1 mL/min; λ = 260 nm; Eluent A = H2O with 0.1% 
TFA; Eluent B = MeCN with 0.05% formic acid; Elution program: 0 to 100% B over 10 
min followed by 100 to 0% B over 5 min and 4 additional min at 0% B (Fig. 3.A30). 
 
3.5.1.3. X-ray crystallography of compounds 3-6 
The single crystal of compound 3 was grown at 4 °C by vapor diffusion of Et2O into a 
CH2Cl2 solution and compounds 4, 5, and 6 were grown at room temperature by vapor 
diffusion of Et2O into CDCl3 solutions. Suitable crystals were selected by microscopic 
examination through crossed polarizers, mounted on a fine glass fibre in polyisobutene oil, 
and cooled to 90 K under a stream of nitrogen. A Bruker D8 Venture diffractometer with 
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graded-multilayer focused MoKα X-rays (λ = 0.71073 Å) was used to collect the 
diffraction data from the crystals. The raw data were integrated, scaled, merged and 
corrected for Lorentz-polarization effects using the APEX3 package.364-365 Space group 
determination and structure solution and refinement were carried out with SHELXT, and 
SHELXL,366-367 respectively. All non-hydrogen atoms were refined with anisotropic 
displacement parameters. Hydrogen atoms were placed at calculated positions and refined 
using a riding model with their isotropic displacement parameters (Uiso) set to either 1.2Uiso 
or 1.5Uiso of the atom to which they were attached. The structures, deposited in the 
Cambridge Structural Database (deposition number = 1889869 (3), 1889576 (4), 1889577 
(5), and 1916580 (6)), were checked for missed higher symmetry, twinning, and overall 
quality with PLATON,368 an R-tensor,369 and finally validated using CheckCIF.368 The X-
ray structures of compounds 3-6 are presented in Fig. 3.3 and the corresponding structure 
refinement data in Table 3.5. 
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Table 3.5. Crystal data and structure refinement for compound 3-6. 
 Compound 3 Compound 4 Compound 5 Compound 6 
Empirical formula C18H28Au2Cl2P2 C37H57AuCl4P4a C18H28Au2Cl2P2 C37H57AuCl4P4a 
Molecular weight 771.18 964.47 771.18 964.47 
Temperature 90.0(2) K 220(2) K 180(2) K 220(2) K 
Wavelength 0.71073 Å 0.71073 Å 0.71073 Å 0.71073 Å 
Crystal system, space 
group 
Orthorhombic, P212121 Orthorhombic, P212121 Orthorhombic, P212121 Orthorhombic, P212121 
Unit cell dimensions a = 16.3388(9) Å, α = 90° 
b = 16.3413(9) Å, β = 90° 
c = 16.4154(8) Å, γ = 90° 
a = 12.6939(5) Å, α = 
90° 
b = 16.5334(8) Å, β = 
90° 
c = 20.1529(8) Å, γ = 
90° 
a = 16.1576(3) Å, α = 
90°  
b = 16.3885(3) Å, β = 
90° 
c = 16.7778(4) Å, γ = 
90° 
a = 12.7646(3) Å, α = 
90° 
b = 16.4972(3) Å, β = 
90° 
c = 20.0823(5) Å, γ = 
90° 
Volume 4382.9(4) Å3 4229.6(3) Å3 4442.74(16) Å3 4228.93(16) Å3 
Z, Calculated density 8, 2.337 Mg/m3 4, 1.515 Mg/m3 8, 2.306 Mg/m3 4, 1.515 Mg/m3 
Absorption coefficient 13.763 mm-1 3.907 mm-1 13.577 mm-1 3.908 mm-1 
F(000) 2864 1944 2864 1944 
Crystal size 0.100 × 0.080 × 0.040 mm 0.140 × 0.100 × 0.070 
mm 
0.220 × 0.200 × 0.160 
mm 
0.120 × 0.090 × 0.090 
mm 
Theta range for data 
collection 
2.777 to 27.506° 3.110 to 28.819° 2.728 to 27.492° 2.861 to 27.505° 
Limiting indices -21 ≤ h ≤ 21, -21 ≤ k ≤ 21, -21 
≤ l ≤ 21 
-17 ≤ h ≤ 17, -22 ≤ k ≤ 
22, -27 ≤ l ≤ 27 
-20 ≤ h ≤ 20, -21 ≤ k ≤ 
21, -21 ≤ l ≤ 21 
-16 ≤ h ≤ 16, -21 ≤ k ≤ 
21, -26 ≤ l ≤ 26 
Reflections collected / 
unique 
64860 / 10048 [R(int) = 
0.0440] 
98447 / 11027 [R(int) = 
0.0479] 
74012 / 10159 [R(int) = 
0.0314] 
78808 / 9679 [R(int) = 
0.0411] 
Completeness to theta = 
25.242 
99.8% 99.7% 99.8% 99.8% 
Absorption correction Semi-empirical from 
equivalents 
Semi-empirical from 
equivalents 
Semi-empirical from 
equivalents 
Semi-empirical from 
equivalents 
Max. and min. 
transmission 
0.746 and 0.431 0.746 and 0.609 0.491 and 0.284 0.746 and 0.665 
Refinement method Full-matrix least-squares on F2 Full-matrix least-
squares on F2 
Full-matrix least-
squares on F2 
Full-matrix least-
squares on F2 
Data / restraints / 
parameters 
10048 / 386 / 442 11027 / 488 / 456 10159 / 36 / 442 9679 / 488 / 454 
Goodness-of-fit on F2 1.069 1.112 1.048 1.060 
Final R indices [I > 
2σ(I)] 
R1 = 0.0213, wR2 = 0.0409 R1 = 0.0262, wR2 = 
0.0571 
R1 = 0.0149, wR2 = 
0.0309 
R1 = 0.0298, wR2 = 
0.0660 
R indices (all data) R1 = 0.0246, wR2 = 0.0417 R1 = 0.0332, wR2 = 
0.0594 
R1 = 0.0160, wR2 = 
0.0312 
R1 = 0.0346, wR2 = 
0.0681 
Absolute structure 
parameter 
0.007(3) 0.016(5) 0.009(2) 0.008(3) 
Extinction coefficient 0.000064(19) 0.00047(11) 0.00049(2) N/A 
Largest diff. peak and 
hole 
1.971 and -1.017 e. Å-3 0.816 and -0.573 e. Å-3 1.007 and -1.056 e. Å-3 1.138 and -0.676 e. Å-3 
a The empirical formula includes a molecule of CHCl3. 
 
3.5.2. Biochemistry and microbiology 
3.5.2.1. Biochemical/biological reagents and instrumentation 
The American Type Culture Collection (ATCC) Candida albicans strains, including 10231 
(strain B), MYA-2876 (strain E), and 64124 (strain F), were a generous gift from Dr. Jon 
Y. Takemoto (Utah State University, Logan, UT, USA). The rest of the C. albicans strains, 
including MYA-1003 (strain A), MYA-1237 (strain C), MYA-2310 (strain D), 90819 
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(strain G), and as well as the non-albicans Candida fungi C. glabrata ATCC 2001 (strain 
H), C. krusei ATCC 6258 (strain I), C. parapsilosis ATCC 22019 (strain J), and 
Cryptococcus neoformans ATCC MYA-85 (strain M) were purchased from the American 
Type Culture Collection (ATCC, Manassas, VA, USA). A panel of Candida auris strains 
were acquired from the CDC & FDA Antibiotic Resistance Isolate Bank (CDC, Atlanta, 
GA, USA), which included C. auris AR Bank # 0381-0390 (strains K, L, and I-VIII). C. 
neoformans clinical isolates CN1-CN3 (strains N-P) were generously provided by Dr. 
Nathan Wiederhold (University of Texas, San Antonio, TX, USA). The filamentous fungi 
Aspergillus nidulans ATCC 38163 (strain Q) and Fusarium graminearum 053 (strain T) 
were kind gifts from Prof. Jon S. Thorson (University of Kentucky, Lexington, KY) and 
Prof. Lisa Vaillancourt (University of Kentucky, Lexington, KY, USA), while the 
Aspergillus terreus ATCC MYA-3633 (strain R) and Aspergillus flavus ATCC MYA-3631 
(strain S) were purchased from the ATCC. Yeast strains were cultured at 35 °C in yeast 
extract peptone dextrose (YEPD) broth. Aspergillus spp. strains were cultured on potato 
dextrose agar (PDA, catalog # 110130, EMD Millipore, Billerica, MA, USA) at 28 °C 
before the spores were harvested. All fungal experiments were carried out in RPMI 1640 
medium (catalog # R6504, Sigma-Aldrich, St. Louis, MO, USA) buffered to pH 7.0 with 
0.165 M MOPS buffer (Sigma-Aldrich, St. Louis, MO, USA). 
 
For cytotoxicity assays, the human embryonic kidney cell line (HEK-293) was purchased 
from the ATCC. The human bronchial epithelial cell line (BEAS-2B), the human lung 
carcinoma cell line (A549), and the mouse macrophage cell line (J774A.1) were generous 
gifts from Prof. David K. Orren (University of Kentucky, Lexington, KY), Prof. Markos 
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Leggas (University of Kentucky, Lexington, KY), and Prof. David J. Feola (University of 
Kentucky, Lexington, KY), respectively. A549, HEK-293, and BEAS-2B cells were 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, catalog # VWRL0100, VWR, 
Chicago, IL) supplemented with 10% fetal bovine serum (FBS; from ATCC) and 1% 
penicillin/streptomycin (from ATCC) at 37 °C with 5% CO2. The J774A.1 cells were 
cultured in DMEM (catalog # 30-2002, ATCC, Manassas, VA), which was also 
supplemented with FBS and antibiotics and grown at 37 °C with 5% CO2. 
 
Instrumentation for fungal assays with yeast were the V-1200 spectrophotometer (VWR, 
Radnor, PA, USA) and the SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, 
CA, USA) for biofilm, cytotoxicity, and hemolysis assays. For the whole cell uptake assay, 
Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES, Agilent, Santa 
Clara, CA, USA). The known antifungal drugs, amphotericin B (AmB, VWR, Chicago, IL, 
USA), caspofungin (CFG, Sigma-Aldrich, St. Louis, MO, USA), fluconazole (FLC, AK 
Scientific, Union City, CA, USA), voriconazole (VRC, AK Scientific, Union City, CA, 
USA), and the antirheumatic drug, auranofin (Santa Cruz Biotechnology, Dallas, TX, 
USA) were used as positive controls. 
 
3.5.2.2. Determination of minimum inhibitory concentration (MIC) values of 
compounds 1-6 
The individual minimum inhibitory concentration (MIC) values of compounds 1-6 were 
measured for each fungal strain. The MIC values were determined using the broth 
microdilution method305 in sterile 96-well plates. Concentrations of compound tested were 
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0.06-31.3 µg/mL. For testing, compounds were dissolved in DMSO at a concentration of 
5 mg/mL allowing the highest concentration of DMSO to be 0.63% in the assay. Serial 
two-fold dilutions of compound were made horizontally across the plate in 100 µL of RPMI 
1640 medium. For yeast, the overnight culture was diluted into RPMI 1640 (25 µL of a 
fungal stock with OD600 of 0.12-0.15 into 10 mL of RPMI 1640 medium, resulting in final 
inoculum size around 1-5×103 CFU/mL) and added to the plate (100 µL per well), making 
a final volume of 200 µL total per well. Similarly, for Aspergillus spp. and F. graminearum 
053, spores were diluted in RPMI 1640 to 5×105 spores/mL then 100 µL of stock was 
seeded in each well.370 The MIC-0 value of each compound was determined by visual 
inspection, MIC-2 values were measured via optical density reading at 600 nm. For 
Candida spp., plates were incubated for 48 h at 35 °C, for Cryptococcus spp. and 
Aspergillus spp. were incubated for 72 h at 35 °C, and F. graminearum 053 was incubated 
at room temperature for 5 days. MIC values for CFG were read at 24 h (Tables 3.1 and 
3.2). 
 
3.5.2.3. Time-kill assays for compounds 4 and 6 
To assess the time-dependent inhibition of compounds 4 and 6 against four yeast strains, 
C. albicans ATCC 10231 (strain B), C. glabrata ATCC 2001 (strain H), C. auris AR Bank 
# 0384 (strain K), and C. auris AR Bank # 0390 (strain L) we performed time-kill assays. 
The protocol for time-kill assays followed methods previously described with minor 
modifications.256, 308 Overnight cultures were grown in YEPD medium at 35 °C with 
shaking at 200 rpm. The overnight cultures were diluted in RPMI 1640 medium to an OD600 
of 0.125 (~1×106 CFU/mL). Then, 200 µL of cells were added to 4.8 mL of RPMI 1640 
173 
medium in sterile culture tubes to afford a fungal cell concentration ~1×105 CFU/mL. 
Compounds were then added to the fungal cells. The treatment conditions included sterile 
control (negative control), growth control, compound 4 at 1× MIC, 4 at 2× MIC, 6 at 1× 
MIC, 6 at 2× MIC, as well as AmB at 1× MIC as a positive control. Treated fungal cultures 
were incubated in the culture tubes at 35 °C with 200 rpm shaking for 24 h. Samples were 
aliquoted from the different treatments at regular time points (0, 3, 6, 9, 12, and 24 h) and 
plated in duplicate onto PDA plates. For each time point, cultures were vortexed, 100 µL 
of culture was aspirated, and 10-fold serial dilutions were made in sterile ddH2O. From the 
appropriate dilutions, 100 µL of fungal suspension was spread on agar plates and incubated 
at 35 °C for 48 h before colony counts were determined. Only plates containing between 
30 and 300 colonies were counted, making 30 CFU/mL the limit of detection. At 24 h, 50 
µL of sterile 2 mM resazurin in phosphate buffered saline (PBS) was added to the 
treatments and incubated at 35 °C with 200 rpm shaking for 2 h in the dark for visual 
inspection. As resazurin (blue-purple) is metabolized by the cells to produce resorufin 
(pink-orange), the addition of resazurin is used as a qualitative measure to confirm the 
relative growth of the fungal cells in the different treatment conditions (Fig. 3.4). 
 
3.5.2.4. Prevention of biofilm formation and disruption of pre-formed biofilm assays 
for compounds 4 and 6 
To evaluate the ability of the gold complexes to prevent formation of biofilms and also 
their ability to disrupt pre-formed biofilms, we conducted assays for compounds 4 and 6 
against sessile yeast cells for four representative yeast strains, C. albicans ATCC 10231 
(strain B), C. glabrata ATCC 2001 (stain H), C. auris AR Bank # 0384 (strain K), and C. 
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auris AR Bank # 0390 (strain L). All biofilm assays were performed in 96-well plates using 
XTT [2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] to 
measure the viability of the biofilm as previously described.309, 371 An overnight culture of 
yeast was grown at 35 °C in YEPD medium with shaking at 200 rpm before dilution in 
RPMI 1640 medium to an OD600 between 0.12 and 0.15. For biofilm prevention assays, 
serial dilutions of compounds were made in 100 µL of RPMI as in the MIC assays and 100 
µL of fungal suspension with OD600 of 0.12-0.15 was added. For assays with a pre-formed 
biofilm, 100 µL of fungal cells were aliquoted in a 96-well plate, leaving one column empty 
for the sterile control. After 24 h incubation at 37 °C, visible biofilms had formed in the 
well. The biofilm was washed three times with 100 µL of PBS. After washing, RPMI 1640 
medium and compound were added to the plate, in a similar fashion to that described for 
the MIC values. All compounds were tested in the concentration range of 0.06-31.3 µg/mL 
and AmB and auranofin were included as controls. Plates were incubated at 37 °C for 24 
h. Finally, the plates were washed three times with PBS before adding 100 µL of XTT dye. 
The XTT was prepared by dissolving XTT at 0.5 mg/mL concentration in sterile PBS. 
Before adding to a plate, 1 µL of 10 mM menadione in acetone was added to 10 mL of the 
0.5 mg/mL solution of XTT. After addition of XTT (containing menadione), the plates 
were incubated for 3 h at 37 °C in the dark. 80 µL of liquid from each well was transferred 
to a new plate and then with the plate reader for absorbance at 450 nm. For these 
experiments, we determined the sessile MIC (SMIC90), which is defined as the compound 
concentration required to inhibit the metabolic activity of biofilm by 90% compared to the 
growth control (Table 3.3). The plates used to determine the SMIC90 values are provided 
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in Fig. 3.5 (prevention of biofilm formation) and Fig. 3.6 (disruption of pre-formed 
biofilm). Each assay was performed in duplicate. 
 
3.5.2.5. Mammalian cytotoxicity assays for compounds 4 and 6 
To examine whether the compounds are safe for human cells, cytotoxicity assays were 
done against four mammalian cell lines: HEK-293, A549, BEAS-2B, and J774A.1 cells. 
Compounds 4 and 6 as well as auranofin were tested against each cell line to measure their 
cytotoxic effect by using a resazurin cell viability assay as previously described with minor 
modifications.244, 372 The assays were done in 96-well plates and cell counts were made 
using a hemacytometer. HEK-293 and J774A.1 cells were plated at 1×104 cells/mL while 
A549 and BEAS-2B were plated at 3×103 cells/mL. Compounds were tested in 
concentrations ranging from 0.06 to 15.6 µg/mL with final concentration of DMSO at 0.5% 
(Fig. 3.7). It is important to note that testing xenobiotics at sub-IC50 concentrations can 
result in increase in cell growth, resulting in >100% cell survival in the treatment groups.244, 
311-314 In instances where >100% cell survival was observed, we displayed the data as 100% 
cell survival in Fig. 3.7. We are providing the data with observed % in Fig. 3.11. All assays 
were done in quadruplicate. 
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Fig. 3.11. Evaluation of cytotoxicity for compound 4 (orange), compound 6 (blue), and auranofin (white) 
with A. A549, B. BEAS-2B, C. HEK-293, and D. J774A.1 cell lines. Controls include treatment with 
Triton-X® (TX, 1% v/v, positive control) and 0.5% DMSO (negative control). 
 
3.5.2.6. Measurement of hemolysis for compounds 4 and 6 
To extend on the cytotoxicity results, compounds 4 and 6 along with auranofin and AmB, 
were tested for their ability to lyse red blood cells (RBCs). Both human and murine RBCs 
were provided in a citrate-treated tube on ice and the hemolysis assay was done as 
previously described with minor modifications and in similar fashion to cytotoxicity 
assays.253, 373-374 The RBCs were washed three times in PBS by resuspending 0.5 mL of 
RBCs in 5 mL PBS and pelleting at 1,000 rpm for 7 min. The RBCs were resuspended in 
PBS to achieve a cell concentration of on the order of 107 cells/mL. Compounds were 
dissolved at concentration of 3.14 mg/mL (200×) in DMSO. Serial double dilutions were 
made in DMSO. A 1:100 dilution of compound in PBS was added to 100 µL of RBCs in a 
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96-well plate (total volume of 200 µL). Compounds were tested in the range of 0.06-15.6 
µg/mL in quadruplicate with 0.5% DMSO and ~5×106 RBCs per tube. The RBCs were 
also treated with 1% Triton-X® (positive control) and PBS (negative control). The RBCs 
were treated for 30 min at 37 °C and the absorbance was read at 595 nm. Hemolysis is 
visually observed by a decrease in optical density of the wells (turbid, dark red to 
transparent pink). Percent hemolysis (Fig. 3.8) was calculated using this equation after 
subtraction of the background absorbance (positive control): 
 
% Hemolysis = 
absorbance of sample
absorbance of RBC+PBS (negative control)
×100 
 
3.5.2.7. Whole cell uptake assay for compounds 4 and 6 
To gain insight into the mechanism of action of these compounds, we measured the uptake 
of the gold-containing compounds into the yeast cells. Compounds 4 and 6 were each tested 
with C. albicans ATCC 10231 (strain B) and C. glabrata ATCC 2001 (strain H) in 
independent triplicates following protocols for whole cell uptake assays as previously 
described with minor modifications.339, 375-376 A single colony was used to inoculate 3 mL 
of YEPD, which was grown overnight at 35 °C with 200 rpm shaking. Overnight culture 
was diluted into 100 mL of YEPD to an OD600 of ~0.075 and grown at 35 °C with 200 rpm 
shaking for 4-6 h until the culture reached an OD600 of ~0.3 indicating logarithmic phase 
growth. The cells were pelleted by centrifugation at 500 ×g for 5 min at room temperature 
and diluted in RPMI to 108 cells/mL in RPMI 1640 medium as determined by counting 
with a hemacytometer. 1 mL of fungal suspension was aliquoted into a 12 mL culture tube. 
Treatment conditions included 10 µM compound, growth control (no compound), medium 
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with compound (no cells), and 10 µM (8.5 µL) compound for ICP-OES analysis (100% 
signal). Each treatment was tested in duplicate at 35 °C with 200 rpm shaking. After 30 
min of treatment, cells were pelleted by centrifugation at 3,000 rpm (~1,000 ×g) for 5 min. 
Cell pellets were washed twice with 1 mL of ice-cold PBS. Cell pellets were digested in 
0.5 mL of concentrated HCl and added to 4.5 mL of ddH2O (10% final concentration of 
HCl). Samples were analyzed for gold content using ICP-OES. Data presented (Fig. 3.9) 
shows values for 10µM compound after subtraction of values for media with compound. 
 
3.5.2.8. Development of fungal resistance for compounds 4 and 6 
To assess the rate at which fungal strains can develop resistance to the gold compounds, 
fungal cells were repeatedly exposed to sub-inhibitory amounts of compound and the MIC 
values for each sub-culture were monitored. The procedure for the development of 
resistance assay was modified for fungal cells following the reported method.373 MIC 
assays were done as described above for compounds 4, 6, and AmB against C. albicans 
ATCC 10231 (strain B) and C. glabrata ATCC 2001 (strain H). Overnight cultures were 
inoculated from fungal cells exposed to ½ the MIC concentration for each compound. This 
was repeated for 15 subcultures (Fig. 3.10). 
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Chapter 4 
 
Broad-spectrum antifungal agents: Fluorinated aryl- and heteroaryl-substituted 
hydrazones 
4.1. ABSTRACT 
Fluorinated aryl- and heteroaryl-substituted monohydrazones displayed excellent broad-
spectrum activity against various fungal strains, including a panel of clinically relevant 
Candida auris strains relative to a control antifungal agent, voriconazole (VRC). These 
monohydrazones displayed less hemolysis of murine red blood cells than that of VRC at 
the same concentrations, possessed fungicidal activity in a time-kill study, and exhibited 
no mammalian cell cytotoxicity. In addition, these monohydrazones prevented the 
formation of biofilms that otherwise block antibiotic effectiveness and did not trigger the 
development of resistance when exposed to C. auris AR Bank # 0390 over 15 passages. 
 
4.2. INTRODUCTION 
Nosocomial fungal infections314, 377-380 represent continuing threats to medical advances 
conjoined with immunosuppression and often afflict nursing home residents or hospitalized 
patients undergoing transplantation,381-384 antiviral,385 and antineoplastic therapies.386-387 In 
addition, the emergence of new strains of fungal pathogens that resist277, 388-389 current drug 
therapies and possess high mortality rates compound these ongoing threats.390-391 
Appearing first in 2009 in Japan,392 Candida auris represents an archetypical, fungal 
infection that presents challenges in terms of its diagnosis393-394 and its treatment because 
some strains are resistant to the three available classes of current antifungals: the azoles 
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(e.g., fluconazole (FLC) and voriconazole (VRC)), the echinocandins (e.g., caspofungin 
(CFG)), and the polyenes (e.g., amphotericin B (AmB)). Front-page articles in The New 
York Times1-3, 395-397 delineate the dangers that C. auris represents and call for research to 
address this healthcare problem at a time of declining investment in antimicrobial drug 
development within the pharmaceutical industry.398 
 
Paramount among the challenges facing investigators intent on antifungal drug 
development are the issues of potency, breadth of selectivity, biofilm penetration or 
prevention, cytotoxicity including erythrocyte hemolysis, and the development of 
resistance. Despite this gamut of hurdles, the complexity of fungal cell architecture offers 
an array of as yet, unexplored targets for drug development. Prior efforts by multiple 
investigators focused on antifungal agents205, 212, 253, 390, 399 possessing chemically diverse 
scaffolds including aminoglycosides,238, 241-244, 246-247 benzimidazoles,205, 212, 400 azoles,183-
184, 338, 401-403 haloperidols,256, 404 gold(I) complexes,405 and ebselen/ebsulfur.253, 406-407 We 
now report the development of fluorinated, diaryl- and heterodiaryl-substituted hydrazones 
as compounds that meet these challenges and represent a new class of potential agents for 
the selective treatment of candidiasis.408-412 Of particular interest, these new agents show 
particular promise for the treatment of C. auris infections that now afflict an increasing 
number of patients in nursing homes and hospitals.413-414 
 
We previously reported the development of bishydrazones I and II (Fig. 4.1) bearing either 
N-amidino or N-aryl groups, respectively, as potential antibacterial and antifungal 
agents.211 Subsequent structure-activity studies revealed that alkoxy-substituted, aryl 
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groups attached to bishydrazones III with biphenyl linkers had greater potency as in vitro 
antifungal agents than as antibacterial agents, possessed minimal toxicity, and exhibited no 
resistance through multiple generations.212 Further work disclosed that no particular 
advantage accrued to symmetrical bishydrazones relative to comparable monohydrazones 
in which an aryl or heteroaryl group replaced the biphenyl linker in III. The 
monohydrazones IV (i.e., compounds 1-7 in Fig. 4.2) bearing fluorinated aryl or heteroaryl 
groups possessed not only the positive spectrum of drug attributes seen for the 
bishydrazones III but also surprising potency and selectivity for ten fungal strains in the 
C. auris family.  
 
 
Fig. 4.1. General structures of N-aryl and N-amidino-substituted bishydrazones (families I-III), as well as 
monohydrazones (family IV) studies herein. The square represents the hydrocarbon platform separating these 
hydrazone groups in families I-III. 
 
4.3. RESULTS AND DISCUSSION  
4.3.1. Synthesis 
The synthesis of 35 family IV monohydrazones in seven series (1-7), each comprised of 
six compounds with varied R2 groups (a-f) entailed the condensation of either substituted 
aldehydes (i.e., benzaldehyde, 3-fluorobenzaldehyde, 4-fluorobenzaldehyde, 4-
chlorobenzaldehyde, 4-methoxybenzaldehyde, 2,4-difluorobenzaldehyde) or 
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acetophenone with 1-2 equivalents of substituted phenylhydrazines at 80 °C to yield 1a-7f 
in 26-98% yields (Fig. 4.2). 
 
 
Fig. 4.2. Synthetic scheme for the preparation of compounds 1a-7f in family IV. 
 
4.3.2. Antifungal activity by determination of minimum inhibitory concentration 
(MIC) values 
To provide comparable data for monohydrazones in family IV relative to their previously 
reported counterparts, namely the bishydrazones in family III, we first tested the 35 
monohydrazones 1a-7f against a panel of seven strains (A-G) of Candida albicans: ATCC 
10231(R) (A), ATCC 64124(R) (B), ATCC MYA-2876(S) (C), ATCC 90819(R) (D), 
ATCC MYA-2310(S) (E), ATCC MYA-1237(R) (F), and ATCC MYA-1003(R) (G) 
(Table 4.1). We also explored their activity against a panel of three non-albicans Candida 
strains: Candida glabrata ATCC 2001 (H), Candida krusei ATCC 6258 (I), and Candida 
parapsilosis ATCC 22019 (J) (Table 4.1). Throughout this study, we employed a range of 
concentrations varying from 0.03 to 31.3 µg/mL for monohydrazones 1a-7f, as well as for 
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the commercially available, positive antifungal controls, amphotericin B (AmB), 
caspofungin (CFG), fluconazole (FLC), and voriconazole (VRC). In Table 4.1, MIC-0 
values (i.e., no visible growth) were reported for monohydrazones 1a-7f and for the 
positive controls AmB and CFG, and MIC-2 values (i.e., 50% growth inhibition) were 
reported for FLC and VRC against all fungal strains tested. Herein, we defined antifungal 
activity as excellent (≤1.95 µg/mL), good (3.9-7.8 µg/mL), or poor (≥15.6 µg/mL) based 
on MIC values, and we utilized a color scheme (excellent, green; good, yellow; and poor, 
pink) to provide an overall visual picture of the performance of individual monohydrazones 
versus positive controls. 
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Table 4.1. MIC values (µg/mL) determined for compounds 1a-7a as well as the antifungal controls AmB, CFG, FLC, and VRC against 
seven Candida albicans strains (A-G) and three non-albicans Candida strains (H-J). The LogP values calculated in ChemDraw and 
Molinspiration are also provided. 
Cpd # LogP value Strain 
ChemDraw Molinspiration A B C D E F G H I J 
1a 3.42 4.76 0.49 7.8 3.9 3.9 7.8 7.8 1.95 15.6 0.98 7.8 
1c 3.58 4.93 0.49 7.8 3.9 7.8 31.3 7.8 1.95 15.6 1.95 7.8 
1d 3.98 5.44 0.98 3.9 3.9 7.8 15.6 1.95 1.95 3.9 0.98 7.8 
1e 3.29 4.82 0.98 3.9 3.9 7.8 15.6 3.9 1.95 3.9 1.95 31.3 
1f 3.73 5.02 0.49 3.9 7.8 7.8 3.9 1.95 3.9 3.9 0.49 7.8 
2a 3.58 4.90 0.98 7.8 7.8 7.8 15.6 7.8 3.9 15.6 3.9 7.8 
2b 3.73 5.04 0.49 0.98 1.95 3.9 1.95 15.6 1.95 3.9 1.95 3.9 
2c 3.73 5.07 0.06 7.8 0.98 15.6 3.9 3.9 15.6 7.8 3.9 7.8 
2d 4.13 5.58 1.95 3.9 3.9 3.9 0.98 3.9 1.95 1.95 3.9 3.9 
2e 3.45 4.96 1.95 7.8 3.9 7.8 1.95 3.9 1.95 15.6 0.12 31.3 
2f 3.89 5.16 0.24 15.6 3.9 7.8 7.8 15.6 0.98 7.8 0.98 7.8 
3a 3.58 4.93 0.24 1.95 1.95 1.95 0.98 1.95 0.98 3.9 0.24 3.9 
3c 3.73 5.09 0.12 7.8 1.95 15.6 7.8 3.9 15.6 15.6 3.9 7.8 
3d 4.13 5.61 7.8 7.8 1.95 7.8 15.6 7.8 1.95 3.9 1.95 31.3 
3f 3.89 5.18 0.12 1.95 3.9 1.95 15.6 1.95 0.98 3.9 0.49 7.8 
4a 3.98 5.44 0.98 7.8 3.9 15.6 31.3 7.8 1.95 >31.3 1.95 15.6 
4b 4.13 5.58 0.49 7.8 1.95 7.8 3.9 7.8 1.95 15.6 0.49 7.8 
4c 4.13 5.61 0.49 7.8 3.9 31.3 7.8 7.8 1.95 15.6 15.6 7.8 
4d 4.53 6.12 3.9 3.9 7.8 15.6 31.3 7.8 3.9 7.8 7.8 31.3 
4e 3.85 5.50 0.98 15.6 15.6 15.6 7.8 7.8 15.6 7.8 7.8 31.3 
4f 4.29 5.70 0.98 7.8 7.8 15.6 31.3 7.8 3.9 15.6 0.98 15.6 
5a 3.29 4.82 0.98 >31.3 >31.3 15.6 >31.3 >31.3 >31.3 >31.3 >31.3 >31.3 
5c 3.45 4.98 0.98 1.95 1.95 3.9 0.98 1.95 0.98 3.9 0.24 3.9 
5d 3.85 5.50 0.12 3.9 3.9 1.95 15.6 7.8 1.95 1.95 0.49 7.8 
5e 3.16 4.88 15.6 7.8 3.9 15.6 15.6 3.9 3.9 31.3 3.9 >31.3 
5f 3.61 5.08 0.49 0.24 3.9 0.98 3.9 0.98 0.49 1.95 0.24 1.95 
6a 3.73 5.02 0.98 7.8 3.9 3.9 7.8 7.8 3.9 15.6 0.98 7.8 
6b 3.89 5.16 0.98 0.98 7.8 15.6 0.98 7.8 0.49 3.9 0.12 7.8 
6c 3.89 5.18 0.24 15.6 1.95 15.6 7.8 7.8 0.98 15.6 1.95 15.6 
6d 4.29 5.70 0.49 1.95 0.98 15.6 1.95 3.9 0.98 1.95 1.95 7.8 
6f 4.05 5.27 0.98 7.8 3.9 3.9 7.8 7.8 1.95 7.8 0.98 7.8 
6g 4.05 5.27 0.12 31.3 1.95 15.6 7.8 15.6 31.3 31.3 1.95 7.8 
6h 4.05 5.27 0.06 15.6 0.98 15.6 3.9 3.9 7.8 7.8 0.98 3.9 
7a 2.98 5.21 7.8 >31.3 >31.3 >31.3 31.3 >31.3 1.95 31.3 15.6 >31.3 
7f 3.3 5.46 0.24 0.49 0.98 >31.3 0.98 7.8 0.49 31.3 0.98 3.9 
AmBa   3.9 3.9 1.95 0.98 1.95 3.9 3.9 1.95 3.9 1.95 
CFGa   0.98 0.24 0.06 0.12 0.12 0.24 0.49 0.06 0.49 1.95 
FLCa   62.5 >125 15.6 >125 >125 62.5 62.5 >31.3 >31.3 1.95 
VRCa   0.24 3.9 1.95 1.95 0.98 7.8 1.95 0.06 0.12 0.03 
Strains: A = C. albicans ATCC 10231, B = C. albicans ATCC 64124, C = C. albicans ATCC MYA-2876(S), D = C. albicans ATCC 
90819(R), E = C. albicans ATCC MYA-2310(S), F = C. albicans ATCC MYA-1237(R), G = C. albicans ATCC MYA-1003(R), H = 
C. glabrata ATCC 2001, I = C. krusei ATCC 6258, and J = C. parapsilosis ATCC 22019. NOTE: Here, the (S) and (R) indicate that 
ATCC reports these strains to be susceptible (S) and resistant (R) to itraconazole (ITC) and FLC. Known antifungal agents: AmB = 
amphotericin B, CFG = caspofungin, FLC = fluconazole, and VRC = voriconazole. MIC-0 values are reported for compounds 1a-7f, 
AmB, and CFG; and MIC-2 values are reported for azoles. Compounds were tested in duplicate. 
a These values were previously reported in ref 247, and are here for comparison purpose. 
 MIC ≤1.95 µg/mL (excellent antifungal activity) 
 MIC = 3.9-7.8 µg/mL (good antifungal activity) 
 MIC ≥15.6 µg/mL (poor antifungal activity) 
 
From a quick glance at the data reported in Table 4.1, we observed that compounds 5a and 
7a generally displayed poor activity against the ten strains (A-J) tested, and we excluded 
them from additional biological studies besides additional MIC values determination. The 
33 remaining monohydrazones synthesized displayed excellent to good activity against 
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these ten fungal strains. A detailed analysis of the seven series (i.e., series 1-7) led to the 
following conclusions. Monohydrazones 1a-1f with no substituents in the benzylidine 
portion of the monohydrazones (i.e., R1 = H; Fig. 4.2) displayed excellent to good activity 
against strains A-J (0.49-7.8 µg/mL) with the exception of compounds 1a (MIC = 15.6 
µg/mL against H), 1c (MIC ≥15.6 µg/mL against E and H), 1d (MIC = 15.6 µg/mL against 
E), and 1e (MIC ≥15.6 µg/mL against E and J). Monohydrazones 2a-2f with meta-
fluorobenzylidene structures (i.e., R1 = m-F; Fig. 4.2) displayed excellent to good activity 
(0.06-7.8 µg/mL) against all fungal strains tested with exception of compounds 2a, 2b, 2c, 
2e, and 2f against strains E and H (15.6 µg/mL), strain F (15.6 µg/mL), strains D and G 
(15.6 µg/mL), strains H and J (15.6 and 31.3 µg/mL), and strains B and F (15.6 µg/mL), 
respectively. Monohydrazones 3a, 3c, 3d, and 3f with para-fluorobenzylidene structures 
(i.e., R1 = p-F; Fig. 4.2) displayed excellent to good activity against strains A-J (0.12-7.8 
µg/mL), but compounds 3c, 3d, and 3f displayed poor activity (15.6-31.3 µg/mL) against 
strains (D, G, and H), strains (E and J), and strain E, respectively. In the case of 
monohydrazones 4a-4f with para-chlorobenzylidene structures (i.e., R1 = p-Cl; Fig. 4.2), 
these compounds displayed excellent to good activity against strains A-C, F, G, and I (0.49-
7.8 µg/mL) with the exception of compounds 4c and 4e, which displayed poor activity 
against strains I, and strains B, C, and G, respectively. In the case of monohydrazones 5a-
5f with para-methoxybenzylidene structures (i.e., R1 = p-OMe; Fig. 4.2), compounds 5c, 
5d, and 5f exhibited excellent to good activity (0.24-7.8 µg/mL) against the whole panel 
of 10 fungal strains tested, with the exception of compound 5d against strain E (15.6 
µg/mL). Compound 5e displayed good activty against strains B, C, F, G, and I (3.9-7.8 
µg/mL). In the case of monohydrazones 6a-6h with ortho,para-difluorobenzylidene 
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structures (i.e., R1 = o,p-diF; Fig. 4.2) compounds 6a, 6b, 6d, 6f, and 6h exhibited excellent 
to good activity (0.06-7.8 µg/mL) against strains A-J with the exception of compounds 6a, 
6b, 6d, and 6h against strain H (15.6 µg/mL), strain D (15.6 µg/mL), strain D (15.6 µg/mL), 
and strains (B and D) (15.6 µg/mL), respectively. Compounds 6c and 6g exhibited excellent 
to good activity against strains (A, C, E-G, and I) (0.24-7.8 µg/mL) and strains (A, C, E, I, 
and J) (0.12-7.8 µg/mL), respectively. Finally, monohydrazone 7f with a 1-
phenylethylidene structure (i.e., R1 = H; Fig. 4.2) displayed excellent to good activity (0.24-
7.8 µg/mL) against strains A-C, E-G, I, and J. In summary, perhaps best grasped from the 
green and yellow colors in Table 4.1, a comparison with the FDA-approved antifungal 
agents, AmB, CFG, FLC, and VRC with some of these monohydrazones revealed that 
monohydrazones exhibited comparable or superior activity against strains A, B, F, G, and 
I. 
 
We next explored the activity of representatives monohydrazones (i.e., 1a, 1c, 1d, 1e, 1f, 
2b, 2d, 2f, 4c, 4d, 5e, 6b, and 7a) against three Aspergillus strains: Aspergillus flavus 
ATCC MYA-3631 (K), Aspergillus nidulans ATCC 38163 (L), and Aspergillus terreus 
ATCC MYA-3633 (M) (Table 4.2). We found all of the representative monohydrazones 
tested to be generally inactive as antifungal agents against Aspergillus strains. As a result, 
we decided against testing the remaining 22 compounds against these three Aspergillus 
strains. From all of the observations made on compounds 1a-7f, we concluded that 
compounds 1d, 2b, 2d, 2e, 3a, 3f, 4b, 5c, 5d, 5f, 6b, 6c, 6d, and 7f displayed better overall 
activity. It is important to point out that these compounds maintained better activity against 
the FLC-resistant C. albicans strain. 
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Table 4.2. MIC values (µg/mL) determined for compounds 1a-7a as well as the 
antifungal controls AmB, CFG, FLC, and VRC against three Aspergillus spp. 
 Filamentous fungi 
Cpd # K L M 
1a >31.3 7.8 >31.3 
1c >31.3 7.8 >31.3 
1d >31.3 31.3 >31.3 
1e >31.3 31.3 >31.3 
1f >31.3 31.3 >31.3 
2b >31.3 7.8 >31.3 
2d >31.3 15.6 >31.3 
2f >31.3 7.8 >31.3 
4c >31.3 7.8 >31.3 
4d >31.3 >31.3 >31.3 
5e >31.3 >31.3 >31.3 
6b >31.3 >31.3 >31.3 
7a >31.3 >31.3 >31.3 
AmBa 15.6 15.6 3.9 
CFGa >31.3 >31.3 >31.3 
FLCa 62.5 62.5 62.5 
VRCa 0.24 0.12 0.12 
Strains: K = A. flavus ATCC MYA-3631, L = A. nidulans ATCC 38163, and M 
= A. terreus ATCC MYA-3633. Known antifungal agents: AmB = amphotericin 
B, CFG = caspofungin, FLC = fluconazole, and VRC = voriconazole. MIC-0 
values are reported for compounds 1a-7f as well as AmB and CFG, whereas MIC-
2 values are reported for azoles. Compounds were tested in duplicate. 
a These values were previously reported in ref 247, and are here for comparison 
purpose. 
 MIC ≤1.95 µg/mL (excellent antifungal activity) 
 MIC = 3.9-7.8 µg/mL (good antifungal activity) 
 MIC ≥15.6 µg/mL (poor antifungal activity) 
 
Based on the promising antifungal activities observed in Table 4.1, we selected seven of 
the best compounds (i.e., 2b, 3f, 4b, 5f, 6b, 6d, and 7f) and two of the worse (i.e., 5a and 
7a as negative controls) for further testing against a panel of ten C. auris strains (AR Bank 
# 0381-0390) and ten other fungal strains including three Candida duobushaemulonii 
strains (AR Bank # 0391, AR Bank # 0392, and AR Bank # 0394), two Candida haemulonii 
strains (AR Bank # 0393, and AR Bank # 0395), two Saccharomyces cerevisiae strains 
(AR Bank # 0399 and AR Bank # 0400), and one each of the following strains: Kodameae 
ohmeri (AR Bank # 0396), Candida krusei (AR Bank # 0397), and Candida lusitaniae (AR 
Bank # 0398) (Table 4.3). Using a concentration range of 0.015-31.3 µg/mL for the nine 
selected monohydrazones and using AmB, CFG, FLC, and VRC as positive controls, we 
obtaind MIC-0 values (i.e., no visible growth) for the monohydrazones and the control 
AmB, and the MIC-2 values (i.e., 50% growth inhibition) for CFG, FLC and VRC. 
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Monohydrazones 2b, 3f, 4b, 5f, 6d, and 7f displayed excellent to good activity against 
(0.015-7.8 µg/mL) all 20 strains tested. Compound 6b exhibited excellent to good activity 
(0.24-7.8 µg/mL) against most of the strains tested, with the exception of strains AR Bank 
# 0383-0385, AR Bank # 0387, AR Bank # 0389, AR Bank # 0399, and AR Bank # 0400 
(15.6-31.3 µg/mL). As expected based on their poor activity against C. albicans, 
compounds 5a and 7a displayed poor activity against the ten C. auris strains tested. 
However, compound 5a displayed excellent to good activity (0.12-7.8 µg/mL) against C. 
duobushaemulonii, C. haemulonii, S. cerevisiae, K. ohmeri, C. krusei, and C. lusitaniae. 
On the other hand, compound 7a only displayed excellent activity (0.49-0.98 µg/mL) 
against strains AR Bank # 0393, AR Bank # 0395, and AR Bank # 0397. Overall, as shown 
in Table 4.3, the most active monohydrazones, namely 2b, 3f, 4b, 5f, 6b, 6d, and 7f, 
displayed excellent activity against a panel of ten C. auris (AR Bank # 0381-0390) and ten 
other fungal strains (AR Bank # 0391-0400). Excluding the C. auris strains, 
monohydrazones 5a and 7a showed promise against other K. ohmeri and other Candida 
strains. 
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Table 4. 3. MIC values (µg/mL) determined for compounds 1a-7a as well as the antifungal controls AmB, CFG, FLC, and VRC against 
ten Candida auris strains (AR Bank # 0381-0390) and ten other fungal strains (AR Bank # 391-0400). 
Strain AR # Cpd # Controls 
2b 3f 4b 5a 5f 6b 6d 7a 7f AmB CFG FLC VRC 
C. auris 0381 0.49 0.24 0.24 31.3 0.24 3.9 0.98 31.3 0.24 0.98 ≤0.06 0.49 0.06 
0382 0.12 0.24 0.24 3.9 0.49 1.95 0.98 31.3 0.49 1.95 ≤0.06 0.49 0.06 
0383 0.49 1.95 0.49 31.3 0.98 15.6 1.95 >31.3 7.8 3.9 ≤0.06 62.6 1.95 
0384 3.9 3.9 1.95 >31.3 3.9 15.6 3.9 >31.3 7.8 1.95 0.12 31.3 0.24 
0385 0.49 0.49 0.49 >31.3 0.98 15.6 0.98 >31.3 0.98 3.9 ≤0.06 62.6 1.95 
0386 0.24 0.24 0.24 7.8 0.24 1.95 0.24 31.3 0.49 0.98 ≤0.06 >62.6 3.9 
0387 0.12 0.12 0.12 31.3 0.12 15.6 0.49 31.3 0.12 1.95 ≤0.06 >62.6 3.9 
0388 0.12 0.12 0.12 15.6 0.12 7.8 0.49 >31.3 0.12 1.95 ≤0.06 0.98 0.06 
0389 0.12 0.12 0.12 15.6 0.24 15.6 0.98 >31.3 ≤0.06 0.98 ≤0.06 >62.6 0.49 
0390 0.98 1.95 0.98 15.6 1.95 7.8 7.8 >31.3 1.95 1.95 ≤0.06 >62.6 0.98 
C. duobushaemulonii 0391 0.12 0.12 0.12 0.98 0.12 0.98 0.12 3.9 0.12 0.98 0.06 >62.6 >31.3 
C. duobushaemulonii 0392 0.49 1.95 0.49 0.24 0.06 0.49 0.24 7.8 >3.9 3.9 0.06 62.6 >31.3 
C. haemulonii 0393 0.24 0.24 0.49 0.24 0.24 0.98 0.12 0.98 0.24 1.95 0.12 >62.6 31.3 
C. duobushaemulonii 0394 0.12 0.12 0.12 3.9 0.98 7.8 0.12 31.3 0.49 0.98 0.06 62.6 >31.3 
C. haemulonii 0395 0.12 0.12 0.12 0.12 0.12 0.24 0.24 0.49 0.12 3.9 0.12 >62.6 3.9 
K. ohmeri 0396 0.49 0.49 0.98 0.24 0.49 0.98 0.98 3.9 0.98 1.95 0.12 7.8 0.06 
C. krusei 0397 0.015 0.03 0.015 0.12 0.03 0.24 0.06 0.49 0.015 0.49 0.12 >62.6 3.9 
C. lusitaniae 0398 1.95 3.9 1.95 1.95 0.98 3.9 0.98 31.3 3.9 3.9 0.12 1.95 0.06 
S. cerevisiae 0399 1.95 3.9 1.95 7.8 0.98 31.3 0.98 31.3 3.9 1.95 0.12 1.95 0.24 
S. cerevisiae 0400 1.95 1.95 1.95 3.9 0.98 15.6 0.98 15.6 1.95 1.95 0.24 3.9 0.12 
Known antifungal agents: AmB = amphotericin B, CFG = caspofungin, FLC = fluconazole, and VRC = voriconazole. MIC-0 values 
are reported for compounds 1a-7f as well as AmB. MIC-2 values are reported for CFG at 24 h and for the azoles, FLC and VRC, at 48 
h. Compounds were tested in duplicate. 
 MIC ≤1.95 µg/mL (excellent antifungal activity) 
 MIC = 3.9-7.8 µg/mL (good antifungal activity) 
 MIC ≥15.6 µg/mL (poor antifungal activity) 
 
4.3.3. Structure-activity relationship (SAR) analysis 
The substitution pattern and identity of the substituent(s) in rings A (R1) and B (R2) had a 
considerable influence on the activity of these monohydrazones. When investigating the 
effect of the R2 substituent while keeping R1 constant (i.e., comparing the monohydrazones 
within each series), we observed that when R1 = H (series 1, Fig. 4.2), the introduction of 
either o,p-diF (1f), p-Cl (1d), or H (1a) as R2 substituents resulted in better antifungal 
activity than other substituents (i.e., m-F, p-F and p-OMe). For series 2 (R1 = m-F), 
compounds 2b, 2d, and 2e that displayed excellent activity had m-F, p-Cl, and p-OMe as 
R2 substituents. In addition, when the R1 groups = p-F, p-Cl, or p-OMe (series 3, series 4, 
or series 5, Fig. 4.2), the most active monohydrazones in each series (i.e., (3a, 3f, and 3d), 
(4b, 4a, and 4c), and (5f, 5c, and 5d)) possessed (H, o,p-diF, and p-Cl), (m-F, H, and p-F), 
and (o,p-diF, m-F, and p-Cl) as R2 substituents, respectively. In series 6 (R1 = o,p-diF), the 
R2 substituents p-Cl (6d), m-F (6b), and o,p-diF (6f) resulted in better activity than the 
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activity observed with other substituents (i.e., H, p-F, p-OMe, o,m-diF, and m,m-diF). In 
general, we observed that in each series (1-6), the majority of the most active 
monohydrazones had either p-Cl (d) and/or o,p-diF (f) as R2 substituents. 
 
When looking at the effect of the R1 substituent while keeping R2 constant (i.e., comparing 
1a-6a, 1b-6b, etc.), we found that the monohydrazones displaying the best antifungal 
activity generally did not have the same R1 substituents. In the case of compounds with R2 
= H (1a, 2a, 3a, 4a, 5a, and 6a), the most active compounds 3a, 1a, and 6a had p-F, H, and 
o,p-diF as R1 substituents. For monohydrazones with R2 = m-F (b), the introduction of m-
F and o,p-diF as R1 substituents resulted in compounds 2b and 6b with better overall 
antifungal activity than those with other substitution patterns. The most active compounds 
in the case of monohydrazones with R2 = p-F, compounds 5c, 6c, and 1c possessed p-OMe, 
o,p-diF, and H as R1 substituents. When R2 group = p-Cl, the most active compounds 6d, 
5d, and 2d possessed o,p-diF, p-OMe, and m-F as R1 substituents. In addition, for 
compounds with R2 = p-OMe or o,p-diF the most active monohydrazones had m-F or H 
(2e and 1e), and p-OMe, p-F, and o,p-diF (5f, 3f, and 6f) as R1 substituents. Overall, we 
observed that most of the monohydrazones with the best antifungal activity with diverse 
R2 groups were from series 6 with R1 = o,p-diF with the sole exception of the 
monohydrazone with R2 = p-OMe (6e). 
 
Since the monohydrazones with o,p-diF groups as either R1 or R2 substituent displayed 
broad-spectrum activity against the fungal strains tested, we explored the effect of R2 = 
o,m-diF and m,m-diF substituents on antifungal activity. The monohydrazones 6g (R1 = 
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o,p-diF, R2 = o,m-diF) and 6h (R1 = o,p-diF, R2 = m,m-diF) were compared to 6f (R1 = o,p-
diF, R2 = o,p-diF). In both cases, the introduction of o,m-diF and m,m-diF as R2 substituents 
led to a decrease in activity profile against the whole panel of fungal strains compared to 
the o,p-diF analogue 6f. Next, we explored the effect of regioisomers by comparing series 
2 (R1 = m-F) with series 3 (R1 = p-F). We observed that the compounds 3a (R1 = p-F, R2 = 
H) and 3f (R1 = p-F, R2 = o,p-diF) performed better than their counterparts 2a (R1 = m-F, 
R2 = H) and 2f (R1 = m-F, R2 = o,p-diF), whereas compounds 2c (R1 = m-F, R2 = p-F) and 
2d (R1 = m-F, R2 = p-Cl) displayed better activity compared to 3c (R1 = p-F, R2 = p-F) and 
3d (R1 = p-F, R2 = p-Cl). From the data reported above, we were unable to point to the 
superiority of one regioisomeric series over another. We then evaluated the impact of the 
specific halogen on antifungal activity by comparing series 3 and series 4 (p-F vs p-Cl). 
Compounds 3a (R1 = p-F, R2 = H), 3d (R1 = p-F, R2 = p-Cl), and 3f (R1 = p-F, R2 = o,p-
diF) exhibited better broad-spectrum activity against various strains than their 
corresponding counterparts 4a (R1 = p-Cl, R2 = H), 4d (R1 = p-Cl, R2 = p-Cl), and 4f (R1 
= p-Cl, R2 = o,p-diF). In this case, monohydrazones where R1 = p-F performed significantly 
better their counterparts where R1 = p-Cl. Finally, we explored the effect of a methyl group 
(where X = Me) on the monohydrazone activity by comparing 7a with 1a and 1f with 7f. 
The addition of a methyl group in compound 1a (where X = H) resulted in compound 7a 
(where X = Me) with decreased antifungal activity against all the strains tested. In contrast, 
when we compared 1f with 7f, the addition of methyl group resulted in a considerable 
increase in antifungal activity. Overall, compounds 3a, 5f, 6d, 5c, 2b, 3f, 7f, 6b, 5d, 1d, 
2d, 2e, 4b, and 6c displayed the broadest spectrum of activity based on their MIC values. 
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4.3.4. Hemolysis assay 
Potency and SAR development are only one facet of antimicrobial drug development. 
Since the monohydrazones displayed potency and broad-spectrum antifungal activity, it 
was additionally important to establish that these agents showed selectivity for fungal cells 
over mammalian cells. Thus, we investigated the hemolytic activity for the most promising 
monohydrazones 2b, 3f, 4b, 5f, 6d, and 7f, as well as controls AmB and VRC against 
murine red blood cells (mRBCs) (Fig. 4.3 and Table 4.4). Monohydrazones 3f and 6d 
displayed <10% and <68% hemolysis at concentrations of 31.3 µg/mL which are 2- to 
1043-fold higher than their overall MIC values. Monohydrazones 2b and 5f displayed 
lower hemolysis levels (<9% at 15.6 µg/mL) than those observed for 7f (<21% at 15.6 
µg/mL). These hemolysis values for 2b, 5f, and 7f were again 1- to 1040-fold higher than 
the overall MIC values reported for these compounds. Finally, monohydrazone 4b 
displayed <62% at 15.6 µg/mL (1- to 1040-fold of its overall MIC values). Overall, the 
monohydrazones 2b, 3f, 5f, 6d, and 7f displayed little to no hemolysis of mRBCs at either 
concentrations either 15.6 or 31.3 µg/mL that lie well above their MIC values. 
 
 
Fig. 4.3. 2D bar graph normalized at 100% depicting the dose-dependent hemolytic activity of 
monohydrazones 2b, 3f, 4b, 5f, 6d, 7f, as well as AmB and VRC against mRBCs. mRBCs were treated and 
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incubated for 1 h at 37 °C with monohydrazones, AmB, and VRC at concentrations ranging from 0.24 to 
31.3 µg/mL. Triton X-100® (TX) (1% v/v) was used as a positive control (100% hemolysis). Compounds 
were tested in quadruplicate. Note: The corresponding non-normalized data are presented in Fig. 4.9. 
 
Table 4.4. Percentage of hemolysis caused by compounds 2b, 3f, 4b, 5f, 6d, and 7f, as well as controls AmB and VRC against murine 
red blood cells (mRBCs) with the error bars (± SDEV). 
Cpd # Concentration (µg/mL) 
TX 0 0.24 0.49 0.98 1.95 3.9 7.8 15.6 31.3 
2b 100 ± 3 2.1 ± 0.3 1.9 ± 0.7 1.9 ± 0.3 1.5 ± 0.4 2.2 ± 0.4 3.0 ± 0.7 4.1 ± 0.7 5.6 ± 2 120 ± 60 
3f 100 ± 5 3.5 ± 0.4 1.9 ± 0.4 3.6 ± 0.1 1.5 ± 0.2 3.2 ± 0.4 1.6 ± 0.3 3.9 ± 0.3 2.8 ± 0.3 9.1 ± 1 
4b 100 ± 2 2.9 ± 0.6 2.4 ± 0.9 2.7 ± 0.5 1.0 ± 0.1 2.9 ± 0.3 2.1 ± 0.3 11 ± 5 61 ± 20 210 ± 50 
5f 100 ± 6 0.85 ± 0.5 0.97 ± 0.2 0.93 ± 0.3 1.1 ± 0.2 1.3 ± 0.3 1.4 ± 0.2 3.8 ± 1 8.3 ± 1 110 ± 20 
6d 100 ± 10 1.3 ± 0.3 0.78 ± 0.6 1.8 ± 0.0 1.2 ± 0.1 1.2 ± 0.2 1.5 ± 0.9 2.9 ± 0.6 13.7 ± 10 67 ± 40 
7f 100 ± 5 3.0 ± 0.5 1.9 ± 1 3.9 ± 0.2 3.3 ± 1 4.2 ± 0.4 4.4 ± 1 6.0 ± 1 20 ± 7 100 ± 3 
AmB 100 ± 5 1.2 ± 0.4 0.93 ± 0.6 2.0 ± 0.8 4.0 ± 1 5.5 ± 2 17 ± 1 67 ± 2 79 ± 0.1 78 ± 1 
VRC 100 ± 3 -1.2 ± 0.4 0.46 ± 0.9 0.23 ± 1 1.4 ± 0.5 1.7 ± 0.1 1.0 ± 0.8 1.8 ± 0.2 1.6 ± 1 0.83 ± 0.3 
Note: Compounds tested in quadruplicate. 
 
4.3.5. Cytotoxicity 
It was also important to consider the toxicity of these monohydrazones towards mammalian 
cell lines. The toxicity profile of compounds 2b, 3f, 4b, 5f, 6d, and 7f, as well as controls 
AmB and VRC (within a concentration range of 0.12-31.3 µg/mL) was investigated against 
three mammalian cell lines A549, J774A.1, and HEK-293 (Fig. 4.4). When tested against 
all three mammalian cell lines at 31.3 µg/mL, none of the monohydrazones tested displayed 
toxicity (with the exception of 4b against J774A.1, which displayed 86% cell survival at 
that concentration). The excellent MIC values of these monohydrazones combined with 
the fact that none of them exhibited toxicity to mammalian cell lines at the highest 
concentration provided still further evidence that these agents warranted additional 
biological evaluation. 
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Fig. 4.4. 2D bar graph normalized at 100% depicting the dose-dependent cytotoxic activity of 
monohydrazones 2b, 3f, 4b, 5f, 6d, 7f, as well as AmB and VRC against A. A549, B. J774A.1, and C. HEK-
293 cell lines. Note: For Triton X-100® (TX) the eight bars are colored differently which corresponds to 
colors of the respective compounds for which TX was used as a positive control. Compounds were tested in 
quadruplicate. Note: The corresponding non-normalized data are presented in Fig. 4.10. 
 
4.3.6. Time-kill studies 
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A time-kill kinetics assay was used to determine whether the monohydrazones are 
fungistatic and simply inhibit growth, or are fungicidal and kill the fungal cells. 
Compounds 2b, 3f, 4b, 5f, 6d, and 7f were tested at ½×, 1×, and 4× MIC against C. albicans 
ATCC 10231 (strain A) to observe the dose-dependent effect and also to account for any 
normal variations in MIC values (Figs. 4.5 and 4.6). In addition, AmB at 1× MIC and VRC 
at 1× MIC-0 against C. albicans ATCC (strain A) were also evaluated for comparison 
purposes. Fungicidal activity is defined as at least a three log10-fold decrease in colony 
forming units (CFU), and this level of decrease is observed with the monohydrazones at 
the 1× MIC concentration for compound 2b at the ½× concentration, compounds 2b, 4f, 
and 5f at the 1× concentration, and all tested at the 4× concentration. CFU counts were 
confirmed by adding the metabolic dye resazurin at the 24 h time point and observing the 
amount of color change over the following two days where no growth is indicated by a 
blue color (Fig. 4.6, panel A). By 72 h, only four sample tubes with C. albicans remain 
blue and these samples include 2b at 4×, 5f at 1× and 4×, and 7f at 4×. A screen with the 
resazurin was performed with C. auris AR Bank # 0384 and # 0390 (Fig. 4.6, panels B and 
C). Except for compound 6d, which had growth at 72 h at the 1× concentration, all 
monohydrazones at 1× and 4× concentrations inhibited C. auris growth up to 72 h. The 
fungicidal activity at and above MICs shows the potential of the monohydrazones to clear, 
not just halt, a fungal infection. 
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Fig. 4.5. Time-killing kinetics for compounds A. 2b, B. 3f, C. 4b, D. 5f, E. 6d, and F. 7f at ½×, 1×, and 4× 
MIC as well as AmB 1× MIC and VRC at 1× MIC-0 against C. albicans ATCC (strain A). To confirm CFU 
counts, the metabolic dye, resazurin, was added at 24 h. Time-points samples were plated in duplicate. 
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Fig. 4.6. Sample tubes for monohydrazones 2b, 3f, 4b, 5f, 6d, and 7f at ½×, 1×, and 4× MICs, as well as 
AmB and VRC at ½×, 1× MIC-0 after the addition of resazurin at 24 h, 48 h, and 72 h (relative to the 
treatment start time) against A. C. albicans ATCC 10231 (strain A), B. C. auris AR Bank # 0384, and C. C. 
auris AR Bank # 0390. Resazurin (blue) is metabolized by the yeast and color change is relative to CFU 
counts (blue < purple < red < pink < orange < yellow) Note: The corresponding kinetic data for C. albicans 
ATCC (strain A) are presented in Fig. 4.5. 
 
4.3.7. Antibiofilm activity 
Fungal biofilms390 are a protective mechanism that allow fungal cells to survive harsh 
conditions including those that may exist within the human body. These biofilms 
commonly occur, for example, on medical devices such as catheters. Once biofilms are 
formed, it is significantly more difficult to eliminate the fungal cells than in their absence. 
The ability of compounds 2b, 3f, 4b, 5f, 6d, and 7f, as well as controls AmB and VRC 
were assessed against C. albicans ATCC 10231 (strain A), C. auris AR Bank # 0384, and 
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C. auris AR Bank # 0390 in two biofilm studies: (i) prevention of biofilm formation and 
(ii) destruction of pre-formed biofilms. 
 
Prevention of biofilm formation. A large fungal load was exposed to the monohydrazones 
at time 0 h to evaluate the ability of the compounds to prevent Candida biofilm formation 
(Table 4.5, Fig. 4.7). We determined the sessile MIC (SMIC) for 50% and 90% inhibition 
of biofilm formation as compared to the no drug control. Monohydrazones 2b and 4b 
displayed excellent activity similar to VRC with SMIC50 values of 1.95 µg/mL against C. 
albicans ATCC 10231 (strain A, which is 4-fold greater than the MIC. Monohydrazones 
5f and 6d also had good activity against C. albicans with SMIC50 of 7.8 and 3.9 µg/mL, 
respectively, and 7f also had some activity as well. Two monohydrazones, 4b and 7f, 
displayed good activity against one C. auris strain, C. auris AR Bank # 0384, with SMIC50 
values of 7.8 µg/mL. Monohydrazones 2b, 5f, and 6d also displayed poor activity against 
C. auris AR Bank # 0384 while compounds 4b, 5f, 6d, and 7f displayed poor activity 
against C. auris AR Bank # 0390 with SMIC50 values of 15.6 µg/mL. Monohydrazones 4b 
and 6d were the most promising as they display SMIC90 values of 7.8 µg/mL against C. 
albicans (16-fold greater than MIC) and 15.6-31.3 µg/mL against the C. auris strains which 
is 4- to 16-fold greater than their MIC values against the same strains. 
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Table 4.5. SMIC50 and SMIC90 values (µg/mL) for prevention of biofilm formation determined for compounds 2b, 3f, 4b, 5f, 6d, 7f as 
well as the antifungal controls AmB and VRC against three fungal strains. 
  SMIC50 (µg/mL) 
Strain  2b 3f 4b 5f 6d 7f AmB VRC 
C. albicans ATCC 10231 
(A) 
SMIC50 1.95 31.3 1.95 7.8 3.9 15.6 0.12 1.95 
 SMIC90 31.3 >31.3 7.8 31.3 7.8 15.6 0.98 3.9 
C. auris AR Bank # 0384 SMIC50 15.6 31.3 7.8 15.6 15.6 7.8 1.95 3.9 
 SMIC90 31.3 >31.3 15.6 31.3 15.6 15.6 7.8 >31.3 
C. auris AR Bank # 0390 SMIC50 31.3 >31.3 15.6 15.6 15.6 15.6 1.95 1.95 
 SMIC90 31.3 >31.3 15.6 31.3 31.3 31.3 3.9 15.6 
Note: Compounds were tested in duplicate. 
 MIC ≤1.95 µg/mL (excellent antifungal activity) 
 MIC = 3.9-7.8 µg/mL (good antifungal activity) 
 MIC ≥15.6 µg/µL (poor antifungal activity) 
 
 
Fig. 4.7. Prevention of biofilm formation of A. C. albicans ATCC 10231 (strain A), B. C. auris AR Bank # 
0384, and C. C. auris AR Bank # 0390 treated at 0 h with 2b, 3f, 4b, 5f, 6d, 7f, AmB, and VRC. XTT dye is 
metabolized by fungal cells to produce an orange color. Compounds were tested in duplicate. The 
corresponding data are presented in Table 4.5. 
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Destruction of pre-formed biofilms. Although the monohydrazones were able to prevent 
biofilm formation, we also evaluated their ability to destroy a pre-formed biofilm 
(treatment after 24 h) (Table 4.6). Overcoming the problem of a biofilm presents is 
challenging, and reflecting this challenge, we report SMIC50 values because no 
monohydrazones were able to decrease biofilm activity by 90%. Against C. albicans 
ATCC 10231 (strain A), compounds 4b and 7f display SMIC50 values of 31.3 µg/mL, 
which matched the value for VRC. Against both C. auris strains, compounds 2b, 4b, and 
6d displayed SMIC50 values of 15.6-31.3 µg/mL, which were better than VRC. Overall, 
compounds 4b and 6d performed the best against biofilms. In both the prevention of biofilm 
formation and destruction of a pre-formed biofilm assays, the monohydrazones appear to 
have similar activity to VRC, but very little activity compared to AmB. 
 
Table 4.6. SMIC50 values (µg/mL) for destruction of a pre-formed biofilm determined for compounds 2b, 3f, 4b, 5f, 6d, 7f as well as 
the antifungal controls AmB and VRC against three fungal strains. 
 SMIC50 (µg/mL) 
Strain 2b 3f 4b 5f 6d 7f AmB VRC 
C. albicans ATCC 10231 (A) >31.3 >31.3 31.3 >31.3 >31.3 31.3 0.24 31.3 
C. auris AR Bank # 0384 15.6 >31.3 31.3 >31.3 15.6 >31.3 0.98 >31.3 
C. auris AR Bank # 0390 31.3 >31.3 15.6 >31.3 15.6 >31.3 1.95 >31.3 
Note: Compounds were tested in duplicate. 
 MIC ≤1.95 µg/mL (excellent antifungal activity) 
 MIC ≥15.6 µg/µL (poor antifungal activity) 
 
4.3.8. Resistance development 
To evaluate the potential of fungi to develop resistance to the monohydrazones, we 
repeatedly exposed C. auris AR Bank # 0390 to the monohydrazones at ½× MIC to 
simulate fungal drug exposure in a clinical setting (Fig. 4.8). Compounds 2b, 3f, 4b, 5f, 
and 6d, as well as controls AmB were investigated. Compound 7f was not included due to 
degradation of the compound when kept in solution. While normal variations in MIC 
values occurred, no significant changes in MIC values were observed as the MIC values 
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remained within 8-fold of the original MIC value. Considering the generally long duration 
of treatment with antifungal drugs, this is a promising result that suggests that a fungal 
strain is not likely to develop resistance to the monohydrazones, even after repeated 
exposures. 
 
 
Fig. 4.8. Graph illustrating fold changes in MIC values (∆ MIC) over fifteen serial passages for 
monohydrazones 2b, 3f, 4b, 5f, 6d, as well as AmB against C. auris AR Bank # 0390. Note: starting MIC 
values were 0.24, 0.49, 0.49, 0.49, 1.95, and 0.98 µg/mL, respectively. MICs were done in duplicate. 
 
4.4. CONCLUSIONS 
In summary, we developed a synthesis of substituted monohydrazones 1a-7f, and 
performed a detailed study of antifungal activity of the compounds 1a-7f against a panel 
of seven strains of C. albicans and three strains of non-albicans Candida. Commercially 
available antifungal agents, AmB, CFG, FLC, and VRC were used as positive controls. 
This SAR studies identified compounds 3a, 5f, 6d, 5c, 2b, 3f, 7f, 6b, 5d, 1d, 2d, 2e, 4b, 
and 6c as having the broadest spectrum of activity based on their MIC values. The seven 
best compounds (2b, 3f, 4b, 5f, 6b, 6d, and 7f) and two of the worse (5a and 7a to serve 
as negative controls) were further tested against a panel of ten C. auris and ten other fungal 
strains. The monohydrazones 2b, 3f, 4b, 5f, 6d, and 7f displayed excellent to good activity 
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(0.015-7.8 µg/mL) against all 20 strains tested. In comparison with the FDA-approved drug 
VRC, monohydrazones 2b, 3f, 5f, 6d, and 7f displayed little to no hemolysis of mRBCs at 
concentrations of either 15.6 or 31.3 µg/mL. In addition, none of the monohydrazones 2b, 
3f, 5f, 6d, and 7f exhibited toxicity against three mammalian cell lines, A549, J774A.1, 
and HEK-293. A time-kill assay over a 24 h period using compounds 2b, 3f, 4b, 5f, 6d, 
and 7f against C. albicans ATCC 10231 (strain A) indicated the monohydrazones were 
fungicidal at and/or above their MIC values. Compounds 2b, 3f, 4b, 5f, 6d, and 7f, as well 
as controls AmB and VRC were assessed against C. albicans ATCC 10231 (strain A), C. 
auris AR Bank # 0384, and C. auris AR Bank # 0390 in two biofilm studies: (i) prevention 
of biofilm formation and (ii) destruction of pre-formed biofilms. The monohydrazones 
were able to prevent the formation of biofilm against these representative strains. When 
exposed to compounds 2b, 3f, 4b, 5f, and 6d over 15 passages, C. auris AR Bank # 0390 
developed no resistance. In conclusion, the fluorinated aryl-and heteroaryl-substituted 
monohydrazones reported herein display promise as a new family of antifungal agents. 
 
4.5. EXPERIMENTAL 
4.5.1. Chemistry 
Materials and instrumentation. The chemicals used in this study were purchased from 
Sigma-Aldrich (St. Louis, MO), AK Scientific (Union City, CA), Acros Organics (New 
Jersey, NJ), TCI America (Portland, OR), Oakwood Chemicals (Estill, SC), Combi-Blocks 
(San Diego, CA), Accela Chembio (San Diego, CA), and Chem-Impex (Wood Dale, IL), 
and used without any further purification. Chemical reactions were monitored by TLC 
(Merck, Silica gel 60 F254) and visualization was achieved using UV light. Compounds 
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were purified by SiO2 flash chromatography (Dynamic Adsorbents Inc., Flash SiO2 gel 32-
63µ) or by filtration of pure solids. 1H and 13C NMR spectra were recorded at 500 MHz or 
400 MHz (for 1H) and 100 MHz (for 13C) on Agilent VNMRS-500 and MR-400 
spectrometers, respectively, using deuterated solvents as specified. Chemical shifts (δ) are 
given in parts per million (ppm). Coupling constants (J) are given in Hertz (Hz), and 
conventional abbreviations used for signal shape are as follows: d, doublet; dd, doublet of 
doublets; ddd, doublet of doublet of doublets; dt, doublet of triplets; m, multiplet; s, singlet; 
t, triplet; td, triplet of doublets; tt, triplet of triplets. Liquid chromatography-mass 
spectrometry (LCMS) was carried out using an Agilent 1200 series Quaternary LC system 
equipped with a diode array detector, and Agilent EC-C18 column (100 mm × 3.0 mm, 4 
µm). LCMS [M + H]+ signals were consistent with the expected molecular weights for all 
the reported compounds. Purity of the compounds was further confirmed to be ≥95% by 
LCMS by using following method: Flow rate = 0.4 mL/min; λ = 254 nm; column = Agilent 
EC-C18, 100 mm × 3.0 mm, 4 µm; eluents: A = H2O + 0.1% formic acid, C = MeCN + 
0.1% formic acid; gradient profile: starting from 5% C, increasing from 5% to 95% C over 
21 min, decreasing from 95% to 5% over 6 min. Prior to each injection, the LCMS column 
was equilibrated for 8 min with 5% C. We were not able to purify compounds 1b, 3b, 3e, 
5b, and 6e and therefore we did not include them in any of the biological assays performed 
in this study. 
 
Preparation of compound 1a (SGT1288). To a solution of 
benzaldehyde (600 mg, 5.65 mmol) in EtOH (8 mL), phenylhydrazine 
(0.67 mL, 6.78 mmol) was added. The reaction mixture was stirred at 80 °C for 1 h and the 
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resulting solution was filtered. The residue obtained was washed with hot EtOH (15 mL) 
to afford compound 1a (742 mg, 66%) as a white solid: 1H NMR (400 MHz, (CD3)2SO, 
Fig. 4.B1 “Disclaimer: All figures are presented for Chapter 3 are presented in Appendix 
B and are listed as Fig. 4.B#”) δ 10.32 (s, 1H), 7.86 (s, 1H), 7.64 (dd, J1 = 8.1 Hz, J2 = 1.1 
Hz, 2H), 7.38 (t, J = 8.0 Hz, 2H), 7.28 (tt, J1 = 7.4 Hz, J2 = 1.2 Hz, 1H), 7.21 (dd, J1 = 8.6 
Hz, J2 = 7.2 Hz, 2H), 7.06 (dd, J1 = 8.6 Hz, J2 = 1.2 Hz, 2H), 6.74 (tt, J1 = 7.3 Hz, J2 = 1.2 
Hz, 1H); 13C NMR (100 MHz, (CD3)2SO, Fig. 4.B2) δ 145.3, 136.4, 135.8, 129.1, 128.6, 
127.9, 125.6, 118.7, 112.0; ; m/z calcd for C13H12N2 196.1; found 197.1 [M+H]+. Purity of 
the compound was further confirmed by LCMS: Rt = 18.55 min (99% pure; Fig. 4.B3). 
 
Preparation of compound 1c (SGT1289). To a solution of 
benzaldehyde (600 mg, 5.65 mmol) in EtOH (8 mL), 4-
fluorophenylhydrazine hydrochloride (1.10 g, 6.78 mmol) was added. The reaction mixture 
was stirred at 80 °C for 1 h and, to the resulting solution, H2O (15 mL) was added. The 
residue obtained was filtered and washed with cold EtOH (15 mL) to afford compound 1c 
(562 mg, 46%) as a pink solid: 1H NMR (400 MHz, (CD3)2SO, Fig. 4.B4) δ 10.31 (s, 1H), 
7.85 (s, 1H), 7.66-7.61 (m, 2H), 7.38 (t, J = 7.2 Hz, 2H), 7.28 (tt, J1 = 7.3 Hz, J2 = 1.4 Hz, 
1H), 7.06 (s, 2H), 7.05 (s, 2H); 13C NMR (100 MHz, (CD3)2SO, Fig. 4.B5) δ 163.2 (d, J = 
232.4 Hz), 142.0 (d, J = 1.8 Hz), 136.5, 135.7, 128.6, 127.9, 125.6, 115.6 (d, J = 22.1 Hz), 
112.9 (d, J = 7.4 Hz); m/z calcd for C13H11FN2 214.1; found 215.2 [M+H]+. Purity of the 
compound was further confirmed by LCMS: Rt = 18.72 min (96% pure; Fig. 4.B6). 
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Preparation of compound 1d (SGT1280). To a solution of 
benzaldehyde (0.29 mL, 2.82 mmol) in EtOH (10 mL), 4-
chlorophenylhydrazine hydrochloride (607 mg, 3.39 mmol) was added. The reaction 
mixture was stirred at 80 °C for 1 h and, to the resulting solution, H2O (25 mL) was added. 
The residue obtained was filtered and dried to afford compound 1d (307 mg, 47%) as a 
pink solid: 1H NMR (400 MHz, (CD3)2SO, Fig. 4.B7) δ 10.46 (s, 1H), 7.87 (s, 1H), 7.67-
7.62 (m, 2H), 7.42-7.36 (m, 2H), 7.30 (tt, J1 = 7.4 Hz, J2 = 1.2 Hz, 1H), 7.24 (d, J = 8.8 
Hz, 2H), 7.06 (d, J = 8.8 Hz, 2H); 13C NMR (100 MHz, (CD3)2SO, Fig. 4.B8) δ 144.2, 
137.3, 135.5, 128.9, 126.6, 128.1, 125.8, 121.9, 113.4; m/z calcd for C13H11ClN2 230.1; 
found 231.1 [M+H]+. Purity of the compound was further confirmed by LCMS: Rt = 20.08 
min (96% pure; Fig. 4.B9). 
 
Preparation of compound 1e (SGT1281). To a solution of 
benzaldehyde (0.29 mL, 2.82 mmol) in EtOH (10 mL), 4-
methoxyphenylhydrazine hydrochloride (592 mg, 3.39 mmol) was added. The reaction 
mixture was stirred at 80 °C for 1 h and, to the resulting solution, H2O (25 mL) was added. 
The residue obtained was filtered and dried to afford compound 1e (396 mg, 62%) as a 
pink solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 4.B10) δ 10.11 (s, 1H), 7.80 (s, 1H), 7.63-
7.59 (m, 2H), 7.39-7.34 (m, 2H), 7.26 (tt, J1 = 7.4 Hz, J2 = 1.3 Hz, 1H), 7.00 (d, J = 9.0 
Hz, 2H), 6.84 (d, J = 9.0 Hz, 2H), 3.69 (s, 3H); 13C NMR (100 MHz, (CD3)2SO, Fig. 4.B11) 
δ 152.6, 139.4, 136.1, 135.2, 128.6, 127.6, 125.4, 114.6, 113.0, 55.3; m/z calcd for 
C14H14N2O 226.1; found 227.1 [M+H]+. Purity of the compound was further confirmed by 
LCMS: Rt = 17.95 min (95% pure; Fig. 4.B12). 
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Preparation of compound 1f (SGT1279). To a solution of 
benzaldehyde (0.29 mL, 2.82 mmol) in EtOH (10 mL), 2,4-
difluorophenylhydrazine hydrochloride (613 mg, 3.39 mmol) was added. The reaction 
mixture was stirred at 80 °C for 1 h and, to the resulting solution, H2O (25 mL) was added. 
The residue obtained was filtered and dried to afford compound 1f (510 mg, 78%) as a pink 
solid: 1H NMR (400 MHz, (CD3)2SO, Fig. 4.B13) δ 10.20 (s, 1H), 8.11 (s, 1H), 7.67-7.62 
(m, 2H), 7.50 (td, J1 = 9.4 Hz, J2 = 6.0 Hz, 1H), 7.42-7.37 (m, 2H), 7.32 (tt, J1 = 7.2 Hz, J2 
= 1.4 Hz, 1H), 7.21 (ddd, J1 = 11.9 Hz, J2 = 8.9 Hz, J3 = 2.8 Hz, 1H), 7.03-6.96 (m, 1H); 
13C NMR (100 MHz, (CD3)2SO, Fig. 4.B14) δ 154.7 (dd, J1 = 235.9 Hz, J2 = 10.8 Hz), 
148.3 (dd, J1 = 241.3 Hz, J2 = 12.0 Hz), 139.4, 135.5, 130.5 (dd, J1 = 9.9 Hz, J2 = 3.0 Hz), 
128.7, 128.3, 125.9, 114.1 (dd, J1 = 8.7 Hz, J2 = 4.6 Hz), 111.4 (dd, J1 = 21.6 Hz, J2 = 3.4 
Hz), 103.8 (dd, J1 = 26.8 Hz, J2 = 22.2 Hz); m/z calcd for C13H10F2N2 232.1; found 233.1 
[M+H]+. Purity of the compound was further confirmed by LCMS: Rt = 19.47 min (99% 
pure; Fig. 4.B15). 
 
Preparation of compound 2a (SGT1296). To a solution of 3-
fluorobenzaldehyde (0.21 mL, 2.08 mmol) in EtOH (10 mL), 
phenylhydrazine (0.24 mL, 2.50 mmol) was added. The reaction mixture was stirred at 80 
°C for 1 h and, to the resulting solution, H2O (40 mL) was added. The residue obtained was 
filtered and dried to afford compound 2a (412 mg, 96%) as an off-white solid: 1H NMR 
(500 MHz, (CD3)2SO, Fig. 4.B16) δ 10.48 (s, 1H), 7.84 (s, 1H), 7.48-7.38 (m, 3H), 7.24-
7.20 (m, 2H), 7.12-7.06 (m, 3H), 6.77 (tt, J1 = 7.3 Hz, J2 = 1.1 Hz, 1H); 13C NMR (100 
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MHz, (CD3)2SO, Fig. 4.B17) δ 162.6 (d, J = 241.7 Hz), 145.0, 138.5 (d, J = 8.0 Hz), 134.9 
(d, J = 3.2 Hz), 130.6 (d, J = 8.5 Hz), 129.1, 121.9 (d, J = 2.6 Hz), 119.1, 114.4 (d, J = 21.4 
Hz), 112.1, 111.4 (d, J = 22.4 Hz); m/z calcd for C13H11FN2 214.1; found 215.1 [M+H]+. 
Purity of the compound was further confirmed by LCMS: Rt = 18.86 min (97% pure; Fig. 
4.B18). 
 
Preparation of compound 2b (SGT1374). To a solution of 3-
fluorobenzaldehyde (0.21 mL, 2.01 mmol) in EtOH (12 mL), 3-
fluorophenylhydrazine hydrochloride (390 mg, 2.4 mmol) was added. The reaction mixture 
was stirred at 90 °C for 100 min and, to the resulting solution, H2O (50 mL) was added and 
stirred for 12 h. The residue obtained was filtered and dried to afford compound 2b (429 
mg, 92%) as a reddish-brown solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 4.B19) δ 10.68 
(s, 1H), 7.87 (s, 1H), 7.52-7.43 (m, 2H), 7.42 (td, J1 = 8.0 Hz, J2 = 5.7 Hz, 1H), 7.23 (td, 
J1 = 8.1 Hz, J2 = 6.8 Hz, 1H), 7.15-7.10 (m, 1H), 6.90 (dt, J1 = 11.7 Hz, J2 = 2.3 Hz, 1H), 
6.84 (ddd, J1 = 8.2 Hz, J2 = 2.1 Hz, J3 = 0.9 Hz, 1H), 6.57-6.51 (m, 1H); 13C NMR (100 
MHz, (CD3)2SO, Fig. 4.B20) δ 164.2 (d, J = 80.1 Hz), 161.8 (d, J = 82.4 Hz), 147.0 (d, J 
= 11.0 Hz), 138.2 (d, J = 8.0 Hz), 136.2 (d, J = 3.2 Hz), 130.7 (d, J = 10.0 Hz), 130.6 (d, J 
= 8.4 Hz), 122.2 (d, J = 2.6 Hz), 114.8 (d, J = 21.4 Hz), 111.8 (d, J = 22.4 Hz), 108.3 (d, J 
= 2.2 Hz), 105.2 (d, J = 21.5 Hz), 98.7 (d, J = 26.1 Hz); m/z calcd for C13H10F2N2 232.1; 
found 233.1 [M+H]+. Purity of the compound was further confirmed by LCMS: Rt = 19.16 
min (90% pure; Fig. 4.B21). 
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Preparation of compound 2c (SGT1386). To a solution of 3-
fluorobenzaldehyde (0.09 mL, 0.81 mmol) in EtOH (8 mL), 4-
fluorophenylhydrazine hydrochloride (157 mg, 0.97 mmol) was added. The reaction 
mixture was stirred at 90 °C for 2 h and, to the resulting solution, H2O (50 mL) was added 
and stirred for 2 h. The residue obtained was filtered and dried to afford compound 2c (166 
mg, 88%) as a peach solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 4.B22) δ 10.49 (s, 1H), 
7.82 (s, 1H), 7.48-7.43 (m, 2H), 7.39 (td, J1 = 7.9 Hz, J2 = 5.7 Hz, 1H), 7.12-7.09 (m, 1H), 
7.07 (s, 2H), 7.06 (d, J = 1.0 Hz, 2H); 13C NMR (100 MHz, CD3OD, Fig. 4.B23) δ 164.6 
(d, J = 242.5 Hz), 158.3 (d, J = 134.2 Hz), 143.2 (d, J = 2.0 Hz), 140.2 (d, J = 7.9 Hz), 
136.3 (d, J = 3.3 Hz), 131.3 (d, J = 8.3 Hz), 123.0 (d, J = 2.7 Hz), 116.4 (d, J = 22.6 Hz), 
115.4 (d, J = 21.9 Hz), 114.3 (d, J = 7.4 Hz), 112.5 (d, J = 22.8 Hz); m/z calcd for 
C13H10F2N2 232.1; found 233.2 [M+H]+. Purity of the compound was further confirmed by 
LCMS: Rt = 19.11 min (95% pure; Fig. 4.B24). 
 
Preparation of compound 2d (SGT1375). To a solution of 3-
fluorobenzaldehyde (0.21 mL, 2.01 mmol) in EtOH (12 mL), 4-
chlorophenylhydrazine hydrochloride (430 mg, 2.4 mmol) was added. The reaction 
mixture was stirred at 90 °C for 1.5 h and, to the resulting solution, H2O (50 mL) was added 
and stirred for 3 h. The residue obtained was filtered and dried to afford compound 2d (412 
mg, 82%) as a brown solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 4.B25) δ 10.61 (s, 1H), 
7.85 (s, 1H), 7.50-7.45 (m, 2H), 7.42 (td, J1 = 8.0 Hz, J2 = 5.8 Hz, 1H), 7.25 (d, J = 8.9 Hz, 
2H), 7.15-7.11 (m, 1H), 7.09 (d, J = 8.9 Hz, 2H); 13C NMR (100 MHz, (CD3)2SO, Fig. 
4.B26) δ 162.5 (d, J = 241.8 Hz), 143.9, 138.3 (d, J = 7.9 Hz), 135.7 (d, J = 3.2 Hz), 130.6 
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(d, J = 8.4 Hz), 128.9, 122.3, 122.0 (d, J = 2.6 Hz), 114.7 (d, J = 21.3 Hz), 113.6, 111.6 (d, 
J = 22.4 Hz); m/z calcd for C13H10ClFN2 248.1; found 249.0 [M+H]+. Purity of the 
compound was further confirmed by LCMS: Rt = 20.30 min (99% pure; Fig. 4.B27). 
 
Preparation of compound 2e (SGT1399). To a solution of 3-
fluorobenzaldehyde (0.09 mL, 0.81 mmol) in EtOH (8 mL), 4-
methoxyphenylhydrazine hydrochloride (211 mg, 1.21 mmol) was added. The reaction 
mixture was stirred at 90 °C for 90 min and, to the resulting solution, H2O (50 mL) was 
added and stirred for 40 min. The residue obtained was filtered and dried to afford 
compound 2e (190 mg, 96%) as a pale yellow solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 
4.B28) δ 10.30 (s, 1H), 7.78 (s, 1H), 7.45-7.37 (m, 3H), 7.10-7.04 (m, 1H), 7.03 (d, J = 8.9 
Hz, 2H), 6.85 (d, J = 9.0 Hz, 2H), 3.69 (s, 3H); 13C NMR (100 MHz, CD3OD, Fig. 4.B29) 
δ 165.1 (d, J = 242.1 Hz), 155.5, 141.3, 141.0 (d, J = 7.9 Hz), 135.8 (d, J = 3.3 Hz), 131.7 
(d, J = 8.4 Hz), 123.2 (d, J = 2.7 Hz), 116.2, 115.6 (d, J = 22.1 Hz), 115.0, 112.8 (d, J = 
22.7 Hz), 56.6; m/z calcd for C14H13FN2O 244.1; found 245.1 [M+H]+. Purity of the 
compound was further confirmed by LCMS: Rt = 18.36 min (98% pure; Fig. 4.B30). 
 
Preparation of compound 2f (SGT1373). To a solution of 3-
fluorobenzaldehyde (0.21 mL, 2.01 mmol) in EtOH (12 mL), 2,4-
difluorophenylhydrazine hydrochloride (433 mg, 2.4 mmol) was added. The reaction 
mixture was stirred at 90 °C for 70 min and, to the resulting solution, H2O (50 mL) was 
added and stirred for 2 h. The residue obtained was filtered and dried to afford compound 
2f (475 mg, 94%) as a tan solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 4.B31) δ 10.37 (s, 
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1H), 8.09 (s, 1H), 7.53 (td, J1 = 9.4 Hz, J2 = 6.0 Hz, 1H), 7.51-7.47 (m, 1H), 7.47-7.40 (m, 
2H), 7.22 (ddd, J1 = 11.9 Hz, J2 = 8.9 Hz, J3 = 2.8 Hz, 1H), 7.16-7.11 (m, 1H), 7.03-6.97 
(m, 1H); 13C NMR (100 MHz, (CD3)2SO, Fig. 4.B32) δ 162.6 (d, J = 241.8 Hz), 154.9 (dd, 
J1 = 236.1 Hz, J2 = 10.9 Hz), 148.4 (dd, J1 = 241.6 Hz, J2 = 11.9 Hz), 138.2 (d, J = 7.9 Hz), 
137.8 (d, J = 3.4 Hz), 130.6 (d, J = 8.4 Hz), 130.1 (dd, J1 = 9.9 Hz, J2 = 3.0 Hz), 122.3 (d, 
J = 2.7 Hz), 114.9 (d, J = 21.6 Hz), 114.4 (dd, J1 = 8.8 Hz, J2 = 4.5 Hz), 111.6 (d, J = 22.3 
Hz), 111.4 (dd, J1 = 21.6 Hz, J2 = 3.4 Hz), 103.8 (dd, J1 = 26.8 Hz, J2 = 22.1 Hz); m/z calcd 
for C13H9F3N2 250.1; found 251.1 [M+H]+. Purity of the compound was further confirmed 
by LCMS: Rt = 19.71 min (99% pure; Fig. 4.B33). 
 
Preparation of compound 3a (SGT1417). To a solution of 4-
fluorobenzaldehyde (0.09 mL, 0.81 mmol) in EtOH (8 mL), 
phenylhydrazine (0.12 mL, 1.21 mmol) was added. The reaction mixture was stirred at 90 
°C for 1.5 h and, to the resulting solution, H2O (50 mL) was added and stirred for 1.5 h. 
The residue obtained was filtered and dried to afford compound 3a (146 mg, 84%) as a 
light pink solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 4.B34) δ 10.33 (s, 1H), 7.85 (s, 1H), 
7.69 (dd, J1 = 8.8 Hz, J2 = 5.7 Hz, 2H), 7.22 (dd, J1 = 9.0 Hz, J2 = 4.3 Hz, 2H), 7.20 (dd, 
J1 = 7.3 Hz, J2 = 2.2 Hz, 2H), 7.05 (dd, J1 = 8.7 Hz, J2 = 1.3 Hz, 2H), 6.74 (tt, J1 = 7.3 Hz, 
J2 = 1.2 Hz, 1H); 13C NMR (100 MHz, CD3OD, Fig. 4.B35) δ 164.0 (d, J = 244.8 Hz), 
146.9, 136.6 (d, J = 12.3 Hz), 134.1 (d, J = 29.6 Hz), 130.0, 128.5 (d, J = 8.1 Hz), 120.2, 
116.4 (d, J = 22.2 Hz), 113.3; m/z calcd for C13H11FN2 214.1; found 215.1 [M+H]+. Purity 
of the compound was further confirmed by LCMS: Rt = 18.75 min (99% pure; Fig. 4.B36). 
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Preparation of compound 3c (SGT1385). To a solution of 4-
fluorobenzaldehyde (0.09 mL, 0.81 mmol) in EtOH (8 mL), 4-
fluorophenylhydrazine hydrochloride (157 mg, 0.97 mmol) was added. The reaction 
mixture was stirred at 90 °C for 2 h and, to the resulting solution, H2O (50 mL) was added 
and stirred for 2 h. The residue obtained was filtered and dried to afford compound 3c (171 
mg, 91%) as a light peach solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 4.B37) δ 10.34 (s, 
1H), 7.84 (s, 1H), 7.69 (dd, J1 = 8.7 Hz, J2 = 5.7 Hz, 2H), 7.22 (app. t, J = 8.9 Hz, 2H), 
7.06 (d, J = 2.9 Hz, 2H), 7.05 (br s, 2H); 13C NMR (100 MHz, (CD3)2SO, Fig. 4.B38) δ 
161.9 (d, J = 244.0 Hz), 155.9 (d, J = 232.9 Hz), 142.0 (d, J = 1.8 Hz), 135.4, 132.4 (d, J 
= 3.0 Hz), 127.5 (d, J = 8.1 Hz), 115.7 (d, J = 1.5 Hz), 115.5, 112.9 (d, J = 7.5 Hz); m/z 
calcd for C13H10F2N2 232.1; found 233.1 [M+H]+. Purity of the compound was further 
confirmed by LCMS: Rt = 18.93 min (98% pure; Fig. 4.B39). 
 
Preparation of compound 3d (SGT1380). To a solution of 4-
fluorobenzaldehyde (0.21 mL, 2.01 mmol) in EtOH (12 mL), 4-
chlorophenylhydrazine hydrochloride (430 mg, 2.4 mmol) was added. The reaction 
mixture was stirred at 90 °C for 80 min and, to the resulting solution, H2O (50 mL) was 
added and stirred for 2 h. The residue obtained was filtered and dried to afford compound 
3d (405 mg, 81%) as a tan solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 4.B40) δ 10.46 (s, 
1H), 7.86 (s, 1H), 7.70 (dd, J1 = 8.7 Hz, J2 = 5.7 Hz, 2H), 7.24 (d, J = 8.9 Hz, 2H), 7.21 (d, 
J = 8.9 Hz, 2H), 7.06 (d, J = 8.9 Hz, 2H); 13C NMR (100 MHz, (CD3)2SO, Fig. 4.B41) δ 
162.0 (d, J = 244.2 Hz), 144.2, 136.2, 132.2 (d, J = 3.0 Hz), 128.9, 127.6 (d, J = 8.1 Hz), 
122.0, 115.6 (d, J = 21.7 Hz), 113.4; m/z calcd for C13H10ClFN2 248.1; found 249.1 
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[M+H]+. Purity of the compound was further confirmed by LCMS: Rt = 20.30 min (99% 
pure; Fig. 4.B42). 
 
Preparation of compound 3f (SGT1379). To a solution of 4-
fluorobenzaldehyde (0.21 mL, 2.01 mmol) in EtOH (12 mL), 2,4-
difluorophenylhydrazine hydrochloride (433 mg, 2.4 mmol) was added. The reaction 
mixture was stirred at 90 °C for 70 min and, to the resulting solution, H2O (50 mL) was 
added and stirred for 4 h. The residue obtained was filtered and dried to afford compound 
3f (493 mg, 98%) as a tan solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 4.B43) δ 10.20 (s, 
1H), 8.10 (s, 1H), 7.69 (dd, J1 = 8.7 Hz, J2 = 5.7 Hz, 2H), 7.49 (td, J1 = 9.4 Hz, J2 = 6.0 
Hz, 1H), 7.23 (t, J = 8.9 Hz, 2H), 7.19 (dd, J1 = 8.9 Hz, J2 = 2.8 Hz, 1H), 7.02-6.96 (m, 
1H); 13C NMR (100 MHz, (CD3)2SO, Fig. 4.B44) δ 162.1 (d, J = 244.4 Hz), 154.7 (dd, J1 
= 235.9 Hz, J2 = 11.0 Hz), 148.4 (dd, J1 = 241.3 Hz, J2 = 11.9 Hz), 138.2, 132.1 (d, J = 3.0 
Hz), 130.4 (dd, J1 = 10.0 Hz, J2 = 3.0 Hz), 127.8 (d, J = 8.2 Hz), 115.6 (d, J = 21.7 Hz), 
114.1 (dd, J1 = 8.8 Hz, J2 = 4.6 Hz), 111.4 (dd, J1 = 21.6 Hz, J2 = 3.4 Hz), 103.8 (dd, J1 = 
26.8 Hz, J2 = 22.1 Hz); m/z calcd for C13H9F3N2 250.1; found 251.1 [M+H]+. Purity of the 
compound was further confirmed by LCMS: Rt = 19.74 min (98% pure; Fig. 4.B45). 
 
Preparation of compound 4a (SGT1287). To a solution of 4-
chlorobenzaldehyde (1.0 g, 7.11 mmol) in EtOH (10 mL), 
phenylhydrazine (0.77 mL, 7.83 mmol) was added. The reaction mixture was stirred at 80 
°C for 1 h and the resulting solution was filtered. The residue obtained was washed with 
hot EtOH (25 mL) to afford compound 4a (1.29 g, 79%) as a white solid: 1H NMR (500 
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MHz, (CD3)2SO, Fig. 4.B46) δ 10.43 (s, 1H), 7.84 (s, 1H), 7.66 (d, J = 8.6 Hz, 2H), 7.43 
(d, J = 8.6 Hz, 2H), 7.21 (dd, J1 = 8.6 Hz, J2 = 7.2 Hz, 2H), 7.06 (dd, J1 = 8.8 Hz, J2 = 1.2 
Hz, 2H), 6.76 (tt, J1 = 7.3 Hz, J2 = 1.2 Hz, 1H); 13C NMR (100 MHz, (CD3)2SO, Fig. 
4.B47) δ 145.1, 135.0, 134.8, 132.1, 129.1, 128.6, 127.1, 118.9, 112.1; m/z calcd for 
C13H11ClN2 230.1; found 231.1 [M+H]+. Purity of the compound was further confirmed by 
LCMS: Rt = 20.19 min (96% pure; Fig. 4.B48). 
 
Preparation of compound 4b (SGT1360). To a solution of 4-
chlorobenzaldehyde (165 mg, 1.17 mmol) in EtOH (7 mL), 3-
fluorophenylhydrazine hydrochloride (229 mg, 1.41 mmol) was added. The reaction 
mixture was stirred at 80 °C for 1 h and, to the resulting solution, H2O (35 mL) was added. 
The residue obtained was filtered and dried to afford compound 4b (258 mg, 89%) as a 
pink solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 4.B49) δ 10.63 (s, 1H), 7.86 (s, 1H), 7.69 
(d, J = 8.5 Hz, 2H), 7.44 (d, J = 8.5 Hz, 2H), 7.23 (td, J1 = 8.2 Hz, J2 = 6.8 Hz, 1H), 6.87 
(dt, J1 = 11.7 Hz, J2 = 2.2 Hz, 1H), 6.83 (ddd, J1 = 8.2 Hz, J2 = 2.1 Hz, J3 = 0.9 Hz, 1H), 
6.56-6.51 (m, 1H); 13C NMR (100 MHz, (CD3)2SO, Fig. 4.B50) δ 163.4 (d, J = 239.4 Hz), 
147.1 (d, J = 11.0 Hz), 136.3, 134.4, 132.5, 130.7 (d, J = 10.1 Hz), 128.7, 127.4, 108.2 (d, 
J = 2.2 Hz), 105.0 (d, J = 21.3 Hz), 98.6 (d, J = 26.1 Hz); m/z calcd for C13H10ClFN2 248.1; 
found 249.1 [M+H]+. Purity of the compound was further confirmed by LCMS: Rt = 20.45 
min (97% pure; Fig. 4.B51). 
 
Preparation of compound 4c (SGT1361). To a solution of 4-
chlorobenzaldehyde (250 mg, 1.78 mmol) in EtOH (10 mL), 4-
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fluorophenylhydrazine hydrochloride (346 mg, 2.13 mmol) was added. The reaction 
mixture was stirred at 80 °C for 1 h and, to the resulting solution, H2O (45 mL) was added. 
The residue obtained was filtered and dried to afford compound 4c (381 mg, 87%) as an 
off-white solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 4.B52) δ 10.42 (s, 1H), 7.82 (s, 1H), 
7.66 (d, J = 8.5 Hz, 2H), 7.43 (d, J = 8.5 Hz, 2H), 7.07-7.04 (m, 4H); 13C NMR (100 MHz, 
(CD3)2SO, Fig. 4.B53) δ 156.0 (d, J = 233.1 Hz), 141.8 (d, J = 1.9 Hz), 135.0, 134.8, 132.1, 
128.6, 127.1, 115.6 (d, J = 22.2 Hz), 113.0 (d, J = 7.4 Hz); m/z calcd for C13H10ClFN2 
248.1; found 249.1 M+H]+. Purity of the compound was further confirmed by LCMS: Rt = 
20.33 min (97% pure; Fig. 4.B54). 
 
Preparation of compound 4d (SGT1291). To a solution of 4-
chlorobenzaldehyde (250 mg, 1.78 mmol) in EtOH (10 mL), 4-
chlorophenylhydrazine hydrochloride (382 mg, 2.13 mmol) was added. The reaction 
mixture was stirred at 80 °C for 1 h and, to the resulting solution, H2O (35 mL) was added. 
The residue obtained was filtered and dried to afford compound 4d (393 mg, 83%) as a 
pink solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 4.B55) δ 10.56 (s, 1H), 7.85 (s, 1H), 7.67 
(d, J = 8.5 Hz, 2H), 7.44 (d, J = 8.5 Hz, 2H), 7.25 (d, J = 8.8 Hz, 2H), 7.07 (d, J = 8.8 Hz, 
2H); 13C NMR (100 MHz, (CD3)2SO, Fig. 4.B56) δ 144.0, 135.9, 134.5, 132.3, 128.9, 
128.7, 127.3, 122.2, 113.5; m/z calcd for C13H10Cl2N2 264.0; found 265.1 [M+H]+. Purity 
of the compound was further confirmed by LCMS: Rt = 21.84 min (99% pure; Fig. 4.B57). 
 
Preparation of compound 4e (SGT1371). To a solution of 4-
cholorobenzaldehyde (100 mg, 0.71 mmol) in EtOH (8 mL), 4-
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methoxyphenylhydrazine hydrochloride (149 mg, 0.85 mmol) was added. The reaction 
mixture was stirred at 90 °C for 1 h and, to the resulting solution, H2O (45 mL) was added. 
The residue obtained was filtered and dried to afford compound 4e (174 mg, 94%) as a 
yellow solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 4.B58) δ 10.25 (s, 1H), 7.77 (s, 1H), 
7.63 (d, J = 8.6 Hz, 2H), 7.41 (d, J = 8.6 Hz, 2H), 7.00 (d, J = 9.0 Hz, 2H), 6.84 (d, J = 9.0 
Hz, 2H), 3.69 (s, 3H); 13C NMR (100 MHz, (CD3)2SO, Fig. 4.B59) δ 152.8, 139.1, 135.1, 
133.8, 131.7, 128.6, 126.9, 114.6, 113.1, 55.3; m/z calcd for C14H13ClN2O 260.1; found 
261.1 [M+H]+. Purity of the compound was further confirmed by LCMS: Rt = 19.63 min 
(98% pure; Fig. 4.B60). 
 
Preparation of compound 4f (SGT1359). To a solution of 4-
chlorobenzaldehyde (250 mg, 1.78 mmol) in EtOH (10 mL), 2,4-
difluorophenylhydrazine hydrochloride (385 mg, 2.13 mmol) was added. The reaction 
mixture was stirred at 80 °C for 1 h and, to the resulting solution, H2O (35 mL) was added. 
The residue obtained was filtered and dried to afford compound 4f (395 mg, 84%) as an 
off-white solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 4.B61) δ 10.31 (s, 1H), 8.08 (s, 1H), 
7.67 (d, J = 8.6 Hz, 2H), 7.50 (td, J1 = 9.4 Hz, J2 = 6.0 Hz, 1H), 7.45 (d, J = 8.6 Hz, 2H), 
7.21 (ddd, J1 = 11.9 Hz, J2 = 8.9 Hz, J3 = 2.8 Hz, 1H), 7.02-6.97 (m, 1H); 13C NMR (100 
MHz, (CD3)2SO, Fig. 4.B62) δ 154.8 (dd, J1 = 235.0 Hz, J2 = 10.9 Hz), 148.4 (dd, J1 = 
241.4 Hz, J2 = 12.0 Hz), 137.9, 134.5, 132.6, 130.2 (dd, J1 = 9.9 Hz, J2 = 3.0 Hz), 128.7, 
127.4, 114.2 (dd, J1 = 8.8 Hz, J2 = 4.5 Hz), 111.4 (dd, J1 = 21.6 Hz, J2 = 3.4 Hz), 103.8 
(dd, J1 = 26.8 Hz, J2 = 22.1 Hz); m/z calcd for C13H9ClF2N2 266.0; found 267.1 [M+H]+. 
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Purity of the compound was further confirmed by LCMS: Rt = 21.04 min (100% pure; Fig. 
4.B63). 
 
Preparation of compound 5a (SGT1284). To a solution of 4-
methoxybenzaldehyde (2.0 g, 14.7 mmol) in EtOH (20 mL), 
phenylhydrazine (1.45 mL, 14.7 mmol) was added. The reaction mixture was stirred at 90 
°C for 1 h and the solid formed was filtered. The product obtained was recrystallized in hot 
EtOH (8 mL) to afford compound 5a (2.21 g, 66%) as white solid: 1H NMR (400 MHz, 
(CD3)2SO, Fig. 4.B64) δ 10.14 (s, 1H), 7.81 (s, 1H), 7.58 (d, J = 8.8 Hz, 2H), 7.19 (dd, J1 
= 8.5 Hz, J2 = 7.2 Hz, 2H), 7.03 (dd, J1 = 8.5 Hz, J2 = 1.2 Hz, 2H), 6.96 (d, J = 8.8 Hz, 
2H), 6.71 (tt, J1 = 7.2 Hz, J2 = 1.2 Hz, 1H), 3.78 (s, 3H); 13C NMR (100 MHz, (CD3)2SO, 
Fig. 4.B65) δ 159.3, 145.6, 136.6, 129.0, 128.5, 127.0, 118.3, 114.2, 111.8, 55.2; m/z calcd 
for C14H14N2O 226.1; found 227.1 [M+H]+. Purity of the compound was further confirmed 
by LCMS: Rt = 16.40 min (99% pure; Fig. 4.B66). 
 
Preparation of compound 5c (SGT1398). To a solution of 4-
methoxybenzaldehyde (0.08 mL, 0.73 mmol) in EtOH (8 mL), 4-
fluorophenylhydrazine hydrochloride (179 mg, 1.10 mmol) was added. The reaction 
mixture was stirred at 90 °C for 100 min and, to the resulting solution, H2O (50 mL) was 
added and stirred for 150 min. The residue obtained was filtered and dried to afford 
compound 5c (175 mg, 98%) as an off-white solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 
4.B67) δ 10.12 (s, 1H), 7.81 (s, 1H), 7.58 (d, J = 8.8 Hz, 2H), 7.04 (d, J = 7.1 Hz, 2H), 7.02 
(d, J = 3.9 Hz, 2H), 6.95 (d, J = 8.8 Hz, 2H), 3.78 (s, 3H); 13C NMR (100 MHz, (CD3)2SO, 
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Fig. 4.B68) δ 159.3, 155.6 (d, J = 232.2 Hz), 142.3 (d, J = 1.8 Hz), 136.7, 128.4, 127.0, 
115.5 (d, J = 22.2 Hz), 114.1, 112.7 (d, J = 7.4 Hz), 55.2; m/z calcd for C134H13FN2O 244.1; 
found 245.1 [M+H]+. Purity of the compound was further confirmed by LCMS: Rt = 18.46 
min (97% pure; Fig. 4.B69). 
 
Preparation of compound 5d (SGT1367). To a solution of 4-
methoxybenzaldehyde (0.22 mL, 1.84 mmol) in EtOH (10 mL), 4-
chlorophenylhydrazine hydrochloride (394 mg, 2.20 mmol) was added. The reaction 
mixture was stirred at 80 °C for 1 h and, to the resulting solution, H2O (45 mL) was added. 
The residue obtained was filtered and dried to afford compound 5d (417 mg, 87%) as a 
pink solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 4.B70) δ 10.27 (s, 1H), 7.82 (s, 1H), 7.58 
(d, J = 8.8 Hz, 2H), 7.22 (d, J = 8.9 Hz, 2H), 7.02 (d, J = 8.9 Hz, 2H), 6.95 (d, J = 8.8 Hz, 
2H), 3.78 (s, 3H); 13C NMR (100 MHz, (CD3)2SO, Fig. 4.B71) δ 159.5, 144.5, 137.4, 
128.8, 128.2, 127.2, 121.5, 114.2, 113.2, 55.2; m/z calcd for C14H13ClN2O 260.1; found 
261.1 [M+H]+. Purity of the compound was further confirmed by LCMS: Rt = 19.71 min 
(97% pure; Fig. 4.B72). 
 
Preparation of compound 5e (SGT1290). To a solution of 4-
methoxybenzaldehyde (0.22 mL, 1.84 mmol) in EtOH (10 mL), 
4-methoxyphenylhydrazine hydrochloride (385 mg, 2.20 mmol) was added. The reaction 
mixture was stirred at 80 °C for 1 h and, to the resulting solution, H2O (35 mL) was added. 
The residue obtained was filtered and dried to afford compound 5e (235 mg, 49%) as a 
yellow solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 4.B73) δ 9.90 (s, 1H), 7.76 (s, 1H), 7.55 
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(d, J = 8.8 Hz, 2H), 6.97 (d, J = 8.9 Hz, 2H), 6.94 (d, J = 8.8 Hz, 2H), 6.82 (d, J = 8.9 Hz, 
2H), 3.77 (s, 3H), 3.68 (s, 3H); 13C NMR (100 MHz, (CD3)2SO, Fig. 4.B74) δ 159.1, 152.3, 
139.7, 135.5, 128.7, 126.8, 114.6, 114.1, 112.8, 55.3, 55.1; m/z calcd for C15H16N2O2 256.1; 
found 257.2 [M+H]+. Purity of the compound was further confirmed by LCMS: Rt = 17.54 
min (99% pure; Fig. 4.B75). 
 
Preparation of compound 5f (SGT1366). To a solution of 4-
methoxybenzaldehyde (0.22 mL, 1.84 mmol) in EtOH (10 mL), 
2,4-difluorophenylhydrazine hydrochloride (397 mg, 2.20 mmol) was added. The reaction 
mixture was stirred at 80 °C for 1 h and, to the resulting solution, H2O (45 mL) was added. 
The residue obtained was filtered and dried to afford compound 5f (429 mg, 89%) as a pink 
solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 4.B76) δ 9.99 (s, 1H), 8.06 (s, 1H), 7.58 (d, J = 
8.8 Hz, 2H), 7.46 (td, J1 = 9.4 Hz, J2 = 6.0 Hz, 1H), 7.18 (ddd, J1 = 11.9 Hz, J2 = 8.9 Hz, 
J3 = 2.9 Hz, 1H), 7.00-6.98 (m, 1H), 6.96 (d, J = 8.8 Hz, 2H), 3.78 (s, 3H); 13C NMR (100 
MHz, (CD3)2SO, Fig. 4.B77) δ 159.6, 154.4 (dd, J1 = 235.3 Hz, J2 = 10.9 Hz), 148.3 (dd, 
J1 = 241.0 Hz, J2 = 12.0 Hz), 139.6, 130.8 (dd, J1 = 9.9 Hz, J2 = 3.0 Hz), 128.2, 127.3, 
114.2, 113.9 (dd, J1 = 8.7 Hz, J2 = 4.7 Hz), 111.3 (dd, J1 = 21.4 Hz, J2 = 3.4 Hz), 103.7 
(dd, J1 = 26.7 Hz, J2 = 22.1 Hz), 55.2; m/z calcd for C14H12F2N2O 262.1; found 263.1 
[M+H]+. Purity of the compound was further confirmed by LCMS: Rt = 19.21 min (99% 
pure; Fig. 4.B78). 
 
Preparation of compound 6a (SGT1294). To a solution of 2,4-
difluorobenzaldehyde (0.19 mL, 1.76 mmol) in EtOH (10 mL), 
220 
phenylhydrazine (0.21 mL, 2.11 mmol) was added. The reaction mixture was stirred at 80 
°C for 1 h and, to the resulting solution, H2O (40 mL) was added. The residue obtained was 
filtered and dried to afford compound 6a (381 mg, 94%) as a pink solid: 1H NMR (500 
MHz, (CD3)2SO, Fig. 4.B79) δ 10.54 (s, 1H), 7.97 (s, 1H), 7.96 (td, J1 = 8.8 Hz, J2 = 6.7 
Hz, 1H), 7.28 (ddd, J1 = 11.4 Hz, J2 = 9.2 Hz, J3 = 2.5 Hz, 1H), 7.25-7.20 (m, 2H), 7.15-
7.10 (m, 1H), 7.07-7.04 (m, 2H), 6.77 (tt, J1 = 7.3 Hz, J2 = 1.1 Hz, 1H); 13C NMR (100 
MHz, (CD3)2SO, Fig. 4.B80) δ 161.8 (dd, J1 = 221.3 Hz, J2 = 12.2 Hz), 159.3 (dd, J1 = 
223.9 Hz, J2 = 12.4 Hz), 144.9, 129.1, 127.9 (dd, J1 = 3.8 Hz, J2 = 2.0 Hz), 126.7 (dd, J1 = 
9.6 Hz, J2 = 5.0 Hz), 120.2 (dd, J1 = 10.3 Hz, J2 = 3.8 Hz), 119.1, 112.2 (dd, J1 = 21.7 Hz, 
J2 = 3.4 Hz), 112.1, 104.1 (t, J = 25.7 Hz); m/z calcd for C13H10F2N2 232.1; found 233.1 
[M+H]+. Purity of the compound was further confirmed by LCMS: Rt = 19.45 min (99% 
pure; Fig. 4.B81). 
 
Preparation of compound 6b (SGT1363). To a solution of 2,4-
difluorobenzaldehyde (0.19 mL, 1.76 mmol) in EtOH (10 mL), 3-
fluorophenylhydrazine hydrochloride (343 mg, 2.11 mmol) was added. The reaction 
mixture was stirred at 80 °C for 1 h and, to the resulting solution, H2O (45 mL) was added. 
The residue obtained was filtered and dried to afford compound 6b (418 mg, 95%) as an 
off-white solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 4.B82) δ 10.75 (s, 1H), 8.02-7.96 (td, 
J1 = 8.7 Hz, J2 = 6.7 Hz, 1H), 8.00 (s, 1H), 7.29 (ddd, J1 = 11.2 Hz, J2 = 9.3 Hz, J3 = 2.5 
Hz, 1H), 7.24 (td, J1 = 8.2 Hz, J2 = 6.8 Hz, 1H), 7.16-7.11 (m, 1H), 6.88 (dt, J1 = 11.7 Hz, 
J2 = 2.3 Hz, 1H), 6.81 (ddd, J1 = 8.2 Hz, J2 = 2.1 Hz, J3 = 0.9 Hz, 1H), 6.58-6.53 (m, 1H); 
13C NMR (100 MHz, (CD3)2SO, Fig. 4.B83) δ 163.4 (d, J = 239.5 Hz), 162.1 (dd, J1 = 
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227.7 Hz, J2 = 12.5 Hz), 159.6 (dd, J1 = 230.1 Hz, J2 = 12.4 Hz), 146.9 (d, J = 11.0 Hz), 
130.8 (d, J = 10.0 Hz), 129.3 (dd, J1 = 3.8 Hz, J2 = 1.9 Hz), 127.1 (dd, J1 = 9.8 Hz, J2 = 4.9 
Hz), 119.8 (dd, J1 = 10.2 Hz, J2 = 3.8 Hz), 112.3 (dd, J1 = 21.7 Hz, J2 = 3.4 Hz), 108.2 (d, 
J = 2.2 Hz), 105.2 (d, J = 21.4 Hz), 104.2 (t, J = 25.6 Hz), 98.6 (d, J = 26.1 Hz); m/z calcd 
for C13H9F3N2 250.1; found 251.1 [M+H]+. Purity of the compound was further confirmed 
by LCMS: Rt = 19.85 min (95% pure; Fig. 4.B84). 
 
Preparation of compound 6c (SGT1364). To a solution of 2,4-
difluorobenzaldehyde (0.19 mL, 1.76 mmol) in EtOH (10 mL), 4-
fluorophenylhydrazine hydrochloride (343 mg, 2.11 mmol) was added. The reaction 
mixture was stirred at 80 °C for 1 h and, to the resulting solution, H2O (45 mL) was added. 
The residue obtained was filtered and dried to afford compound 6c (401 mg, 91%) as a 
yellow solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 4.B85) δ 10.54 (s, 1H), 7.98-7.92 (td, J1 
= 8.7 Hz, J2 = 6.7 Hz, 1H), 7.96 (s, 1H), 7.28 (ddd, J1 = 11.5 Hz, J2 = 9.3 Hz, J3 = 2.6 Hz, 
1H), 7.13 (td, J1 = 8.4 Hz, J2 = 2.6 Hz, 1H), 7.10-7.04 (m, 4H); 13C NMR (100 MHz, 
(CD3)2SO, Fig. 4.B86) δ 161.8 (dd, J1 = 222.5 Hz, J2 = 12.4 Hz), 159.4 (dd, J1 = 225.2 Hz, 
J2 = 12.3 Hz), 156.1 (d, J = 233.2 Hz), 141.6 (d, J = 1.9 Hz), 128.0 (dd, J1 = 5.7 Hz, J2 = 
2.4 Hz), 126.8 (dd, J1 = 9.6 Hz, J2 = 5.0 Hz), 120.1 (dd, J1 = 10.3 Hz, J2 = 3.8 Hz), 115.7 
(d, J = 22.3 Hz), 113.0 (d, J = 7.4 Hz), 112.2 (dd, J1 = 21.7 Hz, J2 = 3.4 Hz), 104.1 (t, J = 
25.6 Hz); m/z calcd for C13H9F3N2 250.1; found 251.1 [M+H]+. Purity of the compound 
was further confirmed by LCMS: Rt = 19.61 min (96% pure; Fig. 4.B87). 
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Preparation of compound 6d (SGT1362). To a solution of 2,4-
difluorobenzaldehyde (0.19 mL, 1.76 mmol) in EtOH (10 mL), 4-
chlorophenylhydrazine hydrochloride (378 mg, 2.11 mmol) was added. The reaction 
mixture was stirred at 80 °C for 1 h and, to the resulting solution, H2O (45 mL) was added. 
The residue obtained was filtered and dried to afford compound 6d (384 mg, 82%) as a 
brown solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 4.B88) δ 10.67 (s, 1H), 7.98 (s, 1H), 7.96 
(td, J1 = 8.8 Hz, J2 = 6.7 Hz, 1H), 7.29 (ddd, J1 = 11.3 Hz, J2 = 9.3 Hz, J3 = 2.6 Hz, 1H), 
7.26 (d, J = 8.9 Hz, 2H), 7.16-7.10 (m, 1H), 7.06 (d, J = 8.9 Hz, 2H); 13C NMR (100 MHz, 
(CD3)2SO, Fig. 4.B89) δ 162.0 (dd, J1 = 226.6 Hz, J2 = 12.4 Hz), 159.5 (dd, J1 = 229.1 Hz, 
J2 = 12.4 Hz), 143.9, 129.0, 128.9 (dd, J1 = 3.8 Hz, J2 = 1.9 Hz), 126.9 (dd, J1 = 9.7 Hz, J2 
= 4.8 Hz), 122.4, 119.9 (dd, J1 = 10.5 Hz, J2 = 3.8 Hz), 113.5, 112.3 (dd, J1 = 21.6 Hz, J2 
= 3.4 Hz), 104.2 (t, J = 25.6 Hz); m/z calcd for C13H9ClF2N2 266.0; found 267.1 [M+H]+. 
Purity of the compound was further confirmed by LCMS: Rt = 20.50 min (100% pure; Fig. 
4.B90). 
 
Preparation of compound 6f (SGT1293). To a solution of 2,4-
difluorobenzaldehyde (0.19 mL, 1.76 mmol) in EtOH (10 mL), 2,4-
difluorophenylhydrazine hydrochloride (349 mg, 1.94 mmol) was added. The reaction 
mixture was stirred at 80 °C for 1 h and, to the resulting solution, H2O (50 mL) was added. 
The residue obtained was filtered and dried to afford compound 6f (458 mg, 97%) as an 
off-white solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 4.B91) δ 10.42 (s, 1H), 8.25 (s, 1H), 
7.98 (td, J1 = 8.7 Hz, J2 = 6.7 Hz, 1H), 7.50 (td, J1 = 9.3 Hz, J2 = 5.9 Hz, 1H), 7.29 (ddd, 
J1 = 11.4 Hz, J2 = 9.2 Hz, J3 = 2.5 Hz, 1H), 7.22 (ddd, J1 = 11.8 Hz, J2 = 8.8 Hz, J3 = 2.8 
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Hz, 1H), 7.17-7.11 (m, 1H), 7.03-6.96 (m, 1H); 13C NMR (100 MHz, (CD3)2SO, Fig. 
4.B92) δ 162.1 (dd, J1 = 228.3 Hz, J2 = 12.4 Hz), 159.6 (dd, J1 = 230.9 Hz, J2 = 12.4 Hz), 
154.9 (dd, J1 = 236.0 Hz, J2 = 10.9 Hz), 148.4 (dd, J1 = 241.6 Hz, J2 = 12.1 Hz), 131.0 (d, 
J = 21.7 Hz), 130.1 (dd, J1 = 9.9 Hz, J2 = 3.0 Hz), 127.0 (dd, J1 = 9.7 Hz, J2 = 4.9 Hz), 
119.9 (dd, J1 = 10.3 Hz, J2 = 3.9 Hz), 114.2 (dd, J1 = 8.8 Hz, J2 = 4.5 Hz), 112.3 (dd, J1 = 
21.6 Hz, J2 = 3.4 Hz), 111.4 (dd, J1 = 21.7 Hz, J2 = 3.4 Hz), 104.2 (t, J = 25.6 Hz), 103.9 
(dd, J1 = 26.9 Hz, J2 = 22.1 Hz); m/z calcd for C13H8F4N2 268.1; found 269.1 [M+H]+. 
Purity of the compound was further confirmed by LCMS: Rt = 20.39 min (99% pure; Fig. 
4.B93). 
 
Preparation of compound 6g (SGT1384). To a solution of 2,4-
difluorobenzaldehyde (0.08 mL, 0.70 mmol) in EtOH (8 mL), 2,5-
difluorophenylhydrazine hydrochloride (122 mg, 0.84 mmol) was added. The reaction 
mixture was stirred at 90 °C for 3.25 h and, to the resulting solution, H2O (50 mL) was 
added and stirred for 2.75 h. The residue obtained was filtered and dried to afford 
compound 6g (181 mg, 96%) as a peach solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 4.B94) 
δ 10.67 (s, 1H), 8.31 (s, 1H), 8.06 (td, J1 = 8.8 Hz, J2 = 6.7 Hz, 1H), 7.30 (ddd, J1 = 11.3 
Hz, J2 = 9.3 Hz, J3 = 2.6 Hz, 1H), 7.26 (ddd, J1 = 10.7 Hz, J2 = 6.6 Hz, J3 = 3.2 Hz, 1H), 
7.18 (ddd, J1 = 11.4 Hz, J2 = 8.9Hz, J3 = 5.0 Hz, 1H), 7.16-7.11 (m, 1H), 6.59-6.53 (m, 
1H); 13C NMR (100 MHz, (CD3)2SO, Fig. 4.B95) δ 162.3 (dd, J1 = 232.2 Hz, J2 = 12.2 
Hz), 159.9 (dd, J1 = 234.8 Hz, J2 = 12.4 Hz), 159.2 (dd, J1 = 236.3 Hz, J2 = 1.7 Hz), 145.2 
(dd, J1 = 234.1 Hz, J2 = 2.2 Hz), 134.5 (t, J = 118.3 Hz), 132.3 (dd, J1 = 4.1 Hz, J2 = 1.9 
Hz), 127.4 (dd, J1 = 9.7 Hz, J2 = 4.7 Hz), 119.6 (dd, J1 = 10.3 Hz, J2 = 3.7 Hz), 116.0 (dd, 
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J1 = 20.3 Hz, J2 = 10.5 Hz), 112.3 (dd, J1 = 21.6 Hz, J2 = 3.3 Hz), 104.3 (dd, J1 = 15.6 Hz, 
J2 = 8.3 Hz), 104.1 (dd, J1 = 14.6 Hz, J2 = 7.2 Hz), 100.5 (dd, J1 = 29.4 Hz, J2 = 3.8 Hz); 
m/z calcd for C13H8F4N2 268.1; found 269.1 [M+H]+. Purity of the compound was further 
confirmed by LCMS: Rt = 20.32 min (99% pure; Fig. 4.B96). 
 
Preparation of compound 6h (SGT1383). To a solution of 2,4-
difluorobenzaldehyde (0.08 mL, 0.70 mmol) in EtOH (8 mL), 3,5-
difluorophenylhydrazine hydrochloride (152 mg, 0.84 mmol) was added. The reaction 
mixture was stirred at 90 °C for 2 h and, to the resulting solution, H2O (50 mL) was added 
and stirred for 3.5 h. The residue obtained was filtered and dried to afford compound 6h 
(179 mg, 95%) as a peach solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 4.B97) δ 10.92 (s, 
1H), 8.01 (s, 1H), 8.02 (td, J1 = 8.7 Hz, J2 = 6.7 Hz, 1H), 7.31 (ddd, J1 = 11.4 Hz, J2 = 9.3 
Hz, J3 = 2.6 Hz, 1H), 7.14 (td, J1 = 8.6 Hz, J2 = 2.5Hz, 1H), 6.68 (dd, J1 = 10.0 Hz, J2 = 
2.4 Hz, 2H), 6.52 (tt, J1 = 9.5 Hz, J2 = 2.4 Hz, 1H); 13C NMR (100 MHz, (CD3)2SO, Fig. 
4.B98) δ 164.0 (dd, J1 = 241.0 Hz, J2 = 15.7 Hz), 162.3 (dd, J1 = 233.0 Hz, J2 = 12.3 Hz), 
159.8 (dd, J1 = 235.3 Hz, J2 = 12.2 Hz), 147.6 (t, J = 13.7 Hz), 130.6 (dd, J1 = 3.8 Hz, J2 = 
1.9 Hz), 127.4 (dd, J1 = 9.7 Hz, J2 = 4.7 Hz), 119.5 (dd, J1 = 10.3 Hz, J2 = 3.7 Hz), 112.3 
(dd, J1 = 21.7 Hz, J2 = 3.3 Hz), 104.2 (t, J = 25.6 Hz), 95.0 (d, J = 29.2 Hz), 93.6 (t, J = 
26.4 Hz); m/z calcd for C13H8F4N2 268.1; found 269.1 [M+H]+. Purity of the compound 
was further confirmed by LCMS: Rt = 20.34 min (95% pure; Fig. 4.B99). 
 
Preparation of compound 7a (SGT1292). To a solution of 
acetophenone (0.49 mL, 4.16 mmol) in EtOH (12 mL), phenylhydrazine 
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(0.49 mL, 4.99 mmol) was added. The reaction mixture was stirred at 80 °C for 1 h and, to 
the resulting solution, H2O (30 mL) was added. The residue obtained was filtered and dried 
to afford compound 7a (228 mg, 26%) as a dark grey solid: 1H NMR (500 MHz, (CD3)2SO, 
Fig. 4.B100) δ 9.25 (s, 1H), 7.80-7.77 (m, 2H), 7.40-7.34 (m, 2H), 7.29 (tt, J1 = 7.2 Hz, J2 
= 1.2 Hz, 1H), 7.25-7.18 (m, 4H), 6.75 (tt, J1 = 6.5 Hz, J2 = 1.9 Hz, 1H), 2.25 (s, 3H); 13C 
NMR (100 MHz, (CD3)2SO, Fig. 4.B101) δ 146.1, 140.4, 139.2, 128.9, 128.2, 127.4, 125.1, 
118.8, 112.8, 12.8; m/z calcd for C14H14N2 210.1; found 211.1 [M+H]+. 
 
Preparation of compound 7f (SGT1295). To a solution of 
acetophenone (0.24 mL, 2.08 mmol) in EtOH (7 mL), 2,4-
difluorophenylhydrazine hydrochloride (451 mg, 2.50 mmol) was added. The reaction 
mixture was stirred at 80 °C for 1 h and, to the resulting solution, H2O (40 mL) was added. 
The residue obtained was filtered and dried to afford compound 7f (396 mg, 77%) as a 
brown solid: 1H NMR (500 MHz, (CD3)2SO, Fig. 4.B102) δ 8.61 (s, 1H), 7.82-7.79 (m, 
2H), 7.56 (td, J1 = 9.3 Hz, J2 = 6.0 Hz, 1H), 7.42-7.37 (m, 2H), 7.35-7.31 (m, 1H), 7.22 
(ddd, J1 = 11.8 Hz, J2 = 8.8 Hz, J3 = 2.8 Hz, 1H), 7.04-6.98 (m, 1H), 2.30 (s, 3H); 13C NMR 
(100 MHz, (CD3)2SO, Fig. 4.B103) δ 155.2 (dd, J1 = 236.2 Hz, J2 = 10.8 Hz), 149.4 (dd, 
J1 = 242.5 Hz, J2 = 11.8 Hz), 145.1, 138.8, 131.3 (dd, J1 = 9.7 Hz, J2 = 3.0 Hz), 128.3, 
128.1, 125.5, 115.7 (dd, J1 = 8.8 Hz, J2 = 4.5 Hz), 111.2 (dd, J1 = 21.6 Hz, J2 = 3.4 Hz), 
103.8 (dd, J1 = 26.7 Hz, J2 = 22.4 Hz), 13.0; m/z calcd for C14H12F2N2 246.1; found 247.1 
[M+H]+. 
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4.5.2. Biochemistry and microbiology 
Biochemical/biological reagents and instrumentation. The American Type Culture 
Collection (ATCC) Candida albicans strains, including 10231 (strain A), 64124 (strain B), 
and MYA-2876(S) (strain C), were a generous gift from Dr. Jon Y. Takemoto (Utah State 
University, Logan, UT, USA). The rest of the C. albicans strains, including 90819(R) 
(strain D), MYA-2310(S) (strain E), MYA-1237(R) (strain F), and MYA-1003(R) (strain 
G), as well as the non-albicans Candida fungi C. glabrata ATCC 2001 (strain H), C. krusei 
ATCC 6258 (strain I), and C. parapsilosis ATCC 22019 (strain J) were purchased from 
the American Type Culture Collection (ATCC, Manassas, VA, USA). A panel of Candida 
auris strains was acquired from the CDC & FDA Antibiotic Resistance Isolate Bank (CDC, 
Atlanta, GA, USA), which included C. auris (AR Bank # 0381-0390), Candida 
duobushaemulonii (AR Bank # 0391, 0392, and 0394), Candida haemulonii (AR Bank # 
0393 and 0395), Kodameae ohmeri (AR Bank # 0396), Candida krusei (AR Bank # 0397), 
Candida lusitaniae (AR Bank # 0398), and Saccharomyces cerevisiae (AR Bank # 0399 
and 0400). The filamentous fungi Aspergillus nidulans ATCC 38163 (strain L) was a kind 
gift from Prof. Jon S. Thorson (University of Kentucky, Lexington, KY), while the 
Aspergillus flavus ATCC MYA-3631 (strain K) and Aspergillus terreus ATCC MYA-3633 
(strain M) were purchased from the ATCC. Yeast strains (strains A-J and AR Bank # 0381-
0400) were cultured at 35 °C in yeast extract peptone dextrose (YEPD) broth. Aspergillus 
spp. strains K-M were cultured on potato dextrose agar (PDA, catalog # 110130, EMD 
Millipore, Billerica, MA, USA) at 28 °C before the spores were harvested. All fungal 
experiments were carried out in RPMI 1640 medium (catalog # R6504, Sigma-Aldrich, St. 
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Louis, MO, USA) buffered to pH 7.0 with 0.165 M MOPS buffer (Sigma-Aldrich, St. 
Louis, MO, USA). 
 
For cytotoxicity assays, the human lung carcinoma cell line, A549, and the mouse 
macrophage cell line, J774A.1, were provided by Profs. Markos Leggas (University of 
Kentucky, Lexington, KY) and David J. Feola (University of Kentucky, Lexington, KY), 
respectively. The human embryonic kidney cell line, HEK-293, was bought from the 
ATCC. The A549 and HEK-293 cells were grown in Dulbecco’s Modified Eagle’s 
Medium (DMEM, catalog # VWRL0100, VWR, Chicago, IL) supplemented with 10% 
fetal bovine serum (FBS; from ATCC) and 1% penicillin/streptomycin (from ATCC) at 37 
°C with 5% CO2. The J774A.1 cells were grown at 37 °C with 5% CO2 in DMEM (catalog 
# 30-2002, ATCC, Manassas, VA) supplemented with FBS and antibiotics. 
 
Instrumentation for fungal assays with yeast were the V-1200 spectrophotometer (VWR, 
Radnor, PA, USA) and the SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, 
CA, USA) for biofilm, cytotoxicity, and hemolysis assays. The known antifungal drugs, 
amphotericin B (AmB, VWR, Chicago, IL, USA), caspofungin (CFG, Sigma-Aldrich, St. 
Louis, MO, USA), fluconazole, (FLC, AK Scientific, Union City, CA, USA) and 
voriconazole (VRC, AK Scientific, Union City, CA, USA) were used as positive controls. 
 
Determination of minimum inhibitory concentration (MIC) values. The individual 
minimum inhibitory concentration (MIC) values of compounds 1a-7f were measured for 
each fungal strain. The MIC values were determined using the broth microdilution method 
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in sterile 96-well plates.305 Concentrations of compound tested were 0.06-31.3 µg/mL 
against strains A-M (Tables 4.1 and 4.2). In cases where MIC values were at or below, 0.06 
µg/mL, compounds were then tested in the range of 0.015-7.8 µg/mL. The select 
compounds, 2b, 3f, 4b, 5a, 5f, 6b, 6d, 7a, and 7f were also tested against the 20 strains 
from the CDC antibiotic resistance bank (Table 4.3). For testing, compounds were 
dissolved in DMSO at a concentration of 5 mg/mL allowing the highest concentration of 
DMSO to be 0.63% in the assay. Serial two-fold dilutions of compound were made 
horizontally across the plate in 100 µL of RPMI 1640 medium. For yeast, the overnight 
culture was diluted into RPMI 1640 (25 µL of a fungal stock with OD600 of 0.12-0.15 into 
10 mL of RPMI 1640 medium, resulting in final inoculum size around 1-5×103 CFU/mL) 
and added to the plate (100 µL per well), making a final volume of 200 µL total per well. 
Similarly, for Aspergillus spp., spores were diluted in RPMI 1640 to 5×105 spores/mL, 
then 100 µL of stock was seeded in each well.370 The MIC value of each compound was 
determined by visual inspection (MIC-0). The known antifungal drugs, AmB, CFG, FLC, 
and VRC were used as controls. In Table 4.1, the MIC-0 values were determined for 
compounds 1a-7f as well as AmB and CFG, whereas MIC-2 values were reported for FLC 
and VRC. For C. auris and other related Candida strains (AR Bank # 0381-0400, Table 
4.3) the MIC-0 was reported for AmB, while for CFG, FLC, and VRC, the MIC-2 was 
recorded. For yeast, plates were incubated for 48 h at 35 °C, except for with CFG, which 
was read at 24 h. Aspergillus spp. were incubated for 72 h at 35 °C. Control values reported 
for C. albicans, non-albicans Candida, and Aspergillus strains (Tables 4.1 and 4.2) MIC 
values for AmB, CFG, FLC, and VRC had been previously reported247 and were included 
for comparison purpose. 
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Hemolysis assays. Hemolytic activity of compounds 2b, 3f, 4b, 5f, 6d, 7f, as well as AmB 
and VRC was assessed using methods previously reported with minor modifications.374 2 
mL of citrate-treated murine red blood cells (mRBCs) were obtained and suspended 10 mL 
of sterile PBS. mRBCs were washed thrice by spinning at 500×g for 7 min. After washing, 
mRBCs were counted using a hemacytometer and diluted in PBS to 5×107 cells/mL. Serial 
dilutions of compounds were made in PBS in 96-well plates (100 µL volume) in similar 
fashion as described for MIC assays (Fig. 4.3). Plates also contained a positive control (1% 
Triton-X®, TX), a negative control (DMSO), and wells with no mRBCs to account for any 
background absorbance. After compounds were added to the plate, 100 µL of mRBCs were 
added to each well and plates were incubated at 37 °C for 30 min. After incubation, plates 
were spun at 500×g for 7 min. 100 µL of supernatant was then transferred to a new 96-well 
plate and the absorbance at 500 nm was read using a spectrophotometer. Percent hemolysis 
was calculated using the following equation after subtraction of the background 
absorbance. These data are presented in Fig. 4.3 and Table 4.4 (normalized to 100%) as 
well as Fig. 4.9 (non-normalized). 
 
% hemolysis= 
Abs500 of compound
Abs500 of TX
×100 
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Fig. 4.9. Non-normalized 2D bar graph depicting the dose-dependent hemolytic activity of monohydrazones 
2b, 3f, 4b, 5f, 6d, 7f, as well as AmB and VRC against mRBCs. mRBCs were treated and incubated for 1 h 
at 37 °C with monohydrazones, AmB, and VRC at concentrations ranging from 0.24 to 31.3 µg/mL. Triton 
X-100® (TX) (1% v/v) was used as a positive control (100% hemolysis). Note: The corresponding data 
normalized at 100% are presented in Fig. 4.3 and Table 4.4. 
 
Mammalian cytotoxicity assays. Cytotoxicity assays were performed as previously 
described244 with slight modifications. A549, J774A.1, and HEK-293 cells were first 
thawed from stocks and grown in Dulbecco’s modified Eagles’s medium (DMEM) 
containing 10% fetal bovine serum (FBS) and 1% antibiotics. The adherent cells (A549 
and HEK-293) were then trypsinized with 0.05% trypsin-0.53 mM EDTA and resuspended 
in fresh DMEM medium. Once the cells were 80% confluent, they were transferred to a 
96-well microtitier plate at density of 5000 cells/well for A549 and 10,000 cells/well for 
HEK-293 and J774A.1. The 96-well plates were incubated 37 °C with 5% CO2 overnight. 
Fresh powder of compounds 2b, 3f, 4b, 5f, 6d, and 7f, as well as controls AmB and VRC 
were prepared as 6.26 mg/mL stock solutions in biological DMSO (200× the highest final 
concentration). The stock solutions were diluted in 1.5 mL eppendorf tubes to achieve 
concentrations of 6.26-0.024 mg/mL (200×). 5 µL of these 200× compound stock solutions 
was then added to 495 µL of DMEM medium in 1.5 mL eppendorf tubes to obtain 
concentrations of 62.6-0.24 µg/mL (2×). The medium in the 96-well plates containing the 
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cells was aspirated and replaced by fresh DMEM medium (100 µL). The serially diluted 
monohydrazones 2b, 3f, 4b, 5f, 6d, and 7f, as well as controls AmB and VRC were added 
to the 96-well plates (µL) to obtain final concentrations of 31.3-0.12 µg/mL. The 96-well 
plates were further incubated for 24 h at 37 °C with 5% CO2 overnight. To evaluate cell 
survival, each well was treated with 10 µL (25 mg/L) of resazurin sodium salt (Sigma-
Aldrich, St. Louis, MO, USA) and was incubated for another 6 h. Metabolically active cells 
can convert resazurin to the highly fluorescent dye, resorufin, and be detected at λ560 
excitation and λ590 emission using a SpectraMax M5 plate reader (Molecular Devices, San 
Jose, CA, USA). Triton X-100® (1%, v/v) was used as positive control, the negative control 
consisted of cells treated with the delivery vehicle (0.05% DMSO), and the blank control 
only had medium with 0.05% DMSO without cells. The percentage survical rates were 
calculated by using the following formula:  
 
% cell survival=
[(fluorescencesample) – (fluorescencebackground)] 
[(fluorescencenegative control) – (fluorescencebackground)]
×100 
 
Experiments were done in quadruplicate. The 100% normalized data are reported in Fig. 
4.4 and the corresponding non-normalized data are reported in Fig 4.10. 
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Fig. 4.10. Non-normalized 2D bar graph depicting the dose-dependent hemolytic activity of monohydrazones 
2b, 3f, 4b, 5f, 6d, 7f, as well as AmB and VRC against mRBCs. mRBCs were treated and incubated for 1 h 
at 37 °C with monohydrazones, AmB, and VRC at concentrations ranging from 0.24 to 31.3 µg/mL. Triton 
X-100® (TX) (1% v/v) was used as a positive control (100% hemolysis). Note: The corresponding data 
normalized at 100% are presented in Fig. 4.3 and Table 4.4. 
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Time-kill assays. Time-killing kinetics were assessed for compounds 2b, 3f, 4b, 5f, 6d, 
7f, as well as AmB and VRC against C. albicans ATCC 10231 (strain A) to evaluate 
whether the compounds act in a fungistatic or fungicidal manner (Figs. 4.5 and 4.6). In 
addition to this, the six compounds plus controls were screened against C. auris AR # 0384 
and C. auris AR # 0390 (Fig. 4.6). For all experiments, 3 mL of YEPD medium was 
inoculated and grown overnight at 35 °C with 200 rpm shaking. In the morning, the 
overnight culture was diluted in RPMI 1640 medium to an OD600 between 0.120 and 0.125 
and aliquoted 5 mL into each sample tube and after compound was added, tubes were 
incubated at 35 °C with 200 rpm shaking. Each compound was tested at ½×, 1×, and 4× 
MICs. For the known antifungal agents, AmB was tested at 1× MIC concentration and 
VRC was tested at 1× MIC-0 concentration for C. albicans ATCC (strain A, 0.98 µg/mL) 
and 31.3 µg/mL for both C. auris strains as the MIC-0 value was ≥31.3 µg/mL. For the 
kinetic analysis, 100 µL samples were taken at 0, 3, 6, 9, 12, and 24 h, serial 10-fold 
dilutions were made in sterile H2O, and 100 µL from the appropriate dilutions were plated 
on PDA plates and incubated at 48 h at 35 °C. After 48 h, the number of colony forming 
units (CFU) on each plate were recorded and plates containing between 30 and 300 CFU 
were used for data analysis. At the 24 h time point, 50 µL of 25 mg/L resazurin was added 
to the sample tubes and incubated in the dark at 35 °C with 200 rpm shaking for 2 h. The 
color change observed with the resazurin was used to confirm colony counts. For the time-
kill screen with the two C. auris strains (Fig. 4.6), sample tubes were prepared in the same 
manner as above. Samples were vortexed occasionally over the 24 h period and resazurin 
was added at 24 h to show the relative growth. After the initial 24 h period, all sample tubes 
were incubated at 35 °C with no shaking and the color was recorded at 48 h and 72 h in 
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addition to the initial 24 h time point to observe if any growth occurred outside of the 24 h 
experimental period. 
 
Biofilm assays. Two variations of the biofilm assay were performed to determine the 
sessile MIC (SMIC) values of compounds 2b, 3f, 4b, 5f, 6d, 7f, as well as AmB and VRC 
against C. albicans ATCC 10231 (strain A) as well as C. auris AR Bank # 0384 and AR 
Bank # 0390. Both biofilm assays followed previous protocols and utilized XTT [2,3-bis(2-
methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] to assess viability of 
fungal biofilms after treatment. Assays were performed in similar fashion to the MIC 
assays for plate setup and compound concentrations using procedures as previously 
described.309 For the first biofilm assay, prevention of biofilm formation, serial dilutions of 
compound were made in RPMI 1640 medium (100 µL) and fungal suspension (OD600 
~0.15) was added to the compounds (200 µL total). Plates were sealed with parafilm and 
incubated at 37 °C for 48 h. At 48 h, the plates were washed thrice with 200 µL of sterile 
phosphate buffered saline (PBS) before the addition of XTT. We reported both the SMIC50 
and SMIC90 which are the concentrations of compound at which 50% and 90% inhibition 
of biofilm activity compared to growth control were observed, respectively (Table 4.5, Fig. 
4.7). For the second assay, destruction of a pre-formed biofilm, 100 µL per well of fungal 
suspension was aliquoted into a 96-well plate and incubated at 37 °C for 24 h. At 24 h, the 
wells were washed thrice with 100 µL sterile PBS. Serial dilutions of compounds were 
made in RPMI 1640 medium in the plate (200 µL total). The treated biofilms were sealed 
with parafilm and incubated at 37 °C. At 24 h, the plates were washed thrice with 200 µL 
PBS before XTT was added (Table 4.6, Fig. 4.11). Directly before use, 1 µL of 10 mM 
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menadione in acetone (per 10 mL XTT) was added to XTT (0.5 mg/mL in sterile PBS). 
100 µL of XTT was aliquoted to each well and allowed to incubate in the dark for 3 h at 
37 °C before being read on the spectrophotometer (λ = 450 nm). As no obvious biofilm 
inhibition was observed, we reported the SMIC50. Each assay was performed in duplicate. 
 
 
Fig. 4.1. Destruction of a pre-formed biofilm of A. C. albicans ATCC 10231 (strain A), B. C. auris AR Bank 
# 0384, and C. C. auris AR Bank # 0390 treated at 24 h with 2b, 3f, 4b, 5f, 6d, 7f, AmB, and VRC. XTT 
dye is metabolized by fungal cells to produce an orange color. The corresponding data are presented in Table 
4.6. 
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Development of fungal resistance. To evaluate the likelihood that fungal strain can 
develop resistance, the change in the MIC of compounds 2b, 3f, 4b, 5f, 6d, as well as AmB 
over 15 serial passages was monitored with C. auris AR Bank # 0390 (Fig. 4.8). The 
procedure was followed from the previously recorded method with little modifications.373 
MIC assays were performed as described above. For the serial passages, cells were selected 
from a well representing ½ the MIC concentration and used to start an overnight culture 
for the following MIC. 
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Chapter 5 
 
Additional ongoing research 
 
5.1. INTRODUCTION 
This section presents five projects that were conceptualized during my time as a graduate 
student, but are incomplete at this time. Four projects explore the utility of an adjuvant 
approach to combat antimicrobial resistance. The first three projects, “fexofenadine and 
azole antifungal combinations,” “ebastine and non-azole antifungal combinations,” and 
“antihistamine and antibiotic combinations” are inspired by the work on antihistamine and 
azole combinations presented in Chapter 2. The fourth project “additional gold (I)-
phosphine complexes” includes data for two different families of gold(I)-phosphine 
complexes related to the complexes presented in Chapter 3. And the final project, 
“monohydrazides” gives preliminary biological data for a series of compounds closely 
related to those presented in Chapter 4. 
 
5.2. RESULTS AND DISCUSSION 
5.2.1. Fexofenadine and azole antifungal combinations 
We previously showed in Chapter 2 that combinations of azoles and antihistamines were 
synergistic against Candida spp.257 These combinations were important because fungi, 
including Candida spp., develop resistance to azoles so that the antifungals are no longer 
effective. The antihistamine terfenadine (TERF, Fig. 5.1) was previously approved by the 
FDA. At the time of its approval, TERF was well regarded as was one of the first second-
239 
generation antihistamines, which do not cause drowsiness. Another second-generation 
antihistamine, ebastine (EBA, Fig. 5.1), has not been approved in the U.S. The major 
downside to using these two antihistamines, specifically with the azoles, is that there are 
drug-drug interactions. The azoles inhibit cytochrome P450 (CYP) proteins283 responsible 
for the metabolism of both TERF and EBA into their active metabolites, fexofenadine 
(FEX) and carebastine, respectively. The CYP inhibition results in toxic levels of TERF 
and EBA in the blood, leading to human ether-à-go-go-related gene (hERG) inhibition and 
potentially fatal heart arrythmia. 
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Fig. 5.1. Structures of the antihistamines terfenadine (TERF), fexofenadine (FEX), ebastine (EBA), and 
carebastine. 
 
In Chapter 2, we observed synergy of TERF with all azole antifungals, except with 
fluconazole (FLC). Less synergy was observed with EBA and it appeared synergy was 
dependent on the fungal strain. Compared to TERF, FEX has an added hydroxyl group and 
is not able to cause hERG inhibition. FEX is currently approved by the FDA and is sold 
under the brand name Allegra®. To avoid drug-drug interactions, combinations with azoles 
and FEX were investigated for synergistic antifungal activity.  
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Combinations of FEX with posaconazole (POS) or voriconazole (VRC) were tested against 
four yeast strains (Table 5.1). The combination of FEX and POS displayed an FICI of 0.63 
against C. albicans ATCC 10231 (strain B) indicating some positive interactions. However, 
it was apparent that FEX displayed no true synergistic effect against fungi. As no 
significant positive interactions were observed, combination with FEX were no longer 
explored. A similar outcome would be predicted for the active metabolite of EBA, 
carebastine. 
 
Table 5.1. Combinational effect of FEX with POS or VRC against a variety of fungal strains. 
Azole Strain MIC alone 
(µg/mL) 
MIC combo 
(µg/mL) 
FICI Interp. Azole Strain MIC alone 
(µg/mL) 
MIC combo 
(µg/mL) 
FICI Interp. 
  Azole FEX Azole FEX     Azole FEX Azole FEX   
POS B 1 >128 0.5 16 0.63 pSYN VRC B 1 >128  128 2.00 ADD 
 F >32 >128 >32 >128 2.00 ADD  F >32 >128 >32 >128 2.00 ADD 
 G >32 >128 >32 >128 2.00 ADD  G >32 >128 >32 >128 2.00 ADD 
 H >32 >128 >32 >128 2.00 ADD  H >32 >128 >32 >128 2.00 ADD 
Strains: A = C. albicans ATCC MYA-1003, B = C. albicans ATCC 10231, C = C. albicans ATCC MYA-1237, D = C. albicans, 
ATCC MYA-2310, E = C. albicans ATCC MYA-2876, F = C. albicans ATCC 64124, G = C. albicans ATCC 90819, H = C. 
glabrata ATCC 2001, I = C. glabrata clinical isolate 1 (CG1), J = C. glabrata clinical isolate 2 (CG2), K = C. glabrata clinical 
isolate 3 (CG3), L = C. krusei ATCC 6258, M = C. parapsilosis ATCC 22019. 
The FICI cutoff values for determining synergy are: synergistic (SYN) if FICI ≤ 0.5, additive (ADD) if 0.5 < FICI ≤ 4, antagonistic 
(ANT) if FICI > 4. 
Note: Where the highest concentration of a compound or azole drug alone did not achieve optical growth inhibition, the MICalone 
value used in the FICI calculation is the highest concentration tested of that compound or azole drug. Combinations were tested in 
duplicate. 
 Indicates partial synergy (pSYN, both drugs showed reduction in MIC values and one drug showed ≥2-fold reduction in 
MIC value). 
 Indicates weak additive effect (ADD, neither of the drugs showed ≥2-fold reduction in MIC value). 
 
5.2.2. Ebastine and non-azole antifungal combinations 
The second strategy to repurpose antihistamines as antifungals was to explore 
combinations with the other two main classes of antifungals, the polyenes (e.g. 
amphotericin B (AmB) and nystatin (NYT)) and the echinocandins (e.g. caspofungin 
(CFG)). Neither of these antifungals are CYP inhibitors and therefore combinations with 
these are not expected to result in major side effects such as hERG inhibition and heart 
problems. Combinations of EBA and antifungals were all tested against four yeast strains 
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(Table 5.2). Both polyenes, AmB and NYT, displayed some positive interactions with EBA 
as both polyene combinations exhibited pSYN against two to three yeast strains. However, 
no synergistic combinations were observed. For CFG, synergy was observed with all four 
yeast strains. To explore whether the combination of EBA and CFG also had activity 
against filamentous fungi, the combination was tested against one A. terreus strain (strain 
L), but the combination was additive. 
 
Table 5.2. Combinations of EBA with the antifungals AmB, NYT, and CFG against a panel of fungi. 
Polyenes Echinocandins 
Azole Strain MIC alone 
(µg/mL) 
MIC combo 
(µg/mL) 
FICI Interp. Azole Strain MIC alone 
(µg/mL) 
MIC combo 
(µg/mL) 
FICI Interp. 
  Azole EBA Azole EBA     Azole EBA Azole EBA   
AmB B 3.9 >25 3.9 25 2.00 ADD CFG B 1 >25 0.016 6.3 0.27 SYN 
 F 3.9 >25 3.9 25 2.00 ADD  F 0.5 >25 0.063 6..3 0.38 SYN 
 G 0.98 >25 0.49 3.1 0.62 pSYN  G 1 >25 0.016 6.3 0.27 SYN 
 H 1.95 >25 0.98 1.6 0.57 pSYN  H >32 >25 1 3.1 0.16 SYN 
         L >32 >25 >32 >25 2.00 ADD 
NYT B 8 >25 4 3.1 0.62 pSYN         
 F 8 >25 4 0.8 0.53 pSYN         
 G 2 >25 2 25 2.00 ADD         
 H 4 >25 2 1.6 0.56 pSYN         
Strains: B = C. albicans ATCC 10231, F = C. albicans ATCC 64124, G = C. albicans ATCC 90819, H = C. glabrata ATCC 2001, 
L= A. terreus ATCC MYA-3633. 
The FICI cutoff values for determining synergy are: synergistic (SYN) if FICI ≤ 0.5, additive (ADD) if 0.5 < FICI ≤ 4, antagonistic 
(ANT) if FICI > 4. 
Note: Where the highest concentration of a compound or azole drug alone did not achieve optical growth inhibition, the MICalone 
value used in the FICI calculation is the highest concentration tested of that compound or azole drug. Combinations were tested in 
duplicate. 
 Indicates synergy (SYN, both drugs showed ≥4-fold reduction in MIC value). 
 Indicates partial synergy (pSYN, both drugs showed reduction in MIC values and one drug showed ≥2-fold reduction in 
MIC value). 
 Indicates weak additive effect (ADD, neither of the drugs showed ≥2-fold reduction in MIC value). 
 
Some parameters that may influence whether synergistic interactions are observed and to 
what extent with CFG are in what MIC assay procedure is followed. For one, there is the 
paradoxical effect with CFG in vitro where to a certain concentration, CFG inhibits fungal 
growth and after a second point at a higher concentration of CFG, fungal growth is no 
longer inhibited likely due to a stress response.147 Due to this and the fungistatic nature of 
CFG, CFG MIC standard protocol in the CSLI standards is to read the MIC-1 at 24 h. 
However, for other antifungals, such as the polyenes, the MIC-0 at 48 h is measured. And 
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in between, the MIC-1 of azoles are measured at 48 h. Here, the MIC-0 at 48 h is reported 
for all combinations, which cause higher MICcombo values. However, maybe these should 
be compared to MIC-1 at 24 h values of CFG instead of MIC-0 at 48 h. It would be 
interesting to see the FICI values then as the paradoxical effect elevates MIC values, 
especially at 48 h. As the EBA and CFG combination appears synergistic, it would be 
useful to further expand the study to other Candida strains, including C. auris. It would 
also be necessary to include the other echinocandins, anidulafungin and micafungin. 
 
5.2.3. Antihistamine and antibiotic combinations 
As the antihistamines EBA and TERF displayed synergistic activity with the azole 
antifungals, it was hypothesized that the antihistamines may also act as an adjuvant with 
antibiotics against bacteria. Some investigations have already demonstrated that TERF 
possesses some antibacterial activity against Gram-positive bacteria284 while FEX does 
not.415 Furthermore, the only class of antibiotics that are CYP inhibitors and would have 
drug-drug interactions with the antihistamines are the macrolides. Therefore, one antibiotic 
each from various classes were selected. Antibiotic classes represented are the β-lactams 
(ampicillin, AMP), the quinolones (ciprofloxacin, CIP), trimethoprim (TRI), tetracycline 
(TET), and aminoglycosides (tobramycin, TOB). The glycopeptide (vancomycin, VAN) 
was also included for Gram-positive strains. 
 
TERF combinations were tested against two Gram-positive and two Gram-negative strains 
(Table 5.3). Only an additive effect was observed with VRE and K. pneumoniae. Some 
cases of partial synergy were observed against B. anthracis and E. cloacae. While S. aureus 
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has not been tested, TERF by itself does exhibit MIC values of 16 and 20 µg/mL against 
the two Gram-positive strains, B. anthracis and VRE, respectively. It is interesting to 
observe that in the cases of partial synergy against B. anthracis, the MICcombo value for 
TERF remains constant while the MICcombo decreased by 4-fold for the antibiotic. 
 
Table 5.3. Combinational effect of antibiotics (AB) with the antihistamine, TERF, against a variety of bacterial strains. 
Gram-positive Gram-negative 
Azole Strain MIC alone 
(µg/mL) 
MIC combo 
(µg/mL) 
FICI Interp. Azole Strain MIC alone 
(µg/mL) 
MIC combo 
(µg/mL) 
FICI Interp. 
  AB TERF AB TERF     AB TERF AB TERF   
VRE AMP >32 20 32 20 2.00 ADD K. pne AMP >32 >40 >32 >40 2.00 ADD 
 CIP >2 20 2 20 2.00 ADD  CIP 0.03 >40 0.03 40 2.00 ADD 
 TRI >32 20 32 20 2.00 ADD  TRI >32 >40 >32 >40 2.00 ADD 
 TET 32 20 32 20 2.00 ADD  TET 1 >40 1 40 2.00 ADD 
 TOB >32 20 32 20 2.00 ADD  TOB 1 >40 1 40 2.00 ADD 
B. ant AMP >32 16 8 8 0.75 pSYN E. clo AMP >32 >40 >32 >40 2.00 ADD 
 CIP 4 16 4 16 2.00 ADD  CIP 0.06 >40 0.03 20 1.00 ADD* 
 TRI >32 16 >32 16 2.00 ADD  TRI >32 >40 4 40 1.13 ADD* 
 TET 0.5 16 0.13 16 0.75 pSYN  TET 2 >40 1 40 1.50 ADD* 
 TOB >32 16 >32 16 2.00 ADD  TOB 2 >40 1 5 0.63 pSYN 
Antibiotics (AB): AMP = ampicillin, CIP = ciprofloxacin, TRI = trimethoprim, TET = tetracycline, TOB = tobramycin, VAN = 
vancomycin. 
Gram-positive: B. ant = Bacillus anthracis Sterne strain, VRE = Vancomycin-resistant Enterococcus 
Gram-negative = E. clo = Enterobacter cloacae ATCC 13047, K. pne = Klebsiella pneumonia ATCC 27736. 
The FICI cutoff values for determining synergy are: synergistic (SYN) if FICI ≤ 0.5, additive (ADD) if 0.5 < FICI ≤ 4, antagonistic 
(ANT) if FICI > 4. 
Note: Where the highest concentration of a compound or azole drug alone did not achieve optical growth inhibition, the MICalone 
value used in the FICI calculation is the highest concentration tested of that compound or azole drug. Combinations were tested in 
duplicate. 
 Indicates partial synergy (pSYN, both drugs showed reduction in MIC values and one drug showed ≥2-fold reduction in MIC 
value). 
 Indicates strong additive effect (ADD*, only one drug showed ≥2-fold reduction in MIC value). 
 Indicates weak additive effect (ADD, neither of the drugs showed ≥2-fold reduction in MIC value). 
 
Combinations with EBA were tested against three Gram-positive and five Gram-negative 
strains (Table 5.4). EBA by itself had antibacterial activity against B. anthracis and VRE. 
Some combinations with partial synergy were displayed against Gram-positive bacteria, 
while combinations against Gram-negative were widely additive. The only exception with 
the Gram-negative bacteria and the only combinations to exhibit synergistic interactions 
were with EBA against the E. coli strain. Overall, both antihistamines, EBA and TERF, 
appear to have some antibiotic activity by themselves against Gram-positive bacteria, but 
are not synergistic with antibiotics. 
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5.2.4. Additional gold(I)-phosphine complexes 
The gold(I)-phosphine complexes discussed in Chapter 3 displayed good to excellent 
antifungal activity against a broad range of fungal species.405 Other gold(I)-phosphine 
complexes were obtained from the Awuah laboratory for antifungal testing (Fig. 5.2).  
Table 5.4. Combinational effect of antibiotics (AB) with the antihistamine, EBA, against a variety of bacterial strains. 
Gram-positive Gram-negative 
Strain AB MIC alone 
(µg/mL) 
MIC combo 
(µg/mL) 
FICI Interp. Strain AB MIC alone 
(µg/mL) 
MIC combo 
(µg/mL) 
FICI Interp. 
  AB EBA AB EBA     AB EBA AB EBA   
B. ant AMP >32 6.3 32 3.1 1.50 ADD* E. coli AMP 8 25 2 12.5 1.00 ADD* 
 CIP 8 6.3 4 3.1 1.00 ADD*  CIP 0.004 >25 0.004 25 2.00 ADD 
 TRI >32 6.3 32 6.3 2.00 ADD  TRI >32 25 0.13 12.5 0.50 SYN 
 TET 0.13 6.3 0.02 3.1 0.65 pSYN  TET 1 >25 0.25 6.3 0.50 SYN 
 TOB >32 6.3 32 6.3 2.00 ADD  TOB       
 VAN 1 6.3 0.25 3.1 0.75 pSYN  VAN       
S. aur AMP 0.13 >25 0.06 6.3 0.75 pSYN E. clo AMP >32 >25 >32 >25 2.00 ADD 
 CIP 0.25 >25 0.25 25 2.00 ADD  CIP 0.06 >25 0.06 25 2.00 ADD 
 TRI >32 >25 >32 >25 2.00 ADD  TRI >32 >25 >32 >25 2.00 ADD 
 TET 1 >25 0.25 12.5 0.75 pSYN  TET 2 >25 2 25 2.00 ADD 
 TOB 0.5 >25 0.5 25 2.00 ADD  TOB 2 >25 2 25 2.00 ADD 
 VAN 0.5 >25 0.5 25 2.00 ADD  VAN       
VRE AMP >32 6.3 32 6.3 2.00 ADD K. pne AMP >32 >25 >32 >25 2.00 ADD 
 CIP >0.06 6.3 0.06 6.3 2.00 ADD  CIP >0.06 >25 >0.06 >25 2.00 ADD 
 TRI >32 6.3 32 6.3 2.00 ADD  TRI >32 >25 >32 >25 2.00 ADD 
 TET 0.5 6.3 0.06 3.1 0.62 pSYN  TET >8 >25 >8 >25 2.00 ADD 
 TOB >32 6.3 >32 6.3 2.00 ADD  TOB       
 VAN 1 6.3 0.25 3.1 0.75 pSYN  VAN       
S. epi AMP       S. ent AMP 4 >25 2 1.6 0.56 pSYN 
 CIP        CIP >0.06 >25 >0.06 >25 2.00 ADD 
 TRI        TRI >32 >25 >32 >25 2.00 ADD 
 TET        TET 8 >25 8 25 2.00 ADD 
 TOB        TOB       
 VAN        VAN       
L. mon AMP       P. aer AMP >32 >25 >32 >25 2.00 ADD 
 CIP        CIP 0.5 >25 0.5 25 2.00 ADD 
 TRI        TRI >32 >25 >32 >25 2.00 ADD 
 TET        TET 8 >25 8 25 2.00 ADD 
 TOB        TOB 1 >25 1 25 2.00 ADD 
 VAN        VAN       
Antibiotics (AB): AMP = ampicillin, CIP = ciprofloxacin, TRI = trimethoprim, TET = tetracycline, TOB = tobramycin, VAN = 
vancomycin. 
Gram-positive: B. ant = Bacillus anthracis Sterne strain, L. mon = Listeria monocytogenes ATCC 19115, S. aur = Staphylococcus 
aureus ATCC 25923, S. epi = Staphylococcus epidermidis ATCC 12228, VRE = Vancomycin-resistant Enterococcus 
Gram-negative = E. clo = Enterobacter cloacae ATCC 13047, E. coli = Escherichia coli MC1060, K. pne = Klebsiella pneumoniae 
ATCC 27736, P. aer = Pseudomonas aeruginosa Boston 41501 ATCC 27853, S. ent = Salmonella enterica ATCC 14028. 
The FICI cutoff values for determining synergy are: synergistic (SYN) if FICI ≤ 0.5, additive (ADD) if 0.5 < FICI ≤ 4, antagonistic 
(ANT) if FICI > 4. 
Note: Where the highest concentration of a compound or azole drug alone did not achieve optical growth inhibition, the MICalone 
value used in the FICI calculation is the highest concentration tested of that compound or azole drug. Combinations were tested in 
duplicate. 
 Indicates synergy (SYN, both drugs showed ≥4-fold reduction in MIC value). 
 Indicates partial synergy (pSYN, both drugs showed reduction in MIC values and one drug showed ≥2-fold reduction in MIC 
value). 
 Indicates strong additive effect (ADD*, only one drug showed ≥2-fold reduction in MIC value). 
 Indicates weak additive effect (ADD, neither of the drugs showed ≥2-fold reduction in MIC value). 
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Fig. 5.2. Structures of cpds 1-9 and auranofin. 
 
5.2.4.1. Minimum inhibitory concentration assays 
All compounds were initially tested against a panel of six fungal strains including three C. 
albicans, one C. parapsilosis, and two Aspergillus spp. Compounds 2 and 3 were also 
tested against a larger panel including thirteen Candida and Aspergillus strains (Table 5.5). 
 
For the first scaffold, the ligand (cpd 1) and the linear molecule (cpd 2) displayed no 
antifungal activity while the square planar complex (cpd 3) had excellent antifungal 
activity against Candida spp. with activity similar to the known antifungal AmB. Against 
Aspergillus spp., cpd 3 displayed some activity, but only poor activity. This corresponds to 
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the trends observed in Chapter 2. Below, cpd 3 was evaluated in cytotoxicity, hemolysis, 
disruption of a pre-formed biofilm, and development of resistance assays as this work was 
done alongside the testing in Chapter 2. Other analogues should be synthesized and tested. 
Additional testing for cpd 3 would be in a time-kill assay to see if it is fungicidal.  
 
With the second scaffold, compounds tested included both the linear cpd 5 and its 
corresponding square planar complex cpd 6. In this case, both compounds were inactive 
against all six fungal strains, similar to auranofin. Auranofin here is used as a standard as 
it is an older FDA approved medicine for rheumatoid arthritis and has more recently been 
investigated for being repurposed as an antimicrobial agent and shows some promise as an 
antibacterial.326-330 This scaffold does not warrant further investigation as an antifungal. 
Instead, cpds 5 and 6 should be checked for antibacterial activity.  
 
The third scaffold consisting of cpds 7-9, displayed good antifungal activity. Compound 8 
displayed the best antifungal activity with MIC values of 0.98-1.95 µg/mL against Candida 
spp. similar to cpd 3 and AmB. It is also important to note that cpd 8 displayed the best 
activity of all nine compounds and AmB against Aspergillus spp. Compound 7 also 
displayed good activity against Candida spp., but had MIC values of 1.95-3.9 µg/mL, 
which is 2-fold greater than for cpd 8. Compound 9 also displayed considerably good MIC 
values against Candida spp., but were in the range of 3.9-7.8 µg/mL, which is 4-fold greater 
than cpd 8. In addition, a fourth scaffold, cpd 4, also exhibits good activity against Candida 
albicans, however, not as good as the third scaffold. This third scaffold, cpds 7-9, warrant 
further investigation including the synthesis of more analogues for a more in-depth SAR 
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study. Cpds 7 and 9 were also included in cytotoxicity studies below. Further biological 
testing with MIC testing against C. auris strains, as well as biofilm, time-kill, and 
development of resistance studies would be beneficial. 
 
Table 5.5. MIC values in µg/mL for compounds 1-9 against various fungal strains. 
Strains  Compound 
  1 2 3 4 5 6 7 8 9 Auranofin AmB 
Candida 
albicans 
A >31.3 15.6 0.98 NT NT NT NT NT NT >31.3 0.98 
B >31.3 >31.3 0.98 NT NT NT NT NT NT >31.3 3.9  
C >31.3 31.3 1.95 NT NT NT NT NT NT >31.3 3.9  
D NT >31.3 1.95 7.8 >31.3 31.3 3.9 1.95 7.8 >31.3 7.8  
E >31.3 >31.3 0.98 NT NT NT NT NT NT >31.3 3.9 
F NT >31.3 0.98 7.8 31.3 15.6 1.95 0.98 3.9 >31.3 3.9 
G >31.3 >31.3 1.95 7.8 31.3 15.6 3.9 1.95 3.9 >31.3 0.98 
Non-
albicans 
Candida 
H >31.3 31.3 0.98 NT NT NT NT NT NT >31.3 1.95 
I NT >31.3 1.95 NT NT NT NT NT NT 31.3 3.9 
J NT >31.3 0.98 15.6 >31.3 >31.3 3.9 1.95 3.9 >31.3 0.98 
Aspergillus K NT >31.3 15.6 15.6 >31.3 >31.3 7.8 1.95 15.6 3.9 >31.3 
L NT 31.3 7.8 31.3 >31.3 >31.3 15.6 3.9 15.6 7.8 >31.3 
 M NT >31.3 >31.3 NT NT NT NT NT NT >31.3 >31.3 
Candida albicans strains: A = C. albicans ATCC MYA-1003, B = C. albicans ATCC 10231, C = C. albicans ATCC MYA-1237, D 
= C. albicans, ATCC MYA-2310, E = C. albicans ATCC MYA-2876, F = C. albicans ATCC 64124, G = C. albicans ATCC 90819. 
Non-albicans Candida strains: H = C. glabrata ATCC 2001, I = C. krusei ATCC 6258, J = C. parapsilosis ATCC 22019. 
Aspergillus strains: K = A. nidulans ATCC 38163, L = A. terreus ATCC MYA-3633, M = A. flavus ATCC MYA-3631. 
Note: Compounds were tested in duplicate. 
 MIC ≤1.95 µg/mL (excellent antifungal activity) 
 MIC = 3.9-7.8 µg/mL (good antifungal activity) 
 MIC ≥15.6 µg/mL (poor antifungal activity) 
 
5.2.4.2. Cytotoxicity 
To establish a therapeutic window for these gold(I)-phosphine complexes, cpds 3, 5, 7, 8, 
and 9 were selected for cytotoxicity testing along with auranofin as a known standard (Fig. 
5.3). Compound 3 and auranofin were tested against four cell lines: human adenocarcinoma 
(A549), a human bronchial epithelial (BEAS-2B), human embryonic kidney (HEK-293), 
and mouse macrophage (J774A.1) cell lines. Less than 50% cell survival is observed with 
the A549, BEAS-2B, and HEK-293 cell lines for cpd 3 at and above 7.8 µg/mL and at 3.9 
µg/mL with the J774A.1 cell line. This demonstrates an approximate 2- to 4-fold 
therapeutic window. Therefore, cpd 3 is less selective for the Candida spp. than desired. 
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Fig. 5.3. Evaluation of cytotoxicity for cpd 3 and auranofin with A. A549, B. BEAS-2B, C. HEK-293, and 
D. J774A.1 cell lines. Controls include treatment with Triton-X® (TX, 1% v/v, positive control) and 0.5% 
DMSO (negative control). Compounds were tested in quadruplicate. 
 
For the other gold(I)-phosphine complexes, cpds 5, 7, 8, and 9, all four compounds display 
at least 50% cell survival against the A549 cell line with cpds 7 and 9 exhibiting near 100% 
cell survival (Fig. 5.4). When tested with HEK-293, all four compounds display greater 
than 50% cell survival up to 7.8 µg/mL. At 15.6 µg/mL cpds 8 and 9 have near 100% cell 
survival, cpd 7 is near 50% and cpd 5 is less than 50%. Compounds 7, 8, and 9 all display 
an approximate 4-fold therapeutic window, although cpds 7 and 8 had the greatest cell 
survival and two lowest MIC values. Compound 9 has greater than 50% cell survival at 
15.6 µg/mL for both cell lines, but MIC values also at 3.9-15.6 µg/mL, which is 2-fold 
higher than cpds 7 and 8. 
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Fig. 5.4. Evaluation of cytotoxicity for cpds 5, 7, 8, and 9 with A. A549 and B. HEK-293 cell lines. Controls 
include treatment with Triton-X® (TX, 1% v/v, positive control) and 0.5% DMSO (negative control). 
Compounds were tested in quadruplicate. 
 
5.2.4.3. Hemolysis 
In addition to cytotoxicity testing, cpd 3 was examined for hemolytic activity with both 
human and murine red blood cells (Fig. 5.5). Here, auranofin and AmB are used as known 
standards. AmB is known to exhibit hemolytic activity and in this experiment, significant 
hemolytic activity was observed beginning at 3.9 µg/mL. Compound 3 displays increased 
hemolytic activity with 100% hemolysis for both human and mouse red blood cells at 7.8 
µg/mL, which is only 2- to 4- fold greater than MIC values with Candida spp. 
  
250 
 
Fig. 5.5. Evaluation of hemolytic activity for cpd 3, auranofin, and AmB with A. human RBCs and B. murine 
RBCs. Controls include treatment with Triton-X® (TX, 1% v/v, positive control) and 0.5% DMSO (negative 
control). Compounds were tested in quadruplicate.  
 
5.2.4.4. Disruption of a pre-formed biofilm 
To further evaluate the antifungal potential of cpd 3, we tested the ability of cpd 3 and the 
ligand, cpd 1, to disrupt a pre-formed biofilm (Table 5.6, Fig. 5.6). The ligand was inactive 
against C. glabrata ATCC 2001 (strain H) and not tested against C. albicans ATCC 10231 
(strain B). Compound 3 was somewhat more effective at disrupting the biofilm of C. 
glabrata ATCC 2001 (strain H) with an SMIC90 value of 7.8 µg/mL, which is only 2-fold 
greater than AmB against the same biofilm and 8-fold greater than the MIC value for cpd 
3 against the same strain. Against C. albicans ATCC 10231 (strain B) cpd 3 exhibited poor 
activity when considering the SMIC90 value, however, the SMIC50 value of 1.95 µg/mL is 
the same SMIC50 value as AmB. Further testing of the antibiofilm activity of cpd 3 should 
include a C. auris strain and also a prevention of biofilm formation assay. 
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Table 5.6. Disruption of a pre-formed biofilm by compounds 1, 3, 
auranofin, and AmB against two fungal strains. 
Strain Compound SMIC50 (µg/mL) SMIC90 (µg/mL) 
B 1   
 3 1.95 15.6 
 Auranofin 3.9 15.6 
 AmB 1.95 >31.3 
H 1 >31.3 >31.3 
 3 3.9 7.8 
 Auranofin 3.9 >31.3 
 AmB 0.49 3.9 
Strains: B = C. albicans ATCC 10231, H = C. glabrata ATCC 2001. 
Note: Compounds were tested in duplicate. 
 MIC ≤1.95 µg/mL (excellent antifungal activity) 
 MIC = 3.9-7.8 µg/mL (good antifungal activity) 
 MIC ≥15.6 µg/mL (poor antifungal activity) 
 
 
Fig. 5.6. Disruption of a pre-formed biofilm for cpd 1, auranofin, cpd 3, and AmB against A. C. albicans 
ATCC 10231 (strain B) and B. C. glabrata ATCC 2001 (strain H). Compounds were tested in duplicate. 
 
5.2.4.5. Development of resistance 
To evaluate whether yeast can develop resistance to cpd 3 during continued exposure, a 
development of resistance assay was performed against C. albicans ATCC 10231 (strain 
B) and C. glabrata ATCC 2001 (strain H) (Fig. 5.7). Against both strains, neither cpd 3 
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nor the control, AmB, exhibited MIC changes greater than 2-fold suggesting that the yeast 
are not able to develop resistance. 
 
 
Fig. 5.7. Fold-change in MIC values of cpd 3 and AmB over 15 passages against A. C. albicans ATCC 10231 
(strain B) and B. C. glabrata ATCC 2001 (strain H). MICs were tested in duplicate. 
 
5.2.5. Monohydrazides 
A sample of hydrazide analogues of the monohydrazone from Chapter 4 were synthesized 
and tested for their antifungal activity. We are currently in the process of expanding the 
library of monohydrazides for a full SAR analysis. The monohydrazides, for drug design 
purposes, improve upon the monohydrazones as the hydrazide is less prone to being 
metabolized. 
 
5.2.5.1. Synthesis 
At this point, twenty-two monohydrazides have been synthesized towards this project (Fig. 
5.8.) as well as a fluorescent analogue and a biotinylated analogue. Synthesis involves 
starting with one of three molecules (2,4-difluorobenzoic acid, picolinic acid, or pyrazinoic 
acid) and doing a condensation with a substituted phenylhydrazine (i.e., 3-fluorobenzyl 
hydrazine, 4-fluorobenzyl hydrazine, 4-chlorobenzyl hydrazine, 4-methoxybenzyl 
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hydrazine, 2,4-difluorobenzyl hydrazine). Synthesis of a full library of compounds for a 
SAR study is in progress and characterization of the monohydrazides will be reported in a 
manuscript in due course. 
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Fig. 5.8. General synthetic scheme for the monohydrazides, cpds 10-32 (the structures of the compounds are 
shown in Tables 5.7-5.9). 
 
5.2.5.2. Minimum inhibitory concentration assays 
Compounds 10-16 were initially tested against a few fungal strains and observed to have 
excellent activity. Therefore, cpds 10-16 testing was expanded to a panel of ten C. auris 
strains (Table 5.7) and ten related drug-resistance Candida strains (Table 5.8). Compound 
demonstrated excellent activity against most Candida strains with MIC values ranging 
from 0.12-3.9 µg/mL. The only exception is cpd 12 which was investigated to identify a 
location on the monohydrazide where a probe could successfully be linked. 
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Table 5.7. MIC values in µg/mL for compounds 10-16 against ten C. auris strains. 
  AR Bank # 
Cpd # Structure 0381 0382 0383 0384 0385 0386 0387 0388 0389 0390 
10 N
N
H
O H
N
F
F  
0.49 0.49 0.49 0.49 0.49 0.49 0.12 0.12 0.24 0.12 
11 
N
N
N
H
O H
N
F
F  
3.9 1.95 0.98 3.9 0.98 0.49 0.49 0.49 0.49 0.98 
12 
N
H
O H
N
F
F
F
F
N3
F
F
 
31.3 3.9 7.8 7.8 3.9 3.9 7.8 >31.3 3.9 7.8 
13 N
N
H
O H
N
F  
0.98 1.95 1.95 3.9 0.98 0.49 0.98 0.98 0.49 0.98 
14 
N
N
H
O H
N F
 
0.49 0.98 1.95 1.95 0.98 0.49 0.49 0.49 0.12 0.24 
15 N
N
H
O H
N
OMe  
1.95 1.95 1.95 3.9 0.98 0.24 0.49 0.49 0.24 0.12 
16 N
N
H
O H
N
Cl  
1.95 3.9 1.95 1.95 1.95 0.98 1.95 1.95 0.98 1.95 
AmB  0.98 0.98 1.95 1.95 1.95 0.98 0.98 1.95 1.95 1.95 
Note: Compounds were tested in duplicate. 
 MIC ≤1.95 µg/mL (excellent antifungal activity) 
 MIC = 3.9-7.8 µg/mL (good antifungal activity) 
 MIC ≥15.6 µg/mL (poor antifungal activity) 
 
 
Table 5.8. MIC values in µg/mL for compounds 10-16 against ten C. auris-related strains. 
  AR Bank # 
Cpd # Structure 0391 0392 0393 0394 0395 0396 0397 0398 0399 0400 
10 N
N
H
O H
N
F
F  
0.12 0.49 0.49 3.9 0.24 0.98 0.03 1.95 0.49 0.49 
11 
N
N
N
H
O H
N
F
F  
0.49 0.24 0.24 7.8 1.95 0.98 1.95 3.9 7.8 1.95 
12 
N
H
O H
N
F
F
F
F
N3
F
F
 
3.9 3.9 0.98 7.8 0.49 0.49 0.24 7.8 31.3 3.9 
13 N
N
H
O H
N
F  
0.49 0.49 0.24 0.24 0.12 0.24 0.24 1.95 3.9 1.95 
14 
N
N
H
O H
N F
 
0.49 0.24 0.12 0.49 ≤0.06 0.24 0.24 0.98 1.95 1.95 
15 N
N
H
O H
N
OMe  
0.98 0.98 0.49 0.98 0.49 0.49 0.49 0.98 1.95 0.98 
16 N
N
H
O H
N
Cl  
0.98 0.98 0.49 0.40 0.12 0.24 0.24 0.98 0.98 0.98 
AmB  7.8 7.8 15.6 0.98 3.9 1.95 0.49 3.9 15.6 1.95 
Strains: AR Bank # 0391, 0392, 0394 = C. duobushaemulonii; 0393, 0395 = C. haemulonii; 0396 = K. ohmeri; 0397 = C. krusei; 
0398 = C. lusitaniae; 0399, 0400 = S. cerevisiae. 
Note: Compounds were tested in duplicate. 
 MIC ≤1.95 µg/mL (excellent antifungal activity) 
 MIC = 3.9-7.8 µg/mL (good antifungal activity) 
 MIC ≥15.6 µg/mL (poor antifungal activity) 
 
255 
As compounds 10, 11, and 13-16 all displayed excellent activity against the twenty strains 
tested, which are known to be drug-resistant, more monohydrazides were synthesized to 
include cpds 17-32. Again, all compounds exhibit good to excellent activity with only a 
few instances of poor activity against a C .auris strains. There is not a clear trend on any 
effect of the R2 substituents. Compounds with picoline do appear to be better than pyrazine 
acid which is better than 2,4-difluoro. For this study, synthesis of the remaining library, 
MIC testing against the full panel of C. albicans and non-albicans Candida, biofilm, time-
kill, cytotoxicity, hemolysis, and development of resistance assays are remaining. 
 
Table 5.9. MIC values in µg/mL for compounds 17-32 against three Candida spp. strains. 
  Strains   Strains 
Cpd # Structure B 0384 0390 Cpd # Structure B 0384 0390 
17 
N
H
O H
N
FF
F F
 
1.95 15.6 7.8 14 
N
N
H
O H
N F
 
0.06 1.95 0.24 
10 N
N
H
O H
N
F
F  
0.12 0.49 0.12 25 
N
N
N
H
O H
N F
 
0.24 0.98 0.98 
11 
N
N
N
H
O H
N
F
F  
0.24 3.9 0.98 15 N
N
H
O H
N
OMe  
0.12 3.9 0.12 
12 
N
H
O H
N
F
F
F
F
N3
F
F
 
0.24 7.8 7.8 26 
N
N
N
H
O H
N
OMe  
0.49 0.48 0.49 
18 N
N
H
O H
N
F
F
 
0.12 0.24 0.98 27 
N
H
O H
N
Cl
F
F  
1.95 7.8 >31.3 
19 
N
N
N
H
O H
N
F
F  
0.24 0.48 1.95 16 N
N
H
O H
N
Cl  
0.12 1.95 1.95 
20 N
N
H
O H
N
F
F
 
≤0.06 0.24 0.49 28 
N
N
N
H
O H
N
Cl  
0.98 1.95 3.9 
21 
N
N
N
H
O H
N
F
F
 
0.24 0.48 1.95 29 
N
N
H
O H
N Cl
 
0.12 0.98 0.98 
22 
N
H
O H
N
F
F
F  
0.49 1.95 1.95 30 N
N
H
O H
N Cl
Cl  
0.24 7.8 1.95 
13 N
N
H
O H
N
F  
0.12 3.9 0.98 31 
N
N
N
H
O H
N
Cl
Cl
 
0.24 1.95 0.98 
23 
N
N
N
H
O H
N
F 
0.24 0.48 0.98 32 
N
N
N
H
O H
N
Cl
Cl
 
0.49 15.6 7.8 
Strains: B = C. albicans ATCC 10231, 0384 = C. auris AR Bank # 0384, 0390 = C. auris AR Bank # 0390. 
Note: Compounds were tested in duplicate. 
 MIC ≤1.95 µg/mL (excellent antifungal activity) 
 MIC = 3.9-7.8 µg/mL (good antifungal activity) 
 MIC ≥15.6 µg/mL (poor antifungal activity) 
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5.2.5.3. Probing the target of monohydrazides 
We have developed two potential approaches to elucidate the target within the fungal cell 
for the monohydrazides and their mechanism of action. Both approaches require chemical 
modification of the monohydrazide molecule to add a probe, either a fluorescent or biotin 
molecule, which acts to detect the monohydrazide within the cell or after cell lysis. 
 
5.2.5.3.1. Analogue for fluorescence microscopy 
The probe was synthesized in the Watt laboratory and given for MIC testing to ensure that 
antifungal activity was retained (Fig. 5.9). The MIC of the probe was tested against four 
fungal strains and shown to be active with good activity (Table 5.10). The probe will next 
be fed to the yeast and imaged using a fluorescent microscope. The goal of the probe is to 
determine the relative area in the cell where the molecule is congregating, and this may be 
useful in identifying a protein target. In addition, microscopy will be used to observe if 
treatment with monohydrazides causes any changes in yeast cell morphology. 
 
N
O
O N
H
O
O
N
H
N
O
H
N
F F
 
Fig. 5.9. Structure of the fluorescent probe, cpd 33 
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Table 5.10. MIC values for cpd 33 against four Candida strains. 
 Strain MIC (µg/mL) 
Candida 
albicans 
B 0.98 
F 3.9 
Candida 
auris 
0384 3.9 
0390 1.95 
Strains: B = C. albicans ATCC 10231, F = C. albicans ATCC 
64124, 0384 = C. auris AR Bank # 0384, 0390 = C. auris AR 
Bank # 0390. 
Note: Compound was tested in duplicate. 
 MIC ≤1.95 µg/mL (excellent antifungal activity) 
 MIC = 3.9-7.8 µg/mL (good antifungal activity) 
 
5.2.5.3.2. Biotinylated analogue for pull-down assay 
The second strategy is to use a biotinylated analogue in a pulldown assay to isolate protein 
to which the monohydrazides bind. The biotinylated analogue, cpd 39, was acquired from 
the Watt laboratory. The probe as well as its intermediates in the synthetic were tested for 
antifungal activity (Table 5.11). As the molecule becomes larger the MIC values increase. 
Fortunately, the biotinylated analogue does retain antifungal activity with a MIC value of 
1.95 µg/mL against C. albicans ATCC 10231 (strain B). As the biotinylated probe still has 
moderate antifungal activity, it can be used in a pull-down assay to try to identify a protein 
target. 
 
Table 5.11. MIC values for cpds 34-39 against one C. albicans strains 
Cpd # Structure  Strain B 
34 
F
FH
N
N
H
O
N
HO
 
≤0.06 
35 
F
FH
N
N
H
O
N
HO  
≤0.06 
36 
F
FH
N
N
H
O
N
O
O
O  
0.12 
37 
F
FH
N
N
H
O
N
O
O
O
 
0.24 
38 
F
FH
N
N
H
O
N
HO
O
HClO  
0.98 
39 F
F
H
N
N
H
O
NO
N
H
O
O
O
H
N
O
S
NHHN
O
 
1.95 
AmB  3.9 
Strains: B = C. albicans ATCC 10231. 
Note: Compounds were tested in duplicate. 
 MIC ≤1.95 µg/mL (excellent antifungal activity) 
 MIC = 3.9-7.8 µg/mL (good antifungal activity) 
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5.3. EXPERIMENTAL 
5.3.1. Strains and culture conditions 
For fungal assays, the Candida albicans strains, including MYA-1003 (strain A), MYA-
1237 (strain C), MYA-2310 (strain D), 90819 (strain G), and as well as the non-albicans 
Candida fungi C. glabrata ATCC 2001 (strain H), C. krusei ATCC 6258 (strain I), C. 
parapsilosis ATCC 22019 (strain J) were purchased from the American Type Culture 
Collection (ATCC, Manassas, VA, USA). The remaining C. albicans strains, including 
10231 (strain B), MYA-2876 (strain E), and 64124 (strain F), were a generous gift from 
Dr. Jon Y. Takemoto (Utah State University, Logan, UT, USA). A panel of Candida auris 
strains were acquired from the CDC & FDA Antibiotic Resistance Isolate Bank (CDC, 
Atlanta, GA, USA), which included C. auris AR Bank # 0381-0390. The filamentous fungi 
Aspergillus nidulans ATCC 38163 (strain K) was a kind gifts from Prof. Jon S. Thorson 
(University of Kentucky, Lexington, KY), while the Aspergillus terreus ATCC MYA-3633 
(strain L) and Aspergillus flavus ATCC MYA-3631 (strain M) were purchased from the 
ATCC. Yeast strains were cultured at 35 °C in yeast extract peptone dextrose (YEPD) 
broth. Aspergillus spp. strains were cultured on potato dextrose agar (PDA, catalog # 
110130, EMD Millipore, Billerica, MA, USA) at 28 °C before the spores were harvested. 
All fungal experiments were carried out in RPMI 1640 medium (catalog # R6504, Sigma-
Aldrich, St. Louis, MO, USA) buffered to pH 7.0 with 0.165 M MOPS buffer (Sigma-
Aldrich, St. Louis, MO, USA). 
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Bacterial strains used included five Gram-positive and five Gram-negative strains. Gram-
positive strains included Bacillus anthracis Sterne strain, Listeria monocytogenes ATCC 
19115, Staphylococcus aureus ATCC 25923, Staphylococcus epidermidis ATCC 12228, 
and vancomycin-resistant Enterococcus (VRE). Gram-negative strains consisted of 
Enterobacter cloacae ATCC 13047, Escherichia coli MC1060, Klebsiella pneumoniae 
ATCC 27736, Pseudomonas aeruginosa Boston 41501 ATCC 27853, and Salmonella 
enterica ATCC 14028. Bacteria were grown at 37 on Mueller Hinton (MH) medium 
(Sigma-Aldrich, St. Louis, MO, USA). VRE was a gift from Prof. David H. Sherman 
(University of Michigan, Ann Arbor, MI, USA). L. monocytogenes ATCC 19115, S. 
enterica ATCC 14028, K. pneumoniae ATCC 27736, and E. coli MC1061 were a kindly 
provided by Prof. Paul J. Hergenrother (University of Illinois at Urbana-Champaign, 
Champaign, IL, USA). E. cloacae ATCC 13047, S. epidermidis ATCC 12228 were a kind 
gift from Prof. Dev P. Arya (Clemson University, Clemson, SC, USA). 
 
For cytotoxicity assays, the human embryonic kidney cell line (HEK-293) was purchased 
from the ATCC. The human bronchial epithelial cell line (BEAS-2B), the human lung 
carcinoma cell line (A549), and the mouse macrophage cell line (J774A.1) were generous 
gifts from Prof. David K. Orren (University of Kentucky, Lexington, KY), Prof. Markos 
Leggas (University of Kentucky, Lexington, KY), and Prof. David J. Feola (University of 
Kentucky, Lexington, KY), respectively. A549, HEK-293, and BEAS-2B cells were 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, catalog # VWRL0100, VWR, 
Chicago, IL) supplemented with 10% fetal bovine serum (FBS; from ATCC) and 1% 
penicillin/streptomycin (from ATCC) at 37 °C with 5% CO2. The J774A.1 cells were 
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cultured in DMEM (catalog # 30-2002, ATCC, Manassas, VA), which was also 
supplemented with FBS and antibiotics and grown at 37 °C with 5% CO2. 
 
Instrumentation for fungal assays with yeast were the V-1200 spectrophotometer (VWR, 
Radnor, PA, USA) and the SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, 
CA, USA) for biofilm, cytotoxicity, and hemolysis assays. The known antifungal drugs, 
amphotericin B (AmB, VWR, Chicago, IL, USA), caspofungin (CFG, Sigma-Aldrich, St. 
Louis, MO, USA), fluconazole (FLC, AK Scientific, Union City, CA, USA), voriconazole 
(VRC, AK Scientific, Union City, CA, USA), and the antirheumatic drug, auranofin (Santa 
Cruz Biotechnology, Dallas, TX, USA) were used as positive controls. All other chemicals 
were supplied from Sigma-Aldrich (St. Louis, MO, USA). 
 
5.3.2. Minimum inhibitory concentration assays.  
The individual minimum inhibitory concentration (MIC) values for all compounds were 
measured using the broth microdilution method305 in sterile 96-well plates as in Chapters 
3, 4, and 5. Compound stocks were made to be 5 mg/mL in DMSO and diluted by serial 
two-fold dilution in the assay to final concentrations of 0.06-31.3 µg/mL. For yeast, the 
overnight culture was diluted into RPMI 1640 (25 µL of a fungal stock with OD600 of 0.12-
0.15 into 10 mL of RPMI 1640 medium, resulting in final inoculum size around 1-5×103 
CFU/mL) and added to the plate (100 µL per well), making a final volume of 200 µL total 
per well. Similarly, for Aspergillus spp., spores were diluted in RPMI 1640 to 5×105 
spores/mL then 100 µL of stock was seeded in each well.370 The MIC value of each 
compound was determined by visual inspection. For Candida spp., plates were incubated 
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for 48 h at 35 °C and Aspergillus spp. were incubated for 72 h at 35 °C (Table 5.5, Table 
5.7-5.11). 
 
5.3.3. Checkerboard assays 
Checkerboard assays for fungal strains were performed as described in Chapter 2. 
Compounds (antifungals and antibiotics) were serially diluted lengthwise in RPMI-1640 
in a 96-well plate. The antihistamines were serially diluted in culture tubes before being 
added to the 96-well plate with serial dilutions going along the width of the plate. The 
antifungals POS, VRC, AmB, CFG, and NYT were tested in the range of 0.06-32 µg/mL 
as well as the antibiotics AMP, CIP, TET, TRI, TOB, and VAN. EBA was tested in the 
range of 0.4-25 µg/mL and TERF was tested from 0.8-40 µg/mL except with B. anthracis 
where TERF was tested in the range of 0.5-32 µg/mL. Yeasts suspensions were prepared 
as described above for MIC assays. For bacterial strains, the same experimental setup was 
used. The overnight bacterial culture was diluted 1:1000 in MH medium. The inoculum is 
then incubated at 37 °C with 200 rpm rotation for 2-4 h until the OD600 is approximately 
0.4. The culture is then diluted 1:1000 into MH medium and 100 mL per well is added to 
the 96-well plate. Bacterial plates are incubated at 37 °C for 24 h. All experiments were 
done in duplicate (Table 5.1-5.4). 
 
5.3.4. Cytotoxicity  
To examine the selectivity index for fungal cells compared to mammalian cells, 
cytotoxicity assays were performed as described in Chapter 3. Four mammalian cell lines, 
HEK-293, A549, BEAS-2B, and J774A.1 cells, were used for testing cpds 3, 5, 7, 8, and 9 
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as well as auranofin. HEK-293 and J774A.1 cells were plated at 1×104 cells/mL while 
A549 and BEAS-2B were plated at 3×103 cells/mL. Compound stocks were dissolved in 
DMSO at 3.14 mg/mL and diluted in DMSO before being further diluted in DMEM and 
added to the 96-well plate with final concentrations ranging from 0.06 to 15.6 µg/mL (Fig. 
5.3 and 5.4). All assays were done in quadruplicate. 
 
5.3.5. Hemolysis 
To extend on the cytotoxicity results, cpds 3 along with auranofin and AmB, were tested 
for their ability to lyse red blood cells (RBCs). Both human and murine RBCs were 
provided in a citrate-treated tube on ice and the hemolysis assay was done as previously 
described in Chapter 3 and in similar fashion to cytotoxicity assays. The RBCs were 
washed three times in PBS before being resuspended in PBS to achieve a cell concentration 
of on the order of 107 cells/mL. Stock concentration of compound were dissolved in DMSO 
at 3.14 mg/mL. Serial double dilutions were made in DMSO before being diluted in PBS 
and added to a 96-well plate to afford final concentrations of 0.06-15.6 µg/mL. Compounds 
were tested in quadruplicate with ~5×106 RBCs per well. The RBCs were also treated with 
1% Triton-X® (positive control) and PBS (negative control). The RBCs were treated for 
30 min at 37 °C and the absorbance was read at 595 nm. Hemolysis is visually observed 
by a decrease in optical density of the wells (turbid, dark red to transparent pink). Percent 
hemolysis (Fig. 5.5) was calculated using this equation after subtraction of the background 
absorbance (positive control): 
 
% Hemolysis = 
absorbance of sample
absorbance of RBC+PBS (negative control)
×100 
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5.3.6. Disruption of a pre-formed biofilm 
The biofilm assay for cpds 1, 3, auranofin, and AmB against C. albicans ATCC 10231 
(strain B) and C. glabrata ATCC 2001 (strain H) was performed as described in Chapter 
3. An overnight fungal culture was diluted to an OD600 of 0.15 in RPMI-1640 medium. 100 
µL of fungal suspension was added per well to a 96-well plate and incubated for 24 at 37 
°C. The plate was then washed thrice with 100 mL PBS before the addition of fresh RPMI-
1640. Serial dilution of compounds was performed in the same fashion as described for 
MIC assays. Plates were again incubated for 24 at 37 °C. Finally, the plate was washed 
thrice with PBS before XTT was added and incubated at 37 °C for 3 h. Absorbance readings 
were read at 490 nm. All compounds were tested in duplicate and the SMIC was calculated 
as compared to the growth control (Table 5.6., Fig. 5.6). 
 
5.3.7. Development of resistance 
The development of resistance assay for cpd 3 was performed as described in Chapter 3. 
AmB and cpd 3 were tested in the concentration range of 0.06-31.3 µg/mL using the MIC 
format described above with C. albicans ATCC 10231 (strain B) and C. glabrata ATCC 
2001 (strain H). Fungal suspension from the ½ × MIC wells were selected to inoculate the 
overnight culture for the following passage. This procedure was repeated for 15 passages 
(Fig. 5.7). 
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Chapter 6 
 
Conclusion and future directions 
 
6.1. A COMBINATIONAL APPROACH 
The first approach taken in this work was to use combinations of azole antifungals and the 
antihistamines terfenadine (TERF) and ebastine (EBA) against a panel of Candida strains, 
covered in Chapter 1. While this is also a repurposing approach, the main goal of this 
project was to use the antihistamines as an adjuvant for the azole antifungals, specifically 
against fungal strains that demonstrate intrinsic or acquired resistance to the azoles. In this 
study, we observed that TERF displayed poor antifungal activity by itself and out of ninety-
one total combinations tested, fourty-one were synergistic with TERF and fourteen 
synergistic with EBA. In Chapter 5, combinations of TERF and/or EBA with polyenes, 
echinocandins, and/or antibiotics were discussed. Of these combinations, the only 
synergistic combination was EBA and caspofungin (CFG). While some studies have 
suggested that antihistamines may inhibit efflux pumps299 and affect sterol metabolism,416-
417 the mechanism of action of the antihistamine antifungal activity is still unclear. By 
themselves, combinations of azole antifungals and antihistamines use an adjuvant approach 
to increasing the azole susceptibility of azole-resistant Candida strains, similar to 
clavulanic acid and amoxicillin for bacterial infections. The azoles are an important class 
of antifungals and used in a synergistic combination would improve efficacy of the azoles 
and likely reduce toxic hepatic side effects. Currently, a combination of AmB and 5FC is 
used for drug-resistant infections, but synergistic combination with azoles would extend 
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treatment options for these drug-resistant infections. If identifying a specific target would 
open doors to new target-based studies for the discovery of novel antifungals, which may 
lead to more success in identifying new classes of antifungal therapeutics. 
 
6.2. GOLD(I)-PHOSPHINE COMPLEXES 
The second approach explored the gold(I)-phosphine complexes, which had been reported 
as an anticancer agent,323, 339-340 but not yet as an antifungal agent. We showed that two 
square-planar gold(I)-phosphine complexes displayed excellent antifungal activity, similar 
to AmB, against a broad range of fungal species not limited to Candida spp., and including 
C. auris. Furthermore, this was the only scaffold tested that had good activity against 
Aspergillus spp, of which there are fewer drug available for treatment.The promising 
activity of the gold complexes was comparable to AmB, however, there does not appear to 
be the desired 8-fold therapeutic window to suggest that the complexes would be safe. As 
gold(I)-phosphine complexes have shown some selectivity for cancer cell lines, future 
cytotoxicity studies should include normal cell lines. New generations of antifungal 
gold(I)-phosphine complexes should strive to increase their selectivity for fungal cells. As 
is, the gold complexes could have potential use for applications on surfaces to mitigate 
toxicity concerns. In Chapter 5, four other gold(I)-phosphine scaffold are discussed, two 
of which show good antifungal activity. In addition to finding new scaffolds with less 
toxicity, future goals for this project is to identify the cellular target for these complexes. 
Gold(I)-phosphine complexes have been reported to inhibit thioredoxin reductase in the 
mitochondria,336-337 but that activity has not been tested yet with complexes discussed here 
and it is possible there is another mechanism of action. 
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6.3. MONOHYDRAZONES 
And finally, as a third approach we were inspired by bis(N,N'-arylhydrazones)212 which 
exhibited good antifungal activity, but poor solubility and decided to eliminate half of the 
molecule to afford the monohydrazones. The monohydrazones displayed good activity 
against C. albicans and surprisingly somewhat better activity against C. auris. In vitro, the 
monohydrazones displayed better MIC activity than AmB with C. auris and related strains 
and exhibited less toxicity in hemolysis and cytotoxicity assays. The monohydrazones also 
performed similarly to VRC in biofilm, hemolysis, and cytotoxicity studies, but have the 
added benefit of being more potent antifungals and having fungicidal activity. This next 
steps for this project are already in progress, as discussed in Chapter 5, with the 
monohydrazides and the fluorescent and biotinylated analogues. Determining the cellular 
target of these molecules and progressing them into animal models are warranted. 
 
6.4. GENERAL APPROACHES TO ANTIMICROBIAL DRUG DISCOVERY 
The story of Alexander Fleming and the discovery of the antibiotic penicillin is well 
known, but what about the first antifungals? The first medicine to be approved specifically 
as an antifungal was nystatin (NYT), which was isolated in 1949 and patented in 1957.418 
The discovery of NYT was a collaboration between Elizabeth Lee Hazen and Rachel Fuller 
Brown who worked for the Division of Laboratories and Research of the New York State 
Department of Health. Hazen collected Actinomycete samples and screened them for 
antifungal activity while Brown extracted and purified the active compound. Their 
discovery, NYT, itself was not an immediate success as it also showed toxicity and was 
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generally unsafe for use with systemic fungal infections, however, it is currently used 
topically today. This was a critical discovery as it caught the attention of pharmaceutical 
companies and provided a platform for more research. This soon resulted in the discovery 
of the gold standard of antifungals, amphotericin B (AmB), which entered the clinic in 
1959.4 The studies in this dissertation, like with NYT, hope to discover a novel antifungal 
that can be used clinically, but are also meant to be the starting collaboration that finds a 
starting point for new and useful antifungals.  
 
The various projects within this dissertation are completely new antifungals. And while we 
use known antifungals as controls so we can compare potency and selectivity of the drugs 
in vitro, these molecules are likely have different mechanisms of action and cannot be 
directly compared to current antifungals. We take a screening approach to identify a 
unique, active scaffold, but lack a clear protein target. A more direct approach to antifungal 
discovery would be to have a specific target in mind and future work is to identify those 
targets as this would allow for more efficient identification of lead compounds and further 
optimization modification of compounds. However, the screening approach appears to be 
the most common method for antifungal discovery at this point. Other considerations in 
antifungal discovery is the method of eliminating an infection and if it is necessary to have 
fungicidal antifungal agents. Some fields within the broader antifungal discovery include 
immunotherapy419 and molecules that prevent fungal adhesion.420 While many patients that 
suffer from fungal infections are immunocompromised, alternate therapeutic strategies 
such as these may be lackluster, there may be other patients where these strategies may be 
beneficial for prevention of infection.  
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APPENDIX A 
 
Compound characterization for Chapter 3 figures 3.A1-3.A30 which includes 1H, 13C 
NMR, and 31P spectra as well as HRMS (ESI) and HPLC traces. 
 
 
Fig. 3.A1: 1H NMR of compound 1 in CDCl3 at 298K. 
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Fig. 3.A2: 13C NMR of compound 1 in CDCl3 at 298K. 
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Fig. 3.A3: 31P NMR of compound 1 in CDCl3 at 298K. 
 
 
Fig. 3.A4: HRMS (ESI) of compound 1. 
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Fig. 3.A5: HPLC trace for compound 1. Rt = 8.82. Purity = 97%. 
 
 
Fig. 3.A6: 1H NMR of compound 2 in CDCl3 at 298K. 
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Fig. 3.A7: 13C NMR of compound 2 in CDCl3 at 298K. 
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Fig. 3.A8: 31P NMR of compound 2 in CDCl3 at 298K. 
 
 
Fig. 3.A9: HRMS (ESI) of compound 2. 
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Fig. 3.A10: HPLC trace for compound 2. Rt = 10.78. Purity = 100%. 
 
 
Fig. 3.A11: 1H NMR of compound 3 in CDCl3 at 298K. 
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Fig. 3.A12: 13C NMR of compound 3 in CDCl3 at 298K. 
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Fig. 3.A13: 31P NMR of compound 3 in CDCl3 at 298K. 
 
 
Fig. 3.A14: HRMS (ESI) of compound 3. 
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Fig. 3.A15: HPLC trace for compound 3. Rt = 7.94. Purity = 97%. 
 
 
Fig. 3.A16: 1H NMR of compound 4 in CDCl3 at 298K. 
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Fig. 3.A17: 13C NMR of compound 4 in CDCl3 at 298K. 
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Fig. 3.A18: 31P NMR of compound 4 in CDCl3 at 298K. 
 
 
Fig. 3.A19: HRMS (ESI) of compound 4. 
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Fig. 3.A20: HPLC trace for compound 4. Rt = 10.81. Purity = 98%. 
 
 
Fig. 3.A21: 1H NMR of compound 5 in CDCl3 at 298K. 
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Fig. 3.A22: 13C NMR of compound 5 in CDCl3 at 298K. 
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Fig. 3.A23: 31P NMR of compound 5 in CDCl3 at 298K. 
 
 
Fig. 3.A24: HRMS (ESI) of compound 5. 
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Fig. 3.A25: HPLC trace for compound 5. Rt = 7.86. Purity = 97%. 
 
 
Fig. 3.A26: 1H NMR of compound 6 in CDCl3 at 298K. 
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Fig. 3.A27: 13C NMR of compound 6 in CDCl3 at 298K. 
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Fig. 3.A28: 31P NMR of compound 6 in CDCl3 at 298K. 
 
 
Fig. 3.A29: HRMS (ESI) of compound 6. 
 
287 
 
Fig. 3.A30: HPLC trace for compound 6. Rt = 10.81. Purity = 97%. 
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APPENDIX B 
 
Compound characterization for Chapter 4 figures 4.A1-4.B103 which includes 1H and 
13C NMR spectra as well as HPLC traces. 
 
 
 
Fig. 4.B1. 1H NMR spectrum for compound 1a in (CD3)2SO (400 MHz). 
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Fig. 4.B2. 13C NMR spectrum for compound 1a in (CD3)2SO (100 MHz). 
 
 
Fig. 4.B3. LCMS trace for compound 1a. Rt = 18.55 min. Purity: 99%. 
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Fig. 4.B4. 1H NMR spectrum for compound 1c in (CD3)2SO (400 MHz). 
 
 
Fig. 4.B5. 13C NMR spectrum for compound 1c in (CD3)2SO (100 MHz). 
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Fig. 4.B6. LCMS trace for compound 1c. Rt = 18.72 min. Purity: 96%. 
 
 
Fig. 4.B7. 1H NMR spectrum for compound 1d in (CD3)2SO (400 MHz). 
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Fig. 4.B8. 13C NMR spectrum for compound 1d in (CD3)2SO (100 MHz). 
 
 
Fig. 4.B9. LCMS trace for compound 1d. Rt = 20.08 min. Purity: 96%. 
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Fig. 4.B10. 1H NMR spectrum for compound 1e in (CD3)2SO (500 MHz). 
 
 
Fig. 4.B11. 13C NMR spectrum for compound 1e in (CD3)2SO (100 MHz). 
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Fig. 4.B12. LCMS trace for compound 1e. Rt = 17.95 min. Purity: 95%. 
 
 
Fig. 4.B13. 1H NMR spectrum for compound 1f in (CD3)2SO (400 MHz). 
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Fig. 4.B14. 13C NMR spectrum for compound 1f in (CD3)2SO (100 MHz). 
 
 
Fig. 4.B15. LCMS trace for compound 1f. Rt = 19.47 min. Purity: 99%. 
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Fig. 4.B16. 1H NMR spectrum for compound 2a in (CD3)2SO (500 MHz). 
 
 
Fig. 4.B17. 13C NMR spectrum for compound 2a in (CD3)2SO (100 MHz). 
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Fig. 4.B18. LCMS trace for compound 2a. Rt = 18.86 min. Purity: 97%. 
 
 
Fig. 4.B19. 1H NMR spectrum for compound 2b in (CD3)2SO (500 MHz). 
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Fig. 4.B20. 13C NMR spectrum for compound 2b in (CD3)2SO (100 MHz). 
 
 
Fig. 4.B21. LCMS trace for compound 2b. Rt = 19.16 min. Purity: 90%. 
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Fig. 4.B22. 1H NMR spectrum for compound 2c in (CD3)2SO (500 MHz). 
 
 
Fig. 4.B23. 13C NMR spectrum for compound 2c in CD3OD (100 MHz). 
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Fig. 4.B24. LCMS trace for compound 2c. Rt = 19.11 min. Purity: 95%. 
 
 
Fig. 4.B25. 1H NMR spectrum for compound 2d in (CD3)2SO (500 MHz). 
 
301 
 
Fig. 4.B26. 13C NMR spectrum for compound 2d in (CD3)2SO (100 MHz). 
 
 
Fig. 4.B27. LCMS trace for compound 2d. Rt = 20.30 min. Purity: 99%. 
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Fig. 4.B28. 1H NMR spectrum for compound 2e in (CD3)2SO (500 MHz). 
 
 
Fig. 4.B29. 13C NMR spectrum for compound 2e in CD3OD (100 MHz). 
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Fig. 4.B30. LCMS trace for compound 2e. Rt = 18.36 min. Purity: 98%. 
 
 
Fig. 4.B31. 1H NMR spectrum for compound 2f in (CD3)2SO (500 MHz). 
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Fig. 4.B32. 13C NMR spectrum for compound 2f in (CD3)2SO (100 MHz). 
 
 
Fig. 4.B33. LCMS trace for compound 2f. Rt = 19.71 min. Purity: 99%. 
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Fig. 4.B34. 1H NMR spectrum for compound 3a in (CD3)2SO (500 MHz). 
 
 
Fig. 4.B35. 13C NMR spectrum for compound 3a in CD3OD (100 MHz). 
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Fig. 4.B36. LCMS trace for compound 3a. Rt = 18.75 min. Purity: 99%. 
 
 
Fig. 4.B37. 1H NMR spectrum for compound 3c in (CD3)2SO (500 MHz). 
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Fig. 4.B38. 13C NMR spectrum for compound 3c in (CD3)2SO (100 MHz). 
 
 
Fig. 4.B39. LCMS trace for compound 3c. Rt = 18.93 min. Purity: 98%. 
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Fig. 4.B40. 1H NMR spectrum for compound 3d in (CD3)2SO (500 MHz). 
 
 
Fig. 4.B41. 13C NMR spectrum for compound 3d in (CD3)2SO (100 MHz). 
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Fig. 4.B42. LCMS trace for compound 3d. Rt = 20.30 min. Purity: 99%. 
 
 
Fig. 4.B43. 1H NMR spectrum for compound 3f in (CD3)2SO (500 MHz). 
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Fig. 4.B44. 13C NMR spectrum for compound 3f in (CD3)2SO (100 MHz). 
 
 
Fig. 4.B45. LCMS trace for compound 3f. Rt = 19.74 min. Purity: 98%. 
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Fig. 4.B46. 1H NMR spectrum for compound 4a in (CD3)2SO (500 MHz). 
 
 
Fig. 4.B47. 13C NMR spectrum for compound 4a in (CD3)2SO (100 MHz). 
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Fig. 4.B48. LCMS trace for compound 4a. Rt = 20.19 min. Purity: 96%. 
 
 
Fig. 4.B49. 1H NMR spectrum for compound 4b in (CD3)2SO (500 MHz). 
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Fig. 4.B50. 13C NMR spectrum for compound 4b in (CD3)2SO (100 MHz). 
 
 
Fig. 4.B51. LCMS trace for compound 4b. Rt = 20.45 min. Purity: 97%. 
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Fig. 4.B 52. 1H NMR spectrum for compound 4c in (CD3)2SO (500 MHz). 
 
 
Fig. 4.B53. 13C NMR spectrum for compound 4c in (CD3)2SO (100 MHz). 
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Fig. 4.B54. LCMS trace for compound 4c. Rt = 20.33 min. Purity: 97%. 
 
 
Fig. 4.B55. 1H NMR spectrum for compound 4d in (CD3)2SO (500 MHz). 
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Fig. 4.B56. 13C NMR spectrum for compound 4d in (CD3)2SO (100 MHz). 
 
 
Fig. 4.B57. LCMS trace for compound 4d. Rt = 21.84 min. Purity: 99%. 
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Fig. 4.B58. 1H NMR spectrum for compound 4e in (CD3)2SO (500 MHz). 
 
 
Fig. 4.B59. 13C NMR spectrum for compound 4e in (CD3)2SO (100 MHz). 
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Fig. 4.B60. LCMS trace for compound 4e. Rt = 19.63 min. Purity: 98%. 
 
 
Fig. 4.B61. 1H NMR spectrum for compound 4f in (CD3)2SO (500 MHz). 
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Fig. 4.B62. 13C NMR spectrum for compound 4f in (CD3)2SO (100 MHz). 
 
 
Fig. 4.B63. LCMS trace for compound 4f. Rt = 21.04 min. Purity: 100%. 
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Fig. 4.B64. 1H NMR spectrum for compound 5a in (CD3)2SO (400 MHz). 
 
 
Fig. 4.B65. 13C NMR spectrum for compound 5a in (CD3)2SO (100 MHz). 
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Fig. 4.B66. LCMS trace for compound 5a. Rt = 16.40 min. Purity: 99%. 
 
 
Fig. 4.B67. 1H NMR spectrum for compound 5c in (CD3)2SO (500 MHz). 
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Fig. 4.B68. 13C NMR spectrum for compound 5c in (CD3)2SO (100 MHz). 
 
 
Fig. 4.B69. LCMS trace for compound 5c. Rt = 18.46 min. Purity: 97%. 
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Fig. 4.B70. 1H NMR spectrum for compound 5d in (CD3)2SO (500 MHz). 
 
 
Fig. 4.B71. 13C NMR spectrum for compound 5d in (CD3)2SO (100 MHz). 
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Fig. 4.B72. LCMS trace for compound 5d. Rt = 19.71 min. Purity: 97%. 
 
 
Fig. 4.B73. 1H NMR spectrum for compound 5e in (CD3)2SO (500 MHz). 
 
325 
 
Fig. 4.B74. 13C NMR spectrum for compound 5e in (CD3)2SO (100 MHz). 
 
 
Fig. 4.B75. LCMS trace for compound 5e. Rt = 17.54 min. Purity: 99%. 
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Fig. 4.B76. 1H NMR spectrum for compound 5f in (CD3)2SO (500 MHz). 
 
 
Fig. 4.B77. 13C NMR spectrum for compound 5f in (CD3)2SO (100 MHz). 
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Fig. 4.B78. LCMS trace for compound 5f. Rt = 19.21 min. Purity: 99%. 
 
 
Fig. 4.B79. 1H NMR spectrum for compound 6a in (CD3)2SO (400 MHz). 
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Fig. 4.B80. 13C NMR spectrum for compound 6a in (CD3)2SO (100 MHz). 
 
 
Fig. 4.B81. LCMS trace for compound 6a. Rt = 19.45 min. Purity: 99%. 
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Fig. 4.B82. 1H NMR spectrum for compound 6b in (CD3)2SO (500 MHz). 
 
 
Fig. 4.B83. 13C NMR spectrum for compound 6b in (CD3)2SO (100 MHz). 
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Fig. 4.B84. LCMS trace for compound 6b. Rt = 19.85 min. Purity: 95%. 
 
 
Fig. 4.B85. 1H NMR spectrum for compound 6c in (CD3)2SO (500 MHz). 
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Fig. 4.B86. 13C NMR spectrum for compound 6c in (CD3)2SO (100 MHz). 
 
 
Fig. 4.B87. LCMS trace for compound 6c. Rt = 19.61 min. Purity: 96%. 
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Fig. 4.B88. 1H NMR spectrum for compound 6d in (CD3)2SO (500 MHz). 
 
 
Fig. 4.B89. 13C NMR spectrum for compound 6d in (CD3)2SO (100 MHz). 
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Fig. 4.B90. LCMS trace for compound 6d. Rt = 20.50 min. Purity: 100%. 
 
 
Fig. 4.B91. 1H NMR spectrum for compound 6f in (CD3)2SO (500 MHz). 
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Fig. 4.B92. 13C NMR spectrum for compound 6f in (CD3)2SO (100 MHz). 
 
 
Fig. 4.B93. LCMS trace for compound 6f. Rt = 20.39 min. Purity: 99%. 
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Fig. 4.B94. 1H NMR spectrum for compound 6g in (CD3)2SO (500 MHz). 
 
 
Fig. 4.B95. 13C NMR spectrum for compound 6g in (CD3)2SO (100 MHz). 
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Fig. 4.B96. LCMS trace for compound 6g. Rt = 20.32 min. Purity: 99%. 
 
 
Fig. 4.B97. 1H NMR spectrum for compound 6h in (CD3)2SO (500 MHz). 
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Fig. 4.B98. 13C NMR spectrum for compound 6h in (CD3)2SO (100 MHz). 
 
 
Fig. 4.B99. LCMS trace for compound 6h. Rt = 20.34 min. Purity: 95%. 
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Fig. 4.B100. 1H NMR spectrum for compound 7a in (CD3)2SO (500 MHz). 
 
 
Fig. 4.B101. 13C NMR spectrum for compound 7a in (CD3)2SO (100 MHz). 
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Fig. 4.B102. 1H NMR spectrum for compound 7f in (CD3)2SO (500 MHz). 
 
 
Fig. 4.B103. 13C NMR spectrum for compound 7f in (CD3)2SO (100 MHz). 
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